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Abstract 
 
Gene therapy is a promising approach for the treatment of cancer. While most progress in gene 
therapy has been achieved using eukaryotic viral vectors, they have had limited success in systemic 
gene therapy applications due to undesired uptake in non-targeted tissues, insertional mutagenesis, 
and immunogenicity. These shortcomings have driven the development of gene delivery vectors 
derived from alternative sources.  
The bacteriophage-derived Adeno-associated virus-phage (AAVP) is a novel hybrid prokaryotic-
eukaryotic viral vector consisting of a mammalian transgene cassette flanked by ITRs from AAV 
serotype 2 inserted into an intergenomic region of an M13 bacteriophage. Anti-tumour therapy 
following systemic administration has previously been demonstrated in several in vivo cancer models, 
with tumour specificity achieved through display of an αv integrin-targeting ligand on the viral capsid. 
However, despite the apparent success of this novel vector in several cancer models, high titres of 
AAVP are required for transduction of mammalian cells. 
The mechanisms of entry and intracellular trafficking of the targeted AAVP vector were therefore 
investigated in order to identify key barriers to transduction. Using a combination of flow cytometry, 
confocal, and electron microscopy techniques, together with pharmacological agents, RNAi and 
dominant negative mutants, it was demonstrated that receptor-mediated endocytosis of the AAVP 
vector is both dynamin and clathrin-dependent. Following endocytosis, the majority of AAVP 
particles are sequestered by the endosomal-lysosomal degradative pathway, which presents a major 
obstacle to gene delivery by the vector. 
The feasibility of improving AAVP-mediated gene transfer through endosomal/lysosomal disruption 
was demonstrated using the lysosomotropic agent chloroquine. Subsequently, novel multifunctional 
AAVP vectors bearing endosomal-escape peptides were generated. These novel vectors demonstrated 
improved transgene expression and retained integrin-targeting capabilities of the RGD peptide. These 
studies will prove invaluable for the future development of AAVP. Furthermore, the findings 
presented in this thesis underline the importance of such studies for the improvement of gene therapy 
vectors. 
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1. Introduction 
 
1.1. Cancer 
The term cancer refers to a broad group of diseases characterised by unrestrained cell proliferation 
leading to disruption of normal tissue functions. Cancer is considered a world-wide health problem, 
accounting for approximately 7.6 million deaths in 2008 (The World Health Organisation; 
www.who.int/mediacentre/factsheets). In the United Kingdom alone, over 320,000 new cancer cases 
were reported in 2009 and more than 155,000 cancer-related deaths were registered in 2010 (Cancer 
Research UK; info.cancerresearchuk.org/cancerstats
Tumourigenesis is a complex multistep process involving a series of genetic and epigenetic changes 
which confer selective growth advantages to neoplastic cells (
).   
Wu et al. 2001). The majority of these 
changes occur through somatic mutation, arising from misincorporation during DNA replication or 
through exposure to exogenous mutagens such as radiation, chemicals or viruses (Greenman et al. 
2007). Germ-line mutations may give predisposition to the development of familial cancers, however, 
an inherited mutation is rarely sufficient to initiate tumourigenesis unless an additional mutation is 
acquired or a second allele is lost (first described as the ‘two-hit hypothesis’ by Knudson (Knudson 
1971).  
Carcinogenesis is rarely caused by a mutation in a single gene, however, malignant transformation 
may occur when mutations accumulate in broad groups of genes which code for proteins involved in 
the regulation cell growth and differentiation, and for maintenance of genetic stability (reviewed by 
(Vogelstein et al. 2004)). 
1.1.2. Cancer genes 
The three major gene types associated with tumourigenesis are proto-oncogenes, tumour-suppressor 
genes, and stability genes. Proto-oncogenes encode proteins that function to stimulate cell division, 
inhibit cell differentiation and halt cell death  (Bast 2000).  Alteration of the structure and/or 
13
expression of proto-oncogenes from chromosomal translocations, gene amplifications or from 
intragenic mutations affecting residues that regulate the activity of the gene product can activate them 
to become oncogenes capable of inducing the neoplastic phenotype in susceptible cells  (Vogelstein et 
al. 2004). Mutations in proto-oncogenes are typically dominant in nature as they have sustained gain-
of-function alterations. 
Tumour-suppressor genes function to prevent cell growth by promoting cell cycle arrest and apoptosis 
(Bast 2000). Loss of tumour suppressor gene function may arise through missense mutations at 
residues that are essential for its activity, mutations resulting in a truncated protein, from deletions or 
insertions within the gene, or from epigenetic silencing (e.g. through DNA hypermethylation or 
histone deacetylation), resulting in promotion of cell survival and proliferation (Vogelstein et al. 
2004). Most loss-of-function mutations of tumour-suppressor genes are recessive, requiring 
inactivation of the second functional allele to have an effect.  
Stability genes (also known as caretaker genes), include DNA mismatch repair (MMR), nucleotide 
excision repair (NER), base-excision repair (BER) genes, as well as genes involved in chromosomal 
segregation and mitotic recombination (Vogelstein et al. 2004). These stability genes are required for 
maintenance of genome integrity, through recognition and repair of mutations acquired during normal 
DNA replication or exposure to mutagens (reviewed by (Hoeijmakers 2001, Levitt et al. 2002)). 
Inactivation of these genes therefore increases the rate of mutations acquired in other genes, including 
tumour-suppressor genes and proto-oncogenes, leading to increased rate of cancer progression. 
The accumulation of such mutations drives neoplastic progression by increasing cell number through 
inhibition of cell death or stimulation of division. Thus, tumourigenesis can be described in terms of 
‘somatic evolution’, by which each genetic change confers  selective growth advantages over normal 
cells, resulting in clonal expansion (Nowell 1976). These genetic changes result in acquisition of 
features termed by Hanahan and Weinburg as the ‘hallmarks of cancer’ (Hanahan et al. 2000). These 
include self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of 
apoptosis, deficient cell cycle control, sustained angiogenesis, and tissue invasion. Further to these 
traits, cancers also develop abnormal metabolic pathways, unstable DNA and chromosomes, immune 
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evasion and inflammation (Hanahan et al. 2011). Acquisition of these aberrations leads to invasion of 
local tissues, disrupting normal tissue function, and eventually to establishment of distant metastases. 
Despite improved knowledge of the molecular mechanisms of cancer progression, diagnostic methods 
and conventional treatments of cancer, poor prognosis and high mortality rates mean that more 
efficient therapeutic methods are required. Conventional treatments include surgery, chemotherapy, 
radiotherapy and hormone therapy. However, the genetic mutations responsible for carcinogenesis 
may increase the resistance of malignant cells to these conventional treatments, thus ensuring the 
survival of cancer cells and uninterrupted tumour growth. Cancer cells develop resistance to a range 
of chemotherapeutic agents and radiation treatment. For example, tumour cells with defective MMR 
have been shown to display reduced sensitivity to DNA-damaging chemotherapeutic drugs such as 
cisplatin (Aebi et al. 1996) and doxorubicin (Drummond et al. 1996). In addition to therapeutic 
resistance, chemo and radiation therapies are at a disadvantage due to lack of specificity, leading to 
toxicity in normal tissues.  
By contrast, gene therapy has attracted attention for its potential to specifically and efficiently target 
cancer cells with minimal toxicity to normal cells. The improved understanding of the molecular 
biology of cancer has made it possible to treat malignancies on the basis of their molecular 
characteristics (Gottesman 2003). Furthermore, gene therapy approaches can be used in combination 
with conventional treatments, and have been shown to increase the sensitivity of cancer cells to 
chemotherapy and radiotherapy (Gridley et al. 2004b, Gridley et al. 2004a).  
1.2. Cancer gene therapy strategies 
Gene therapy can be defined as the introduction of exogenous genetic material including DNA, RNA 
or oligonucleotides for the treatment of disease. Gene therapy strategies were initially developed as a 
method for treating inherited monogenic disorders (such as cystic fibrosis or adenosine deaminase 
deficiency) by introducing a functionally normal gene into the host genome to compensate for the 
consequences of the disease mutations. The concept has since expanded to include strategies using 
genetic material to prevent or treat a variety of complex acquired diseases and cancer. Over the past 
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50 years gene therapy has progressed from a theoretical principle to clinical trials, with over 1000 
clinical trials completed to date (Journal of Gene Medicine clinical trials database 2012, 
www.wiley.co.uk). Over 60% of all gene therapy trials conducted thus far have been for the treatment 
of cancer (Figure 1.1).  
 
Figure 1.1. Gene therapy trials by target disease.  
From the Journal of Gene Medicine (www.wiley.co.uk, 2012). 
 
Several strategies are available for gene therapy of cancer, due to the complex nature of the disease. 
These include restoring tumour-suppressor gene function or inactivation of oncogenes, or promoting 
tumour cell death through immunopotentiation, desensitisation of normal tissues to chemotherapy, 
anti-angiogenesis, and expression of cytotoxic (suicide) genes (Gottesman 2003).  
1.2.1. Cancer gene replacement therapy 
As cancer is caused by multiple genetic factors, it is not possible to correct all of the defective genes 
responsible for a malignant phenotype. However, significant inhibition of tumour growth has been 
demonstrated following correction of certain tumour-suppressor genes or inactivation of oncogenes. 
Several studies have aimed at restoring function of the tumour-suppressor gene p53 (reviewed by 
(Lane et al. 2010)). The p53 protein is a transcription factor which functions to inhibit cell growth and 
stimulates cell death when induced by cellular stress (Vogelstein et al. 2000, Oren 2003, Vogelstein et 
al. 2004). Inactivation of the p53 gene is the most frequent abnormality identified in human tumours 
(Hollstein et al. 1991, Hollstein et al. 1998). Inactivation of p53 can occur through point mutations 
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that prevent its capacity to bind cognate recognition sequence, or through infection with DNA tumour 
viruses whose products (such as the E6 protein of human papilloma virus, Simian virus  (SV) 40 large 
tumour antigen or adenovirus E1B-55Kd protein) bind to, and functionally inactivate p53 in order to 
promote viral replication (Vogelstein et al. 2004). 
Transfection of the wild-type p53 gene into a variety of human tumour cells was shown in the late 
1980s and early 1990s to induce apoptosis and growth inhibition (Lane et al. 2010). Adenovirus (Ad) 
vectors expressing wild-type p53 also showed therapeutic effect in rodents with subcutaneously and 
orthotypically implanted tumours (Kock et al. 1996, Li et al. 1999). p53 gene therapy has also been 
demonstrated in man. In 1996, Roth and co-workers demonstrated tumour regression in patients 
following intra-tumoural injection of Ad-p53 (Roth et al. 1996). Phase I and I/II clinical trials have 
since demonstrated the safety of Ad-p53 therapy alone and in combination with radiotherapy, 
chemotherapy, or surgery in patients with various cancer types (Li et al. , Clayman et al. 1999, 
Swisher et al. 1999, Swisher et al. 2003). Following phase III clinical trials, China approved the use 
of a replication-deficient Ad-p53 vector (Gendicine) for the treatment of head and neck cancer in 
conjunction with radiotherapy (Pearson et al. 2004, Peng 2005). Gendicine presented the first 
approved commercial gene therapy product in the world.  
Inactivation of dominant oncogenes presents an alternative gene replacement strategy for cancer gene 
therapy. One example is the ras family of oncogenes, which are among the most commonly activated 
oncogenes found in human cancers, present in approximately 30% of human neoplasms (Bos 1989). 
Each mammalian cell contains at least three distinct ras proto-oncogenes (K-ras, H-ras and N-ras) 
encoding closely related proteins. Single point mutations in the ras proto-oncogenes gene can lead to 
constitutive activation of the Ras proteins through impaired GTPase activity. The activated Ras 
stimulates downstream effectors (Raf-1, Rac, Rho, and Phosphatidylinositide 3-kinases; PI3-K) which 
results in continuous stimulation of cell proliferation (Bos 1989, Adjei 2001, Adjei 2008). Anti-
tumour effects have been demonstrated following in vitro and in vivo inhibition of ras oncogene 
activity using virally-delivered anti-sense oligonucleotides targeting K-ras or RNA interference 
(RNAi) (Georges et al. 1993, Zhang et al. 1993, Zhang et al. 2006).  
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However, the replacement of tumour suppressor genes or inactivation of oncogenes in cancer gene 
therapy is difficult, as malignant phenotype is not caused by single mutations, and due to the difficulty 
in transducing the entire tumour population. These treatment strategies are therefore often combined 
with other conventional therapeutic options. Alternative approaches that are independent of the host 
genome have therefore been widely researched. These include anti-angiogenic, immuotherapeutic, 
chemoprotective, suicide gene therapies and oncolytic virotherapies.  
1.2.2. Anti-angiogenic therapy 
The generation of new blood vessels, termed angiogenesis, is required for tumour proliferation and 
metastasis (Folkman 1971). Angiogenesis is required to fulfil the metabolic requirements of the 
expanding tumour, and involves induction of new vessel formation from the existing vascular bed. 
The acquisition of an angiogenic phenotype involves a number of interacting processes and factors, 
such as pro-angiogenic growth factors, including vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (bFGF), as well as receptor tyrosine kinases, matrix metalloproteinases 
(MMPs),  and integrins (Brock et al. 2002, Persano et al. 2007). The vasculature of a solid tumour is 
an attractive target for intervention because the tumour vascular endothelium expresses several cell-
surface receptors that are essentially absent or barely detectable in normal blood vessels (St Croix et 
al. 2000). This enables tumour-targeting specificity of systemically delivered therapeutics.  
Anti-angiogenic therapies can be achieved through increasing expression of endogenous angiogenesis 
inhibitors such as angiostatin, endostatin, or thrombospondins, or through inhibiting pro-angiogenic 
molecules such as growth factors bFGF and VEGF (for review see (Tandle et al. 2004)). One of the 
principle regulators of angiogenesis is VEGF, which induces tumour endothelial cell (EC) 
proliferation, differentiation and migration. Upregulated expression of VEGF is caused by mutations 
in tumour suppressor genes such as ras, raf and p53 (Kieser et al. 1994, Grugel et al. 1995). Inhibition 
of VEGF isoforms or their receptors has been widely researched as an anti-angiogenic therapy. 
Reduced tumour cell growth has been demonstrated in vitro in cells directly transfected with antisense 
VEGF (Cheng et al. 1996), and in vivo with DNA vector-based RNA interference (RNAi) (Zhang et 
al. 2003). Vectors encoding soluble VEGF receptors have also been developed, expression of the 
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soluble receptors sequesters VEGF and prevents binding to endogenous receptors, limiting VEGF 
signalling and therefore vascular growth (Goldman et al. 1998, Sallinen et al. 2009). 
1.2.3. Cancer immunotherapy 
The concept of cancer immunotherapy (or cancer vaccination) is based on the theory that the patient’s 
own immune system can be primed to recognise and destroy cancer cells. This can be achieved 
through induction of tumour-antigen-specific immune responses, both cellular and humoral, and also 
the generation of immunological memory. 
Cancer immunotherapies are characterised as either active immunisation or passive transfer 
approaches. Passive (or adoptive) therapies involve the transfer of immune cells with anti-tumour 
reactivity, whereas active immunisation involves the transduction of cancer cells with genes encoding 
immunostimulatory factors such as cytokines.  
The identification of tumour-associated antigens (TAAs) has prompted extensive research into 
manipulation of the antitumor immune response by actively trying to stimulate immunity against these 
specific TAAs and consequently against the tumour itself. This can be achieved through transduction 
of antigen-presenting cells (APC) to display TAAs for activation of tumour-specific T-lymphocytes, 
expression of TAA-specific T-cell receptors (TCRs) on T-lymphocytes or transduction of tumour 
cells with major histocompatability complex (MHC) class I molecules (reviewed by (Rosenberg et al. 
2004, Breckpot et al. 2007).  
As dendritic cells (DC) are considered to be the most potent APCs of the immune system, one well-
studied approach is the use of ex vivo-generated DCs loaded with TAAs in order to induce anti-
tumour immune responses in cancer patients. Both human and murine virally transduced DC have 
been shown to activate established CD4+ and CD8+ T-cell lines/clones specific for epitopes derived 
from various TAAs, such as melanoma antigen gene 3 (MAGE-3) (Breckpot et al. 2004), melanoma 
antigen A (Melan-A)/melanoma antigen recognised by T-cells 1 (MART-1) (Butterfield et al. 2008) 
and tyrosinase (Lizee et al. 2004). Importantly, specific transduction of APCs has been demonstrated 
in vivo following systemic administration of viral vectors encoding TAAs, thus eliminating the need 
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to isolate a patient’s DCs for transduction ex vivo (VandenDriessche et al. 2002, Esslinger et al. 
2003).  
In a similar approach, genes encoding T-cell receptors specific for TAAs have been isolated from 
high avidity T cells and retroviral or lentiviral vectors used to redirect non-tumour-specific 
lymphocytes to these cancer antigens (reviewed by (Ngo et al. 2011)). This adoptive t-cell therapy has 
been achieved in T-cells genetically engineered with TCRs to recognise TAAs such as MART-1 
(Clay et al. 1999) and the human homologue of murine double-minute 2 (MDM2) (Stanislawski et al. 
2001). 
1.2.4. Chemoprotective therapy 
Chemoprotective therapies aim to improve resistance to chemotherapy in healthy tissues to order to 
overcome toxic side effects of off-target cell death, particularly to haemopoeitic stem cells (HSCs). 
This is important as chemotherapy dose-limitation hinders potential clinical efficacy. To enable 
tolerance of higher drug doses, drug resistance genes may be conferred to HSCs to improve 
chemoprotection. For example, the multi-drug resistance 1 (MDR-1) gene encodes an ATP-dependent 
plasma membrane efflux pump, P-glycoprotein (P-gp). P-gp extrudes a broad range of hydrophobic 
drugs from cells, including vinca alkaloids, anthracyclines, epipodophyllotoxins, colchicine, 
actinomycin D, taxol and taxotere (Ambudkar et al. 2003). Virally-mediated expression of human 
MDR-1 in haematopoietic stem and progenitor cells and subsequent re-engraftment has been 
demonstrated in humans to protect haematopoietic cells against myelotoxic drugs (Abonour et al. 
2000). Other examples include the genes encoding multidrug resistance-associated protein 1 (MRP-1), 
dihydrofolate reductase (DHFR), aldehyde-dehydrogenase (ALDH), glutathione-S-transferase (GST), 
cytosine deaminase (CDD) and methylguanine-DNA-methyltransferase (MGMT) (reviewed by 
(Zaboikin et al. 2006)). 
HSCs have typically been isolated and transduced ex vivo, using lentiviral vectors, and reintroduced 
before selecting for drug resistance in vivo. In vivo expansion of transduced cells can be achieved 
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through introducing genes which provide proliferative advantage over resident cells (such as HoxB4 
or other growth factors), or following initial chemotherapy regimens (Zaboikin et al. 2006). 
1.2.5. Suicide gene therapy 
Suicide gene therapy presents an alternative route of therapy by which transgenes delivered to the 
target cell promote cell death by apoptosis. A widely used approach has been to deliver genes 
encoding enzymes which can metabolise a systemically-administered inactive prodrug into cytotoxic 
derivatives. This is also known as Gene-directed Enzyme Prodrug Therapy or GDEPT (reviewed by 
(Greco et al. 2001, Denny 2003)). The prodrugs are relatively non-toxic at high concentrations, until 
converted to toxic metabolites specifically in the transduced tumour cells. The most extensively 
studied GDEPT has been the use of the herpes simplex type-1 thymidine kinase enzyme (HSV-Tk) in 
combination with guanosine-based prodrugs (e.g. ganciclovir) (Moolten 1986). The virus thymidine 
kinase converts the prodrug to monophosphates, which are converted by cellular enzymes to 
triphosphates. The ganciclovir (GCV)-triphosphates compete with deoxyguanosine triphosphate for 
incorporation into elongating DNA during cell division, causing inhibition of the DNA polymerase 
and single strand breaks, leading to apoptosis (Matthews et al. 1988). 
An additional advantage to GDEPT is that the toxic form of the prodrug is able to pass to 
neighbouring cells through intercellular gap junctions (Touraine et al. 1998), via apoptotic vesicles 
(Freeman et al. 1993), or through diffusion of soluble toxic metabolites (Wei et al. 1995). 
Furthermore, GDEPT may enhance tumour cell killing through systemic immune stimulation both at 
the tumour site and at distant metastases (Bi et al. 1997, Vile et al. 1997). Thus, these ‘bystander 
effects’ reduce the proportion of the tumour cells that need to be transduced in order to mediate 
therapeutic effect. Furthermore, targeted suicide gene delivery to the tumour vascular endothelium 
can increase efficacy through destruction of the tumour vasculature, accentuating the therapeutic 
effect. Preclinical studies have demonstrated that tumour regression can be achieved when only 10% 
of the tumour cells expressed suicide genes (Caruso et al. 1993).  
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1.2.6. Oncolytic viruses/virotherapy 
Virotherapy utilises oncolytic viruses for the treatment of cancer, an idea first inspired over one 
hundred years ago by the observation that some tumours regressed in cancer patients suffering from 
some virus infections or following vaccinations (Kelly et al. 2007). The term ‘oncolytic virus’ (OV) 
applies to viruses that are able to replicate specifically in neoplastic cells, leading to tumour cell lysis 
as a consequence of the viral replication cycle. This mechanism of tumour destruction is 
therapeutically complimented by associated secondary mechanisms including induction of tumour-
specific immunity and anti-vascular effects (Liu et al. 2007). 
Cancer-targeting of properties of oncolytic viruses can either be inherent to certain virus species (for 
example RNA viruses, poxviruses) or genetically engineered (Liu et al. 2008). Identification of 
molecular defects in cancer has made it possible to design vectors that can selectively replicate in 
tumour cells. One such example is the conditionally-replicating adenovirus dl1520, also known as 
ONYX-015 (Heise et al. 1997). Deletion of the gene encoding the viral early protein E1B-55kD was 
thought to render the virus incapable of replicating in cells expressing normal levels of the tumour-
suppressor p53, but allow replication and lysis of tumour cells lacking the functional tumour-
suppressor. Later studies found that tumour selectivity was independent of p53 status (Goodrum et al. 
1998, Rothmann et al. 1998), however the vector still preferentially replicates in cancer cells (O'Shea 
et al. 2004). ONYX-015 showed a good safety profile in several phase I/II clinical trials, 
unfortunately, the vector lacked efficacy as a stand-alone treatment (Kirn 2001). However, in 2005 
China approved the use of a similar engineered Ad vector termed H101, which also carries an E1B-
55kD gene deletion. When used in combination with chemotherapy, 78% of patients enrolled in a 
phase III clinical trial showed reduction in tumour size (Xia et al. 2004). This presents the first 
oncolytic virus product approved by a government agency for human use.  
Although efficacy of OVs has been established in animal models, efficacy in human trials has been 
much more limited, particularly when used as monotherapy (reviewed by (Liu et al. 2008). Strategies 
to enhance the efficacy of OVs include enhancing tumour cell killing specificity and potency by using 
such agents in combination with established antitumor therapies such as radiation or chemotherapy. 
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Furthermore, in addition to tumour killing by replication, OVs have been generated with genes 
incorporated to enhance immunostimulatory effect of the viruses (Hu et al. 2006, Liu et al. 2008). 
1.3. Gene delivery vectors 
Naked therapeutic genetic molecules are difficult to administer to specific tissues due primarily to 
rapid clearance, DNA and RNA nucleases, lack of control in targeting specific tissues, and low 
cellular uptake following systemic administration (Kawabata et al. 1995, Gao et al. 2007). Improved 
delivery methods for naked genetic molecules, such as hydrodynamic gene transfer (Liu et al. 1999), 
gene gun (Yang et al. 1990) or electroporation (Rols et al. 1998) can overcome some of these 
restrictions, however these have had limited efficacy, and are not practical for treatment of 
disseminated disease such as metastatic cancers.  
Thus, one of the main concerns in gene therapy is the lack of efficient and safe delivery systems for in 
vivo applications. Several methods of encapsulating nucleic acids have therefore been devised 
(reviewed by (Verma et al. 2005, Gao et al. 2007, Seow et al. 2009)). These gene delivery vehicles 
(GDV) are typically categorised by whether they are viral or non-viral in origin. The choice of GDV 
is determined to an extent by the size of the gene product, type of nucleic acid, immunogenicity, as 
well as the target tissue. Viral vectors, cationic liposomes and polyplexes are currently the most 
widely used GDVs and have been relatively successful with a large number in clinical trial (Gene 
Therapy Clinical Trials Worldwide;  www.wiley.co.uk/genetherapy/clinical
1.3.1. Non-viral gene delivery vehicles 
).   
The field of gene therapy was severely impacted by highly publicised cases of severe side effects to 
viral gene delivery. In 1999, massive inflammatory response to an adenovirus vector resulted in the 
death of a teenager undergoing treatment for ornithine transcarbamylase (OTC) deficiency (Lehrman 
1999, Raper et al. 2003). Furthermore, genotoxicity of retroviruses was observed in two clinical trials 
for X-linked severe combined immunodeficiency (X-SCID), where 5 out of the 20 patients enrolled in 
the French and English trials developed abnormal white blood cell growth as a result of viral 
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integration leading to activation of proto-oncogenes (Hacein-Bey-Abina et al. 2003, Kohn et al. 2003, 
Hacein-Bey-Abina et al. 2008). 
Following these incidents, emphasis has been placed on firstly, understanding the consequences of 
using viruses as gene delivery vehicles, and secondly, developing alternative methods of gene 
transfer. There are now several strategies for non-viral delivery of therapeutic nucleotides. Plasmid 
DNA, small interfering RNA (siRNA), microRNA and oligonucleotides are highly hydrophilic 
molecules with negative charges, which restricts their binding to and diffusion across negatively 
charged plasma membrane. One common feature of non-viral GDVs has therefore been to complex 
nucleotides with a positive (cationic) charge that enables them to transfer across the negatively 
charged phospholid bilayer of the plasma membrane. The most extensively utilised non-viral delivery 
agents are cationic lipids or polymers, or a combination of both.  
Non-viral strategies for gene delivery have several advantages, with respect to their lack of inducing a 
specific immune response, simplicity, packaging capacity, and potential for large scale production. 
Furthermore, agents complimentary to therapy can be delivered alongside genetic material, such as 
chemotherapeutic drugs and inflammation suppressors to reduce cytokine production triggered by 
plasmid DNA. 
1.3.1.1. Cationic lipids 
Cationic lipid-based gene transfer was first pioneered in 1987 (Felgner et al. 1987). This method 
represents the most extensively investigated non-viral gene delivery system, although alternatives are 
becoming increasingly popular (Seow et al. 2009). Hundreds of different lipid formulations have been 
developed for gene transfer (reviewed by (Gao et al. 2007, Al-Dosari et al. 2009)). The amphiphilic 
lipid molecules commonly consist of a hydrophilic ‘head’ and hydrophobic ‘tail’ connected by a 
linker structure. The hydrophilic head groups typically consist of primary, secondary or tertiary 
amines, or quaternary ammonium salts. Lipids containing guanidino, imidazole, pyridinium, 
phosphorous, and arsenic have also been used (Al-Dosari et al. 2009). The hydrophobic tails of the 
lipids may consist of aliphatic chains, cholesterol or steroid rings. Furthermore, helper lipids (or co-
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lipids) such as cholesterol and dioleoylphosphatidylethanolamine (DOPE) can be incorporated.  The 
presence of  these helper lipids can improve stability against serum components and improve 
transfection efficiency in vivo (Li et al. 1998b). Additionally, surface shielding through the use of 
neutral polymers such as polyethyleneglycol (PEG) can reduce charge-charge interactions and 
prolong the circulation time of lipoplexes (Harvie et al. 2000).  
The positively charged head groups are necessary for interacting with negatively-charged phosphate 
backbones of the nucleic acids.  This interaction forms cationic lipoplexes, with nucleic acids 
surrounded by lipids which protect them from nucleases and allow them to cross the plasma 
membrane. The transfection efficiency of the cationic lipids varies depending on the structure of the 
lipid, the number of charged head groups per molecule, the charge-ratio used to form DNA-lipid 
complexes, and the properties of the co-lipids (Al-Dosari et al. 2009). Lipoplexes have been used for 
gene delivery for over two decades, with numerous gene therapy trials conducted for lipoplex-
mediated gene transfer in humans for cancer and cystic fibrosis (Nabel et al. 1993, Caplen et al. 1995, 
Gill et al. 1997, Alton et al. 1999).  
1.3.1.2. Cationic polymers 
Another extensively studied non-viral synthetic delivery system utilises cationic polymers to 
encapsulate nucleic acids. Cationic polymers form polyplexes when combined with nucleic acids. 
These polyplexes are also diverse in composition, and may include chitosan (Lee et al. 1998), poly-L-
lysine (Wu et al. 1988), however the most commonly utilised is polyethyleneimine (PEI) (Boussif et 
al. 1995). PEI has been widely used as a non-viral transfection agent both in vitro and in vivo. PEI 
may exist in branched or linear form, and the degree of branching, molecular weight, and cationic 
charge dictates cytotoxic effects and DNA complexing. High molecular weight (MW) PEI (over 
25kDa) is more toxic to cells, however smaller PEI molecules have lower transfection efficiencies 
(Fischer et al. 2003). An advantage of using PEI as a gene transfer agent is the ‘proton sponge’ effect, 
whereby non-protonated amines of PEI impart a buffering potential which can neutralise the acidic 
environment of the endosomes and lead to hypoosmotic endosomal lysis and release of genetic 
material from the degradative pathway (Akinc et al. 2005). 
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1.3.1.3. Targeting cationic lipoplexes and polyplexes for cancer therapy 
Targeted delivery of lipoplexes or polyplexes for cancer treatment may be achieved through 
incorporation of peptides or monoclonal antibodies with specificity for receptors over-expressed on 
tumour cells. For example, targeted delivery of DNA and siRNA to tumour cells has been achieved 
through the use of lipoplexes coated with transferrin, or with anti-transferrin receptor monoclonal 
antibodies, which bind to transferrin receptors over-expressed on tumour cells (Xu et al. 2002, Neves 
et al. 2009). Similarly, tumour-targeting of PEI-based polyplexes has also been achieved through 
incorporation of ligands or peptides such as transferrin (Kircheis et al. 2002), epidermal growth factor 
(EGF) (Ogris et al. 2003), and Arginine-Glycine-Aspartate (RGD) ligands (which target integrin 
receptors overexpressed on tumour cells and tumour vascular endothelium) (Schiffelers et al. 2004). 
Systemic administration of therapeutics is required for treatment of metastatic cancers. Unfortunately, 
systemic targeting of tumours via the bloodstream remains challenging for these non-viral vectors. 
Toxicity has been observed following systemic administration of both lipoplexes and polyplexes. The 
presence of unmethylated CpG-containing plasmid DNA or siRNAs can stimulate rapid production of 
inflammatory responses and lead to rapid clearance of the therapeutic (Zhang et al. 2005). It has been 
demonstrated that retention of even one single CpG in plasmid DNA is sufficient to elicit an 
inflammatory response (Hyde et al. 2008). Furthermore, biodistribution studies have shown that 
systemically administered polycations are rapidly eliminated from the circulatory system and 
accumulate in the lungs, liver and spleen (Liu et al. 1997) (reviewed in (Morille et al. 2008)). This 
accumulation is due to aggregation of the positively charged complexes when applied at the high 
concentrations required to mediate sufficient therapeutic response. Surface shielding through the use 
of neutral polymers such as PEG can reduce charge-charge interactions and prolong the circulation 
time of lipoplexes and polyplexes (Ogris et al. 1999, Harvie et al. 2000, Li et al. 2006). Furthermore, 
PEGylated vectors have been shown to accumulate in highly vascularised tissues, such as tumours, 
which is referred to as the enhanced permeability and retention (EPR) (Brannon-Peppas et al. 2004).  
26
1.3.2. Viral gene delivery vehicles 
Viruses have long been used as gene delivery vehicles as they have essentially evolved for this 
purpose.  Viruses are capable of efficiently gaining access to host cells through various mechanisms 
to exploit the host cellular machinery for their replicative needs (discussed in section 1.5.4). 
A successful viral gene therapy depends on the generation of efficient and targeted viral vectors able 
to produce sustained transgene expression efficiently but with limited toxicity. This often requires the 
ablation of a virus’ natural tropism for mammalian cells to facilitate retargeting to specific tissue types 
(reviewed by (Waehler et al. 2007)), which is especially necessary when attempting systemic therapy. 
Furthermore, expression of viral genes that lead to replication and toxicity must be avoided. This is 
achieved through removal of coding regions from the viral genome (which further increases the 
packaging capacity of the vector) necessary for replication in the host, but maintenance of sequences 
that are required in cis for functions such as vector packaging in the viral capsid or integration into the 
host genome. The deleted genes may be included in a separate construct to provide helper functions in 
trans. Cells are then co-transfected to produce recombinant viral particles in vitro, which are titred 
before application in vivo (reviewed by (Thomas et al. 2003)). 
Viral vectors may be characterised based on their genome (DNA or RNA), structure (enveloped or 
non-enveloped) or whether their genomes integrate into the host chromasomes or persist episomally. 
Three popularly used viral gene delivery vectors are based on adenoviruses (Ad), adeno-associated 
viruses (AAV) and retroviruses (particularly lentivirus).  
1.3.2.1. Adenovirus biology and vector systems 
The Adenoviridae family of viruses commonly cause respiratory, ocular and gastrointestinal disease 
in humans (McConnell et al. 2004). The family consists of over 50 distinct serotypes and can be 
categorised into six subgroups (A-F) based on DNA sequence homology. Human subgroup C 
adenoviruses have been the most extensively characterized, with serotypes 2 and 5 emerging as the 
viral platforms most commonly used for gene delivery purposes (reviewed by (Volpers et al. 2004).  
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 Figure 1.2. Organisation of the adenovirus particle. 
Diagramatic representation of the adenovirus capsid structure. The outer capsid contains 3 major capsid 
proteins, hexon, penton base and fiber, which enclose the core composed of core protein surrounding the 
dsDNA genome flanked at either end by terminal proteins. 
 
The adenovirus virion is a non-enveloped isosahedral particle approximately 70-90 nm in size 
consisting of an outer protein shell surrounding an inner nucleoprotein core containing the 34–48 kb 
double-stranded linear DNA linear genome (McConnell et al. 2004). The structure of the outer capsid 
is composed primarily of hexon protein trimers and contains 12 vertices consisting of penton base 
(Pb) containing an exposed RGD motif and the protruding fiber protein which attaches the particle to 
target cells (Stewart et al. 1997, Russell 2009). In several adenovirus species (in particular subgroup 
C), the first interaction event of the virus with host cells is mediated through binding of the knob 
domain of the fiber capsid protein to the Coxsackie B and Adenovirus receptor (CAR) (Bergelson et 
al. 1998). Following initial attachment to CAR, RGD sequences on the five polypeptide subunits of 
the viral penton base interact with αv integrins, triggering integrin activation of cell signalling 
pathways which promote receptor-mediated endocytosis of the virus (Wickham et al. 1993, Li et al. 
1998a). The low pH environment of the endosomes permits partial uncoating of the virions which 
allows endosomal escape and subsequent interaction with microtubules facilitates trafficking to the 
nucleus for replication (Blumenthal et al. 1986, Suomalainen et al. 1999, Meier et al. 2002). The first 
genes to be transcribed are E1A and E1B, which act as transcriptional activators of early viral genes 
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(E1-E4) and viral genomic replication as well as dysregulators of the cell cycle. After genome 
replication is initiated, the viral late promoter drives transcription of structural genes. Virions are 
assembled in the nucleus and released following final proteolytic maturation by host cell lysis 
(reviewed by (McConnell et al. 2004). 
 
 
 
Figure 1.3. The Adenovius genome.  
The adenoviral genome contains early (E1-4), intermediate (IX and Iva2) and late (L1-5) genes flanked by 
inverted terminal repeat sequences. Also shown are the major late promoter (MLP) and packaging element (ψ). 
 
1.3.2.2. Adenoviral vectors 
Several features of adenovirus make it well suited for gene delivery. Adenoviral vectors can be grown 
to high titres, they have a relatively large capacity for transgenes, and are relatively efficient at 
transducing cells in vivo (McConnell et al. 2004). Additionally, their genome rarely integrates into the 
host chromosome, which is suitable for applications requiring transient gene expression (Harui et al. 
1999). However, while adenoviruses have been successful at short-term gene delivery, long-term 
therapy has been hampered by innate and adaptive immune responses to the vectors (reviewed by 
(Muruve 2004)). Furthermore, a high prevalence of pre-existing immunity in the human population 
limits the use of some serotypes (Sumida et al. 2005). Activation of the innate immune response is 
stimulated by the virus particles, irrespective of transcription from viral DNA. The response can cause 
inflammation of the target and surrounding tissues, which reduces the numbers of transduced cells and 
may lead to severe systemic toxicity (Muruve et al. 1999, Liu et al. 2003). Following initial innate 
responses, neutralising antibodies are produced, which can block targeting motifs on the vector 
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surface and reduce the transduction of target cells by adenoviral gene therapy vectors. Moreover, 
cytotoxic T cell immune responses against both vector capsid components and transgene products 
eliminate target cells expressing these proteins (Yang et al. 1995). 
Adenovirus vectors have therefore been extensively engineered to reduce their immunogenicity 
(reviewed by (McConnell et al. 2004). Replication-deficient ‘first-generation’ adenovirus vectors 
were based on the substitution of viral early genes (E1 and E3) by transgenes or therapeutic genes to 
be delivered to target cells. Deletion of E1 and E3 genes yields vectors with a total transgene capacity 
of 8 kb. Cells transduced with these vectors expressed other adenoviral genes at low levels, which 
induced cytotoxic T-cell responses that rapidly eliminated transgene expression (Gilgenkrantz et al. 
1995).Therefore, additional genes necessary for viral gene regulation were removed (E2 and/or E4), 
to generate second generation adenoviruses (Engelhardt et al. 1994, Armentano et al. 1995). Deletion 
of these regions increased the packaging capacity to 14 kb and therefore increased the vector cloning 
capacity (Armentano et al. 1997, Amalfitano et al. 1998). Second generation adenoviruses showed 
improved transgene persistence and decreased the inflammatory response in some studies. However, 
the development of helper-dependent, or ‘gutless’ adenoviruses that are deleted for all viral genes 
have since improved prospects for adenovirus as long-term gene therapy vectors due to further 
reduced immunogenicity and high packaging capabilities. Gutless Ad vectors are devoid of all coding 
viral genes, containing only the inverted terminal repeat (ITR) cis elements and the packaging signal 
(Ψ) viral elements (Clemens et al. 1996, Chen et al. 1997). As a result, gutless Ads can accommodate 
up to 36 kb of non-viral DNA so that large cDNAs, longer tissue-specific or regulatable promoters, or 
several expression cassettes can be transferred (reviewed by (Volpers et al. 2004)). 
Adenoviral vectors have been used extensively for cancer gene therapy, as short-term gene expression 
is sufficient to mediate a therapeutic response. Clinical studies in humans using adenoviral vectors for 
GDEPT therapy has shown promising results for the treatment of various cancer types, including 
glioma (Sandmair et al. 2000, Immonen et al. 2004), prostate cancer (Shalev et al. 2000), melanoma 
(Morris et al. 2000) and ovarian cancers (Alvarez et al. 2000). 
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1.3.2.3. Adeno-associated virus biology and vector systems 
Human adeno-associated viruses (AAV) are a small collection of viruses, numbering 7 species (11 
serotypes) that belong to the genus of Dependovirus, within the family of Parvoviridae (Muzyczka et 
al. 2001). The classification of Dependovirus is due to the necessity for co-infection of unrelated 
helper viruses such as adenovirus (Hoggan et al. 1966) or herpesvirus (Conway et al. 1997) for 
productive infection. 
Parvoviruses are the smallest of the known human viruses, with a non-enveloped isosahedral capsid of 
22-26 nm in diameter. AAV has a ssDNA genome of approximately 4.7 kb that contains two open 
reading frames (ORFs) and ITR sequences flanking the genome. The two ORFs, rep and cap, encode 
the 7 AAV proteins, through the use of alternative promoters and differential splicing. Cap encodes 
the three viral capsid proteins (VP1, VP2 and VP3), rep encodes the four nonstructural proteins 
(Rep78, Rep 68, Rep 52 and Rep 40) necessary for transcription, replication, viral assembly, and site-
specific integration (Goncalves 2005). 
AAV serotype 2 is among the best characterised and utilised naturally occurring serotype isolated to 
date. AAV infection is initiated through binding to cell surface receptors and interaction with cell 
surface moieties. Different AAV serotypes are infectious in different cell types, depending on the 
availability of suitable high-affinity receptor molecules (Choi et al. 2005). In AAV-2, cap encoded 
VPs bind to heparan sulphate proteoglycans (Summerford et al. 1998, Kern et al. 2003), after which 
interactions with fibroblast growth factor receptor (FGFR) (Qing et al. 1999) or αvβ5 integrin 
(Summerford et al. 1999) facilitate coreceptor-dependent endocytosis. Following endocytosis, the 
virus is delivered to the endosomes, where low pH is required for viral escape and translocation to the 
nucleus (Bartlett et al. 2000). Once inside the nucleus, the presence or absence of a helper virus 
dictates whether AAV enters a lytic or latent life cycle. In the absence of helper functions, AAV 
enters a latent cycle and integrates at a site-specific locus known as AAVS1 on chromosome 19 
(Kotin et al. 1990, Samulski et al. 1991, Kotin et al. 1992). Site-specific integration requires cis 
components supplied by the ITRs and two viral encoded Rep proteins, Rep78 and Rep68 (Smith 
2008).  
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Figure 1.4. The adeno-associated virus genome.  
The AAV genome contains two open reading frames encoding four replication proteins (rep78, rep68, rep52 and 
rep40) and three structural proteins (VP1, VP2 and VP3) which are generated by alternative splicing. The 
replicative and structural genes are flanked by inverted terminal repeat sequences. 
 
1.3.2.4. Adeno-associated viral vectors 
AAV has several advantages as a potential viral vector. The absence of AAV-associated human 
disease reduces the safety concerns associated with other viral vectors. Furthermore, AAV vectors 
demonstrate long-term gene expression which can persist over several years.  
In the recombinant virus, rep and cap are replaced by therapeutic transgene cassettes in order to 
produce replication-defective virus with optimal transgene insertion capacity of between 4.1 and 4.9 
kb (Dong et al. 1996). Recombinant vectors are produced by transient cell transfections with a vector 
plasmid and an AAV helper plasmid. The excised structural and nonstructural proteins can be 
provided in trans by the helper plasmid which does not contain ITR sequences. In the vector plasmid, 
the therapeutic transgenes are flanked by the ITR cis elements which serve as an origin of replication 
(Samulski et al. 1987, Buning et al. 2008).  
Upon entry into the cell, the viral genome is converted to double-stranded transcriptionally active 
DNA which is predominantly expressed as a circularised non-integrated episomal form. The circular 
intermediates have a head-to-tail configuration consisting of monomer genomes which convert to 
multimers and may persist long-term (over 80 days) in muscle tissues (Duan et al. 1998). However, 
chromosomal integration of AAV genomes can occur (rarely), as the site-specificity is dictated by 
Rep78 and Rep68, these integrations are at random, and are associated with chromosomal deletions 
and rearrangements in transcriptionally active regions, which has raised some safety concerns over 
AAV vectors (Miller et al. 2002, Nakai et al. 2003).  
As with adenoviral vectors, one of the largest challenges facing AAV-mediated gene delivery is the 
host immune response. A large proportion of the population are seropositive for AAV-2, prior 
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infection with the parental virus therefore limits vector administration and transgene expression due to 
the presence of pre-existing neutralising antibodies to AAV vectors (Erles et al. 1999, Moskalenko et 
al. 2000, Scallan et al. 2006). Furthermore, it has been reported that AAV vectors are capable of 
inducing adaptive immune responses to the viral capsid (Manno et al. 2006, Madsen et al. 2009), as 
well as the transgene product (Siders et al. 2009). 
Although recombinant adenoviral vectors have been utilised for a majority of both preclinical and 
clinical trials in cancer gene therapy, studies in animal models have suggested therapeutic benefits for 
tumour treatment using AAV vectors (reviewed by (Li et al. 2005a). AAV-mediated anti-angiogenic 
gene therapy has been demonstrated in several in vivo studies by delivery of various transgenes, 
including those encoding angiostatin, endostatin, and soluble VEGF-R (Flk-1) (Davidoff et al. 2002, 
Lalani et al. 2004, Li et al. 2005b). GDEPT has also been achieved using AAV vectors, with tumour 
growth inhibition demonstrated in several in vivo models of human cancers, including human oral 
squamous cell carcinoma, glioma, sarcoma and bladder carcinoma (Mizuno et al. 1998, Fukui et al. 
2001, Veldwijk et al. 2004, Pan et al. 2012). Furthermore, cancer gene replacement is a viable 
strategy for AAV gene therapy as these vectors are capable of producing long-term gene expression in 
vivo. For example, tumour suppressor gene replacement therapy has been achieved using AAV 
vectors carrying the wild-type p53 gene or mapsin (Qazilbash et al. 1997, Watanabe et al. 2005) 
1.3.2.5. Retrovirus biology and vector systems 
Retroviridae comprise a large and diverse family of enveloped RNA viruses defined by structure, 
composition, and replicative properties (Coffin et al. 1997). The family is divided into two 
subfamilies; Orthoretrovirinae which contains 6 recognised genera (alpharetrovirus, betaretrovirus, 
deltaretrovirus, epsilonretrovirus, gammaretrovirus and lentivirus) and Spumaretrovirinae which 
contains one recognised genera (spumavirus).  
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Figure 1.5. Organisation of the retrovirus particle. 
A diagrammatic representation of the basic structure of a retrovirus. The two copies of the viral RNA genome 
and viral enzymes are protected by a protein coat (capsid) enclosed in a host-derived lipid membrane containing 
viral glycoproteins which mediate attachment to host cell receptors. 
 
Retroviruses are approximately 80-100 nm in size, and consist of a host-derived lipid envelope 
containing viral glycoproteins and surrounding a core of viral structural and replicative proteins and 
two copies of a single-stranded positive-sense RNA genome. The genome is approximately 7-12kb 
long, containing long terminal repeat (LTR) sequences which flank genome structures of varying 
complexities (Coffin et al. 1997). Both simple and complex retroviral genomes encode the essential 
genes gag (group-specific antigen), pro (protease), pol (polymerase), and env (envelope). Complex 
viruses encode multiple accessory proteins, for example, the lentivirus human immunodeficiency 
virus-1 (HIV-1) encodes tat, rev, nef, vif, vpr, and vpu genes, which have various functions in viral 
replication and persistence (Hu et al. 2000). 
During infection, viral glycoproteins interact with distinct target cell receptors, which differ among 
the major viral subgroups. The viral membrane then either fuses with the plasma membrane or is 
endocytosed, via interactions with surface (SU) envelope glycoprotein.  The viral core is subsequently 
released into the cytoplasm and viral RNA reverse transcribed into a DNA copy by the virally 
encoded enzyme reverse transcriptase, which is present within the virion. This DNA copy is 
integrated into the host genome by the virally encoded enzyme integrase. In its integrated form, the 
viral genome is known as the provirus. The integrated provirus is transcribed by host RNA 
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polymerase II to generate both spliced and full-length transcripts. The host translational machinery 
synthesises and modifies the viral proteins which assemble with full-length RNAs to form new 
viruses which bud out of the host cells (Coffin et al. 1997).  
 
 
Figure 1.6. Simple and complex retrovirus genomes.  
The proviral (DNA) form is shown. Oncoretroviruses (such as MLV) share similar organisation of gag, pol, and 
env genes with lentiviruses (such as HIV-1). The additional accessory proteins of lentiviruses, Tat, Rev, Nef, Vif, 
Vpr, and Vpu, are expressed from multiply spliced mRNA, and have various functions in regulation of viral 
gene expression and infectivity. The viral packaging element is denoted ψ. 
 
1.3.2.6. Retroviral vectors 
Many of the initial cancer gene therapy studies utilised retroviral vectors, and they remain the second 
most widely used vectors for gene therapy (Journal of Gene Medicine clinical trials database 2012, 
www.wiley.co.uk
As with other viral vector systems, it is not desirable to deliver a replication-competent retrovirus into 
a patient because the virus may spread beyond the targeted tissue and cause adverse pathogenic 
effects. Therefore, in most retroviral systems the viral components are divided into a vector and a 
helper construct to limit the ability of the virus to replicate in vivo (
). Retroviral vectors have several advantages as gene delivery vehicles, in that they 
are able to integrate and therefore establish long-term gene expression, and reduced immunogenicity 
compared to other viral vectors.  
Hu et al. 2000). Furthermore, 
deletion of replicative genes allows for a larger transgene packaging capacity, which is approximately 
8 kb.  
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Replication-defective retroviral vectors are engineered by insertion of the desired gene of interest and 
retention of cis-acting viral elements necessary for gene expression. These cis-acting elements include 
the viral LTRs which enable initiation of reverse transcription, proviral integration and transcription 
of the integrated provirus, and viral packaging is enabled by packaging sequences (ψ) in or near the 
LTR. Production of the vectors in mammalian culture systems requires the essential genes gag, pol, 
and env to be supplied in trans, which are expressed on one or more additional plasmid. These can be 
either provided in an integrated form in helper cell lines, or by cotransfection along with the vector 
plasmid. In order to prevent homologous recombination events resulting in production of replication-
competent viruses, helper cell lines frequently express the viral polyproteins from separate plasmids 
(i.e. the viral Gag/Gag-Pol polyproteins are expressed from one plasmid and the Env from a second). 
Following transfection of helper cell lines, the vector DNA is transcribed into RNA, and the packing 
signals present in the vector RNA allow recruitment of the polyproteins provided by the helper 
constructs, to produce the viral particles. These viral particles can infect target cells, reverse transcribe 
the vector RNA to form a double-stranded DNA copy, and integrate the DNA into the host genome to 
form a provirus. This provirus encodes the transgene(s) of interest and is expressed by the host cell 
machinery. However, as the vector does not express any viral proteins, it cannot generate infectious 
viral particles that can spread beyond the target cells (reviewed by (Hu et al. 2000). 
Initial studies utilised retroviral vectors based on the Moloney murine leukaemia virus (Mo-MLV), 
with transgene expression driven by the promoter/enhancer elements in the U3 region of the 5’ LTR, 
which is copied from the 3’ LTR upon reverse transcription (Mann et al. 1983). However, serious 
genotoxicity arising from integration and LTR-mediated transcriptional activation of proto-oncogenes 
has placed emphasis on the use of self-inactivating (SIN) retroviral vectors (Hacein-Bey-Abina et al. 
2008, Biasco et al. 2012). These vectors contain a deletion on the 3’ LTR, which inactivates the 
function of both enhancer and promoter (Yu et al. 1986). When the vector genome is reverse 
transcribed, this deletion is transferred to the 5’ LTR, which abolishes transcriptional activity of the 
integrated provirus. However, promoters internal to the LTRs remain capable of promoting expression 
of therapeutic genes. 
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The use of oncoretroviral vectors such as Mo-MLV is limited to certain cell types as these vectors 
cannot cross the nuclear membrane and are therefore unable to transduce non-dividing or quiescent 
cells (Miller et al. 1990). In order to overcome this limitation, vectors derived from lentiviruses (in 
particular HIV-1) were therefore developed, as these have the propensity to transfect both quiescent 
and dividing cells (Lewis et al. 1992, Naldini et al. 1996). As HIV-1 is a human pathogen, it is critical 
that lentiviral vectors based on this virus are replication-defective. SIN lentiviral vectors are therefore 
most widely utilised, with tat-independent expression driven by mammalian promoters, and non-
essential viral accessory genes (vpr, vpu, vif and nef ) omitted from  the vectors (Zufferey et al. 1997, 
Miyoshi et al. 1998, Zufferey et al. 1998).   
However, a limiting factor for the use of retroviral vectors is inefficient production of high viral titers. 
Researchers have therefore attempted to improve retroviral vector titres through various methods. 
Replacement of the U3 region of the 5’LTR with the mammalian cytomegalovirus (CMV) promoter 
has been shown to improve vector production. Furthermore, the use of packaging cell lines expressing 
other viral envelope glycoproteins, such as vesicular stomatitis virus glycoprotein (VSV-G) can 
improve both the range of target cell tropism and vector stability, allowing concentration to  higher 
titres (Burns et al. 1993, Yee et al. 1994). 
The ability of lentiviral vectors to transduce non-dividing cells has been exploited for cancer 
immunotherapy (reviewed by (Breckpot et al. 2007)). Dendritic cells transduced to express TAAs ex 
vivo have been evaluated for CTL activation and tumour immunotherapy following readministration 
in various in vivo cancer models (Firat et al. 2002, He et al. 2005, Wang et al. 2006). Furthermore, 
induction of specific CTL responses by targeted transduction of dendritic cells in vivo by lentiviruses 
encoding TAAs has been demonstrated in cancer models, including breast cancer (Kim et al. 2005) 
and melanoma (Dullaers et al. 2006). Retrovirally-mediated suicide gene therapy has also been 
demonstrated in preclinical studies, including those of sarcoma (Moolten et al. 1990), glioma 
(Ezzeddine et al. 1991, Ram et al. 1993), and gastric carcinoma (Yoshida et al. 1995), among others, 
and has been evaluated in several phase II and one phase III clinical trial (Journal of Gene Medicine 
clinical trials database 2012, www.wiley.co.uk).  
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1.3.2.7. Modification of viral vector tropism for cancer gene therapy 
In order for a viral gene therapy vector to be considered successful, sustained transgene delivery must 
be achieved in targeted tissues only and therefore with limited toxicity to non-targeted sites. Ablation 
of native viral tropism for off-target tissues is particularly necessary when attempting systemic gene 
therapy for disseminated diseases, such as metastatic cancers. As a substantial amount of research has 
been invested in the use of cytotoxic transgenes for tumour cell killing, it is therefore of particular 
importance to limit delivery of these genes to the tumour sites. Tissue-targeted gene expression may 
be achieved through either modification of viral vector tropism (also known as transductional 
targeting) or by limiting off-target gene expression by transcriptional control, or a combination of the 
two (reviewed by (Haviv et al. 2001, Waehler et al. 2007)).  
In transductional targeting, the interaction between the vector and the cell surface determines the 
efficiency of targeting. Pseudotyping was the first method used to alter viral vector tropism. This 
involves transferring viral attachment proteins either between strains within a family of viruses or 
between virus families and has been used extensively to pseudotype AAV and lentiviral vectors 
(Waehler et al. 2007).  Alternatively, viral tropism may be modified by the addition of tissue-specific 
peptide ligands or antibodies to capsid proteins in order to mediate a ligand-receptor interaction on the 
target tissue. A number of such ligands have been identified by in vivo Phage Display Technology, a 
screening method by which peptides homing to specific vascular beds or tissues can be identified 
(discussed in greater detail in section 1.4.1.2) 
Regulation of gene expression in target tissues may be achieved through transcriptional targeting, 
whereby the therapeutic gene is placed under the control of a tissue-specific promoter which is 
activated under certain intracellular conditions (Haviv et al. 2001). Alternatively, gene expression 
regulation can be achieved through incorporation of micro RNA targets into vector genomes. The 
virally encoded miRNA targeting elements can be recognised and regulated by endogenous cellular 
miRNAs, resulting in silencing of gene expression in off-target tissues such as the liver (reviewed by 
(Kelly et al. 2009)).  
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1.3.2.7.1. Regulation of viral vector-mediated gene expression 
Transcriptional targeting of viral vectors has been attempted using tissue-specific promoters to limit 
transgene expression to cancer cells (reviewed by (Haviv et al. 2001). Using this strategy, 
transcription of the gene of interest will be limited to occur under cellular conditions in which the 
tissue-specific promoter is activated. For cancer gene therapy, several tissue-specific promoters have 
been identified and utilised, including α-fetoprotein (AFP) and carcinoembryonic antigen (CEA) 
promoters for hepatomas (Richards et al. 1995, Kanai et al. 1997), cyclo-oxygenase-2 (Cox-2) for 
ovarian and gastric cancers (Casado et al. 2001, Yamamoto et al. 2001) and tyrosinase for melanomas 
(Vile et al. 1993). 
Additionally, temporal control of gene expression can be achieved through the use of inducible 
promoters which are activated in conditions which induce cellular stress, such as hypoxia, heat, 
glucose deprivation, antibiotics, irradiation, and chemotherapy (Haviv et al. 2001). Controlled 
transgene expression has been achieved using heat shock protein promoters, such as heat-shock 
protein 70 (HSP70) and glucose-regulated protein 78 kDa (GRP78), which are activated under a 
variety of environmental stresses, including heat, hypoxia, hypoglycaemia, and osmotic changes, 
many of which exist in poorly vascularised tumours (Gazit et al. 1995, Blackburn et al. 1998). 
Alternatively, promoters induced by chemotherapeutic agents, such as those of multi-drug resistance 
gene-1 (MDR-1) have been utilised to drive gene expression in tumours exposed to cytostatic drugs 
such as doxorubicin (Walther et al. 2000). 
Vector tropism may also be regulated through the use of micro RNA targeting elements to silence 
gene expression in off-target tissues. For example, transgene expression in APCs can lead to immune-
related vector clearance and therefore limit therapeutic efficacy. To overcome this issue, lentiviral 
vectors containing miRNA target sites complemenatary to miR-142-3p (which is highly expressed in 
immune cells) was shown to limit transgene expression to non-haemopoetic cells and result in 
transgene expression in target tissues (Brown et al. 2006). Similar approaches have been used to limit 
hepatotoxicity in adenovirus-mediated oncolytic virotherapy, through incorporation of miRNA 
targeting elements of liver-specific miRNA miR-22. In vivo studies demonstrated that these miRNA-
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restricted adenoviral vectors showed reduced viral replication in the liver and therefore limited liver 
toxicity (Cawood et al. 2009). Thus, by taking advantage of endogenous miRNA regulation, the 
expression of therapeutic transgenes can be regulated to minimise toxic off-target effects. 
However, the use of gene regulation strategies alone is limited as high titres of virus need to be 
injected in order to achieve efficient transgene expression in targeted cells, and immunogenic effects 
can arise from mislocalisation of vectors to normal tissues. Therefore, transcriptional targeting is often 
utilised in combination with transductional targeting. 
1.3.2.7.2. Transductional targeting of viral vectors 
Targeting viral vectors to the tumour site frequently requires ablation of the virus’ native tropism for 
off-target tissues. For example, it has been suggested that expression of CAR is a rate-limiting factor 
for cancer therapy using adenovirus-based vectors. Expression of CAR on human tumours is highly 
variable, and loss of CAR expression may be associated with malignant progression and tumour 
aggressiveness in some cancer types (Okegawa et al. 2001, Sachs et al. 2002). Therefore, efforts have 
been made to ablate adenovirus tropism for CAR, either by genetic or non-covalent modification of 
the viral vectors.  
Non-covalent modification of vector tropism may be achieved through the use of antibody-based 
strategies, including fusion of cell-targeting peptides or proteins to anti-fiber knob single-chain 
antibodies (scFv) or antigen-binding fragments (Fabs) (Nicklin et al. 2000, Trepel et al. 2000). 
Additionally, bifunctional peptides which include a fiber-binding moiety attached to a cell targeting 
motif (such as EGF) have also demonstrated improved tumour-targeting capabilities (Dmitriev et al. 
2000). 
Genetic modification of vector tropism can be achieved through pseudotyping adenoviral vectors by  
substitution of the Ad5 fiber knob domain with that of Ad3, which binds independently of CAR, 
resulting in improved  transgene delivery to tumour cells (Kanerva et al. 2002). Genetic modification 
of adenoviral vectors to ablate CAR tropism may also be achieved through either removing critical 
CAR/binding residues in the fiber knob domain or inserting sequences that ablate CAR binding and 
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facilitate association with alternative receptors (reviewed by (Tanaka et al. 2007)). Peptide sequences 
may be inserted into the HI loop or c-terminal of the adenovirus fiber, without affecting viral particle 
stability. Improvement of CAR-independent  targeting of adenoviral vectors was demonstrated by 
addition of charged polylysine (pK7) motifs which facilitate binding to heparan sulfate proteoglycans 
present on various cell types (Wickham et al. 1996, Staba et al. 2000). However, this retargeting 
strategy does not limit transduction to cancer cells alone. Adenoviral retargeting to tumour cells by 
incorporation of the integrin-binding RGD sequence into fiber has been therefore extensively studied 
(Dmitriev et al. 1998, Staba et al. 2000, Koizumi et al. 2001, Nakamura et al. 2002, Dehari et al. 
2003).  
Similar approaches have been utilised for the modification of retroviral and adeno-associated viral 
vectors. The broad tissue tropism of AAV-2 limits effectiveness in cancer gene therapy. In order to 
overcome this limitation, the tumour-targeting ligand NGR (which binds CD13, a receptor present on 
angiogenic vasculature), identified by phage display, was incorporated into the AAV-2 capsid and 
demonstrated improved cancer cell targeting properties over the wild-type vector (Grifman et al. 
2001). Similarly, inclusion of RGD-containing peptides in the AAV-2 VP3 capsid protein has enabled 
transduction of integrin-expressing cells independently of heparin receptor binding and led to 
increased transduction in tumour cell lines which express integrin, but few heparin-binding receptors 
(Shi et al. 2003). 
However, transductional targeting strategies for eukaryotic virus modification are not without 
problems. In some cases, addition of targeting ligands to eukaryotic viruses can alter the structure of 
the viral capsid and diminish targeting properties of the peptides themselves. Insertion of targeting 
ligands into the glycoproteins of enveloped viruses has been reported to block virus-cell fusion and 
therefore inhibit gene transfer (Zhao et al. 1999). For example, initial attempts to modify retroviral 
vectors by creating N-terminal fusions of the Mo-MLV env with single-chain antibody molecules 
(scFv) resulted in low viral titers and poor transduction efficiencies, despite cell surface binding, 
presumably due to alteration or masking of the surface (SU) glycoprotein by the scFv molecule 
(Cosset et al. 1995, Valsesia-Wittmann et al. 1996).  
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1.4. Prokaryotic viral gene delivery systems 
1.4.1. Bacteriophage  
Recently the prokaryotic virus bacteriophage (phage) has been utilised as a gene delivery vehicle. 
Bacteriophage-based vectors have some potential advantages over eukaryotic viruses for delivery of 
transgenes to mammalian cells. Bacteriophage has no intrinsic tropism for mammalian cell receptors 
but can be modified to display tissue-specific ligands on the capsidic proteins without disruption of 
virus structure. Additionally, bacteriophage have a large gene packaging capacity, beyond the 
limitations of eukaryotic viral vectors such as adenovirus, AAV, and lentiviruses.  
1.4.1.1. The discovery of bacteriophage and phage therapy 
Bacteriophage are a diverse family of viruses that have evolved to replicate in bacteria. They are 
amongst the most common and diverse entities in the biosphere, with the number of phage species in 
nature estimated at several 100,000 to millions (Rohwer 2003). Phage are classified by the 
International Committee on Taxonomy of Viruses (ICTV) according to morphology and genome. 
Phage may have double-stranded or single-stranded DNA or RNA genomes, with a circular or linear 
arrangement. The particles may be tailed or polyhedral, filamentous or pleomorphic. During bacterial 
infection, they may either incorporate viral DNA into the host genome and replicate as part of the host 
(lysogeny), or multiply inside the host cell before releasing phage particles either by budding from the 
membrane or by actively lysing the cell. 
The potential use of bacteriophage as a therapeutic was discovered in the early 20th century. The 
discovery of bacteriophage remains controversial, as it has been attributed to both by Frederick Twort 
(in 1915), and by Felix d’Herelle (1917) (reviewed by (Duckworth 1976). However, D’Herelle was 
the first to pioneer the use of phage therapy to treat bacterial infections. The first human study was 
performed in 1919, where type-specific phage were used against  Shigella dysenteriae to treat infected 
children suffering from diarrhoea (reviewed by (Summers 2001)). Bacteriophage therapy has since 
demonstrated efficacy in treating numerous bacterial infections in humans without serious side-effect 
(reviewed by (Sulakvelidze et al. 2001)). However, following the advent and application of antibiotics 
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in the 1930s and 1940s, clinical studies with bacteriophage declined in the United States and Western 
Europe.  Phage have continued to be utilized in the former Soviet Union and Eastern Europe 
(Sulakvelidze et al. 2001). Recently there has been resurgence in interest in phage therapy with the 
emergence of pathogenic bacterial strains resistant to most currently available antimicrobial agents. 
Phage have also recently been approved by the Food and Drug Administration of the United States 
(USFDA) as an antibacterial food additive.   
1.4.1.2. Phage display 
Further to interest in bacteriophage for their antibiotic potency, they have been important tools for 
biotechnology. ‘Phage display’ technology was first described in 1985 by George Smith, who 
demonstrated that peptides could be displayed on the surface of bacteriophage particle through 
transcriptional fusion with a coat-protein gene (Smith 1985). Subsequently, phage display technology 
was further developed as a powerful method of identification of peptides and proteins capable of 
binding antibodies, cellular receptors and other biological molecules (reviewed in (Carlos F. Barbas et 
al. 2004)). Various phage have been used for phage display purposes, including lambda (Sternberg et 
al. 1995), T4 (Malys et al. 2002) and T7 (Rosenberg et al. 1996), however systems based on M13 and 
related filamentous phages of Escherichia coli (Smith et al. 1993) remain the most widely utilised. 
The filamentous phage (genus Inovirus) are a group of viruses that contain a circular single-stranded 
DNA genome encased in a long protein capsid cylinder. The Ff class of filamentous phage (f1, fd and 
M13) have been most extensively studied. The Ff phages are non-lytic, and infect E. coli harbouring 
the F plasmid. The capsid proteins are synthesised as integral membrane-proteins that assemble as a 
cylinder around the 6.4 kb phage genome as it extrudes from the bacterial host. Of note, this process 
continues until the end of the circular DNA genome is reached, so there is little constraint on the size 
of DNA packaged. The wild-type virus structure consists of approximately 2,700 copies of the major 
coat protein pVIII, and at the ends of the phage particle there are five copies each of the gene products 
of genes 3, 6, 7 and 9 (pIII, pVI, pVII, and pIX). The remaining five genes are necessary for DNA 
replication and assembly of the phage coat proteins (reviewed by (Carlos F. Barbas et al. 2004)). 
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In-frame splicing of foreign oligonucleotides into genes encoding coat proteins results in the 
expression of the foreign amino acids as part of the corresponding coat protein, creating a hybrid 
fusion protein displayed on the surface of the phage particles. Large libraries of different peptides and 
antibodies have been made using the minor coat protein pIII as the display vehicle (Smith et al. 1993, 
Winter et al. 1994). Peptides and proteins have also been fused to the amino-terminal portion of the 
major capsid protein pVIII (Iannolo et al. 1995, Malik et al. 1996), but also to the amino terminus of 
the pVII and pIX (Gao et al. 1999). The size of the foreign peptide displayed on every copy of the 
chosen coat protein limits the use of phage display as larger peptides interfere with the coat protein 
function in viral packaging and bacterial infectivity. This is particularly relevant to display on the 
major capsid protein pVIII, which can only accommodate short peptides of 6-8 amino acids in length 
(Iannolo et al. 1995). The pIII capsid protein has therefore been most extensively used for phage 
display, as larger peptide inserts are tolerated in the pIII (Carlos F. Barbas et al. 2004). 
Phage displayed peptide libraries contain between 107-1011 recombinants, and are screened through in 
vitro and/or in vivo ‘biopanning’ which allows for enrichment of phage which bind with high affinity 
to interacting partners. A schematic representation of the basic steps of phage display are shown in 
figure 1.7. Initial phage libraries were screened by biopanning against purified protein or antibodies 
bound to a solid phase in vitro (Smith et al. 1993). Subsequently, the use of phage display in vivo 
demonstrated that phage binding to specific organs could be isolated and enriched following 
subsequent rounds of administration (Pasqualini et al. 1996). Phage-display has also been used to 
study the biodistribution of vascular markers in man, demonstrating that differential expression of 
cell-surface proteins on the vascular endothelium defines the vascular ‘address’ of different tissues 
(Arap et al. 2002b). Importantly, in vivo phage display was used to show that tumour vascular 
endothelium expresses protein markers that are absent or expressed at low levels in normal tissues. 
This has allowed the identification of numerous tumour-specific ligands which can target therapeutic 
agents to receptors expressed on the tumour vasculature following systemic administration. 
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Figure 1.7. Phage display technology. 
A heterologous mixture of recombinant phage (in this example, filamentous phage displaying peptides on the 
pIII minor coat protein) are administered either in vitro or in vivo. The phage which bind to proteins (such as 
receptors) with high affinity are isolated and propagated in E.Coli before subsequent rounds of administration 
and enrichment. The genomes of the enriched phage clones are subsequently sequenced for identification of the 
tissue-specific ligands. 
 
1.4.1.3. Phage display applications in cancer therapy 
The peptides and antibodies selected from phage display libraries can target biologically relevant sites 
on the surface of target proteins (enzyme inhibitors, receptor agonists and antagonists) and therefore 
may interfere with the activity of the target protein (reviewed by (Molek et al. 2011)). These have 
been of importance for anti-cancer drug discovery and design through screening for receptor agonists 
and antagonists. Peptides and antibodies identified through phage display have been used as cancer 
therapies, for example, through blocking binding of ligands such as angiogenic growth factors to their 
receptors (such as VEGF, FGF, and insulin-like growth factor, IGF) (Binetruy-Tournaire et al. 2000, 
Burtrum et al. 2003, El-Mousawi et al. 2003, Martinez-Torrecuadrada et al. 2005)  or cell adhesion 
molecules (such as αv integrins) (Brooks et al. 1994b). 
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Furthermore, tumour-specific peptides and antibodies identified by phage display have been directly 
conjugated to  cytostatic drugs (Arap et al. 1998), pro-apoptotic agents (Ellerby et al. 1999, Arap et 
al. 2002a), cytokines (Curnis et al. 2000), and superantigens (Tordsson et al. 2000). This approach 
has demonstrated improved tumour-targeting of the conjugated molecules, increasing efficacy and 
limiting toxicity to normal tissues.  
Recently, phage capsid proteins displaying tumour-targeted peptides have been incorporated into 
doxorubicin-loaded PEGylated liposomes for enhanced tumour-targeting (Jayanna et al. 2010, Wang 
et al. 2010). Phage particles may also be used as nanomedicine platforms for delivery of toxic agents. 
For example, growth inhibition of cancer cells has been demonstrated following administration of a 
tumour-targeted filamentous phage carrying chemically conjugated cytotoxic drug doxorubicin in 
vitro (Bar et al. 2008). 
Peptides identified by phage display have also been incorporated into the capsid proteins of 
eukaryotic viral vectors to enhance tumour-targeting specificities (Grifman et al. 2001).  However, as 
previously stated, inclusion of such peptides has the potential to alter the structure of eukaryotic viral 
capsids and affect the targeting attributes of the ligand, or prevent transduction by the viral particles. 
Bacteriophage themselves have been proposed as gene delivery agents, the potential advantage of this 
is that targeting ligands are selected in the context of the phage capsid, and therefore do not suffer the 
problem of capsid modification rendering the particles non-viable. 
One limiting factor in the use of bacteriophage for in vivo gene therapies is recognition by the immune 
system. Phage are highly immunogenic and are capable of inducing both humoural and cellular 
immune responses to naïve phage capsid proteins and phage DNA (Mori et al. 1996, Fogelman et al. 
2000, Eriksson et al. 2007). Systemically-administered unmodified phage are rapidly eliminated by 
the reticulo-endothelial system, with significant degradation of particles occurring in the lungs, liver 
and spleen (Molenaar et al. 2002). However, surface display of tissue-specific internalising peptides 
allows rapid uptake in targeted tissues following intravenous administration (Molenaar et al. 2002). 
Furthermore, despite the potent immunogenicity of bacteriophage, high titres have been delivered to 
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animals and humans without significant adverse effect (Sulakvelidze et al. 2001, Krag et al. 2002). 
Phage are thus considered to be safe candidates in the development of gene delivery agents.  
1.4.1.4. Bacteriophage as gene delivery vehicles 
Bacteriophage-derived vectors have some potential advantages over eukaryotic viruses for delivery of 
transgenes to mammalian cells. As previously described, bacteriophage has no intrinsic tropism for 
mammalian cell receptors but can be modified to display tissue-specific ligands on the capsidic 
proteins without disruption of virus structure. Additionally, bacteriophage have a large gene 
packaging capacity beyond the limitations of eukaryotic viral vectors such as adenovirus, AAV, and 
lentiviruses. Lambda phage is capable of holding 53 kb (Chauthaiwale et al. 1992), while M13 phage 
theoretically has an almost unlimited packaging capacity (Carlos F. Barbas et al. 2004). Moreover, the 
production of phage vectors is simple and cost-effective; they are easily produced at high titres in 
E.Coli and can be purified at large scale. 
In addition to their use for identifying tumour-specific peptides and antibodies, phage display systems 
have been adapted to promote ligand-receptor binding which leads internalisation of the phage 
particles. Hart and colleagues demonstrated that filamentous phage displaying RGD ligands could 
internalise in mammalian cells through integrin receptor-mediated endocytosis (Hart et al. 1994). 
Subsequently Barry and colleagues demonstrated that peptides that promote internalisation could be 
selected from display libraries following lysis of cells and recovery of intracellular phage clones 
(Barry et al. 1996). In a similar manner, it was demonstrated that internalising peptides or antibodies 
could be identified from libraries displayed on the filamentous phage pVIII (Ivanenkov et al. 1999b, 
Poul et al. 2000). 
Gene delivery by phage vectors bearing internalising ligands was demonstrated following insertion of 
reporter genes (such as green fluorescent protein, luciferase, or β-galactosidase), under the control of 
viral promoters which drive transgene expression in mammalian cells (such as that of 
Cytomegalovirus, CMV). In 1996, Dunn was the first to describe gene transfer in mammalian cells 
mediated by a genetically targeted bacteriophage lambda (Dunn 1996). In this study, the phage was 
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modified to display an integrin-binding RGD peptide fused to the lambda major tail protein and a 
mammalian promoter driving the expression of β-galactosidase. The modified lambda vectors were 
capable of transducing COS-1 cells while unmodified phage showed no activity. In 1998, Larroca and 
colleagues demonstrated that filamentous bacteriophage-mediated gene delivery could occur 
following targeting of biotinylated phage via streptavidin and biotinylated FGF, EGF or transferrin to 
mammalian cells expressing the receptors (Larocca et al. 1998). The authors subsequently 
demonstrated that genetically modified filamentous phage displaying FGF as a fusion with the minor 
coat protein pIII were capable of transducing COS-1 cells, albeit at low efficiency (Larocca et al. 
1999). Using a similar approach, Poul and co-workers demonstrated that filamentous phage 
displaying scFv capable of binding the ErbB2 growth factor receptor were able to undergo receptor-
mediated endocytosis and achieve up to 4% transgene expression efficiency in cells overexpressing 
the receptor (Poul et al. 1999).  
Since these initial reports, several groups have attempted to improve bacteriophage-mediated gene 
transfer by display of virally-derived motifs with functions in cell entry (such as HIV tat protein, or 
adenovirus penton base) (Di Giovine et al. 2001, Eguchi et al. 2001) or in post-entry events, such as 
nuclear localisation  (Akuta et al. 2002).  
In an attempt to increase phage-mediated transgene expression in mammalian cells, Hajitou and 
colleagues took an alternative approach to modification of bacteriophage vectors.  The authors 
reported the generation of hybrid prokaryotic-eukaryotic viral vectors termed AAVP or AAV/phage, 
which was generated as a chimera between AAV and M13 filamentous bacteriophage (Hajitou et al. 
2006).  
1.4.2. Adeno-Associated Virus/Phage (AAVP) 
In the targeted AAVP prototype vector, a mammalian transgene cassette under the control of a CMV 
promoter and flanked by ITRs from AAV serotype 2, was inserted into an intergenomic region of an 
RGD-fUSE5 bacteriophage clone displaying a double-cyclic RGD ligand (CDCRGDCFC) on the 
minor pIII coat protein (Hajitou et al. 2006, Hajitou et al. 2007). This double-cyclic RGD peptide was 
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identified as a targeting motif for αvβ3 and αvβ5 integrins which are overexpressed in tumour vascular 
endothelium and tumour cells but absent or expressed at very low levels in normal endothelial cells 
(Ruoslahti 1996, Pasqualini et al. 1997). A schematic representation of the targeted AAVP vector is 
shown in Figure 1.8. 
 
 
 
Figure 1.8. Organisation of the targeted AAVP particle. 
The targeted AAVP vector displays double-cyclic RGD peptides on the minor pIII coat proteins and contains a 
mammalian transgene cassette flanked by ITRs of AAV serotype 2. 
 
The introduction of AAV ITRs into the phage vector resulted in increased transduction efficiency 
over conventional phage-based vectors. The authors reported that improved mammalian transduction 
efficiency was associated with improved fate of the delivered transgene, maintenance of the entire 
mammalian transgene cassette, better persistence of episomal DNA and formation of concatamers of 
the transgene cassette (Hajitou et al. 2006). The vector was shown to be tissue-specific; AAVP-
mediated expression of reporter transgenes was observed in αv integrin-expressing mammalian cells 
treated with targeted AAVP (RGD-AAVP) only, while non-targeted or AAVP bearing 
scrambled/mutated ligands were unable to bind nor transduce these cells in vitro (Hajitou et al. 2006). 
The therapeutic efficacy of RGD-AAVP vector was evaluated using GDEPT therapy by delivery of 
HSVtk gene in combination with the prodrug GCV to in vivo models of cancer. Systemic delivery of 
RGD- AAVP-HSVtk to immunodeficient mice bearing human Karposi’s sarcoma (KS1767) cell-
derived tumours resulted in marked tumour growth suppression compared to non-targeted AAVP 
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following a single intravenous dose. Similarly, tumour growth suppression was observed in nude mice 
bearing DU145-derived prostate carcinomas and immunocompetant BALB/c mice bearing 
subcutaneous EF43-FGF4 mammary tumours (Hajitou et al. 2006). The RGD-AAVP-HSVtk vector 
was also administered to athymic rats bearing human soft tissue sarcoma, and histopathologic analysis 
seven days after therapy showed extensive destruction of the tumours, associated with disruption and 
apoptosis of tumour blood vessels (Hajitou et al. 2008). Biodistribution of the targeted RGD-AAVP 
was monitored using in vivo bioluminescence imaging of luciferase reporter gene expression and 
Positron Emission Tomography (PET) imaging of HSVtk and [18F]-FEAU in in vivo models of 
prostate carcinoma in nude mice (Hajitou et al. 2006) and human soft tissue-sarcoma in athymic rats 
(Hajitou et al. 2008). The results revealed a specific tumour expression of the luciferase and HSVtk 
imaging transgenes. Interestingly, despite non-specific hepatic clearance of phage particles, no 
expression was observed in the liver or other non-targeted control organs (Hajitou et al. 2006, Hajitou 
et al. 2008). Furthermore, multiple rounds of high titre administration of RGD-AAVP-HSVtk were 
well-tolerated and consistently inhibited tumour growth in immunocompetant mice, despite the 
presence of circulating anti-phage IgG, leading to the suggestion that immune response to the 
bacteriophage vector does not neutralise tumour-targeting efficiency (Hajitou et al. 2006). 
Further to these experiments, researchers at the National Cancer Institute have recently used the 
cancer-targeting properties of RGD-AAVP to deliver the anti-vascular agent Tumour Necrosis Factor 
α (TNFα) to mice bearing melanoma, and to pet dogs with spontaneous cancers. Systemic 
administration showed tumour-specific TNFα expression leading to induction of apoptosis in tumour 
blood vessels and significant inhibition of tumour growth without systemic toxicity to control organs 
(Paoloni et al. 2009, Tandle et al. 2009). 
Given the estimates that up of 100 tumour cells are sustained by a single endothelial cell (Folkman 
1997), gene targeting of angiogenic vasculature often leads to enhanced therapeutic efficacy in vivo. 
Moreover, AAVP was recently shown to mediate tumour cell killing in vitro and in vivo via a 
heterotypic bystander effect between HSVtk-transduced endothelial cells and non-transduced tumour 
cells (Trepel et al. 2009).  The bystander effect, combined with vascular targeting, resulted in 
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significant tumour regression and therefore reduced the need for high numbers of cells to be 
transduced in order to mediate a therapeutic effect. 
1.4.2.1. Barriers to transduction by AAVP 
Despite the apparent success of AAVP in several in vivo cancer models, high titres are required for 
transduction of large numbers of mammalian cells. The process of transgene delivery is presumably 
inefficient because bacteriophage are prokaryotic viruses that have not undergone the evolutionary 
adaptations necessary for transduction of mammalian cells. Inclusion of AAV-2 derived ITRs into the 
genome of the AAVP vector has improved transgene expression over conventional phage-based 
vectors, but reporter gene expression remains low compared to eukaryotic virus-derived vectors 
(Hajitou et al. 2006, Hajitou et al. 2007). In vitro experiments have shown that 100% of cells 
internalise AAVP but only up to 10% express the transgene (Hajitou et al. 2006, Hajitou et al. 2007). 
Understanding the primary steps of entry can have important implications for determining parameters 
for efficient gene delivery of these vectors. It is well established that overall efficiency of transduction 
by receptor-mediated gene transfer is dependent on success of  overcoming three hurdles; 1) 
endocytosis by receptor-ligand targeting, 2) endosomal escape and 3) nuclear localisation (Martin et 
al. 2007). Thus, the plasma membrane presents the first barrier that needs to be circumvented in order 
to deliver transgenes to targeted cells. Eukaryotic viruses are able to bypass this barrier through either 
direct fusion at the plasma membrane or through manipulation of the cell’s endocytic pathways. 
Following endocytosis, mammalian viruses have developed several mechanisms of escaping the cell’s 
degradative pathways in order to access the cytoplasm and subsequently traffic to the nucleus, if 
necessary for replication.  
1.5. Endocytic pathways utilised by eukaryotic viruses 
Cells utilise a number of cell-type and cargo-specific mechanisms for internalisation of extracellular 
particles and solutes which are collectively known as endocytosis. Eukaryotic cell endocytosis is 
driven by vesicle formation at the plasma membrane and serves to sample the extracellular 
environment and regulate the composition of the plasma membrane and activity of cell-surface 
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receptors (Gruenberg 2001). Numerous pathogens have evolved to exploit endocytosis to gain entry 
into host cells for exertion of infectious or toxic activity. There are several biochemically and 
morphologically distinct endocytic pathways utilised by pathogens, including clathrin-mediated 
endocytosis (CME), caveolae formation, macropinocytosis, and non-clathrin, non-caveolae pathways 
(Sieczkarski et al. 2002a). The major routes of viral uptake are summarised in Figure 1.9. 
 
 
 
Figure 1.9. The major endocytic pathways utilised by viruses in mammalian cells. 
Viruses can utilise various cell-type and cargo-specific mechanisms for gaining access to the cell. These include 
clathrin- and caveolae-mediated endocytosis and macropinocytosis. Following entry, vesicle fusion and 
trafficking is coordinated by Rab GTPases (shown in yellow) and various effector proteins are acquired as the 
vesicles mature (shown in orange). Cargo destined for degradation is sorted into multivesicular bodies (MVB) 
or late endosomes prior to hetertotypic fusion with the lysosomes. Viruses have developed several strategies to 
escape the degradative pathway, which are activated by the low pH environment of the early endosomes or late 
endosomes, and allow viral partial uncoating and access to the cytoplasm. Figure derived from (Wieffer et al. 
2009, McMahon et al. 2011). 
52
1.5.1. Clathrin-dependent endocytosis 
Clathrin-coated vesicles (CCVs) were the first membrane protein transport vesicles for to be identified 
and have consequently been the most heavily studied mechanism of endocytosis (Roth et al. 1964, 
Brodsky et al. 2001). Clathrin-mediated endocytosis occurs in all known eukaryotic cells, and 
functions as a route of endocytosis for a variety of different cargoes, including viruses (reviewed by 
(McMahon et al. 2011)). Several viral species have been reported to use clathrin-dependent pathways 
to gain entry into eukaryotic cells, including semliki forest virus (SFV) (Helenius et al. 1980), HIV-1 
(Daecke et al. 2005) and several adenovirus serotypes (Chardonnet et al. 1970, Meier et al. 2002), to 
name a few. 
Clathrin-mediated endocytosis of cargo receptors can be either stimulated by ligand binding, while 
other receptors may be constitutively internalised (Hopkins et al. 1985). During endocytosis, a protein 
coat is assembled at the cytoplasmic face of the plasma membrane, which induces formation of an 
invagination termed a clathrin-coated pit (CCP) which matures to form a mature coated pit, and 
eventually buds away from the plasma membrane as a clathrin-coated vesicle (CCV). This coat is 
formed of clathrin polymers and several associated adaptor and accessory proteins. The adaptor and 
accessory proteins coordinate clathrin localisation to sites of the plasma membrane destined for 
internalisation. The main adaptor protein functioning to recruit clathrin is the adaptor protein (AP)-2 
complex, although several other proteins are involved in linking clathrin to the plasma membrane. 
The established model of AP-2-dependent clathrin-mediated endocytosis proceeds as follows. 
Initiation of clathrin-coated pit formation begins with recruitment of AP-2 to the cytosolic face of the 
plasma membrane (Brodsky et al. 2001). AP-2 is considered to be the central hub of protein-protein 
interactions that regulates recruitment of clathrin to cargo sites and invagination and budding of the 
CCP. AP-2 is a heterotetrameric protein complex containing two large (~100 kDa) α- and β2 subunits, 
and smaller (50KDa) µ2-, and (17KDa) σ2- subunits (Matsui et al. 1990). The α-subunit of AP-2 has 
high affinity for phosphatidylinositol-4,5-bisphosphate (PI4,5P2) which is localised to distinct regions 
of the plasma membrane (Honing et al. 2005). This association is further enhanced by 
phosphorylation of the μ2 subunit of AP2, which promotes PI4,5P2 binding to a distinct site on μ2-
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subunit (Rohde et al. 2002). Recruitment of AP-2 to the plasma membrane also requires recognition 
of sorting motifs encoded in the cytoplasmic termini of cargo molecules by the µ2- and σ2- subunits. 
AP-2 can also interact indirectly with cargo displaying alternative sequence motifs using appendage 
domains to bind accessory proteins termed clathrin-associated sorting proteins (CLASPs) which 
recognise these sequences. Various accessory proteins are involved in this process and may bind AP-
2, clathrin, or both, and frequently associate with phosphoinositides at the plasma membrane (Owen et 
al. 2004). 
Clathrin monomers are recruited to sites of AP-2 concentration at the plasma membrane through 
interaction with the β-propeller domain on the ends of the clathrin triskelia with the β2-subunit of AP-
2. Clathrin triskelia polymerise to form a lattice structure and stabilise the curvature of the pit which 
then invaginates from the plasma membrane. Vesicle budding is facilitated by actin, which is 
recruited by the actin-nucleating complex actin-related protein 2/3 (ARP2/3) to the budding vesicle. 
This can be mediated by cortactin or by neural Wiskott–Aldrich syndrome protein (N-WASP), which 
is recruited by the SH3 domains of Bin–Amphiphysin–Rvs (BAR) domain-containing proteins 
(Merrifield et al. 2004, Ferguson et al. 2009). The large GTPase dynamin is coincidentally recruited 
to the neck of the budding vesicle by cortactin and BAR domain-containing proteins and polymerises 
to form a ring structure which mediates fission of the CCV from the plasma membrane through a GTP 
hydrolysis-dependent step (Hinshaw et al. 1995, Ferguson et al. 2012). Following detachment from 
the plasma membrane, the clathrin coat is disassembled from its lattice arrangement back to triskelia 
by the ATPase heat shock cognate 70 (Hsc70) and auxilin (Schlossman et al. 1984, Ungewickell et al. 
1995). Uncoating of AP-2 from the vesicle is coordinated by the GTPase ras-associated binding (Rab) 
protein 5 and its associated guanine nucleotide exchange factors (GEFs) by promoting 
dephosphorylation of the µ2- subunit and dissociation from PI4,5P2 (Semerdjieva et al. 2008). Rab5 
then mediates uncoated vesicle fusion with early endosomes (EEs). 
1.5.1.1. Cargo selection in clathrin-mediated endocytosis 
Cargo selection in clathrin-mediated endocytosis is mediated by direct interactions of AP-2 with the 
cytoplasmic termini of receptors, or indirectly through association with CLASPs. The AP-2 
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interactome is summarised in Figure 1.10.  The AP-2 µ2- subunits recognise the sequence motif 
YXXφ (where X is any amino acid, φ stands for a hydrophobic residue), and σ2- subunits interact 
with dileucine motifs (LL) in the cytoplasmic tails of transmembrane receptors (Ohno et al. 1995, 
Kelly et al. 2008). The affinity of AP-2 for these sorting motifs is regulated by cycles of 
phosphorylation and dephosphorylation of the subunits. The binding of AP-2 µ2-subunit to the YXXφ 
sorting signals is controlled by phosphorylation status of the subunit which is closed in its 
dephosphorylated state. Phosphorylation of the µ2-subunit residue Thr156 by Adaptor-Associated 
Kinase 1 (AAK-1) shifts the protein to an open conformation which allows AP-2 binding to the cargo 
sorting motif (Conner et al. 2002, Ricotta et al. 2002). Binding of the σ2- subunit to di-leucine 
requires the displacement of the β2 subunit (which may occur through phophorylation of the Tyr6 
residue), which blocks the binding sites of σ2-subunit in the inactive AP-2 form (Kelly et al. 2008). 
 
 
Figure 1.10. The AP-2/clathrin interactome.  
Clathrin-mediated endocytosis is initiated by PI(4,5)P2 and cargo-dependent recruitment of AP-2 to the plasma 
membrane. The heterotetrameric AP-2 complex links various cargo to the clathrin coat, accessory proteins, and 
other adaptors. CLASPs are highlighted in purple. Proteins which function in uncoating are shown in green. 
Adapted from (Wieffer et al. 2009). 
 
AP-2 can also interact indirectly with cargo displaying alternative sequence motifs using appendage 
domains to bind CLASPs. These interactions are complex, and different cargos can use various 
alternative adaptor and accessory proteins for endocytosis (Schmid et al. 2007). It has been suggested 
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that CLASPs may mediate clathrin endocytosis in the absence of AP-2, however this is controversial 
(Boucrot et al. 2010, McMahon et al. 2011). Examples of these accessory proteins include adaptor 
protein 180 (AP180), EGF receptor pathway substrate 15 (Eps15) and arrestins (for review see (Traub 
2009). These CLASPs recognise signal motifs such as the [FY]XNPX[YF] or NPX[YF] (e.g. on the β 
chain of some integrins) through phosphoTyr-binding (PTB) domains. Alternatively, post-
translational modification of transmembrane receptors, such as ubiquitination is recognised by others 
(Traub 2009).  Furthermore, these accessory proteins may participate in CME by aiding membrane 
curvature as well as scaffolding functions (Doherty et al. 2009). One example is Eps15, which 
contains a C-terminal AP-2 binding domain (Iannolo et al. 1997) and N-terminal region with Eps15 
Homology (EH) domains which interact with Aspartate-Proline-Phenylalanine (NPF) motifs on Epsin, 
AP180 and synaptojanin. During internalisation of EGFR, the ubiquitin-interaction motif (UIM) on 
Eps15 binds to ubiquitinated intracellular domains of EGFR (following activation of the receptor), 
recruiting it to the forming coated pit. Eps15 also provides scaffolding function by binding to and 
thereby stabilising AP-2 at the plasma membrane and through EH-domain binding to other accessory 
proteins which in turn may bind clathrin (van Bergen En Henegouwen 2009). Inhibition of Eps15 
function through microinjection of Eps15 antibodies, or mutation of Eps15 EH domains, arrests 
clathrin-mediated endocytosis of epidermal growth factor receptor (EGFR) and transferrin (Carbone 
et al. 1997, Benmerah et al. 1999). AP-2 complexes do not self-polymerise and so concentration and 
stabilisation of adaptor protein complexes requires recruitment of such binding partners.  
1.5.2. Clathrin-independent endocytosis 
1.5.2.1. Caveolae/lipid raft-mediated endocytosis 
While clathrin-mediated endocytosis has been extensively studied, the lesser-characterised clathrin-
independent mechanisms of entry are gaining increasing attention. These include lipid raft/caveolae 
and macropinocytosis, although other non-clathrin, non-caveolar pathways have been described. 
Caveolae are small (50-80nm), flask-shaped plasma membrane invaginations found in several cell 
types. Caveolae have a filamentous protein coat composed primarily of caveolin-1 (Rothberg et al. 
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1992). Caveolae are subdomains of glycolipid rafts which are enriched in glycosphingolipids (for 
example GM1) and cholesterol. However, their morphology and association with caveolin expression 
means that their internalisation is considered different from that of lipid rafts (Rothberg et al. 1992, 
Kurzchalia et al. 1999).  There are three mammalian caveolin proteins, caveolin-3 is found in muscle 
cells only, while caveolin-1 and -2 are expressed on several cell types. Interestingly, overexpression 
of caveolin-1 in normally deficient cell lines is sufficient to induce formation of caveolae-like 
structures (Lipardi et al. 1998). Caveolin-mediated caveolae formation involves oligomerisation of 
caveolins and binding to cholesterol associated with lipid rafts. Caveolae are not constituitively 
endocytosed, and are maintained as stable and highly immobile structures at the plasma membrane by 
the cortical actin cytoskeleton unless induced to internalise following specific signalling events 
(Thomsen et al. 2002). Caveolin-1 appears to be a negative regulator of caveolae/lipid raft dependent 
endocytosis (Le et al. 2002). This has led to the suggestion that caveolin-1 functions to stabilise 
plasma membrane association of invaginated rafts and retard their detachment. 
Caveolae and raft pathways have been implicated in endocytosis, transcytosis and cell signalling 
events (Parton et al. 2007). They have been proposed as endocytic entry portals for viral pathogens, 
including simian virus 40 (SV40), mouse polyomavirus, echovirus 1, and BK virus (Pelkmans et al. 
2001, Marjomaki et al. 2002, Moriyama et al. 2007). Much of what is known about claveolae-
mediated endocytsosis has been elucidated by the study of caveolar ligands such as SV40 and cholera 
toxin, however, cellular entry of both can also occur independently of caveolae (Torgersen et al. 2001, 
Damm et al. 2005). Recent studies suggest that caveolae-mediated entry of SV40 is not necessary for 
infection, as the virus is capable of inducing membrane curvature itself from the extracellular side of 
the plasma membrane through multivalent binding of its capsid protein VP1 pentamers to cell surface 
GM1(Ewers et al. 2010). However, SV40 is still considered a model for caveolae-mediated 
endocytosis, which proceeds as follows. SV40 particles bind to the plasma membrane and diffuse 
laterally along the plasma membrane until they become entrapped in caveolae (Pelkmans et al. 2001). 
Once inside the caveolae, the SV40 particles trigger a signal transduction cascade that leads to local 
tyrosine phosphorylation and depolymerisation of the cortical actin cytoskeleton and recruitment of 
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actin monomers to the caveolae (Pelkmans et al. 2002). The caveolae then bud away from the 
membrane through the GTPase action of dynamin (in a similar manner to clathrin-mediated 
endocytosis) and are transported to an endosomal structure known as the caveosome (Henley et al. 
1998). The fusion of caveolae with the caveosome can occur in a Rab5-independent manner (Parton et 
al. 2007). The caveosome exists as a separate entity from endosomes and recycling endosomes, and is 
distinguished by expression of caveolin-1, lack of expression of markers of the clathrin-mediated 
endocytic pathway (such as early-endosome antigen-1 and transferrin) and has neutral pH (Pelkmans 
et al. 2001). From the caveosome, SV40 is sorted into vesicular membrane structures that are drawn 
along microtubules to the smooth endoplasmic reticulum (ER) (Pelkmans et al. 2001).  
Cholera toxin is a hexameric bacterial toxin which consists of an enzymatic A (active) subunit 
surrounded by a pentamer of binding (B) subunits which bind to the GM1 ganglioside. Early studies 
found caveolae to be important for cholera toxin endocytosis and it was therefore considered to be a 
marker for this pathway, however it is now known that it can enter by both clathrin-dependent and 
independent mechanisms (Montesano et al. 1982, Orlandi et al. 1998, Torgersen et al. 2001). In 
caveolin-1-expressing cells which have inhibited clathrin function, cholera toxin is observed to 
accumulate in caveolin-1 positive endosomes (caveosomes) en route to the golgi complex and ER 
(Nichols 2002). However, several reports suggest that cholera toxin accumulates in early-endosome 
antigen 1 (EEA-1) positive endosomes following caveolae-mediated uptake. To address this, studies 
by Pelkmans et al. demonstrated that caveolae containing SV40 and cholera toxin subunit B could 
also fuse to early endosomes in a Rab5-dependent manner, suggesting that caveolin-stabilised vesicles 
may also have a role in cargo sorting (Pelkmans et al. 2004). 
1.5.2.2. Macropinocytosis 
In addition to clathrin and caveolae-dependent endocytic pathways, several other non-clathrin and 
non-caveolae pathways have been recently described. These have differential requirements for 
cellular proteins such as dynamin, flotillin, small GTPases as well as cholesterol and other specific 
lipids (reviewed in (Doherty et al. 2009)), and can be exploited by viruses for infection (Van Hamme 
et al. 2008, Wang et al. 2008, Misinzo et al. 2009, Gold et al. 2010). One of the most heavily 
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researched of these is macropinocytosis. Macropinocytosis is considered a major endocytic pathway, 
and has been identified in epithelial cells, fibroblasts, neutrophils and macrophages. Macropinosomes 
form primarily at sites of membrane ruffling, are heterogeneous in size, and can grow as large as 5 µm 
in diameter (Swanson et al. 1995). Macropinosomes do not contain a protein coat, as with caveolae or 
clathrin, but are compositionally similar to plasma membrane. Unlike receptor-mediated endocytic 
mechanisms, macropinocytosis is not regulated by the direct action of cargo or receptor molecules 
recruiting specific adaptor molecules to particular sites of the plasma membrane (Kerr et al. 2009). 
Macropinocytosis is typically induced through activation of receptor tyrosine kinases (RTKs) by 
growth factors such as EGF (Haigler et al. 1979) and platelet-derived growth factor (PDGF) 
(Mellstroom et al. 1983). Ras GTPase activation by RTKs initiates three parallel signalling pathways 
which involve the Rho GTPase Rac-1, Rab5, Arf6 and PI3K, which function to modulate actin-
mediated membrane ruffling, macropinosome closure and membrane trafficking (reviewed by 
(Mercer et al. 2009)). Closure of macropinosomes appears to be dynamin-independent, and instead 
membrane fission requires C-terminal-binding protein/brefeldin A-ADP ribosylated substrate 
(CtBP1/BARS) (Liberali et al. 2008). Following closure, macropinosomes move further into the 
cytoplasmic space, from which they may either recycle back to the plasma membrane  or undergo 
acidification, homotypic fusion, and gain of early and late endosomal markers (such as EEA-1, Rab5 
and Rab7) before fusion with the lysosome (Hewlett et al. 1994, Harrison et al. 2003, Hamasaki et al. 
2004, Kerr et al. 2006). 
Macropinocytosis has been implicated as an entry pathway for several viruses, including vaccinia 
extracellular and mature virions (Mercer et al. 2008, Schmidt et al. 2011), adenovirus serotype 3 
(Amstutz et al. 2008), and Coxsakievirus B (Coyne et al. 2007), among others . Macropinocytosis can 
either be used as a primary entry route or induced following binding and endocytosis through 
additional pathways. For example, in addition to clathrin-mediated endocytosis, Adenovirus serotype 
3 binding to CD46 and αv integrins activates Rac1-mediated macropinocytosis of the virions and 
PAK1 and CtBP1-mediated closure of macropinosomes (Amstutz et al. 2008). Furthermore, 
macropinocytosis appears to function as an accessory pathway for adenovirus type 2 and 5; αv 
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integrin-binding of the viruses has been reported to induce macropinocytosis (as demonstrated using 
fluid-phase markers), however the virus does not enter the induced macropinosomes (Meier et al. 
2002). 
1.5.3. Endosomal sorting and the degradative pathway 
Following detachment of uptake carriers such as CCVs and caveolae from the plasma membrane, 
these vesicles may fuse with early endosomal organelles. Endosomal trafficking is an important 
process which functions to sort cargos for degradation or recycling to the plasma membrane, as well 
as transport from the biosynthetic pathways. In eukaryotic cells, the process of trafficking of 
membrane and proteins through the biosynthetic and endocytic pathways is subject to regulation by a 
large family of small GTPases, termed  ras-associated binding (Rab) GTPases (for review see 
(Stenmark 2009). Rab GTPases are distributed to distinct intracellular compartments where they 
function as molecular switches by cycling between GTP-bound ‘active’ and GDP-bound ‘inactive’ 
forms. The cycle of active and inactive Rab GTPases imposes temporal and spacial regulation to 
membrane transport by controlling assembly of effector complexes on the cytoplasmic surface of 
endosomes that regulate fusion of incoming vesicles, homotypic fusion of early endosomes, and 
transport along microtubules (Zerial et al. 2001). The Rab GTPases associated with the endocytic 
pathway include Rab5 (present on endocytic vesicles and early endosomes), Rab4 (early endosomes 
and recycling endosomes), Rab7 (late endosomes and lysosomes) (Stenmark 2009).  
Rab 5 GTPase regulates clathrin-coated and caveolar vesicle transport from the plasma membrane to 
the early endosomes and is associated with endocytic vesicle uncoating and fusion with these vesicles 
(Pelkmans et al. 2004, Semerdjieva et al. 2008). Early endosomes are a dynamic array of tubules and 
vesicles distributed throughout the cytoplasm which contain a mosaic of different domains in the 
limiting membrane which control out-going and in-coming vesicle traffic (Gruenberg 2001). 
Homotypic fusion of early endosomes is also regulated by Rab5, which, in its active form, recruits a 
wide range of molecules that cooperate to mediate fusion of endosomal membranes including EEA-1 
and rabenosyn 5 which act as tethering factors (Stenmark et al. 1994, Christoforidis et al. 1999, 
Nielsen et al. 2000). Interaction of EEA-1 with endosomal N-ethylmaleimide–sensitive factor (NSF) 
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attachment protein (SNAP) receptor (SNARE) synataxin-6 and rabenosyn 5 with the SNARE 
regulator protein sorting-associated protein 45 (VPS45) promotes membrane fusion (Christoforidis et 
al. 1999, Nielsen et al. 2000). SNAREs by themselves do not determine fusion specificity of 
organelles and therefore require the presence of these organelle-specific tethering factors (Brandhorst 
et al. 2006). 
The early endosomes are slightly acidic (pH~6.0-6.8), which allows dissociation of ligand-receptor 
complexes. Rab4-positive tubular extensions of the EEs containing dissociated receptors (such as 
transferrin or low density lipoprotein  receptor) may then be recycled back to the plasma membrane 
via recycling endosomes (Yamashiro et al. 1984). The acidic environment of the early endosomes 
also induces fusion of enveloped viruses with the endosomal membrane, or conformational changes in 
the capsidic proteins of non-enveloped viruses which penetrate the endosomal membrane and allow 
viral escape to the cytoplasm (reviewed by (Marsh et al. 2006)).   
The cargos destined for degradation remain in the vacuolar part of the endosome and are sorted into 
intraluminal vesicles during formation of intermediate vesicles. Cargo sorting into intralumenal 
vesicles is highly regulated and occurs by modification of lysosome targeting signals in the cytosolic 
domains of transmembrane proteins destined for degradation. For example, the downregulation of 
certain receptors is facilitated by attachment of ubiquitin to their cytoplasmic domains (Hicke et al. 
2003). Following ubiquitination, the cytosolic domain of the protein then interacts with UIMs present 
on hepatocyte growth-factor-regulated tyrosine kinase substrate (Hrs). Hrs contains a clathrin binding 
motif which associates with flat bilayered clathrin coats present on EEs (which are independent of 
CCPs of endocytic vesicles) (Raiborg et al. 2002, Sachse et al. 2002) . It is thought that this coat 
prevents the cargo from being recycled to the plasma membrane and retains them for formation of 
intraluminal vesicles, which is promoted through Hrs recruitment of endosomal sorting complexes 
required for transport I (ESCRT-I) (Bache et al. 2003).  
Intermediate vesicles (termed endosomal carrier vesicles/multivesicular bodies, ECV/MVB) are 
drawn along microtubules and fuse with late endosomes which are more acidic (pH<5.5) (Gruenberg 
2001) . It remains unclear whether these intermediate ECV/MVBs are formed by detachment from the 
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EE (stable compartment model) or mature as part of the EE (maturation model) (discussed by 
(Gruenberg et al. 2004)). However, it has recently been demonstrated, using fast live-cell imaging, 
that Rab5 and the late endosome GTPase Rab7 are exchanged (by a Rab7 GEF) on maturing 
endosomes during acquisition of degradative cargo, giving further evidence for the maturation model 
of events (Rink et al. 2005). The maturing ECV/MVBs then fuse with Rab7-positive late endosomes, 
which are highly dynamic, with a complex organisation, containing cisternal, tubular and vesicular 
regions and numerous membrane invaginations (Griffiths et al. 1988). Late endosomes also contain 
lysosomal glycoproteins (such as lysosome-associated membrane protein-1, LAMP-1), however are 
considered a distinct entity from lysosomes based on morphology, and on the lack of certain late 
endosomal markers on lysosomes (such as lysobisphosphatidic acid or mannose-6-phosphate 
receptor) (Griffiths et al. 1988, Kobayashi et al. 1998, Gruenberg 2001) . The late endosomes may 
then fuse with lysosomes and proteins which have been sorted into the intralumenal vesicles 
subsequently degraded by lysosomal proteases (Bright et al. 1997, Mullock et al. 1998).  
1.5.4. Viral escape from the degradative pathway 
As obligatory intracellular parasites, viruses must gain entry into host cells in order to initiate 
replication and spread. The composition of a particular virus structure and genome determines the 
method of cell penetration and the location of replication within the cell. The viral genome can enter 
the cytoplasm either directly at the cell surface by viral penetration of the plasma membrane, or 
disrupting membranes of intracellular organelles such as the endosome following endocytosis 
(reviewed by (Sieczkarski et al. 2002a)). In simplistic terms, some viruses require the low pH 
environment of the endo-lysosomal system to initiate fusion or penetration of the organelle 
membranes for escape to the cytoplasm. pH-independent viruses, such as some retroviruses, undergo 
penetration or fusion at the cell surface for release of the internal virion components to the cytoplasm 
(reviewed by (Marsh et al. 2000)). Following penetration into the cytoplasm, the viral genome must 
be either transported to the nucleus (as is the case for many DNA viruses and negative-stranded RNA 
viruses) or maintained in the cytoplasm for replication by the host machinery (as is the case for most 
positive-stranded RNA viruses). 
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Several virus species utilise endocytic pathways to gain access to the cell. This has the distinct 
advantage that the viruses can be drawn deeper into the cell within the endocytic machinery, thus 
offering a convenient and rapid means of traversing the cytoplasm to the vicinity of the nucleus 
(Sieczkarski et al. 2002a). Escape from the degradative system can either be induced by low pH 
causing conformational changes or proteolytic cleavage of the capsidic proteins (of non-enveloped 
viruses), or fusion of enveloped viruses with the endosomal membrane, allowing uncoating or 
penetration. 
1.5.4.1. Enveloped viruses 
For enveloped viruses, endosomal escape is mediated by virally encoded hydrophobic peptides which 
promote the fusion of the viral and cellular membranes. The viral nucleoprotein complex is then 
delivered across the membrane into the cell cytoplasm. A well-characterised example of this type of 
entry is utilised by influenza virus. Sialic acid residues on glycoproteins and glycolipids at the cell 
surface serve as receptors for the influenza haemagglutinin (HA) glycoprotein spike (Wiley et al. 
1987, Skehel et al. 2000). HA is a homotrimer in which each monomer consists of two disulfide-
linked polypeptides, HA1 and HA2, generated by proteolytic cleavage of the primary translation 
product, HA0  (Maeda et al. 1981). The N-terminus of the HA2 polypeptide contains nonpolar amino 
acids which form a hydrophobic fusion peptide. Following receptor-mediated endocytosis, the virus is 
trafficked through the endo-lysosomal system to the late endosomes, where the low pH (5.5) triggers 
conformational changes to HA, which exposes the HA2 fusion peptide and leads to insertion into the 
endosomal membrane (Carr et al. 1993, Bullough et al. 1994). This causes a membrane fusion 
reaction when the viral and cell membranes are drawn close to one another, and release of the viral 
capsid into the cytosol before transport to the nucleus for replication, while the viral membrane 
remains associated with the endosome (Martin et al. 1991). 
1.5.4.2. Non-enveloped viruses 
Studies of several animal viruses, such as adenovirus, reovirus, rotavirus and poliovirus have 
demonstrated some general features of membrane penetration by non-enveloped viruses (reviewed by 
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(Tsai 2007)). To initiate membrane penetration, viruses undergo conformational changes in response 
to external stimuli such as binding to cell receptors, proteolytic digestion, or acidification in 
endosomes, resulting in exposure of hydrophobic moieties or release of lytic factors (Tsai 2007). 
Reorganisation or disruption of the lipid bilayer then enables cytosolic translocation of the viral 
genome, transcription complex or partially dissembled virus capsid. 
Low pH requirement is demonstrated by some adenovirus species. Species C Adenoviruses bind to 
mammalian cells via interactions between CAR and the fiber protein, following attachment, 
secondary engagement of RGD motifs on the penton base capsid protein and αv integrins promotes 
entry through clathrin-mediated endocytosis (Nemerow 2000). Internalisation of Ad triggers capsid 
disassembly, starting with the loss of the fiber protein at the cell surface. It is thought that integrin 
binding by the penton base results in the release of the CAR-bound fiber protein from the capsid 
(Nakano et al. 2000). Subsequently, the low pH environment of the endosomes promotes further 
destabilisation of the adenovirus capsid (Greber et al. 1993), which is enhanced by interactions 
between the penton base and αv integrins (Wickham et al. 1994). The destabilisation of the virus leads 
to release of capsid proteins such as internal capsid protein VI (Greber et al. 1993). The N-terminal 
region of pVI contains a putative amphipathic α-helical domain that exhibits potent membrane lytic 
activity (as measured by the disruption of artificial lipid membranes) (Wiethoff et al. 2005). 
Disruption of liposomal membranes by pVI occurs by reorganisation of the lipid bilayer to induce 
positive membrane curvature (Maier et al. 2010). Disruption of the endocytic membranes then allows 
release of the remaining viral proteins and genome into the cytoplasm.  
Alternatively, Reovirus entry requires proteolytic cleavage of capsidic proteins to initiate membrane 
penetration. Reoviruses are non-enveloped, double-stranded RNA viruses with two concentric 
icosahedral protein capsids. Attachment to the host plasma membrane is mediated through interaction 
with junctional adhesion molecule- A (JAM-A) (Barton et al. 2001), and endocytosis promoted 
through interaction with β1 integrins (Maginnis et al. 2006, Maginnis et al. 2008). During 
internalisation, the virus undergoes proteolytic cleavage by endosomal cathepsin proteases which 
removes the outer-capsid protein σ3 and induces conformational changes which convert the native 
64
virion into the intermediate subvirion particle (ISVP) (Ebert et al. 2002). This particle is further 
processed to generate a second distinct intermediate particle (ISVP*), characterised by the 
autocatalytic cleavage of outer capsid protein µ1. Autolytic cleavage of µ1 releases the N-terminal 
myristoylated peptide μ1N (Nibert et al. 2005), which is able to penetrate endosomal membranes and 
form pores (Zhang et al. 2009). These pores are too small for passage of the reovirus core (Agosto et 
al. 2006), so additional cellular factors may increase their size, or the endosomes may rupture through 
osmotic swelling and lysis (Moyer et al. 2011). 
1.6. Thesis aims 
As viruses of bacteria, bacteriophage lack the evolutionary adaptations necessary for endosomal 
escape and nuclear localisation in mammalian cells. Thus, it was hypothesised that low transgene 
expression levels mediated by the bacteriophage-derived AAVP vector may be due to sequestration 
by the degradative pathways which eukaryotic viruses have adapted to utilise or avoid. The endocytic 
entry pathways and role of cellular degradative pathways in limiting efficiency of AAVP-mediated 
gene transfer were therefore investigated, with the aim of producing a more efficient gene transfer 
vectors capable of overcoming the identified barriers to transduction. 
 
The aims of the work presented were to: 
1. Elucidate the mechanisms involved in entry and intracellular trafficking of  RGD-
AAVP in order to identify intracellular barriers to transduction 
- Establish human cell lines as models for evaluation of RGD-AAVP-mediated gene 
transfer in vitro (detailed in Chapter 3) 
- Develop quantifiable methods of detection of internalised AAVP particles (Chapter 3) 
- Utilise chemical inhibitors, dominant negative mutant constructs, and RNAi to 
determine the entry events involved in RGD-AAVP uptake (Chapter 4) 
- Develop confocal and electron microscopic methods for investigation of the 
intracellular trafficking of RGD-AAVP (Chapter 4) 
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2. Engineer an improved AAVP vector based on evidence from objective 1  
- Demonstrate improvement to RGD-AAVP-mediated gene transfer through the use of 
pharmacological agents (Chapter 5) 
- Design and construct novel multifunctional RGD-AAVP vectors through genetic 
modification of the capsid and evaluate these for improved gene delivery in vitro 
(Chapter 5) 
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2. Materials and Methods 
 
2.1. Materials 
The components of complex reagents can be found in Appendix Section A. 
The cells lines, chemical inhibitors, and antibodies used in these studies are listed in tables 2.1, 2.2 
and 2.3, respectively. The sequences of oligonucleotides are indicated in table 2.4.  
2.1.1. Cell lines 
Name Tissue Origin Source 
HEK293 Human Embryonic Kidney American Type Culture Collection (ATCC) 
HeLa Human Cervical Cancer ATCC 
U87 Human Glioblastoma Cancer Research UK 
DU145 Human Prostate Cancer Dr Paul Mintz (Imperial College London) 
M21 Human Melanoma Professor David Cheresh (University of California, San Diego) 
M21-L Human Melanoma (M21-derived) Professor David Cheresh (University of California, San Diego) 
Table 2.1. Cell lines used during the investigation 
 
2.1.2. Pharmacological agents 
Chemical Diluant Action 
Sucrose Culture Medium Inhibits clathrin-mediated endocytosis through stabilisation of clathrin as microcages (Heuser et al. 1989) 
Dynasore DMSO Acute inhibitor of Dynamin 1 and 2 (Macia et al. 2006) 
Filipin III complex DMSO Sequesters Cholesterol from the plasma membrane (Bolard 1986) 
Chloroquine Water Lysosomotropic weak base, inhibits acidification of late endosomes/lysosomes (de Duve et al. 1974) 
Bafilomycin DMSO Inhibits acidification and protein degradation in lysosomes (Yoshimori et al. 1991) 
Table 2.2. Chemical agents used during the investigation.  
All the above chemicals were obtained from Sigma. 
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2.1.3. Antibodies 
 
Primary Antibodies 
Name Conjugation Species raised Application Source 
Anti-fd phage - Rabbit IFM, FC, EM Sigma 
Anti-Clathrin (Heavy Chain) - Mouse WB Santa Cruz 
Anti-GAPDH - Mouse WB Santa Cruz 
Anti-EEA-1 - Mouse IFM BD Biosciences 
Anti-LAMP-1 - Mouse IFM Abcam 
Anti-αv integrin - Rabbit IFM Sigma 
Anti-αvβ3 integrin (clone 
LM609) FITC Mouse FC Millipore 
Anti-αvβ5 integrin (clone P1F6) FITC Mouse FC Millipore 
Secondary Antibodies 
Name  Conjugation Species raised Application Source 
Anti-rabbit AlexaFluor-488 Goat IFM Invitrogen 
Anti-rabbit AlexaFluor-594 Goat IFM Invitrogen 
Anti-rabbit AlexaFluor-647 Goat IFM, FC Invitrogen 
Anti-mouse AlexaFluor-488 Goat IFM Invitrogen 
Anti-mouse AlexaFluor-594 Goat IFM Invitrogen 
Anti-mouse HRP Goat WB Sigma 
Protein conjugates/other markers 
Name Conjugation Application Source 
Transferrin AlexaFluor-594 IFM Invitrogen 
Transferrin AlexaFluor-647 IFM, FC Invitrogen 
Transferrin HRP EM Invitrogen * 
Cholera Toxin B AlexaFluor-647 IFM, FC Invitrogen 
Cholera Toxin B AlexaFluor-594 IFM Invitrogen 
Cholera Toxin B HRP EM Invitrogen * 
HRP - EM Serva 
Protein-A-Gold 9nm Gold colloid EM Prepared in-house (Reagents from Sigma) 
 
Table 2.3. Antibodies, markers, and protein conjugates used during the investigation 
IFM=Immunofluorecence Microscopy, FC=Flow Cytomtery, EM=Electron Microscopy, WB=Western Blot 
* Kind gift from Michael Hollinshead, Microscopy Centre, St Mary’s Campus, Imperial College London
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2.1.5. siRNA 
Human clathrin heavy chain (CHC, isoform 17) targeted siRNAs siCHC1 (targeted to sequence 
AAGCAATGAGCTGTTTGAAGA) (Huang et al. 2004), siCHC2 (Hs_CLTC_10HP) and non-
targeted “allstars” negative control siRNA were purchased from Qiagen (Qiagen, Crawley, UK). The 
siRNAs were diluted in RNAse-free molecular grade H2O to 20 µM stock concentrations and stored at 
-20°C in single-use aliquots.  
2.1.6. Plasmids 
The GFP-tagged dominant negative mutant Dynamin II-K44A plasmid was a kind gift from Professor 
Ari Helenius and Dr Jason Mercer (ETH-Zurich) and was obtained with the permission of Dr Mark 
McNiven (Mayo Clinic, Rochester). The GFP-tagged Caveolin-1 dominant negative mutant was also 
obtained from Professor Ari Helenius and Dr Jason Mercer. The dominant negative GFP-tagged 
Eps15 (named EH29) was kindly provided by Dr Alexandre Benmerah (Institut Cochin, Paris). 
2.2. Cell culture 
2.2.1. Cell lines 
The cell lines used in this study are listed in Table 2.1. Cells were maintained at 37°C with 5 % CO2 
atmosphere. Adherent cells were passaged as follows; HEK293, U87, DU145, and M21 were cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma-Aldrich, Poole, UK) and HeLa cells were 
cultured in Eagle’s Minimum Essential Medium (MEM, Sigma). All media were supplemented with 
10% Foetal Bovine Serum (FBS, Sigma), Penicillin (100 units/ml, Sigma), Streptomycin (100 μg/ml, 
Sigma) and L-Glutamine (2mM, Sigma). The FBS was heated for one hour at 56°C to inactivate 
complement before use. Cells were passaged when they reached 80-90 % confluence, the medium 
was removed and cells washed in sterile 1X Phosphate-buffered saline (PBS, Sigma) before addition 
of 2ml trypsin-ethylenediaminetetra acetic acid (Trypsin-EDTA, Sigma) and incubated at 37°C until 
the cells detached. Complete medium was added to the cell suspension to neutralise trypsin and an 
aliquot transferred to a fresh 75 cm2 flask containing 10 ml complete medium. 
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The non-adherent M21L cell line were cultured in DMEM supplemented with 10 % Foetal Bovine 
Serum (FBS, Sigma), Penicillin (100 units/ml, Sigma), Streptomycin (100 μg/ml, Sigma) and L-
Glutamine (2 mM, Sigma). Cells were cultured at 37°C in an atmosphere of 5 % CO2 in tissue culture 
flasks and were passaged every three days by transfer of 1 ml of cell suspension into a new 75 cm3 
tissue culture flask containing 10 ml complete DMEM. 
2.2.2. Freezing and thawing of cell lines  
Adherent cell lines were grown in two 175 cm3 tissue culture flasks until 80- 90% confluent. Cells 
were removed from the bottom of the flask by incubation with trypsin-EDTA, suspended in complete 
DMEM or MEM, and pelleted by centrifugation at 1000 rpm for 5 minutes. The cell pellet was re-
suspended in 10 ml of freezing mixture comprised of 5 % dimethyl sulfoxide (DMSO, Sigma) in FBS, 
and 1ml aliquots of the cell suspension were added to cryotubes. Cryotubes were placed in a 
cryofreezing container lined with isopropanol and placed at -80°C, the tubes were subsequently 
placed in liquid nitrogen for long-term storage.  
Non-adherent cell lines were grown in two 175 cm3  tissue culture flasks for three days, after which 
the cells were pelleted by centrifugation at 1000 revolutions per minute (rpm) for 5 minutes, re-
suspended in 10ml of freezing mixture and aliquotted  into cryotubes that were treated in the same 
manner as described above for adherent cell lines.  
Frozen cells were rapidly thawed at 37°C in a water bath and decanted into a 50 ml centrifuge tubes 
containing 10ml complete medium. Cells were pelleted by centrifugation at 1000 rpm for 5 minutes 
and re-suspended in 10ml complete DMEM or MEM before transfer to a 75cm3 flask for culture at 
37°C in an atmosphere of 5% CO2. 
2.2.3. Mycoplasma testing 
Cells were tested for Mycoplasma contamination at regular intervals with the MycoAlert® 
Mycoplasma detection kit (Lonza, Basel, Switzerland). When cells were 80-90 % confluent, a 1.5 ml 
aliquot of culture medium was centrifuged in an eppendorf tube at 400 g for 5 minutes and a 100 μl 
aliquot of the supernatant was transferred to a white 96 well-plate. 100 μl of MycoAlert Reagent was 
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added and the plate incubated at room temperature for 5 minutes, then placed in a Promega Glomax 
microplate luminometer (Promega, Fitchburg, Wisconsin) for a single luminescence reading. 100 μl 
of MycoAlert Substrate was then added and the plate incubated for 10 minutes at room temperature. A 
second luminescence reading was taken and the cell-line was considered negative for Mycoplasma 
contamination if the ratio of the second reading over the first was less than 1. Mycoplasma-negative 
cell cultures were used in subsequent experiments. 
2.2.4. Cell viability assays 
Stock solutions of chemical inhibitors were either prepared in DMSO or sterile tissue culture-grade 
water. Chemical inhibitors used in this study are shown in table 2.2.  The toxicity of chemical 
inhibitors was determined the MTT cell viability assay. The cells were seeded in 96-well plates and 
allowed to proliferate at 37˚C until 70 -80 % confluent. The cells were then treated with varying 
concentrations of the chemical agents in complete medium for 4 hours. After these incubation periods, 
the medium was removed and replaced with 100 μl fresh complete medium, with the exception of 
cells treated with chloroquine, which received an equal volume of complete medium (which was 
replaced the following day). A 5 mg/ml stock solution of Methylthiazolyldiphenyl-tetrazolium 
bromide (MTT, Sigma) was prepared in PBS and sterile-filtered through a 0.2 µm filter. 10 μl of this 
added to the cells 48 hours following chemical treatment and incubated for 4 hours at 37°C to allow 
the formation of purple formazan crystals. The medium was removed and 100μl DMSO added to 
dissolve the formazan crystals. The absorbance was read using a Glomax plate reader (Promega) 
using a test wavelength of 595 nm and a reference wavelength of 655 nm. Cell viability experiments 
were repeated three times for each chemical. 
2.3. AAVP preparation 
2.3.1. AAVP production 
Stocks of AAVP were stored at 4°C, and virus production from stock solutions was performed 
following the standard published protocol (Hajitou et al. 2007). 7 ml Terrific Broth (TB) was 
inoculated with Kanamycin-resistant Escherichia coli (K91) and grown at 37°C, in a shaking 
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incubator at 250 rpm until log-phase growth was obtained at optical density (OD) between 1.6 and 2.0 
(OD600). 1 ml of this was incubated with 1ul AAVP for 1 hr at room temperature. This was then 
transferred to 450 ml Luria-Bertani (LB) broth containing 40 µg/ml Tetracycline (Sigma) and 100 
µg/ml Kanamycin (Sigma). 1mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Ambion) was 
added when culturing AAVP constructs bearing inserts on the recombinant pVIII. Cultures were 
grown for 16 hours at 37°C (250 rpm). 
For phage production from miniprep cultures, 50 µl of miniprep culture was used to inoculate 1 ml 
K91 at log-phase growth for one hour at room temperature. The K91/phage was then transferred to 15 
ml LB broth containing 40 µg/ml tetracycline, 100 μg/ml kanamycin, with 1mM IPTG and incubated 
5-6 hours at 37°C, 250 rpm. This was then transferred to 450 ml LB broth containing 40 µg/ml 
Tetracycline and 100 μg/ml Kanamycin with 1 mM IPTG and incubated for 16 hours at 37°C (250 
rpm). 
2.3.2. AAVP purification 
Cultures were centrifuged at 6000 g for 30 minutes at 4°C to remove bacterial debris. The supernatant 
was collected and centrifuged again at 6000 g for 30 minutes at 4°C to remove residual bacterial 
debris. Cold Polyethylene-glycol/Sodium chloride (PEG/NaCl) was added to the centrifuge bottles at 
15% of the supernatant volume and incubated for 2 hours on ice to precipitate the phage particles. The 
suspension was centrifuged at 10,000 g for 30 minutes at 4°C in order to obtain a viral pellet. The 
supernatant was discarded and the pellet resuspended in 10ml 1xPBS with agitation for 30 minutes at 
37°C. PEG/NaCl was then added to the PBS (15% of volume) to repeat precipitation of the phage 
particles. This was incubated for 30minutes on ice before centrifugation at 14,000 g for 30minutes, 
4°C. The supernatant was discarded and the pellet resuspended in 600 μl-1ml sterile PBS, depending 
on the size of the pellet obtained. The resulting viral stock was sterile filtered through a 0.45μm filter 
before titration. 
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2.3.3. AAVP titration 
7ml TB medium was inoculated with K91 E.Coli and grown at 37°C, 250 rpm, until OD600 reached 
1.6-2.0. A dilution series of AAVP stock was prepared in PBS in order to obtain 108 and 109 fold 
dilutions. 1ml K91 was infected with 5μl of 108 and 109 fold diluted AAVP stock. This was incubated 
for 20minutes at room temperature before 200 μl was inoculated onto LB-Agar Plates containing 
40µg/ml tetracycline and 100μg/ml kanamycin. The plates were incubated overnight at 37°C and 
colonies counted the following day, the titre was defined as the average number of colonies from 
triplicate plates, giving the number of bacterial transducing units per μl (BTU/μl) of stock. On 
average, AAVP titres of approximately 1x1010 BTU/μl were obtained per round of production (per 
900 ml culture). 
2.4. AAVP transduction  
2.4.1. Cell transduction 
4x104 HEK293, 4x104 U87, 2x104 HeLa, or 2x104 DU145 cells were seeded in 48-well plates (Nunc.) 
and allowed to proliferate until 70-80 % confluent. The cells were incubated with targeted (RGD-
AAVP) or parental non-targeted (fd-AAVP) phage encoding either luciferase (Luc) or Green 
Fluorescent Protein (GFP) reporter genes at varying transducing units per cell (BTU/cell) in the 
presence or absence of pharmacological agents which interfere with cellular endocytic and 
degradative pathways. Transduction with AAVP was conducted in the absence of serum as this 
contains proteins which compete for cell binding by the phage vector. Old medium was removed from 
the cells before transduction and serum-free medium containing phage and inhibitors was added 
directly to the cells. The cells were incubated for 4 hours 37˚ C, 5% CO2 and rotated every 30 minutes 
to ensure coverage of the cells with phage. Following transduction, the serum-free medium and phage 
were removed and replaced with complete medium, with the exception of chloroquine-treated cells, 
which received an equal volume of medium and were incubated in the presence of the inhibitor 
overnight (medium was changed the following day). GFP expression was monitored using a Nikon 
Eclipse TE2000-S fluorescence microscope fitted Nikon digital camera (DXM1200F). For 
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quantification of GFP transduction, cells were transduced in triplicate wells and GFP-positive cells 
counted in 10 fields-of-view per well. 
2.4.2. Luciferase assay 
The Promega Steady-glo® luciferase assay kit was used to determine Luciferase reporter transgene 
expression in AAVP-transduced cells. At indicated time-points, the old culture medium was removed 
and the cells washed with 1xPBS (to remove remaining phenol-red). 100 μl glo-lysis buffer was added 
to the cells and incubated at room temperature for 10 minutes. 50 μl was stored at -80°C for the 
Bradford assay and 50 μl added to 50 μl Steady-glo® reagent in a white polystyrene 96-well plate. 
After 10 minutes incubation at room temperature, luciferase expression was quantified using a 
Promega Glomax microplate reader. Luciferase assays were performed in triplicate and normalised to 
100 µg cell protein, as determined by the Bradford assay. 
2.4.3. Bradford assay 
The Bradford total protein assay (Sigma) was used to quantify protein levels in samples taken for the 
luciferase assay (and for western blotting). Samples were stored at -80°C before thawing to ensure 
complete lysis of the cells. A standard curve of Bovine Serum Albumin (BSA, Sigma) was produced 
from a two-fold dilution series in PBS. The samples were then diluted to 1 in 5 times in PBS and 5 μl 
of standards/samples added to a clear 96-well plate in triplicate. 250 μl Bradford reagent was added 
and incubated for 10minutes at room temperature and the plate read using a Promega Glomax 
microplate reader at an absorbance of 600 nm. 
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Figure 2.1. Example standard curve used for quantification of protein concentration. 
A two-fold dilution series of BSA was diluted in PBS and 5µl mixed with 250 µl Bradford reagent in a 96-well 
plate, incubated for 10 minutes at room temperature and analysed using a Promega Glomax microplate reader at 
an absorbance of 600nm. 
 
2.5. Molecular biology 
2.5.1. Oligonucleotides  
Oligonucleotide sequences were designed to contain overhangs corresponding to HindIII and PstI 
restriction sites for insertion into the recombinant pVIII of the f88.4 vector. All oligonucleotides were 
oobtained from Invitrogen, and were acquired with phosphorylated 5’ ends. Table 2.4 gives details of 
oligonucleotide sequences and original references for the sequences. Oligonucleotides were diluted in 
molecular biology grade water (Sigma) to a stock concentration of 100 pmol/µl and stocks stored at -
20°C. For annealing of oligonucleotides, stock oligonucleotides were diluted to a working 
concentration of 20 pmol/µl. Oligonucleotides were annealed by adding equal volumes of working 
stock solution of sense to the corresponding anti-sense oligonucleotide at a final dilution of 1 pmole/ul 
each in molecular grade water in PCR tubes. The mixture was transferred to a thermal cycler (Bio-
Rad) set to perform the following program profile: 95 °C for 5 minutes, 85 °C for 5 minutes, 75 °C for 
5 minutes, 65 °C for 5 minutes, 55 °C for 5 minutes, 45 °C for 5 minutes. The annealed 
oligonucleotides were analysed by gel electrophoresis to determine the presence of the product. 
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2.5.2. Bacterial transformation 
An aliquot of frozen NEB 5α competent E.coli (New England BioLabs) were thawed on ice. 2 µl of 
ligation reaction was added to 50 μl of thawed competent cells, flicked to mix and returned to ice for 
30 minutes. The cells were then heat-shocked at 42°C for 30 seconds before returning to ice for a 
further 5 minutes.  250 µl SOC medium (Invitrogen) was added and the cells incubated in a shaking 
incubator at 37°C at 250 rpm for 1 hour. The cells were then spread on LB-agar plates containing 40 
μg/ml tetracycline and incubated at 37°C overnight. 
2.5.3. Plasmid DNA extraction  
Bacterial plasmid DNA was isolated using the QIAprep spin miniprep and midiprep kits (Qiagen, 
UK). Small amounts of bacterial plasmid DNA (up to 20 µg) was extracted using a QIAprep Spin 
Miniprep Kit (Qiagen, UK). Briefly, a suspension of transformed E. Coli were pelleted at 8000 rpm 
for 8 minutes and re-suspended in 250 μl buffer P1 to which 250 μl of the alkaline lysis buffer P2 
were added. This was neutralised by the addition of 350 μl of buffer N3, which also precipitated 
denatured proteins, cellular debris and chromosomal DNA that were subsequently removed by 
centrifugation (at 13,000 rpm for 10 minutes). The supernatant fluid (containing the plasmid) was 
applied to a QIAprep spin column that was washed sequentially with buffers PB and PE before 
plasmid DNA was eluted into 50 μl of Buffer EB.  
For purification of larger amounts of bacterial plasmid DNA (up to 100µg DNA), the QIAprep Spin 
Midiprep kit was used. Single colonies of transformed bacteria were picked and grown in starter 
cultures of 7 ml LB medium for 5-6 hours at 37°C, 250 rpm. 500 µl of this was transferred to 150 ml 
LB broth containing the appropriate antibiotics (40µg/ml tetracycline or 100µg/ml kanamycin) and 
grown for 16 hours at 37°C, 250rpm.  Bacteria were pelleted by centrifugation at 6000g for 15 
minutes (at 4°C). The pellet was resuspended in 10 ml STE buffer and pelleted again. 6 ml buffer P1 
was added and pellet resuspended by vortexing. 6ml lysis buffer P2 was added and neutralised by 
addition of 6 ml cold buffer P3 and incubated on ice for 15 minutes. The lysate was passed through a 
QIAfilter Midiprep cartridge to remove insoluble complexes (chromosomal DNA, salt, detergent and 
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proteins). The cleared lysate was then passed through a QIAGEN-tip, and DNA bound to the resin 
was washed with wash buffer QC before elution in 5ml of buffer QF. DNA was precipitated by 
addition of 3.5 ml isopropanol and centrifuged. The pellet was washed in 2 ml 70% ethanol and 
centrifuged once more before DNA was dissolved in Buffer EB. 
2.5.4. Restriction enzyme digests 
Restriction digests were performed in the buffers recommended by the manufacturer (NEB). Per 10 
µg of plasmid DNA, 10 units of restriction enzyme, 5 µl of 10X NEBuffer, BSA at a final 
concentration of 100 µg (if necessary) and molecular grade water were combined and digests 
performed at 37°C. For analytical purposes, digests were performed for one hour at 37°C, preparative 
digests were performed for 3 hours. Digestion was confirmed by gel electrophoresis. 
2.5.5. Dephosphorylation 
When required, 5’ ends of digested DNA fragments were dephosphorylated (prior to ligation), using 
alkaline phosphatase (Roche, Welwyn Garden City, UK). 1µl alkaline phosphatase was added to 50µl 
reaction product and incubated at 37°C for one hour. The enzyme was inactivated at 65°C for 30 
minutes. 
2.5.6. Gel electrophoresis 
For both analytical and preparative gel electrophoresis, 1% agarose gels were prepared by dissolving 
0.5g agarose (Sigma) in 50 ml of fresh 1X Tris-acetate-EDTA (TAE) buffer while heating until 
boiling. The mixture was allowed to cool after the agarose was fully dissolved, and 7 µl Ethidium 
bromide added (Sigma). The gel was poured into a casting tray and allowed to set for 30 minutes until 
solid. The gel was placed into the electrophoresis chamber of assembled electrophoresis apparatus, 
with enough 1X TAE added to cover the gel. The samples were prepared by addition if the 
appropriate volume of 6X Sample Loading Buffer (BioLabs). The ExACTGene 24kb DNA ladder 
standard or ExACTGene low range standard (Fisher Scientific) were used to determine fragment size. 
Electrophoresis was carried out at 100V for approximately 45 minutes. DNA was visualised by 
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illumination on a long wave UV light box and photographed. The size of the DNA fragments was 
estimated by comparing their relative mobility to that of the DNA ladder standard. 
2.5.7. Gel extraction and purification 
DNA fragments were extracted and purified using the Qiaquick gel extraction kit (Qiagen). The DNA 
fragment of interest was excised from agarose gel using a clean scalpel and transferred to a pre-
weighed eppendorf tube. The agarose gel was weighed and 3 volumes of buffer QG was added to 1 
volume of the agarose gel. The gel was dissolved by incubation at 50°C for 10 minutes. One gel 
volume of isopropanol was added to the sample and the sample centrifuged through a Quiaquick spin 
column to allow DNA binding to the column. The flow-through was discarded and the column 
washed with buffer QG and buffer PE. DNA was eluted from the column using 50 µl of Buffer EB 
(10 mM Tris-Cl, pH 8.5). A sample was analysed by gel electrophoresis to check for purity and 
correct fragment size. 
2.5.8. Ligation 
Ligations were performed with 30-50ng of vector DNA and typically 1:5 molar ratio of vector to 
insert DNA was used (either a purified DNA fragment, or a pair of annealed oligonucleotides). All 
ligation reactions were performed in a final volume of 20 μl composed of 1x T4 DNA ligase buffer 
and 1μl T4 DNA ligase (Fermentas). Ligation reactions were performed in a thermal cycler set to 
22°C for 4 hours followed by 18°C overnight. 
2.5.9. PCR 
Polymerase-Chain Reaction (PCR) was performed in order to verify the purity of the AAVP stocks by 
amplifying the pIII insertion site for the targeting ligand. PCR was also performed to confirm the 
presence of oligonucleotide inserts into the recombinant pVIII gene. 1 μl of phage stock was diluted 
1:1000 in 1 ml sterile water (Sigma) and 5 µl mixed with 45 µl of PCR master mix containing 10 mM 
dNTPs, Taq Polymerase buffer, 2% DMSO, 25 mM MgCl2, 0.25 µl Go Taq Polymerase (Promega) 
and primers (Invitrogen). The following primer sets were used: 
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For PCR spanning the PIII minor coat protein:  
Forward: 5’-TAATACGACTCACTATAGGGCAAGCTGATAAACCGATACAATT-3’  
Reverse: 5’-CCCTCATAGTTAGCGTAACGATCT-3’  
- For PCR spanning the PVIII major coat protein:  
Forward: 5’-TCTGTTGCTGTTGCGACTCT-3’  
Reverse: 5’-CCTCAAGCTCAGGGGAGTAA-3’ 
 
The pIII DNA was amplified using a Biorad PCR machine at the following conditions; 1 cycle at 
94°C (5 minutes), 35 cycles at 94°C (30 seconds), 60˚ C (1 minute), 72°C (1 minute) and 1 cycle at 
72°C (5 minutes). For amplification of the pVIII, the following conditions were used; DNA was 
denatured at 95°C for 2 min; 35 cycles of 30 seconds at 95°C, 1 min at 55°C and 1 min at 72°C; 
followed by a final extension step of 72°C for 5 minutes. 
The final DNA products were analysed by gel electrophoresis. Samples containing 10ng/100bp DNA 
together with reverse primers were sequenced using the Imperial College Sequencing Service based at 
Hammersmith Hospital Campus. Sequences were verified using DNA Dynamo software. 
2.5.10. Transient transfection 
2.5.10.1. Plasmid DNA 
Cells were transiently transfected with GFP-tagged plasmids using FuGENE6 transfection reagent 
(Promega). Cells were seeded in either 24-well plates (for flow cytometry experiments) or on 
coverslips in 12-well plates (for confocal experiments) and allowed to proliferate to 50-60% 
confluence before transfection. Transfection conditions were first optimised in HEK293 and HeLa 
cells and a ratio of fuGENE (µl) to plasmid DNA (µg) of 6:1 was chosen. 0.5 µg plasmid DNA was 
used per well for transfection of 12-well plates, and 0.25 µg per well of 24-well plates. The 
transfection reagent was added to serum-free (antibiotic-free) medium in eppendorf tubes and mixed 
by flicking. 5 minutes later, plasmid DNA was added to the mixture and tube tapped to mix. The 
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reagent was incubated for 45minutes at room temperature before being added dropwise to the wells of 
the tissue culture plates. Experiments were performed 24 hours after transfection, as some dominant 
negative mutants were toxic to the cells. Transfection efficiency was checked by immunofluorescence 
microscopy prior to experiments using a Nikon Eclipse TE2000-S fluorescence microscope fitted 
Nikon digital camera (DXM1200F). 
2.5.10.2. siRNA 
HEK293 cells were transfected using Lipofectamine RNAiMax (Invitrogen), according to the 
manufacturer’s instructions. Cells were seeded in 6-well plates (in DMEM containing no antibiotic) 
and transfected the following day. 30 pmol siRNA was mixed with 6 µl RNAiMax in 200 µl 
Optimem (Invitrogen) and incubated for 10 minutes at room temperature before addition to each well. 
The following day, the cells were seeded in 24-well plates and experiments performed a further 48-
hours later. 
2.6. Confocal microscopy 
2.6.1. Immunofluorescence staining for confocal microscopy 
18 mm coverslips (VWR) were coated with poly-D-Lysine (Sigma) in order to encourage stable cell 
attachment. Autoclaved coverslips were added to the wells of 12-well tissue culture plate. Poly-D-
lysine was diluted to 50 μg/ml with sterile tissue-culture grade water (Sigma) and 500 μl added to 
each well. Plates were incubated for 15 minutes at 37°C before washing three times with water and 
drying. Cells were seeded on the coverslips and allowed to proliferate until approximately 60-70% 
confluent before experiments were performed. The cells were first cooled on ice and fixed in 4% 
paraformaldehyde (PFA, pH 7.2) in 250 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPEs) buffer (Sigma) for 10 minutes on ice, followed by 20 minutes in 8% PFA at room 
temperature. The cells were washed three times (5 minutes per wash) in 1X PBS before addition of 
50mM Ammonium Chloride (in PBS) to quench free aldehyde groups from fixation. The cells were 
washed three times for 5 minutes in PBS before permeabilisation with 0.2% Triton X-100 (Sigma) for 
5 minutes at room temperature. The cells were washed three times in PBS and blocked for 30 minutes 
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in 2% BSA. The BSA was removed and cells incubated with primary antibodies diluted in PBS-1% 
BSA for 1hour at room temperature. The coverslips were then washed tree times for 5 minutes in 1% 
BSA in PBS before incubation with fluorophore-conjugated secondary antibodies +/- 0.05μg/ml 4’,6-
diamidino-2-phenylindole (DAPI, Sigma) diluted in 1% BSA in darkness for one hour.  The 
coverslips were then washed three times (5 minutes per wash) in PBS-1% BSA to block non-specific 
antibody binding, and three times in 1xPBS. The coverslips were then rinsed in sterile double-distilled 
(MilliQ) water, allowed to air-dry briefly, and mounted in Mowiol (Fluka) mounting medium 
(prepared in-house). 
2.6.2. Image acquisition and rendering 
Confocal images were acquired using a Leica SP5 confocal microscope or a Zeiss Pascal confocal 
microscope fitted with Argon, UV and HeNe lasers, using 63x oil objectives. Images were acquired as 
full z-stacks and presented as either single section images or projections of full z-stacks (indicated in 
figure legends).  Images were processed using ImageJ and Adobe Photoshop (Adobe Systems). 
2.7. Live cell imaging 
2.7.1. Fluorescent labelling of AAVP 
AAVP particles were fluorescently labelled using Invitrogen’s AlexaFluor-546 protein labelling kit. 
The AlexaFluor- 546 reactive dye has a succinimidyl ester moiety that reacts with a limited number of 
exposed primary amines of phage coat proteins (primarily pVIII). The following  protocol was 
adapted from publications describing fluorescent labelling of M13 bacteriophage particles (Knurr et 
al. 2003, Jaye et al. 2004). 1x1013 RGD-AAVP or fd-AAVP particles were diluted in 1X PBS 
containing 0.1 M sodium bicarbonate to a final volume of 800 µl. This was added to a vial of reactive 
dye and incubated at room temperature for two hours, to allow sufficient phage labelling. Phage was 
purified from the mixture by precipitation in PEG/NaCl (15% of phage/PBS volume was added) for 
one hour on ice, followed by centrifugation at 10,000 g for 10 minutes, and removal of supernatant 
containing free dye. The pellet was resuspended by incubation in PBS overnight, and PEG/NaCl 
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precipitation repeated twice more. The phage were re-titred before experiments were performed, 
fluorescent labelling of virions was confirmed by confocal microscopy. 
2.7.2. Live cell imaging 
HeLa cells were grown on 35mm dishes containing coverslips (designed for live cell imaging, 
Mattek) to 70% confluency. Serum-free medium (without phenol red) was added and cells incubated 
for 30minutes before cooling on ice. RGD-AAVP-AlexaFluor-546 was added to the cells at 1x106 
BTU/cell and incubated for a further 30 minutes on ice. The cells were warmed by washing in pre-
conditioned MEM and incubation at 37°C in a Zeiss Meta 510 microscope incubation chamber. Z-
stack projections were recorded every 1.97 seconds (the speed at which a full stack could be imaged). 
Live confocal data were analysed using imageJ plugin MtrackJ, and the distance travelled by 
fluorescent phage particles was plotted over time. 
2.8. Transmission electron microscopy 
2.8.1. Negative staining and immunogold labelling on EM grids 
For negative staining of RGD-AAVP particles, phage stock solution was diluted in sterile double-
distilled water and 400 mesh formvar-coated grids applied to 5µl drops of sample for 2 minutes. The 
grids were then washed in water and stained using 1% Uranyl acetate (TAAB) for 30 seconds, after 
which the excess stain was removed and grids air-dried. 
Immunogold labelling of RGD-AAVP was first characterised on virus particles bound to EM grids. 
5µl drops of diluted phage were applied to formvar-coated grids. The grids were blocked in 5 % 
Foetal Calf Serum (FCS) prior to addition of anti-fd antibody diluted 1:100 in 5 % FCS for 60 
minutes at room temperature. The grids were washed in PBS and incubated with protein-A-gold 
(9nm) diluted 1:100 in PBS for 45 minutes. The grids were washed in PBS, then in water before 
incubation with 1 % Uranyl acetate for 30 seconds, and air-dried before imaging. 
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2.8.2. Pre-embedding immunogold labelling of AAVP  
HEK293 cells were seeded in poly-lysine coated 35 mm dishes (Falcon) and grown until 70 % 
confluent. The complete medium was removed from the cells and replaced with serum-free medium 
before cooling the cells on ice for 15 minutes. 1x1012 phage particles were added to the cells and 
incubated for 30 minutes on ice to allow phage binding. The cells were then washed three times with 
ice-cold 2%BSA-PBS before addition of a polyclonal rabbit anti-fd antibody (Sigma), diluted 1:100 in 
BSA-PBS. The cells were incubated on ice for 30 minutes before washing three times with 2% BSA-
PBS and subsequently incubated with protein-A-gold (9 nm particles) diluted 1:100 in BSA-PBS for 
60 minutes. The cells were washed three times with 1% BSA-PBS and before addition of warm 
medium containing 10 mg/ml Horse Radish Peroxidise (HRP), 5 µg/ml HRP-Transferrin or 5 µg/ml 
HRP-Cholera Toxin B. A schematic of the pre-embedding immunogold labelling strategy is shown in 
Figure 2.2. 
 
 
 
Figure 2.2. Pre-embedding immunogold labelling of RGD-AAVP. 
 RGD-AAVP was bound to HEK293 cells on ice to allow binding but not internalisation. Cells were washed and 
blocked in ice-cold 2% BSA-PBS before addition of a polyclonal rabbit anti-fd antibody, diluted 1:100 in BSA-
PBS. The cells were incubated on ice for 30 minutes before washing three times with 2% BSA-PBS and 
subsequently incubated with protein-A-gold (9 nm particles) diluted 1:100 in BSA-PBS for 60 minutes. The 
cells were washed three times with 1% BSA-PBS and before addition of warm medium to allow uptake. 
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2.8.3. Embedding and analysis 
The cells were first cooled on ice to halt endocytosis, washed in cold PBS and fixed in 0.5% 
glutaraldehyde (Agar Scientific) in 200mM sodium cacodylate (pH 7.4, TAAB) on ice for 30 minutes. 
The cells were subsequently washed three times in 200 mM sodium cacodylate and cells which had 
received HRP or HRP-tagged protein markers were stained using the Metal Enhanced DAB Substrate 
kit (Thermo Scientific) for 30 minutes before washing  again with 200 mM sodium cacodylate. The 
cells were embedded in epon resin following previously published protocols (Hollinshead et al. 1999). 
The cells were post-fixed in 1% osmium tetroxide–1.5% potassium ferrocyanide for 60 minutes at 
room temperature (in darkness). Following three washes in distilled water, the cells were incubated in 
0.5% magnesium-uranyl acetate overnight at 4°C. The following day, the cells were washed again in 
water before dehydration in increasing concentrations of ethanol; the samples were first incubated in 
70% ethanol for 10 minutes, 90% ethanol for 10 minutes, and 100% ethanol twice for 10 minutes. The 
cell monolayers were then embedded flat by infiltration with increasing concentrations of Epon 812 
resin (TAAB) in ethanol, at a ratio of 3:1 (ethanol:epon) for 30 minutes, followed by 1:1 
(ethanol:epon) for 2 hours at room temperature, subsequently the samples were incubated in 1:3 
(ethanol:epon) overnight. The ethanol:epon mix was removed from the samples and replaced with 
100% epon. The samples were degassed for one hour and the resin cured by baking overnight at 52°C. 
The following day, gelatine capsules containing 100 % epon resin were applied to the surface of the 
flat-embedded cells and baked overnight. The resin-filled stubs attached to flat-embedded monolayers 
were cut away from the tissue culture dish and milled for sectioning (see Figure 2.3). 70 nm or 140 
nm thick sections were cut parallel to the surface of the dish using a Leica ultramicrotome. The 
sections were collected onto 50 mesh formvar-coated grids and stained for 30 seconds in Reynold’s 
lead citrate, washed with water and air-dried before analysis. Samples were viewed by using an FEI 
Tecnai G2 electron microscope with a Soft Imaging System Megaview III CCD camera. Images were 
collected at 1376x1032x16 pixels using AnalySIS version Docu software (Olympus Soft Imaging 
Solutions). Image acquisition and analysis was performed with the assistance of Michael Hollinshead 
(Henry Wellcome Imaging Centre, Section of Virology, Imperial College London). 
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 Figure 2.3. Embedding and sectioning cell monolayers for electron microscopy. 
Following incubation with the phage or lysosomal markers the cells were fixed in glutaraldehyde, post-fixed in 
osmium tetroxide and stained with uranyl acetate. Cells were infiltrated with epon resin and cured before 
addition of rein-filled ‘stubs’. After curing the stubs containing monolayers were milled and ultrathin sections 
cut using a diamond knife. Sections were collected on formvar-coated EM grids and stained with reynold’s lead 
cutrate prior to imaging. 
 
2.8.4. Protein A-gold preparation 
9nm protein-A-gold was prepared in-house using the following procedure. 2.5 ml 1 % Gold chloride 
(Sigma) solution was added to 200 ml double-distilled water (VWR) and heated to 60°C. 10 ml 1 % 
tri-sodium citrate was then added to 40 ml ddH2O with 250 µl 1% tannic acid and also warmed to 
60°C. The two solutions were mixed while stirring and heated to 95°C before cooling on ice. When 
cool, the pH was adjusted to 6 using 0.1N sodium hydroxide. 100ml of the gold solution was added to 
250 μl of 1 mg/ml Protein-A (Abcam). The protein-A-gold was centrifuged in a Beckman 
Ultracentrifuge using a Ti70 fixed-angle rotor for 30 minutes at 30,000 rpm (4°C). The clear 
supernatant was removed and the dark protein-A-gold pellet collected and layered onto a continuous 
10-30% glycerol gradient in 10 ml centrifuge tubes. This was ultracentrifuged at 20,000 rpm using a 
SW40 swing rotor for 45 minutes at 4°C. The protein-A-gold fraction was removed and dialysed 
overnight at 4°C in 50 % glycerol-PBS. Gold particles were checked for uniformity in size by electron 
microscopy.  
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2.9. Flow cytometry 
2.9.1. Immunofluorescence labelling of live cells for flow cytometry 
Cells were grown to 70 % confluence before washing with PBS and were detached from tissue culture 
flasks using 5 ml 2 mM EDTA. The cells were counted and 5x105 cells transferred to eppendorf tubes 
containing ice-cold PBS. Cells were pelleted by centrigugation at 2000 rpm for 5 minutes and 
resuspended with 500ul 2% BSA in PBS and incubated on ice for 30 minutes. Cells were pelleted and 
100 µl FITC conjugated mouse anti-αvβ3 diluted 1:100 or mouse anti- αvβ5 diluted 1:500 added. Cells 
were incubated for one hour on ice before centrifugation and resuspension in 1 % BSA-PBS three 
times, then once in PBS and immediate analysis by flow cytometry. 
2.9.2. Acridine orange uptake in live cells for flow cytometry 
For acridine orange experiments, HEK293 and HeLa cells were seeded in 12-well plates and allowed 
to proliferate until the cells reached 70-80 % confluency. Chloroquine or bafilomycin were added to 
the cells at non-toxic concentrations (as determined by MTT) for 4 hours. In the case of chloroquine, 
after 4 hour incubation, an equal volume of medium was added to the cells and the cells incubated 
overnight. Following treatment with the chemicals, the cells were incubated with 0.5 µg/ml acridine 
orange for 15 minutes at 37°C. The cells were then cooled on ice, washed three times in PBS, and 
removed from culture dishes with trypsin. The cells were resuspended in cold medium, pelleted by 
centrifugation at 2000 rpm for 5 minutes, and resuspended in 500 μl cold PBS. The live cells were 
analysed immediately by flow cytometry (samples were kept on ice during analysis). Acridine orange 
fluorescence was detected in the FL3 channel, non-treated cells served as negative controls and cells 
receiving acridine orange only served as positive control. 
2.9.3. Immunofluorescence labelling of fixed cells for flow cytometry 
Cells were immunofluorescence-stained for analysis by flow cytometry as follows. The cells which 
received transferrin or cholera toxin B were washed with ice-cold acidic glycine wash buffer (0.1 M 
glycine, 0.1 M sodium chloride, pH 3) and once with cold PBS before trypsinisation. The cells which 
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received AAVP were washed three times with cold PBS before trypsinisation to remove the cells from 
culture dishes. The cells transferred to eppendorf tubes and pelleted by centrifugation at 1000 rpm for 
5 minutes before fixation in 100 µl 4% PFA (in 1XPBS, pH 7.2) for 10 minutes. The cells to be 
stained for internalised AAVP were blocked for 30 minutes in 0.1% saponin in 2% BSA-PBS prior to 
staining with rabbit anti-fd-phage primary antibody (diluted 1:1000) in 0.1% saponin in 1% BSA-PBS 
for 1 hour at room temperature. The cells were washed and pelleted three times in 0.1% saponin in 
1% BSA-PBS before incubation with goat anti-rabbit AlexaFluor-647 (diluted 1:500) for 1 hour at 
room temperature (in darkness). The cells were washed twice with 0.1% saponin-PBS and 
resuspended in 500 μl PBS prior to analysis.  
2.9.4. Analysis of flow cytometry data 
FACs analysis was performed using a BD FACscalibur Flow Cytometer (BD Biosciences) equipped 
with an argon-ion laser (488 nm) and red-diode laser (635 nm). Analysis was performed on at least 
10,000 cells per triplicate well. For GFP-plasmid transfected cells, the mean fluorescence intensity of 
FL4 was measured for the GFP (FL1) positive cell population. Data were analysed using FloJo 
(TreeStar) software. Figure 2.3 gives an example of how mean fluorescence intensity values were 
obtained. Cell populations were first defined by adjusting the forward-scatter (FS) and side-scatter 
(SS) dot plots to obtain a distinct population. For non-transfected cells, this population was analysed 
for mean fluorescence intensity of the appropriate fluorescent marker (FL1 for green 
(GFP/FITC/Alexafluor-488), FL3 for acridine orange, and FL4 for far-red (Alexafluor-647). For 
GFP-transfected cells, the FS-SS population was analysed for GFP fluorescence in the FL1 channel, 
then the mean fluorescence intensity of the FL4 channel was measured for the GFP-positive 
population. 
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Figure 2.4. Example analyses of flow cytometry experiments. 
The cell population was defined using the forward-scatter (FS) vs. side-scatter (SS) dot plot. The mean 
fluorescence intensity of far-red fluorescence (FL4 channel) of non-transfected cells was calculated from the 
entire cell population. GFP-positive populations of transfected cells were selected in GFP vs SS plots and mean 
fluorescence intensity values determined for GFP-positive cells. 
 
2.10. Western blotting 
To prepare whole cell extracts for western blotting, cell monolayers were washed three times in cold 
PBS and lysed in extraction buffer supplemented with a protease inhibitor cocktail (Roche) on ice. 
Protein concentration was determined using the Bradford assay with BSA standards (as described in 
section 2.4.3). Per sample treatment, 20 µg protein was solubilised in SDS sample buffer heated to 
100°C for 5 minutes. The samples were briefly centrifuged and separated by SDS-PAGE using an 8% 
poly-acrilamide gel (with 5% stacking gel) in Tris-Glycine-SDS buffer (at 110V). 
The proteins were electroblotted onto PVDF membranes (Immobilon-P, Millipore) in transfer buffer, 
using a ‘wet’ transfer kit (at 400mA). Membranes were blocked overnight at 4°C in 5% milk in tris-
buffered saline plus 0.1% tween (TBST). The following day, the membranes were cut and incubated 
with mouse anti-clathrin heavy chain (diluted 1:500) or mouse anti- Glyceraldehyde 3-phosphate 
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dehydrogenase (GAPDH, diluted 1:5000) primary antibodies diluted in 2% milk-TBST for two hours 
at room temperature. Following three 5 minute washes in 2% milk-TBST, the membranes were 
incubated with donkey anti-mouse secondary antibodies (diluted 1:5000) conjugated to HRP for 1 
hour at room temperature. The membranes were then washed three times (10 minutes per wash) in 
TBST. The proteins were detected using supersignal west pico chemiluminescent substrate (Thermo 
Scientific). Rainbow molecular weight markers (GE Healthcare) were used to assess protein sizes, and 
expected band sizes of the proteins are indicted in kDa. The membranes were exposed to Kodak 
BioMax film, which was developed using a Kodak X-OMAT processor. 
2.11. Statistical Analyses 
Statistical analyses were performed by using GraphPad Prism 5.0 software (GraphPad Software Inc, 
La Jolla, CA, USA). Error bars represent standard error of the mean (SEM). Analysis of significance 
between two groups (e.g. treated and non-treated) was performed using Two-tailed Student’s t-test. 
For comparisons of more than two groups one-way ANOVA (analysis of variance) with Bonferroni 
post-hoc analysis was performed. P values of less than 0.05 were considered significant, with scores 
are denoted as follows: *p < 0.05, **p < 0.01 and ***p < 0.001. 
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3. Evaluation of AAVP-mediated gene transfer in vitro 
 
3.1. Introduction 
The targeted AAVP vector displays a double-cyclic RGD ligand (CDCRGDCFC) on the minor pIII 
coat protein (Hajitou et al. 2006, Hajitou et al. 2007) which was identified as a targeting motif for 
αvβ3 and αvβ5 integrins which are over expressed in tumour vascular endothelium and tumour cells 
but absent or expressed at very low levels in normal endothelial cells (Ruoslahti 1996, Pasqualini et 
al. 1997). The purpose of the present study was to confirm that this interaction facilitates receptor-
mediated endocytosis of the targeted vector, and to establish in vitro cell models for subsequent 
studies.  
Integrins are a large family of cell surface receptors that mediate adhesion to the extracellular matrix 
(ECM), organise the cytoskeleton and activate intracellular signalling pathways (Guo et al. 2004). 
Integrins exist as transmembrane receptor proteins composed of heterodimeric complexes of non-
covalently linked α and β chains. There are 18 α and 8 β subunits which combine to form 24 
variations of integrin heterodimers, the extracellular portions of which bind distinct subsets of ECM 
ligand (Guo et al. 2004). The intracellular association with cytoskeletal elements such as actin 
filaments reinforces tissue integrity and cell adhesion during migration. In addition to their role as 
adhesion molecules, interaction of integrins with ECM proteins clusters the receptors and their 
associated cofactors, activating integrin-regulated signalling pathways (Jin et al. 2004). While 
integrins lack enzymatic activity, they regulate signalling through activation of kinases such as focal 
adhesion kinases (FAKs), integrin-linked kinases (ILKs), p21-activated kinase (PAK), Src family 
kinases (SFKs) or through interaction with growth factors or their receptors (Schlaepfer et al. 1994, 
Hruska et al. 1995, Hannigan et al. 1996, Miyamoto et al. 1996, Arias-Salgado et al. 2003, Hood et 
al. 2003). These signalling events exert control over cell survival, and determine migration and 
proliferation in response to growth factors and cytokines (Guo et al. 2004). For example, integrin-
induced FAK activation leads to activation of the RAS-extracellular-signal-regulated kinase (ERK) 
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pathway, which promotes cell proliferation (Hood et al. 2002). Integrins are continuously 
endocytosed and recycled through interactions with the ECM, as part of the processes mediating cell 
adhesion, migration and maintenance of cell polarity (Caswell et al. 2009). The receptors are also 
commonly exploited by pathogens for invasion of eukaryotic cells. Integrins are utilised as receptors 
or co-receptors for several viral species, including adenovirus (Wickham et al. 1993), foot-and-mouth 
disease virus (FMDV) (Fox et al. 1989), hantavirus (Gavrilovskaya et al. 1998) and echovirus 1 
(Evans et al. 1998), among others. In a similar manner to ECM association, virus binding induces 
integrin clustering or conformational changes in integrin quaternary structure which illicit cell-
signalling events leading to increased ligand avidity, promotion of cytoskeletal arrangements and 
internalisation (Stewart et al. 2007). 
As described in Chapter 1, dominant mutations in oncogenes and recessive mutations in tumour-
suppressor genes disrupt regulation of cell fate, leading to proliferation and survival of neoplastic 
cells. Neoplastic cells become self-sufficient in growth signalling (Hanahan et al. 2000), and are less 
dependent on ECM adhesion for survival and proliferation. Tumour invasiveness correlates with 
overexpression of integrins which favour proliferation, survival and migration while integrins which 
have negative effects on these behaviours are downregulated (i.e. integrins that secure adhesion to the 
basement membrane, or maintain quiescence) (Felding-Habermann et al. 1992, Desgrosellier et al. 
2010). For example, tumour cell expression of αvβ3, αvβ5, α5β1, α6β4, α4β1, and αvβ6 integrins 
correlates with disease progression in various cancer types (Desgrosellier et al. 2010). Aberrant 
expression of integrins during neoplastic transformation has been implicated in all steps of tumour 
progression, including detachment of tumour cells from the primary site, invasion of ECM, 
intravasation into the blood stream, dissemination through the circulation, extravasation into distant 
target organs, and formation of the secondary lesions (reviewed by (Guo et al. 2004, Desgrosellier et 
al. 2010).   
The angiogenic tumour endothelium expresses high levels of certain integrins, notably αv integrin 
heterodimers and α5β1 (reviewed by (Guo et al. 2004, Weis et al. 2011). Both αvβ3 and αvβ5 integrins 
are known to promote angiogenesis. Cooperation of these integrins with growth factor receptors 
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confers responsiveness to angiogenic growth factors highly expressed in tumours. Integrin αvβ3 is 
overexpressed in activated endothelial cells during tumour-induced angiogenesis, whereas it is absent 
in quiescent endothelial cells and normal tissues (Brooks et al. 1994a). Interaction of bFGF or TNFα 
with integrin αvβ3 downstream of bFGF or TNFα binding induces angiogenesis, whereas angiogenesis 
induced by VEGF or transforming growth factor α (TGF-α) requires the function of integrin αvβ5 
(Friedlander et al. 1995). Preventing ligand binding of αvβ3 and αvβ5 integrins has been shown to 
cause apoptosis of tumour endothelial cells of newly formed blood vessels (Brooks et al. 1994b). As 
these integrins are accessible to circulating ligands, they are attractive targets for therapy. These 
observations have led to the development of peptide agonists and antibodies that mimic ligands of 
these integrins, which have demonstrated inhibition of tumour angiogenesis, growth and metastasis 
(Brooks et al. 1994b, Mitjans et al. 1995, Carron et al. 1998). 
In particular, the Arginine-Glycine-Aspartic acid (RGD) sequence (present on certain matrix proteins 
such as fibronectin, vitronectin, osteospondin, thrombospondin, fibrinogen and von Willebrand factor) 
was identified as a ligand for integrins such as αvβ3, αvβ5 and α5β1 (Pierschbacher et al. 1984, Pytela 
et al. 1985, Suzuki et al. 1986). Soluble cyclic RGD peptides or function-blocking integrin antibodies 
competitively disrupt integrin-ligand binding and perturb integrin-mediated signalling pathways, 
which leads to inhibition of angiogenesis or induction of apoptosis (Brooks et al. 1994b, Brooks et al. 
1995, Buckley et al. 1999). Furthermore, as these integrins are overexpressed in the tumour 
endothelium while absent or barely detectable in normal tissues, systemic delivery of RGD-targeted 
nanoparticles carrying anti-angiogenic or anti-tumour therapeutics can be achieved without damaging 
the vasculature of normal tissues (reviewed by (Temming et al. 2005).  
For these reasons, the tumour-targeted AAVP carries a double-cyclic RGD ligand on the phage pIII 
minor coat protein which is highly selective for αvβ3 and αvβ5 integrins (Koivunen et al. 1995, 
Ruoslahti 1996, Pasqualini et al. 1997, Hajitou et al. 2006). RGD-AAVP has exhibited tumour 
targeting and therapy in several in vivo cancer models. However, despite the apparent success of this 
novel vector in vivo, high titres of AAVP are required for mammalian cell transduction. Integrin-
AAVP interaction was previously shown by either blocking RGD-AAVP binding to the αv integrin-
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positive KS1767 (Karposi’s sarcoma) cell line using synthetic RGD ligand, before cell lysis and 
titration of internalised particles, or by comparison of internalisation of RGD-AAVP or AAVP 
bearing scrambled/mutated ligands by immunofluorescence staining and microscopy (Hajitou et al. 
2006). In vitro experiments have shown that while 100% of cells internalise targeted RGD-AAVP, 
only up to 10% express the transgene (Hajitou et al. 2006, Hajitou et al. 2007). Past these initial 
experiments, little is known about the mechanisms of RGD-AAVP endocytosis and intracellular 
trafficking. Understanding these mechanisms could have important implications for achieving 
efficient gene delivery. To explore the limitations of RGD-AAVP-mediated gene delivery in vitro, 
experiments were first performed to confirm that the angiogenic αv integrin heterodimers mediate 
efficient uptake of the RGD-AAVP vector. These experiments also served to establish in vitro models 
of endocytosis and gene delivery for subsequent investigations. 
3.2. Results 
3.2.1. αv integrin-mediated endocytosis of RGD-AAVP 
The M21 and M21-L cell lines were used to confirm αv integrin-mediated endocytosis of AAVP, and 
to establish a protocol for flow cytometric analysis of internalised AAVP. The adhesion variant M21-
L cell line is derived from the M21 melanoma cell line (which overexpress αv integrin heterodimers), 
but lacks α chain integrin mRNA, which therefore reduces tumourigenicity of the cell line in vivo 
(Cheresh et al. 1987, Felding-Habermann et al. 1992).  
M21 or M21-L cells were incubated with 1x105 BTU/cell of the targeted vector (RGD-AAVP) or 
non-targeted parental vector (fd-AAVP) for 2 hours at 37°C, after which the cells were washed to 
remove unbound virus, trypsinised to remove surface bound virus, and fixed. The cells were 
permeabilised and stained for internal particles (see materials and methods section) using an anti-fd 
phage primary antibody and AlexaFluor-647 conjugated secondary antibody prior to analysis by flow 
cytometry. RGD-AAVP internalisation in αv integrin-deficient M21-L melanoma cells was 
significantly reduced (P<0.001) when compared to αv integrin-positive M21 melanoma cells. Uptake 
of the targeted vector did not differ significantly from uptake of non-targeted control fd-AAVP in 
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M21-L cells (Figure 3.1A). Background fluorescence was determined by staining non-infected cells 
with primary and secondary antibodies, flow cytometer setting were adjusted according to this 
negative control. 
The differential expression of αv integrins in the two cell lines was confirmed by flow cytometry. Live 
cells were stained using FITC-conjugated antibodies against the integrin heterodimers αvβ3 (antibody 
clone LM609) and αvβ5 (clone P1F6). As anticipated, the M21 cells were positive for both 
heterodimers (as described by (Cheresh et al. 1987, Wayner et al. 1991), αvβ3 was particularly 
strongly expressed, while M21-L cells were negative or at levels equal to background fluorescence 
(Figure 3.1B). 
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Figure 3.1. Requirement of αv integrin receptors for cellular entry of RGD-AAVP. 
(A) Uptake of RGD-AAVP and non-targeted fd-AAVP virus was compared in M21 and M21-L cell lines. RGD 
or fd-AAVP was added to cells at 1x105 BTU/cell and incubated for 2 hours. Cells were then washed, fixed and 
immunofluorescence stained using anti-fd-phage primary and goat anti-rabbit AlexaFluor-647 secondary 
antibodies before analysis of phage-associated immunofluorescence by flow cytometry. Experiments were 
performed in triplicate wells, results show the mean fluorescence intensity (FL4) from n=4 experiments, + SEM. 
Statistical analysis was performed using two-way ANOVA, with bonferroni post-test, * p<0.05, ** p<0.01, *** 
p<0.001 (n.s = not significant). (B) αvβ3 and αvβ5 integrin expression was determined by flow cytometry of live 
cells stained with FITC-conjugated mouse anti- αvβ3 and αvβ5 antibodies. Histograms are representative of three 
independent experiments. 
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3.2.2. AAVP endocytosis in four model cell lines 
The study was extended to investigate endocytosis of RGD-AAVP and fd-AAVP in a further four cell 
lines; HEK293 cells, which have been previously used as an in vitro model for transduction by RGD-
AAVP (Hajitou et al. 2006), and three human cancer cell lines; HeLa (cervical cancer), U87 
(glioblastoma), and DU145 (prostate cancer).  
In order to establish the suitability of these cell lines as models for endocytosis of the targeted vector, 
αv integrin expression in the four cell lines was first confirmed by confocal microscopy and flow 
cytomtery. Cells seeded on coverslips were fixed and immunofluorescence-stained using anti- αv 
integrin antibody and AlexaFluor-488 secondary antibody. Immunofluorescence staining for αv 
integrins was detected by confocal microscopy. As shown in Figure 3.2A, all cell lines tested were 
positive for αv integrins, with the integrin-associated staining appearing as punctate patches on the cell 
plasma membrane and dispersed throughout the cytoplasm. Interestingly, integrin localisation to focal 
adhesions on the basolateral face (substratum-facing side) of HeLa and DU145 cells were particularly 
apparent. Cells stained with secondary antibodies were used to determine background fluorescence 
confocal settings adjusted to eliminate background labelling.  
Expression of the integrin heterodimers αvβ3 and αvβ5 was then investigated in the same four cell 
lines. Live cells were stained for the integrin heterodimers using FITC-conjugated antibodies and 
analysed by flow cytometry. As shown in Figure 3.2B, all of the cell lines tested were positive for the 
integrin heterodimers, to varying degrees.  
Uptake of RGD-AAVP and fd-AAVP was then investigated in the four cell lines. HEK293, HeLa, 
U87 or DU145 cells seeded on glass coverslips were incubated with 1x105 BTU/cell RGD-AAVP or 
fd-AAVP for 2 hours at 37°C. After this time, the cells were washed to remove non-bound virus and 
fixed in paraformaldehyde. The cells were blocked and permeabilised before immunofluorescence 
staining with anti-fd phage primary and AlexaFluor-594 secondary antibodies.  The cells were 
analysed by confocal microscopy and representative z-stack projections are shown in Figure 3.3A. 
Internalisation of RGD-AAVP was demonstrated in all cell lines tested, 100% of the cells stained 
positive for the targeted vector (phage is shown in red, DAPI in blue). External phage particles at the 
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cell surface appeared filamentous, while internalised particles appeared spherical, and spread 
throughout the cytoplasm after 2 hours uptake. Cells which received the non-targeted fd-AAVP were 
occasionally positive for the vector, though not to the extent of the targeted vector. Cells which 
received no virus served as staining controls, no immunofluorescence staining was observed in these 
cells. 
Subsequently, AAVP uptake was quantified in the four cell lines by flow cytometry. Cells were 
incubated with the targeted and non-targeted vectors at 1x105 BTU/cell for 2 hours at 37°C. The cells 
were washed to remove non-bound virus and trypsinised to remove surface-bound particles. The cells 
were fixed and permeabilised before immunofluorescence-staining for internalised particles using 
anti-fd phage primary and AlexaFluor-647 secondary antibodies. Flow cytometric analysis of AAVP-
associated fluorescence revealed that internalisation of the targeted vector was significantly greater 
than the non-targeted vector in HEK293 (P<0.001), HeLa (P<0.001), U87 (P<0.001), and DU145 
(P<0.01) cell lines (Figure 3.3B), consistent with results from the confocal experiments.  
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 Figure 3.2. Detection of αv integrin receptors in four model cell lines. 
(A) HEK293, HeLa, U87 and DU145 cells were seeded on coverslips and fixed before immunofluorescence 
staining using rabbit anti-αv-integrin primary and goat anti-rabbit AlexaFluor-488 secondary antibodies. αv 
integrin-associated fluorescence is shown in green and nuclei (DAPI) in blue, scale bars= 10 µm.(B) αvβ3 and 
αvβ5 integrin expression was determined by flow cytometry of live cells stained with FITC-conjugated mouse 
anti- αvβ3 and αvβ5 antibodies. Histograms are representative of three independent experiments. 
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 Figure 3.3. Uptake of RGD-AAVP and fd-AAVP in four model cell lines. 
(A) HEK293, HeLa, U87 and DU145 cells were incubated with 1x105 BTU/cell of RGD or fd-AAVP for 2 
hours. Cells were washed, fixed and immunofluorescence stained using anti-fd-phage primary and goat anti-
rabbit AlexaFluor-594 secondary antibodies before analysis of phage-associated immunofluorescence by 
confocal microscopy. Phage-associated fluorescence is shown in red and nuclei (DAPI) in blue, scale bars= 10 
µm. (B) Uptake of RGD-AAVP and fd-AAVP was measured in the four cell lines by flow cytometry. Cells 
were incubated with 1x105 BTU/cell for 2 hours before fixation and immunofluorescence staining. Experiments 
were performed in triplicate wells, results represent the mean fluorescence intensity (FL4) from n=3 
experiments, + SEM. Statistical analysis was performed using one-way ANOVA, with bonferroni post-test, * 
p<0.05, ** p<0.01, *** p<0.001. 
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3.2.3. RGD-AAVP-mediated transgene expression in four model cell lines 
Having established the presence of αvβ3 and αvβ5 heterodimers, and high levels of RGD-AAVP 
uptake, RGD-AAVP-mediated gene delivery was investigated in the four model cell lines. Time-
course experiments were performed to establish levels of AAVP-mediated luciferase reporter gene 
expression over time, and to establish a time of peak transgene expression in vitro. Cells were 
transduced with 1x106 BTU/cell (in line with previous experimental procedures (Hajitou et al. 2006)) 
RGD-AAVP or fd-AAVP bearing the luciferase reporter gene (RGD-AAVP-LUC or fd-AAVP-LUC) 
and assayed for luciferase expression at Day 0 (D0, immediately after transduction), D1, D2, D3, D5 
and D7 post-transduction. Luciferase expression was normalised to protein levels, as determined by 
Bradford assay. Non-transduced cells served as negative controls, to show background luminescence 
levels. AAVP-mediated luciferase expression was detected in HEK293 and U87 cells between 24 and 
48 hours post-transduction, consistent with previously published data (Hajitou et al. 2006). RGD-
AAVP-mediated luciferase expression was observed to climb over the 7 days post-transduction, after 
which the cells could no longer be maintained in culture. Transduction with the targeted vector was 
consistently higher than the non-targeted control over all the experimental repeats in these cell lines. 
However, no luciferase expression was observed in HeLa or DU145 cells at any time, relative 
luminescence units were determined as background by comparison to non-transduced (NT) cells 
(Figure 3.4). Next, AAVP-mediated transgene expression was further investigated in the cell line 
perceived as the most ‘permissive’ to the vector. HEK293 cells were transduced with RGD-AAVP-
LUC and fd-AAVP-LUC constructs at 1x103, 1x104, 5x104, 1x105, 2.5x105, 5x105, or 1x106 BTU/cell. 
The HEK293 cells which received RGD-AAVP-LUC or control fd-AAVP-LUC were lysed at day 7 
post-transduction for luciferase assay and normalised to protein concentration. The data in Figure 
3.5A demonstrate that in HEK293 cells, transgene expression is dose-dependent. In order to 
determine the transduction efficiency in terms of percentage of cells expressing transgenes, HEK293 
cells were also transduced with RGD-AAVP and fd-AAVP bearing the GFP reporter gene at 1x106 
BTU/cell and the number of GFP-positive cells was determined at day 7 post-transduction using flow 
cytometry. An example GFP vs. side-scatter plot is shown (Figure 3.5B). HEK293 cells transduced 
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with RGD-AAVP-GFP at 1x106 TU/cell demonstrate typically low transduction efficiency, with 2.5% 
GFP positive cells at day 7. Non-targeted AAVP also demonstrated some ability to transduce cells at 
this titre, but again this was much lower than the targeted vector (0.4% transduction efficiency).  
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Figure 3.4. AAVP-mediated luciferase expression in four model cell lines. 
Time-courses measuring AAVP-mediated luciferase expression were performed in HEK293, HeLa, DU145 and 
U87 cell lines. Cells were transduced with 1x106 BTU/cell RGD-AAVP-LUC or fd-AAVP-LUC for 4 hours. 
Luciferase assays were performed immediately after transduction (day 0) and on days 1, 2, 3, 5 and 7 post-
transduction and normalised to protein concentration. The results show the mean relative luminescence units 
(RLU) per 100 µg protein of triplicate wells ± SEM, from one representative of three independent experiments. 
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Figure 3.5. Transduction efficiency of RGD-AAVP in HEK293 cells. 
(A) HEK293 cells were transduced with increasing BTU/cell RGD-AAVP-LUC or fd-AAVP-LUC for 4 hours. 
Luciferase assays were performed on day 7 post-transduction and normalised to protein content. The results 
show the mean relative luminescence units (RLU) per 100 µg protein of triplicate wells + SEM, from one 
representative of two independent experiments. (B) Percentage transduction efficiency was determined in 
HEK293 cells transduced with 1x106 BTU/cell RGD-AAVP-GFP or fd-AAVP-GFP for 4 hours. GFP 
expression was determined by flow cytometry of cells fixed at day 7 post-transduction. Representative dot plots 
of GFP vs. SS are shown, gates to indicate positive cells were placed using non-transduced cells as a negative 
control (not shown), percentage positive cells after transduction with RGD-AAVP-GFP or fd-AAVP-GFP are 
indicated.  
 
 
 
 
 
 
105
3.3. Discussion 
The RGD-AAVP vector has demonstrated in vivo tumour targeting and therapy in several cancer 
models, however this process is inefficient. In previous reports, it was demonstrated that while all 
targeted cells internalise the vector, only up to 10 % have detectable levels of transgenes expression 
(Hajitou et al. 2006, Hajitou et al. 2007). A key limitation of gene therapy is circumvention of the 
plasma membrane to deliver transgenes to target cells. Incorporation of ligands which promote 
endocytosis is therefore a widely used approach in the development of gene therapy vectors. This 
strategy has been employed in AAVP through display of RGD ligands on the pIII minor coat protein 
which are capable of binding to αv integrins. The efficiency by which this interaction promotes 
internalisation of the vector is therefore a major factor in determining transgene delivery. 
The aim of the present study was firstly to establish a quantifiable method for measuring vector 
internalisation in mammalian cells, in order to determine whether the vector is efficiently endocytosed 
into targeted cells expressing the integrin receptors. A second aim was to validate cell lines as models 
for further experiments investigating endocytosis and intracellular trafficking, with a view to further 
elucidating the limitations of RGD-AAVP-mediated gene transfer. 
In previous studies, the principle experiments for quantifying uptake of phage in mammalian cells 
involved lysis of the cells and titration of released phage by infection of E.coli and plaque assay 
(Ivanenkov et al. 1999a). These procedures were attempted during the course of these investigations, 
however they were found to be technically demanding and as a result there was large amount of 
variability observed between experiments. Therefore, new methods of detection of internalised AAVP 
were developed in order to reduce variability between experiments.  A protocol for flow cytometric 
analysis of immunofluorescently labelled internalised AAVP particles was developed and validated 
using the M21 and M21-L cell lines. The adhesion variant M21-L cell line is derived from the M21 
melanoma cell line (which overexpresses αv integrins), but lacks α chain integrin mRNA and therefore 
lacks αv integrin heterodimers (Cheresh et al. 1987). Internalisation of targeted (RGD) and non-
targeted (fd)-AAVP was compared in M21 and M21-L cells, and the presence of the αvβ3 and αvβ5 
integrin heterodimers confirmed by flow cytometry. As anticipated, endocytosis of RGD-AAVP was 
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significantly reduced in M21-L cells lacking the integrins compared to M21 cells (Figure 3.1A), 
which stained positive for the heterodimers (Figure 3.1B). Non-specific uptake was demonstrated 
using the of fd-AAVP control, uptake of which was significantly lower than the targeted vector in 
M21 cells. These data validate the use of flow cytometry to analyse AAVP internalisation, and 
reinforce previous findings that endocytosis of RGD-AAVP is mediated by αv integrin heterodimers.   
In order to establish model cell lines for subsequent analysis of RGD-AAVP intracellular trafficking, 
four candidate cell lines were chosen for analysis of integrin expression and AAVP endocytosis. The 
cell lines chosen were HEK293 cells, which have been previously used as an in vitro model for 
transduction by RGD-AAVP (Hajitou et al. 2006), and three human cancer cell lines; HeLa (cervical 
cancer), U87 (glioblastoma), and DU145 (prostate cancer). Integrin expression in the four cell lines 
was confirmed by confocal microscopy and flow cytometry (Figure 3.2). Endocytosis of RGD-AAVP 
and fd-AAVP in the four cell lines was also analysed by confocal microscopy and flow cytometry 
(Figure 3.3). Interestingly, flow cytometric analysis revealed that endocytosis of RGD-AAVP was 
lower in HeLa and DU145 cells compared to HEK293 cells, despite higher levels of surface integrin 
expression.  This may be due to the surface availability of the integrin receptors to the phage. 
Confocal analysis of integrin expression showed distinct patches of integrin expression on the 
basolateral face of HeLa and DU145 cells, which may be the sites of focal adhesions. Sequestration of 
integrins to focal adhesion sites in certain cell types may restrict the number of receptors available to 
the phage applied to the culture medium and therefore result in lower levels of endocytosed vector in 
vitro. 
Having established the four cell lines as models for receptor-mediated endocytosis of RGD-AAVP, 
the efficiency of transgene expression was next analysed. Timecourses of AAVP-mediated luciferase 
expression were performed to identify the peak of transgene expression. AAVP-mediated luciferase 
expression was detected in HEK293 and U87 cells between 24 and 48 hours post-transduction, 
consistent with previously published data (Hajitou et al. 2006), and observed to climb over 7 days 
post-transduction (Figure 3.4). Transduction with the targeted vector was consistently higher than the 
non-targeted control over all the experimental repeats in HEK293 and U87 cell lines. However, no 
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luciferase expression was observed in HeLa or DU145 cells at any time. It is unclear why some cell 
lines appear permissive to transduction by RGD-AAVP while others are not. This may be a dose-
dependent effect, as HeLa and DU145 cells endocytosed lower amounts of the vector than HEK293 
and U87 cells. Dose-dependence in relation to transgene expression was demonstrated in HEK293 
cells transduced with increasing titres of RGD-AAVP-LUC or fd-AAVP-LUC (Figure 3.5A). 
However, while transgene expression was shown to be dose-dependent, transduction efficiency 
remained low when cells were incubated with high titres of phage particles. Transduction of HEK293 
cells (which are perceived to be the most permissive to AAVP transduction) with RGD-AAVP-GFP 
at 1x106 BTU/cell  resulted in only 2.5% transduction efficiency by day 7 post transduction (Figure 
3.5B). These data support the findings of Hajitou et al. who demonstrated that while all of the cells 
incubated with the targeted vector internalised the RGD-AAVP, only modest transgene expression 
was observed in vitro (Hajitou et al. 2006, Hajitou et al. 2007).  
 The apparent discrepancy between reporter gene expression in vitro and reported therapeutic efficacy 
in vivo is likely due to a combination of factors. In vivo therapeutic data can be partially attributed to 
amplification of therapeutic effect by choice of therapeutic transgenes. Tumour therapy was 
demonstrated using GDEPT therapy by delivery of HSVtk gene in combination with the prodrug GCV 
to several in vivo models of cancer, including immunodeficient mice bearing human Karposi’s 
sarcoma (KS1767) and DU145-derived prostate carcinomas. RGD-AAVP-HSVtk has also 
demonstrated therapy in immunocompetant BALB/c mice bearing subcutaneous EF43-FGF4 
mammary tumours (Hajitou et al. 2006) and athymic rats bearing human soft tissue sarcoma (Hajitou 
et al. 2008). An advantage of GDEPT is that the toxic form of the prodrug is able to pass to 
neighbouring cells through intercellular gap junctions (Touraine et al. 1998), via apoptotic vesicles 
(Freeman et al. 1993), or through diffusion of soluble toxic metabolites (Wei et al. 1995). Therefore, 
this bystander effect reduces the proportion of tumour cells that need to be transduced in order to 
mediate therapeutic effect. AAVP was recently shown to mediate tumour cell killing in vitro and in 
vivo via a heterotypic bystander effect between HSVtk-transduced endothelial cells and non-
transduced tumour cells (Trepel et al. 2009).  The bystander effect resulted in significant tumour 
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regression and reduced the need for high numbers of cells to be transduced in order to mediate a 
therapeutic effect. Furthermore, given the estimates that up of 100 tumour cells are sustained by a 
single endothelial cell (Folkman 1997), gene targeting of angiogenic vasculature often leads to 
enhanced therapeutic efficacy in vivo. Therefore, while the transduction efficiency of RGD-AAVP is 
low, the therapeutic effect in vivo is likely to be substantially increased by the combination of tumour 
endothelium destruction and heterotypic bystander effect from the GDEPT therapy. 
Improvement of RGD-AAVP-mediated gene delivery is desirable in order to further enhance 
therapeutic effect and reduce the need for repeated doses in vivo. The data presented in the current 
chapter illustrate the need for improved transgene delivery, as high titres of RGD-AAVP are required 
to mediate only very modest reporter gene expression in vitro. Given that receptor-mediated 
endocytosis of the vector appears to be efficient, it is likely that downstream trafficking events limit 
efficacy of gene delivery. Therefore, these studies underline the requirement for further elucidation of 
the endocytosis and intracellular trafficking mechanisms involved in RGD-AAVP uptake and gene 
delivery. 
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4. Endocytosis and intracellular trafficking of AAVP 
 
4.1. Introduction 
RGD-AAVP has the capacity to transduce mammalian cells both in vitro and in vivo, albeit at low 
efficiency. The process of transgene delivery is presumably inefficient because bacteriophage are 
prokaryotic viruses that have not undergone the evolutionary adaptations necessary for transduction of 
mammalian cells. Inclusion of AAV-2-derived ITRs in the genome of the AAVP vector has improved 
transgene expression over conventional phage-based vectors, but reporter gene expression remains 
low compared to eukaryotic virus-derived vectors (Hajitou et al. 2006, Hajitou et al. 2007). Given that 
cellular entry of the vector appears to be efficient (as demonstrated in the previous chapter), it was 
hypothesised that the intracellular vectors may be sequestered by the degradative pathways which 
eukaryotic viruses are able to avoid.  
As described in the preceding chapter, the targeted AAVP vector carries an RGD ligand which allows 
binding and internalisation via the angiogenic αvβ3 and αvβ5 integrin heterodimers. Integrins are 
continuously endocytosed and recycled through interactions with the ECM, as part of the processes 
mediating cell adhesion, migration and maintenance of cell polarity. The way in which they are 
endocytosed influences their function (Caswell et al. 2009). Integrins are known to be endocytosed by 
clathrin-mediated endocytosis, caveolae-mediated endocytosis, and clathrin- and caveolin-
independent endocytosis (including macropinocytosis). It is also possible that a given type of integrin 
heterodimer follows more than one route to internalisation depending on regions within a cell, cell 
conditions, and cell type (Margadant et al. 2011). For example, α5β1 integrins can be internalised by 
both caveolar endocytosis during fibronectin turnover (Shi et al. 2008), and clathrin-dependent 
endocytosis during focal adhesion disassembly (Ezratty et al. 2009). Similarly αvβ3 integrins can be 
recruited to caveolae and internalised in a cholesterol and caveolin-1-dependent manner (Galvez et al. 
2004), and can also internalise via clathrin-mediated endocytosis (De Deyne et al. 1998, Nishimura et 
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al. 2007). Furthermore, following growth factor signalling, β3 integrins can be redistributed to, and 
internalised via circular dorsal ruffles and macropinocytosis during cell migration (Gu et al. 2011). 
Integrins are also commonly used by pathogens for invasion of eukaryotic cells. In a similar manner 
to ECM association, virus binding induces integrin clustering or conformational changes in integrin 
quaternary structure which elicit cell-signalling events leading to increased ligand avidity and 
promotion of cytoskeletal arrangements and internalisation (Stewart et al. 2007). αv integrins are 
commonly used receptors (or co-receptors) for entry of eukaryotic viruses, recognising RGD 
sequences displayed on the exposed loops of viral capsid proteins of several adenovirus serotypes, 
foot and mouth disease virus (FMDV), and coxsackievirus A9 (Fox et al. 1989, Roivainen et al. 1991, 
Wickham et al. 1993), among others. Adenovirus serotype 2 is one such example. Binding to the cell 
surface is mediated by high affinity interactions between the adenovirus fiber knob and the Coxsackie 
and Adenovirus Receptor (CAR). A second low-affinity interaction between RGD domains on the 
adenovirus penton base and αvβ3 and αvβ5 integrins triggers receptor-mediated endocytosis into 
clathrin-coated pits (Wickham et al. 1993, Meier et al. 2002). Following endocytosis, the virus is then 
able to rapidly escape the endosome to the cytosol and avoid lysosomal degradation in a step 
attributed to the penton base (Medina-Kauwe 2003). Similarly, FMDV interacts with αv integrins 
through a conserved RGD sequence on the βG-βH loop of the capsid protein VP1. Binding initiates 
clathrin-mediated endocytosis and intracellular trafficking to the early endosomes, from which the 
virus escapes in order for viral replication to occur (O'Donnell et al. 2005). αv integrins have also been 
demonstrated to support virus entry via clathrin-independent endocytosis. Herpes Simplex Virus 
(HSV) was observed to enter CHO-nectin 1 (nectin 1 is a major HSV receptor which is bound by the 
viral Glycoprotein D) cells expressing αvβ3 integrins through a pathway dependent on lipid rafts and 
dynamin, but not caveolin-1 (Gianni et al. 2010). Coxsackievirus A9 (CAV9) is able to enter A549 
human lung carcinoma cells in a caveolin- and clathrin-independent, but dynamin-dependent manner 
(Heikkila et al. 2010). Furthermore, αv integrin binding by adenovirus serotypes 2, 3 and 5 has also 
been demonstrated to activate phosphatidylinositol (PI) 3-kinase (PI3K) cell signalling pathways and 
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Rho family GTPases to induce macropinocytosis in HeLa cells, together with its clathrin-mediated 
uptake (Meier et al. 2002, Amstutz et al. 2008). 
From the given examples, it is clear that αv integrin-binding can mediate virus entry through several 
distinct endocytic pathways. In order to investigate the entry and intracellular events involved in 
RGD-AAVP uptake, a combination of pharmacological agents, dominant negative mutants and RNA 
interference (RNAi) were used together with flow cytometry, confocal, and electron microscopy. 
Entry experiments were carried out in HEK293 and HeLa cells, and intracellular trafficking in 
HEK293, HeLa, U87 and DU145 cells to determine cell-type specificity of the observed events. 
Transferrin and Cholera Toxin subunit B protein markers were used as controls for inhibition of these 
trafficking pathways. Transferrin is a commonly used marker for clathrin-mediated endocytosis, and it 
is reported that its uptake is mediated exclusively by this pathway (Willingham et al. 1984). Cholera 
toxin subunit B (which lacks the toxic A subunit) was used as an alternative endocytic marker, cholera 
toxin has been reported to follow caveolar/lipid raft-mediated as well as clathrin-mediated pathways 
(Orlandi et al. 1998, Torgersen et al. 2001), so cholera toxin B was included in these investigations as 
an alternative to transferrin. 
4.2. Results  
4.2.1. Endocytosis of RGD-AAVP 
4.2.1.1. Dynamin is required for uptake of RGD-AAVP 
In order to elucidate the mechanisms involved in endocytosis of RGD-AAVP, the effect of dynamin 
inhibition on entry of the vector was first investigated.  As previously described, dynamin is a 
cytosolic GTPase which is required for clathrin-mediated endocytosis as well as formation of 
caveolae but is not required for macropinocytosis (Damke et al. 1994, Damke et al. 1995, Henley et 
al. 1998). Dynamin is involved in vesicle budding from the plasma membrane, and inhibition of its 
activity arrests vesicle formation at the stage of clathrin coat formation or vesicle scission (van der 
Bliek et al. 1993). 
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Dyansore, a pharmacological agent which functions as an acute  inhibitor of dynamin 1 and dynamin 
2 GTPase activity in vitro and blocks endocytic functions previously shown to require dynamin 
(Macia et al. 2006, Thompson et al. 2006), was first utilised to study the effect of dynamin inhibition 
on uptake of the vector. Non-toxic concentrations of dynasore were first determined using the MTT 
cell viability assay (Figure 4.1A). HEK293 cells were treated with increasing concentrations of the 
agent for 4 hours and cell viability analysis performed 48 hours later. Chemical agent concentrations 
which resulted in less than 20% cell death were deemed non-toxic for all of the following 
experiments. A dynasore concentration of 80 µM was therefore used for uptake experiments involving 
dynasore. 
HEK293 cells were treated with 80 µM dynasore for 30 minutes prior to, and during incubation with, 
RGD-AAVP, fd-AAVP (1x105 BTU/cell), fluorescently-labelled transferrin (5 µg/ml) or cholera toxin 
B (1 µg/ml). The cells which received AAVP were fixed after 2 hours and immunofluorescence-
stained for internalised phage particles (see materials and methods). Cells which received transferrin 
or cholera toxin were fixed after 30 minutes. Internalised transferrin, cholera toxin and phage-
associated fluorescence were determined by flow cytometry. Flow cytometric analysis revealed a 
marked decrease in the uptake of RGD-AAVP (P<0.05), transferrin (P<0.05) and cholera toxin 
(P<0.05), in the presence of dynasore, while the vehicle control DMSO had little or no effect on 
endocytosis (Figure 4.1B). The mean decrease in uptake of RGD-AAVP was 42.5% (SEM 7.5%) in 
three independent experiments. 
In order to confirm the involvement of dynamin in RGD-AAVP entry, the effect of expression of the 
GFP-tagged dominant negative mutant dynamin II-K44A was investigated, which is defective in GTP 
binding and hydrolysis (Damke et al. 1994). This construct has been demonstrated to inhibit both 
clathrin and caveolar-mediated endocytosis, but not constitutive pinocytosis (Damke et al. 1994, 
Damke et al. 1995, Henley et al. 1998). 
HEK293 cells were transiently transfected with dynamin II-K44A 24 hours prior to addition of RGD-
AAVP, fd-AAVP (1x105 BTU/cell) or transferrin or cholera toxin B controls. Internalised phage or 
control-associated fluorescence was determined by flow cytometry. HEK293 cells expressing 
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dynamin II-K44A showed a significant decrease in endocytosis of RGD-AAVP (P<0.001), with a 
mean decrease of 45.6% (SEM 11.4%) across three independent experiments. Significant inhibition of 
Transferrin (P<0.001), and cholera toxin B (P<0.01) controls were also observed compared to non-
transfected controls (Figure 4.2).  
Inhibition of RGD-AAVP, transferrin, and cholera toxin B uptake by dynamin II-K44A was 
demonstrated by confocal microscopy in HEK293 and HeLa cells. Cells were transiently transfected 
24 hours prior to addition of RGD-AAVP (1x105 BTU/cell), transferrin, or cholera toxin B. Internal 
and external phage were discriminated through a double-immunofluorescence-staining protocol; 
external phage particles were first immunofluorescently stained before permeabilisation of the cells 
and staining for internal phage. Representative z-stack projections of HEK293 cells are shown in 
Figure 4.3. Internalised RGD-AAVP (Figure 4.3Bi) was observed as punctuate spherical structures 
in the cytoplasm, whereas the majority of external phage appears filamentous. A 57% decrease in the 
mean number of internalised particles was observed in the cells expressing dynamin II-K44A-GFP 
compared to non-transfected cells (P<0.001, Figure 4.3A). Transferrin and cholera toxin B were used 
as positive controls, uptake of which was strongly inhibited by expression of dynamin II-K44A-GFP 
(Figure 4.3Bii and Figure 4.3Biii). A 65% decrease in particle uptake was also observed in dynamin 
II-K44A transfected HeLa cells, demonstrating that this effect is not limited to HEK293 cells. 
Representative z-stack projects of transferrin, cholera toxin B and RGD-AAVP inhibition by dynamin 
II-K44A in HeLa cells are shown in Figure 4.4.  
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Figure 4.1. Flow cytometric analysis of AAVP uptake in dynasore-treated HEK293 cells. 
(A) Non-toxic concentrations of dynasore were determined by MTT assay. Cells were treated with increasing 
concentrations of the inhibitor for 4 hours and assayed 48 hours later.  Non-toxic concentrations were 
determined as those which resulted in less than 20% cell death. Mean cell viability was normalised to non-
treated controls, with the mean of n=3 independent experiments shown. (B) The effect of dynasore on uptake of 
RGD-AAVP (black bars), transferrin-647 (white bars), and cholera toxin B-647 (grey bars), was investigated in 
HEK293 cells. Cells were pre-treated with dynasore for 30 minutes prior to addition of the virus and protein 
conjugates. Cells which received the controls were fixed after 30minutes. Cells which received AAVP were 
fixed and immunofluorescence-stained using rabbit anti-fd primary and goat anti-rabbit AlexaFluor-647 
secondary antibodies after 2 hours incubation. Mean fluorescence intensity values were calculated from RGD-
AAVP fluorescence normalised to non-specific fluorescence from non-targeted fd-AAVP uptake. Mean 
fluorescence intensity is expressed as a percentage of control cells (cells which did not receive dynasore), data 
represent the mean + SEM of triplicate samples from one representative experiment of three, significant 
difference; n.s-not significant, * p<0.05, ** p<0.01, *** p<0.001 (one way ANOVA with Bonferroni post-test). 
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Figure 4.2. Flow cytometric analysis of AAVP uptake in dynamin II-K44A-transfected HEK293 cells. 
The effect of dynamin II-K44A expression on uptake of RGD-AAVP (black bars), transferrin-647 (white bars), 
and cholera toxin B-647 (grey bars), was investigated in HEK293 cells. Cells were transfected 24 hours prior to 
addition of the virus and protein conjugates. Cells which received the controls were fixed after 30 minutes. Cells 
which received AAVP were fixed and immunofluorescence-stained using rabbit anti-fd primary and goat anti-
rabbit AlexaFluor-647 secondary antibodies after 2 hours incubation. Mean fluorescence intensity values were 
calculated from RGD-AAVP fluorescence normalised to non-specific fluorescence from non-targeted fd-AAVP 
uptake. Mean fluorescence intensity is expressed as a percentage of control cells (non-transfected), data 
represent the mean + SEM of triplicate samples from one representative experiment of three, significant 
difference; n.s-not significant, * p<0.05, ** p<0.01, *** p<0.001 (two-tailed student’s t-test). 
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Figure 4.3. Confocal analysis of RGD-AAVP uptake in dynamin II-K44A-transfected HEK293 cells. 
RGD-AAVP, transferrin and cholera toxin B uptake was assessed in GFP-tagged dynamin II-K44A-transfected 
HEK293 cells by confocal microscopy. The cells were fixed and stained after incubation with RGD-AAVP for 2 
hours, or transferrin/cholera toxin B controls for 30 minutes. The cells were first stained for external phage 
(RGD-AAVP Ex) using anti-fd-phage primary and goat anti-rabbit AlexaFluor-594 secondary antibodies before 
permeabilisation and immunofluorescence staining for internal particles (RGD-AAVP Int) using the same 
primary and goat anti-rabbit AlexaFluor-647 antibodies. (A) Internalised RGD-AAVP particles were counted in 
the transfected and non-transfected cells, n=number of cells in which particles were counted. Data represent the 
mean + SEM normalised to non-transfected control cells from one representative experiment of two, significant 
difference; n.s-not significant, * p<0.05, ** p<0.01, *** p<0.001 (two-tailed Student’s t-test) (B) Representative 
confocal z-stack projections are shown. The upper panels (Bi) show external (red) and internal (blue) RGD-
AAVP. Internalisation of the control AlexaFluor-594 transferrin (Bii) and cholera toxin B (Biii) are shown in 
red. Transfected cells are shown in green. Scale bars =10 μm. 
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Figure 4.4. Confocal analysis of RGD-AAVP uptake in dynamin II-K44A-transfected HeLa cells.  
RGD-AAVP, transferrin and cholera toxin B uptake was assessed in GFP-tagged dynamin II-K44A-transfected 
HeLa cells by confocal microscopy. The cells were fixed and stained after incubation with RGD-AAVP for 2 
hours, or transferrin/cholera toxin B controls for 30 minutes. The cells were first stained for external phage 
(RGD-AAVP Ex) using anti-fd-phage primary and goat anti-rabbit AlexaFluor-594 secondary antibodies before 
permeabilisation and immunofluorescence staining for internal particles (RGD-AAVP Int) using the same 
primary and goat anti-rabbit AlexaFluor-647 antibodies. (A) Internalised RGD-AAVP particles were counted in 
the transfected and non-transfected cells, n=number of cells in which particles were counted. Data represent the 
mean + SEM normalised to non-transfected control cells from one representative experiment of two, significant 
difference; n.s-not significant, * p<0.05, ** p<0.01, *** p<0.001 (two-tailed Student’s t-test) (B) Representative 
confocal z-stack projections are shown. The upper panels (Bi) show external (red) and internal (blue) RGD-
AAVP. Internalisation of the control AlexaFluor-594 transferrin (Bii) and cholera toxin B (Biii) are shown in 
red. Transfected cells are shown in green. Scale bars =10 μm. 
 
118
4.2.1.2. Clathrin is required for uptake of RGD-AAVP 
Having established a role for dynamin in cellular entry of RGD-AAVP, the involvement of clathrin in 
entry of the vector was investigated, as dynamin is essential for clathrin-mediated endocytosis. The 
ability of sucrose to inhibit clathrin-mediated endocytosis was first studied. Hyperosmolar sucrose 
treatment has been shown to lead to the formation of clathrin microcages on the inner surface of the 
plasma membrane which depletes the cytoplasmic pools of clathrin necessary for normal coated pit 
formation (Heuser et al. 1989). Non-toxic concentrations of sucrose were first determined by MTT 
cell viability assay (Figure 4.5A). HEK293 cells were incubated with increasing concentrations of 
sucrose for 4 hours and viability assayed 48 hours later. Concentrations of up to 0.4M were 
determined non-toxic for the subsequent experiments. 
HEK293 cells were treated with 0.4 M sucrose for 30 minutes prior to, and during incubation with, 
RGD or fd-AAVP (1x105 BTU/cell), transferrin, or cholera toxin B. Cells were incubated with the 
viruses for 2 hours or protein conjugates for 30 minutes before fixation. AAVP-treated cells were 
immunofluorescence stained for internalised particles. Flow cytometric analysis revealed a significant 
decrease (P<0.001) in uptake of the targeted vector (Figure 4.5). The mean decrease in phage-
associated fluorescence was 42.1% (SEM 0.6%) across three independent experiments. The ability of 
sucrose to inhibit clathrin-mediated endocytosis was again determined by measuring uptake of 
transferrin, treatment with 0.4 M sucrose significantly decreased (P<0.001) uptake of transferrin 
compared to non-treated cells. Interestingly, cholera toxin B uptake was also significantly decreased 
in these cells after sucrose treatment (P<0.001). 
In order to further elucidate the involvement of clathrin in endocytosis of RGD-AAVP, a dominant 
negative inhibitor of the clathrin pit component EGFR pathway substrate 15 (Eps15) was utilised. The 
dominant negative mutant of Eps15, which contains a deletion of the Eps15 homology (EH) domain 
(EΔ95/295, also known as EH29) is defective in recruitment of the AP-2 adapter protein to the plasma 
membrane and results in arrested formation of clathrin-coated pits (Benmerah et al. 1999). Inhibition 
of Eps15 has previously been shown to prevent clathrin-mediated endocytosis of transferrin (Carbone 
et al. 1997, Benmerah et al. 1998). 
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HEK293 cells were transiently transfected with GFP-tagged EH29 construct 24 hours prior to addition 
of RGD-AAVP, fd-AAVP (1x105 BTU/cell), or transferrin or cholera toxin B controls. Internalised 
phage or control-associated fluorescence was determined by flow cytometry (Figure 4.6). Uptake of 
RGD-AAVP was not significantly altered by expression of the dominant negative mutant. However, 
transferrin uptake decreased (P<0.001), demonstrating that Eps15 was indeed inhibited. No change in 
cholera toxin B uptake was observed in transfected cells (Figure 4.6).  
Confocal experiments were performed in HEK293 and HeLa cells to confirm the flow cytometry data. 
Cells were transiently transfected 24 hours prior to addition of RGD-AAVP (1x105TU/cell), 
transferrin, or cholera toxin B. Internal and external phage were again discriminated through a double-
immunofluorescence-staining protocol; external phage particles were first immunofluorescently 
stained before permeabilisation of the cells and staining for internal phage. Expression of EH29 had 
no effect on the number of internalised RGD-AAVP particles (Figure 4.7A). Representative z-stack 
projections of transfected HEK293 cells are shown in Figure 4.7B. Uptake of transferrin was 
inhibited by expression of EH29 (Figure 4.7Bii) while cholera toxin B uptake appeared unchanged 
(Figure 4.7Biii). Similar results were observed by confocal analysis of HeLa cells (Figure 4.8), 
representative z-stack projections demonstrate that while RGD-AAVP and cholera toxin B were not 
affected by expression of EH29, transferrin endocytosis was inhibited by expression of the dominant 
negative mutant (Figure 4.8Bii)  
Given the conflicting data between experiments using sucrose and EH29 for inhibition of RGD-
AAVP uptake, a third inhibitor of clathrin was also employed. Clathrin-mediated endocytosis of the 
vector was investigated using siRNAs against clathrin heavy chain (isoform 17). HEK293 cells were 
transfected with two siRNAs against clathrin heavy chain (siCHC1 and siCHC2) 72 hours prior to 
uptake experiments. Non-targeted siRNAs were used as a control for off-target effects of transfection. 
RGD-AAVP or fd-AAVP (1x105 BTU/cell) were applied to the cells and incubated for 2 hours before 
fixation and immunofluorescence staining for internalised phage particles. Transferrin was used as a 
control for inhibition of clathrin-mediated endocytosis. Flow cytometric analysis revealed a marked 
decrease (P<0.001) in phage-associated fluorescence following treatment with siCHC1, with a mean 
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decrease in phage-associated fluorescence of 41.8 % (SEM 8.2%) compared to cells transfected with 
negative control siRNA, across three independent experiments (Figure 4.9A). Transfection with the 
second siRNA, siCHC2, also significantly inhibited endocytosis of the vector (P<0.05), though less 
efficiently than with siCHC1 (with 27.9 % inhibition across three experiments, SEM 5.2 %). Off-
target effects of transfection were minimal, as there was little effect from transfection with non-
targeted control siRNA. These data are mirrored by the transferrin control, uptake of which was also 
significantly inhibited (P<0.001) by transfection with the two siRNAs, again the negative control 
siRNA had no effect on uptake. siRNA-mediated knock-down of CHC expression was confirmed by 
western blot.  Cells to be analysed by western blotting were transfected at the same time as those used 
for uptake experiments. As shown in Figure 4.9B, transfection with negative control siRNA had no 
apparent effect on clathrin expression, whereas cells receiving siCHC1 and siCHC2 were depleted of 
clathrin heavy chain (GAPDH was used as a protein loading control). siCHC2-mediated clathrin 
knockdown was less efficient than siCHC1, this observation is reflected in the flow cytometry data. 
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Figure 4.5. Flow cytometric analysis of AAVP uptake in sucrose-treated HEK293 cells. 
(A) Non-toxic concentrations of sucrose were determined by MTT assay. Cells were treated with increasing 
concentrations of the inhibitor for 4 hours and assayed 48 hours later.  Non-toxic concentrations were 
determined as those which resulted in less than 20% cell death. Mean cell viability was normalised to non-
treated controls, with the mean of n=3 independent experiments shown. (B) The effect of sucrose on uptake of 
RGD-AAVP, transferrin-657, and cholera toxin B-647, was investigated in HEK293 cells. Cells were pre-
treated with sucrose for 30 minutes prior to addition of the virus and protein conjugates. Cells which received 
the controls were fixed after 30 minutes. Cells which received AAVP were fixed and immunofluorescence-
stained using rabbit anti-fd primary and goat anti-rabbit AlexaFluor-647 secondary antibodies after 2 hours 
incubation. Mean fluorescence intensity values were calculated from RGD-AAVP fluorescence normalised to 
non-specific fluorescence from non-targeted fd-AAVP uptake. Mean fluorescence intensity is expressed as a 
percentage of control cells (cells which did not receive sucrose), data represent the mean + SEM of triplicate 
samples from one representative experiment of three, significant difference; n.s-not significant, * p<0.05, ** 
p<0.01, *** p<0.001 (two-tailed Student’s t-test). 
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Figure 4.6. Flow cytometric analysis of AAVP uptake in EH29-transfected HEK293 cells.  
he effect of EH29 expression on uptake of RGD-AAVP (black bars), transferrin-647 (white bars), and cholera 
toxin B-647 (grey bars), was investigated in HEK293 cells. Cells were transfected 24 hours prior to addition of 
the virus and protein conjugates. Cells which received the controls were fixed after 30 minutes. Cells which 
received AAVP were fixed and immunofluorescence-stained using rabbit anti-fd primary and goat anti-rabbit 
AlexaFluor-647 secondary antibodies after 2 hours incubation. Mean fluorescence intensity values were 
calculated from RGD-AAVP fluorescence normalised to non-specific fluorescence from non-targeted fd-AAVP 
uptake. Mean fluorescence intensity is expressed as a percentage of control cells (non-transfected), data 
represent the mean + SEM of triplicate samples from one representative experiment of three, significant 
difference; n.s-not significant, * p<0.05, ** p<0.01, *** p<0.001 (two-tailed Student’s t-test). 
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Figure 4.7. Confocal analysis of RGD-AAVP uptake in EH29-transfected HEK293 cells.  
RGD-AAVP, transferrin and cholera toxin B uptake was assessed in GFP-tagged EH29-transfected HEK293 
cells by confocal microscopy. The cells were fixed and stained after incubation with RGD-AAVP for 2 hours, or 
transferrin/cholera toxin B controls for 30 minutes. The cells were first stained for external phage (RGD-AAVP 
Ex) using anti-fd-phage primary and goat anti-rabbit AlexaFluor-594 secondary antibodies before 
permeabilisation and immunofluorescence staining for internal particles (RGD-AAVP Int) using the same 
primary and goat anti-rabbit AlexaFluor-647 antibodies. (A) Internalised RGD-AAVP particles were counted in 
the transfected and non-transfected cells, n=number of cells in which particles were counted. Data represent the 
mean + SEM normalised to non-transfected control cells from one representative experiment of two, significant 
difference; n.s-not significant, * p<0.05, ** p<0.01, *** p<0.001 (two-tailed Student’s t-test) (B) Representative 
confocal z-stack projections are shown. The upper panels (Bi) show external (red) and internal (blue) RGD-
AAVP. Internalisation of the control AlexaFluor-594 transferrin (Bii) and cholera toxin B (Biii) are shown in 
red. Transfected cells are shown in green. Scale bars =10 μm. 
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Figure 4.8. Confocal analysis of RGD-AAVP uptake in EH29-transfected HeLa cells.  
RGD-AAVP, transferrin and cholera toxin B uptake was assessed in GFP-tagged EH29-transfected HeLa cells 
by confocal microscopy. The cells were fixed and stained after incubation with RGD-AAVP for 2 hours, or 
transferrin/cholera toxin B controls for 30 minutes. The cells were first stained for external phage (RGD-AAVP 
Ex) using anti-fd-phage primary and goat anti-rabbit AlexaFluor-594 secondary antibodies before 
permeabilisation and immunofluorescence staining for internal particles (RGD-AAVP Int) using the same 
primary and goat anti-rabbit AlexaFluor-647 antibodies. (A) Internalised RGD-AAVP particles were counted in 
the transfected and non-transfected cells, n=number of cells in which particles were counted. Data represent the 
mean + SEM normalised to non-transfected control cells from one representative experiment of two, significant 
difference; n.s-not significant, * p<0.05, ** p<0.01, *** p<0.001 (two-tailed Student’s t-test) (B) Representative 
confocal z-stack projections are shown. The upper panels (Bi) show external (red) and internal (blue) RGD-
AAVP. Internalisation of the control AlexaFluor-594 transferrin (Bii) and cholera toxin B (Biii) are shown in 
red. Transfected cells are shown in green. Scale bars =10 μm. 
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Figure 4.9. Flow cytometric analysis of AAVP uptake following knock-down of clathrin heavy chain.  
(A) The effect of siRNA-mediated knockdown of CHC on uptake of RGD-AAVP and transferrin was 
investigated in HEK293 cells. Cells were transfected with two siRNAs against CHC (siCHC1, siCHC2) or 
negative control (non-targeted) siRNA 72 hours prior to uptake analysis. Cells were incubated with phage for 2 
hours or transferrin for 30 minutes before fixation. Cells receiving AAVP were immunofluorescently stained for 
internalised particles using rabbit anti-fd primary and goat anti-rabbit AlexaFluor-647 secondary antibodies 
before flow cytometric analysis of phage-associated fluorescence. Mean fluorescence intensity values were 
calculated from RGD-AAVP fluorescence normalised to non-specific fluorescence from non-targeted fd-AAVP 
uptake. Mean fluorescence intensity is expressed as a percentage of control cells (NT, non-transfected), data 
represent the mean + SEM of triplicate samples from one representative experiment of three, significant 
difference; n.s-not significant, * p<0.05, ** p<0.01, *** p<0.001 (one-way ANOVA with Bonferroni post-test). 
(B) siRNA-mediated knockdown of CHC was confirmed by western blotting. Western blotting was performed 
on cells transfected in parallel to those used for flow cytometry experiments. The cells were lysed and proteins 
separated by SDS-PAGE before immunoblotting for CHC (isoform 17) or GAPDH (loading control). Expected 
band sizes are indicated (KDa). 
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4.2.1.3. Cholesterol is required for uptake of RGD-AAVP, but not Caveolin-1 
Having established a role of dynamin and clathrin in endocytosis of RGD-AAVP, the involvement of 
clathrin-independent pathways was investigated. Clathrin-independent endocytosis includes the 
constitutive macropinocytotic pathway as well as endocytosis mediated by caveolae and glycolipid 
rafts (reviewed by (Nabi et al. 2003). Glycolipid rafts are detergent insoluble low-density membrane 
fractions that are rich in cholesterol, sphingolipids and glycosylphosphatidyl-inositol (GPI)-anchored 
proteins. Caveolae are subdomains of glycolipid rafts, however their morphology and association with 
caveolin expression means that their internalisation is considered different from that of lipid rafts 
(Rothberg et al. 1992, Kurzchalia et al. 1999). Cholesterol depletion using agents such as nystatin, 
filipin and methyl-β-cyclodextrin inhibits caveolae and lipid raft-mediated endocytosis and has been 
used to distinguish these pathways from both the clathrin-dependent and constitutive pinocytotic 
pathways (Rothberg et al. 1992, Schnitzer et al. 1994, Hailstones et al. 1998). Caveolae and lipid rafts 
function in several cellular events, including cholesterol trafficking, and internalisation of viruses, 
bacteria and bacterial toxins (reviewed by (Nabi et al. 2003)). Cholera toxin B subunit has been 
reported to use caveolae as a route of entry into certain cell types (Orlandi et al. 1998). 
Filipin III complex was used to determine the effect of cholesterol depletion on the uptake of RGD-
AAVP in HEK293 cells.  Non-toxic concentrations of filipin III complex were first determined by the 
MTT cell viability assay (Figure 4.10A). HEK293 cells were treated with increasing concentrations 
of the agent for 4 hours and cell viability analysis performed 48 hours later. Concentrations of up to 
5µM were determined non-toxic for the subsequent experiments. HEK293 cells were treated with 
5µM filipin III complex for 30 minutes prior to, and during incubation with, RGD-AAVP, fd-AAVP 
(1x105 BTU/cell), transferrin, or cholera toxin B. The cells which received AAVP were fixed after 2 
hours and immunofluorescence-stained for internalised phage particles and cells which received 
transferrin or cholera toxin were fixed after 30 minutes. Internalised transferrin, cholera toxin and 
phage-associated fluorescence were determined by flow cytometry. Flow cytometric analysis revealed 
a marked decrease in the uptake of RGD-AAVP (P<0.001), and cholera toxin B (P<0.001), while 
transferrin uptake was unaffected in the presence of filipin. The vehicle control DMSO had little or no 
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effect on endocytosis (Figure 4.10B). The mean decrease in uptake of RGD-AAVP was 42.5 % 
(SEM 1%) in three independent experiments. 
Following the observation that sequestering cholesterol inhibited RGD-AAVP uptake, the role of 
caveolae in endocytosis of RGD-AAVP was assessed. An N-terminally GFP-tagged caveolin-1 
construct served as dominant negative inhibitor of caveolar endocytosis (Cav-1-DN). This has been 
shown to inhibit uptake of SV40 virus particles, which require caveolae for endocytosis (Pelkmans et 
al. 2001). The effect of expression of the dominant negative caveolin-1 construct on RGD-AAVP 
uptake was determined in HEK293 cells by flow cytometry. HEK293 cells were transiently 
transfected with the GFP-tagged Cav-1-DN construct 24 hours prior to addition of RGD-AAVP, fd-
AAVP (1x105 BTU/cell), or transferrin or cholera toxin B controls. Internalised phage or control-
associated fluorescence was determined by flow cytometry (Figure 4.11). Uptake of RGD-AAVP, 
transferrin and cholera toxin B were not significantly altered by expression of the dominant negative 
mutant in this cell line. 
Confocal experiments were performed in HEK293 and HeLa cells to confirm the flow cytometry data. 
Cells were transiently transfected 24 hours prior to addition of RGD-AAVP (1x105 BTU/cell), 
transferrin, or cholera toxin B. Internal and external phage were again discriminated through a double-
immunofluorescence-staining protocol; external phage particles were first immunofluorescently 
stained before permeabilisation of the cells and staining for internal phage. Expression of Cav-1 DN 
had no effect on the number of internalised RGD-AAVP particles (Figure 4.12A). Representative z-
stack projections of transfected HEK293 cells are shown in Figure 4.12B. Uptake of transferrin 
(Figure 4.12ii) and cholera toxin B (Figure 4.12Biii) were not affected in HEK293 cells expressing 
the dominant negative construct. Expression of Cav-1 DN in HeLa cells also had no effect on uptake 
of RGD-AAVP (Figure 4.13A). Representative z-stack images demonstrate that RGD-AAVP and 
transferrin uptake remained unchanged in GFP-positive cells (Figure 4.13Bi and 4.13Bii). However, 
cholera toxin B uptake was reduced in the Cav-1 DN transfected HeLa cells (Figure 4.13Biii), 
suggesting differential requirements of caveolin-1 for cholera toxin B uptake in the HEK293 and 
HeLa cell lines.   
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Figure 4.10. Flow cytometric analysis of AAVP uptake in filipin III-treated HEK293 cells.  
(A) Non-toxic concentrations of filipin III complex were determined by MTT assay. Cells were treated with 
increasing concentrations of the inhibitor for 4 hours and assayed 48 hours later.  Non-toxic concentrations were 
determined as those which resulted in less than 20% cell death. Mean cell viability was normalised to non-
treated controls, with the mean of n=3 independent experiments shown. (B) The effect of filipin III treatment on 
uptake of RGD-AAVP (black bars), transferrin-647 (white bars), and cholera toxin B-647 (grey bars), was 
investigated in HEK293 cells. Cells were pre-treated with the inhibitor for 30 minutes prior to addition of the 
virus and protein conjugates. Cells which received the controls were fixed after 30minutes. Cells which received 
AAVP were fixed and immunofluorescence-stained using rabbit anti-fd primary and goat anti-rabbit 
AlexaFluor-647 secondary antibodies after 2 hours incubation. Mean fluorescence intensity values were 
calculated from RGD-AAVP fluorescence normalised to non-specific fluorescence from non-targeted fd-AAVP 
uptake. Mean fluorescence intensity is expressed as a percentage of control cells (cells which did not receive 
filipin), DMSO treatment was used as a vehicle control. Data represent the mean + SEM of triplicate samples 
from one representative experiment of three, significant difference; n.s-not significant, * p<0.05, ** p<0.01, *** 
p<0.001 (one way ANOVA with Bonferroni post-test). 
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Figure 4.11. Flow cytometric analysis of AAVP uptake in dominant-negative caveolin-1 transfected 
HEK293 cells. 
The effect of Cav-1 DN expression on uptake of RGD-AAVP (black bars), transferrin-647 (white bars), and 
cholera toxin B-647 (grey bars), was investigated in HEK293 cells. Cells were transfected 24 hours prior to 
addition of the virus and protein conjugates. Cells which received the controls were fixed after 30 minutes. Cells 
which received AAVP were fixed and immunofluorescence-stained using rabbit anti-fd primary and goat anti-
rabbit AlexaFluor-647 secondary antibodies after 2 hours incubation. Mean fluorescence intensity values were 
calculated from RGD-AAVP fluorescence normalised to non-specific fluorescence from non-targeted fd-AAVP 
uptake. Mean fluorescence intensity is expressed as a percentage of control cells (non-transfected), data 
represent the mean + SEM of triplicate samples from one representative experiment of three, significant 
difference; n.s-not significant, * p<0.05, ** p<0.01, *** p<0.001 (two-tailed student’s T-test). 
  
130
 
 
Figure 4.12. Confocal analysis of RGD-AAVP uptake in dominant negative caveolin-1-transfected 
HEK293 cells.  
RGD-AAVP, transferrin and cholera toxin B uptake was assessed in GFP-tagged Cav-1-DN-transfected 
HEK293 cells by confocal microscopy. The cells were fixed and stained after incubation with RGD-AAVP for 2 
hours, or transferrin/cholera toxin B controls for 30 minutes. The cells were first stained for external phage 
(RGD-AAVP Ex) using anti-fd-phage primary and goat anti-rabbit AlexaFluor-594 secondary antibodies before 
permeabilisation and immunofluorescence staining for internal particles (RGD-AAVP Int) using the same 
primary and goat anti-rabbit AlexaFluor-647 antibodies. (A) Internalised RGD-AAVP particles were counted in 
the transfected and non-transfected cells, n=number of cells in which particles were counted. Data represent the 
mean + SEM normalised to non-transfected control cells from one representative experiment of two, significant 
difference; n.s-not significant, * p<0.05, ** p<0.01, *** p<0.001 (two-tailed Student’s t-test) (B) Representative 
confocal z-stack projections are shown. The upper panels (Bi) show external (red) and internal (blue) RGD-
AAVP. Internalisation of the control AlexaFluor-594 transferrin (Bii) and cholera toxin B (Biii) are shown in 
red. Transfected cells are shown in green. Scale bars =10 μm. 
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Figure 4.13. Confocal analysis of RGD-AAVP uptake in dominant negative caveolin-1-transfected HeLa 
cells. 
RGD-AAVP, transferrin and cholera toxin B uptake was assessed in GFP-tagged Cav-1-DN-transfected HeLa 
cells by confocal microscopy. The cells were fixed and stained after incubation with RGD-AAVP for 2 hours, or 
transferrin/cholera toxin B controls for 30 minutes. The cells were first stained for external phage (RGD-AAVP 
Ex) using anti-fd-phage primary and goat anti-rabbit AlexaFluor-594 secondary antibodies before 
permeabilisation and immunofluorescence staining for internal particles (RGD-AAVP Int) using the same 
primary and goat anti-rabbit AlexaFluor-647 antibodies. (A) Internalised RGD-AAVP particles were counted in 
the transfected and non-transfected cells, n=number of cells in which particles were counted. Data represent the 
mean + SEM normalised to non-transfected control cells from one representative experiment of two, significant 
difference; n.s-not significant, * p<0.05, ** p<0.01, *** p<0.001 (two-tailed Student’s t-test) (B) Representative 
confocal z-stack projections are shown. The upper panels (Bi) show external (red) and internal (blue) RGD-
AAVP. Internalisation of the control AlexaFluor-594 transferrin (Bii) and cholera toxin B (Biii) are shown in 
red. Transfected cells (Cav1DN-GFP) are shown in green. Scale bars =10 μm. 
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4.2.2. Intracellular trafficking of RGD-AAVP 
Following the investigation into the mechanisms involved in entry of RGD-AAVP into mammalian 
cells, downstream intracellular trafficking of the vector was elucidated by developing methods of 
microscopic analysis. 
4.2.2.1. Live cell imaging of RGD-AAVP trafficking 
Initial attempts to investigate intracellular trafficking of RGD-AAVP were made by directly labelling 
the phage particles with AlexaFluor Protein labelling kits, in order to image RGD-AAVP trafficking 
in live cells. This was performed with a view to combining live cell imaging of AAVP with 
fluorescent protein conjugate markers of various endocytic pathways. Several groups have reported 
fluorescent labelling of filamentous phage for the use of phage as a detection method for bacterial 
infection and for in vivo imaging of tissue-targeted phage-display particles (Knurr et al. 2003, Jaye et 
al. 2004, Hilderbrand et al. 2008). A protocol for labelling AAVP was developed based on these 
publications. 1x1013 BTU of RGD-AAVP were labelled per vial of AlexaFluor-546 reactive dye for 2 
hours at room temperature. The labelled particles were purified by three successive PEG/NaCl 
precipitations before resuspension in PBS. The phage were re-titred before analysis by live-cell 
imaging. RGD-AAVP (1x105 BTU/cell) was cold-bound to HeLa cells for 30 minutes before cold-
washing to remove non-bound virus and warming to 37°C. Following incubation at 37°C for 10 
minutes, the live cells were imaged by confocal microscopy, and single-plane images were scanned 
continuously. A representative analysis is shown in Figure 4.14. In this example, HeLa cells were 
continuously scanned 50 times (for a total of 1 minute, 37 seconds, each scan taking 1.97 seconds). 
Brightfield and fluorescent images of the final scan are shown in Figure 4.14Ai and Figure 4.14Aii, 
respectively. The tracks of four phage particles are shown in Figure 4.14iii (analysis was performed 
using MTrackJ function of ImageJ). Single fluorescence images of the movements of particle 1 are 
shown in Figure 4.14B. The distance of particles travelled over time was quantified and average 
speeds shown in Table 4.1. 
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Particle Total Distance (µm) Time (seconds) Average Speed (µm/sec) 
1 24.3 94.56 0.26 
2 4.4 96.53 0.05 
3 17.2 94.56 0.18 
4 20.4 96.53 0.21 
 
Table 4.1. RGD-AAVP particle movements in HeLa cells. 
 
While particle 2 movement was essentially stable over time, the other three particles displayed 
oscillated movements, with average speeds of approximately 0.2µm/sec observed. These oscillatory 
movements are consistent with vesicle trafficking along microtubules (Murray et al. 2000). This is not 
surprising, given that most organelle movements are driven along microtubules and actin filaments. 
These experiments are, to our knowledge, the first to demonstrate live-cell imaging of filamentous 
phage trafficking. However, this experimental method of imaging AAVP trafficking is technically 
difficult and live cell imaging was not continued past these preliminary experiments. AAVP 
trafficking was therefore investigated in chemically fixed cells using confocal and electron 
microscopy for the subsequent experiments. 
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Figure 4.14. Live cell imaging of RGD-AAVP trafficking. 
HeLa cells were incubated with AlexaFluor-546-conjugated RGD-AAVP for 30 minutes on ice to allow 
binding, but not endocytosis. The cells were washed and placed in warm medium and incubated for 10 minutes 
at 37°C before live cell imaging. 50 continuous confocal image scans were taken over a period of 1 minute, 37 
seconds (A) Confocal images showing (i) brightfield image of analysed HeLa cells and (ii) fluorescence image 
of fluorescent particles whose movements were tracked (numbered 1-4). (Aiii) shows the tracks of the phage 
particles measured over time. (B) Serial confocal images of RGD-AAVP particle 1 trafficking over time (time in 
seconds indicated in bottom left corners). (C) Distance travelled by RGD-AAVP particles was plotted over time. 
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4.2.2.2. Electron and confocal microscopic imaging of RGD-AAVP trafficking 
4.2.2.2.1. Electron microscopy of RGD-AAVP 
Intracellular trafficking of RGD-AAVP was further investigated by developing transmission electron 
microscopy (TEM) methods of detection. RGD-AAVP particles were first characterised by negative 
staining of the virus bound to formvar-coated EM grids (Figure 4.15A). As anticipated, the particles 
were observed to have similar morphology to that of wild-type M13 filamentous phage, with the 
exception that particles were measured at approximately 1.4 μm long, compared to approximately 900 
nm reported for the wild-type M13 virus. This is consistent with previous observations that the 
filamentous phage-derived particles can grow in length to accommodate DNA from inserted 
transgenes (Zacher et al. 1980). Figure 4.15B shows the appearance of immunofluorescence-stained 
RGD-AAVP, which also appears filamentous when bound to the cell surface. 
Initial attempts to investigate endocytosis of RGD-AAVP in HEK293 cells by TEM were hindered as 
the virions could not be detected in epon resin-embedded samples. A pre-embedding immunogold-
labelling protocol was therefore developed in order to visualise intracellular trafficking of RGD-
AAVP. Negative-stained RGD-AAVP was first compared to RGD-AAVP labelled with the anti-fd 
phage polyclonal antibody and protein-A-gold (9 nm), bound to formvar-coated EM grids (Figure 
4.15C and 4.15D). As demonstrated in Figure 4.15D, TEM analysis of the labelled vector shows 
efficient decoration of the length of the filamentous phage particles with the colloidal gold.   
In order to demonstrate visualisation of RGD-AAVP in resin-embedded samples, RGD-AAVP was 
first cold-bound to the surface of HEK293 cells before fixation and labelling with anti-fd phage 
antibody and protein-A-gold. The cells were embedded in epon and visualised by TEM. Gold-labelled 
RGD-AAVP is shown in Figure 4.15E, while the 9 nm colloidal gold particles can be clearly 
visualised, little or no contrast was observed from the AAVP particles themselves (see expanded 
image). 
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Figure 4.15. Electron microscopic analysis of RGD-AAVP.  
(A) Single RGD-AAVP particles were characterised by negative staining and analysis by transmission electron 
microscopy (TEM). (B) Confocal image of immunofluorescence-stained RGD-AAVP shows filamentous 
appearance when bound to the cell surface. (C) Negative-stained RGD-AAVP particles were compared to 
immunogold-labelled particles bound to EM grids (D). (E) RGD-AAVP was cold-bound to the surface of 
HEK293 cells before fixation and immunogold labelling. Cells were embedded in epon resin and 140 nm 
sections cut for imaging by TEM. The micrographs show immunogold-labelled RGD-AAVP particles.  
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4.2.2.2.2. RGD-AAVP colocalises with transferrin and cholera toxin B 
Having established a protocol for visualisation of RGD-AAVP by pre-embedding immunogold 
labelling, this method was used to investigate intracellular trafficking of the vector in HEK293 cells. 
Given that inhibition experiments suggest that dynamin and clathrin are involved in RGD-AAVP 
endocytosis, HRP-labelled transferrin was used as a marker for this pathway.  
HEK293 cells were incubated with HRP-transferrin and RGD-AAVP on ice, to allow binding but not 
endocytosis, before immunogold labelling the RGD-AAVP (while on ice). The cells were warmed to 
37 °C for 10 or 20 minutes before fixation (control cells were fixed while on ice). The HRP was 
reacted with silver-enhanced diaminobenzidine, in order to visualise the HRP-transferrin, which 
appears as a dark precipitate in endocytic vesicles. The cells were embedded in epon and 70 nm 
sections cut before visualisation by TEM. Background gold labelling was determined in cells which 
did not receive RGD-AAVP, but were stained with the anti-fd antibody and protein-A-gold. As shown 
in Figure 4.16A, the level of background labelling was low, with few single gold particles observed at 
the plasma membrane. Clathrin coated pits (CCP) were also observed in the control cells, these were 
identified by a characteristic electron-dense coat.  Phage-associated gold labelling was observed at the 
plasma membrane of HEK293 cells which had not been warmed before fixation (Figure 4.16B). 
HRP-transferrin was observed in CCPs at the cell surface (Figure 4.16C). Gold particles were 
observed in transferrin-positive early endosomes (EE, Figure 4.16D) after 10 minutes, and 
transferrin-positive multivesicular bodies after 20 minutes incubation at 37 °C (MVB, Figure 4.16E). 
Colocalisation of RGD-AAVP with transferrin in early endosomes was further confirmed by confocal 
microscopy. RGD-AAVP and fluorescently-labelled transferrin were cold-bound to HEK293 or HeLa 
cells before warming to 37°C and fixation after 5, 10, 30 and 60 minutes (0-timepoint control cells 
were fixed without warming). Early endosomes were distinguished using antibodies against the early 
endosomal marker EEA-1, which is a Rab5 effector protein essential for early endosomal membrane 
fusion and trafficking (Mu et al. 1995, Christoforidis et al. 1999). Confocal analysis revealed 
colocalisation of RGD-AAVP with transferrin in EEA-1 positive endosomes between 10 and 60 
minutes post-warming in HEK293 cells and 5 and 60 minutes in HeLa cells. Representative single-
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plane confocal images are shown in Figure 4.17 and Figure 4.18, arrows indicate colocalisation of 
transferrin and RGD-AAVP. 
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Figure 4.16. Electron microscopic analysis of RGD-AAVP colocalisation with transferrin in HEK293 
cells. 
HEK293 cells were incubated with HRP-transferrin and RGD-AAVP on ice, to allow binding but not 
endocytosis. The RGD-AAVP particles were immunogold-labelled with anti-fd antibody and protein-A-gold 
(9nm). Cells were either fixed while on ice (0-timepoint controls) or warmed to 37°C before fixation after 10 
and 20 minutes. (A) Immunogold-labelled control cells (which received no tracer or phage) were fixed while on 
ice to determine background gold labelling (asterisk indicates gold particles). (B) Cold-bound phage particles 
could be visualised at the plasma membrane and (C) Cold-bound HRP-transferrin could be identified in CCPs at 
the plasma membrane (arrows indicate clathrin coating, expanded). (D) Gold particles were observed in 
transferrin-positive early-endosomes (EE) after 10 minutes and (E) multivesicular bodies (MVB) after 20 
minutes at 37°C. 
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Figure 4.17. Confocal microscopic analysis of RGD-AAVP colocalisation with transferrin in HEK293 
cells. 
RGD-AAVP and transferrin-594 were cold-bound to HEK293 cells for 30 minutes before either fixation while 
on ice (0-timepoint) or warming to 37°C for 5, 10, 30 and 60 minutes (times indicated). The RGD-AAVP was 
Immunofluorescence-stained using rabbit anti-fd primary and goat anti-rabbit AlexaFluor-647 secondary 
antibodies (shown in red), early-endosomes were detected using mouse anti-EEA-1 primary and AlexaFluor-488 
secondary antibodies (green), transferrin-594 is shown in blue. Arrows indicate colocalised fluorescence. 
Representative single optical sections are shown, scale bars=10 μm. 
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Figure 4.18. Confocal microscopic analysis of RGD-AAVP colocalisation with transferrin in HeLa cells.  
 
RGD-AAVP and transferrin-594 were cold-bound to HeLa cells for 30 minutes before either fixation while on 
ice (0-timepoint) or warming to 37°C for 5, 10, 30 and 60 minutes (times indicated). The RGD-AAVP was 
Immunofluorescence-stained using rabbit anti-fd primary and goat anti-rabbit AlexaFluor-647 secondary 
antibodies (shown in red), early-endosomes were detected using mouse anti-EEA-1 primary and AlexaFluor-488 
secondary antibodies (green), transferrin-594 is shown in blue. Arrows indicate colocalised fluorescence. 
Representative single optical sections are shown, scale bars=10 μm. 
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Dynamin and clathrin inhibition studies demonstrated that cholera toxin B may also share common 
entry mechanisms with RGD-AAVP in HEK293 cells. TEM experiments were therefore performed 
using HRP-labelled cholera toxin B as an alternative endocytic marker to transferrin. TEM 
experiments were performed as with HRP-transferrin; HEK293 cells were incubated with HRP-
cholera toxin B and RGD-AAVP on ice, to allow binding but not endocytosis, before immunogold 
labelling the RGD-AAVP (while on ice). The cells were warmed to 37 °C for 10 or 20 minutes before 
fixation (control cells were fixed while on ice). DAB reactions were performed in order to visualise 
the HRP-cholera toxin B. The cells were embedded in epon and 70nm sections cut before 
visualisation by TEM. Background gold labelling was determined in cells which did not receive 
RGD-AAVP, but were stained with the anti-fd antibody and protein-A-gold (indicated by asterisk, 
Figure 4.19A). Phage-associated gold labelling was again observed at the plasma membrane of 
HEK293 cells which had not been warmed before fixation (Figure 4.19B). Interestingly, HRP-cholera 
toxin B was observed in CCPs at the cell surface (Figure 4.19C). Very few caveolae were observed 
by TEM in this cell line, suggesting that cholera toxin B is predominantly internalised by clathrin-
mediated endocytosis in HEK293 cells. Gold particles were observed in cholera toxin B-positive early 
endosomes (EE, Figure 4.19D) after 10 minutes, and early endosomes/multivesicular bodies after 20 
minutes incubation at 37 °C (EE/MVB, Figure 4.19E). The evidence from TEM experiments was 
again confirmed by confocal microscopy in HEK293 and HeLa cells. RGD-AAVP and fluorescently-
labelled cholera toxin B were cold-bound to HEK293 or HeLa cells before warming to 37°C and 
fixation after 5, 10, 30 and 60 minutes (0-timepoint control cells were fixed without warming). Early 
endosomes were detected using antibodies against EEA-1. Confocal analysis revealed colocalisation 
of RGD-AAVP with cholera toxin B after 10minutes at 37C and in cholera toxin B and EEA-1 
positive endosomes between 30 and 60 minutes post-warming in HEK293 cells and 5 and 60 minutes 
in HeLa cells, demonstrating that this effect is not restricted to a single cell type. Representative 
single-plane confocal images are shown in Figure 4.20 and Figure 4.21, arrows indicate 
colocalisation of cholera toxin B and RGD-AAVP. 
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Figure 4.19. Electron microscopic analysis of RGD-AAVP colocalisation with cholera toxin B in HEK293 
cells.  
HEK293 cells were incubated with HRP-cholera toxin B and RGD-AAVP on ice, to allow binding but not 
endocytosis. The RGD-AAVP particles were immunogold-labelled with anti-fd antibody and protein-A-gold 
(9nm). Cells were either fixed while on ice (0-timepoint controls) or warmed to 37°C before fixation after 10 
and 20 minutes. (A) Immunogold-labelled control cells (which received no tracer or phage) were fixed while on 
ice to determine background gold labelling (asterisk indicates gold particles). (B) Cold-bound phage particles 
could be visualised at the plasma membrane and (C) Cold-bound HRP-cholera toxin B could be identified in 
CCPs at the plasma membrane (arrows indicate clathrin coating, expanded). (D) Gold particles were observed in 
cholera toxin B-positive early-endosomes (EE) after 10 minutes and (E) early endosomes/multivesicular bodies 
(EE/MVB) after 20 minutes at 37°C. 
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Figure 4.20. Confocal microscopic analysis of RGD-AAVP colocalisation with cholera toxin B in HEK293 
cells.  
RGD-AAVP and cholera toxin B-594 were cold-bound to HEK293 cells for 30 minutes before either fixation 
while on ice (0-timepoint) or warming to 37°C for 5, 10, 30 and 60 minutes (times indicated). The RGD-AAVP 
was Immunofluorescence-stained using rabbit anti-fd primary and goat anti-rabbit AlexaFluor-647 secondary 
antibodies (shown in red), early-endosomes were detected using mouse anti-EEA-1 primary and AlexaFluor-488 
secondary antibodies (green), cholera toxin B-594 is shown in blue. Arrows indicate colocalised fluorescence. 
Representative single optical sections are shown, scale bars=10 μm. 
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Figure 4.21. Confocal microscopic analysis of RGD-AAVP colocalisation with cholera toxin B in HeLa 
cells.  
RGD-AAVP and Cholera toxin B-594 were cold-bound to HeLa cells for 30 minutes before either fixation 
while on ice (0-timepoint) or warming to 37°C for 5, 10, 30 and 60 minutes (times indicated). The RGD-AAVP 
was Immunofluorescence-stained using rabbit anti-fd primary and goat anti-rabbit AlexaFluor-647 secondary 
antibodies (shown in red), early-endosomes were detected using mouse anti-EEA-1 primary and AlexaFluor-488 
secondary antibodies (green), cholera toxin B-594 is shown in blue. Arrows indicate colocalised fluorescence. 
Representative single optical sections are shown, scale bars=10 μm. 
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4.2.2.2.3. RGD-AAVP colocalises with markers of the endosomal-lysosomal pathway 
Having observed RGD-AAVP colocalisation with transferrin and cholera toxin B in early endosomes 
and multivesicular bodies, it was hypothesised that RGD-AAVP may further traffic to the late 
endosomal-lysosomal degradative pathway which eukaryotic viruses are able to escape or avoid. 
RGD-AAVP endocytosis was investigated in HEK293 cells by transmission electron microscopy, 
using the fluid-phase marker HRP, which is an established marker of early/late endosomes and 
lysosomes. RGD-AAVP was cold-bound to HEK293 cells and immunogold labelled while on ice. 
Warm medium containing HRP (10 mg/ml) was added and the cells fixed after different time-points.  
AAVP-associated gold particles were observed in early entry vesicles which were in close proximity 
to clathrin coated pits after 10 minutes (indicated by arrows, Figure 4.22A). Gold particles were also 
observed in HRP-positive early endosomes after 20 minutes (Figure 4.22B) and multivesicular bodies 
after 30 minutes (Figure 4.22C), confirming data from previous TEM observations using HRP-
transferrin and HRP-cholera toxin B. Gold particles were seen to accumulate over time in larger 
multivesicular bodies after 1 hour (Figure 4.22D) and in dense multilammelar lysosomes 4 hours 
post-warming (LYS, Figure 4.22E). Immunofluorescence experiments were performed in order to 
confirm RGD-AAVP trafficking to the endosomal-lysosomal degradative pathway in other cell lines. 
Time-course experiments of RGD- AAVP internalisation were performed in HEK293, HeLa, U87 and 
DU145 cells. RGD-AAVP was first cold-bound to the cells before warming and fixation after 0, 10, 
30, 60 and 240 minutes. Transient colocalisation with EEA-1 was observed in all four cells lines 
between 10 and 60 minutes post-warming. Figure 4.23 shows representative images of the four cell 
lines after 30 minutes at 37°C (arrows indicate colocalisation). Full time-course images of the four 
cell lines can be found in Appendix section B. Confocal timecourse experiments were also performed 
using an antibody against the late endosomal/lysosomal marker lysosome-associated membrane 
protein-1 (LAMP-1) (Fukuda 1990). RGD-AAVP was also observed to colocalise with LAMP-1 
between 1 and 4 hours post-warming. Figure 4.24 shows colocalisation of RGD-AAVP and LAMP-1 
after 4 hours in all four cell lines, demonstrating RGD-AAVP accumulation in the late 
endosomes/lysosomes (full time-course images of the four cell lines are appended in Appendix 
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section C). Extended confocal experiments were performed to confirm that the vector remained 
associated with the lysosomes, and colocalisation of RGD-AAVP and LAMP-1 was observed after 24 
hours in all cell lines tested (Figure 4.25). 
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Figure 4.22. Electron microscopic analysis of endosomal-lysosomal trafficking of RGD-AAVP in HEK293 
cells. 
RGD-AAVP was cold-bound to HEK293 cells and immunogold-labelled while on ice. The cells were washed to 
remove unbound phage/gold before adding warm medium containing 10mg/ml HRP (fluid-phase marker). Cells 
were fixed after 10 (A), 20 (B), 30 (C), 60 (D) and 240 minutes (E) before DAB staining and embedding in 
resin. Sections were cut at 140 nm (A) or 70 nm (B, C, D, E) before imaging by TEM. Clathrin-coated pits 
(CCP) are indicated (A). Gold particles were observed in HRP-positive entry vesicles, early endosomes (EE), 
multivesicular bodies (MVB) and lysosomes (LYS).  
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Figure 4.23. RGD-AAVP transiently colocalises with EEA-1. 
RGD-AAVP uptake was analysed in HEK293, HeLa, U87 and DU145 cells by confocal microscopy. Phage was 
cold-bound to the cells for 30 minutes, followed by warming and fixation after 30 minutes at 37 °C. The RGD-
AAVP was Immunofluorescence-stained using rabbit anti-fd-phage primary and goat anti-rabbit AlexaFluor-
594 secondary antibodies (shown in red) and early-endosomes were detected using mouse anti-EEA-1 primary 
and AlexaFluor-488 secondary antibodies (green), arrows indicate colocalised fluorescence. Representative 
single optical sections are shown, scale bars=10 μm. 
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Figure 4.24. RGD-AAVP colocalises with LAMP-1. 
RGD-AAVP uptake was analysed in HEK293, HeLa, U87 and DU145 cells by confocal microscopy. RGD-
AAVP was cold-bound to the cells for 30 minutes, warmed, and fixed after 4 hours. The RGD-AAVP was 
immunofluorescence-stained using rabbit anti-fd-phage primary and goat anti-rabbit AlexaFluor-594 secondary 
antibodies (shown in red) and lysosomes were detected using mouse anti-LAMP-1 primary and AlexaFluor-488 
secondary antibodies (green), arrows indicate colocalised fluorescence. Representative single optical slices are 
shown, scale bar=10μm. 
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Figure 4.25. RGD-AAVP remains colocalised with LAMP-1.  
RGD-AAVP uptake was analysed in HEK293, HeLa, U87 and DU145 cells by confocal microscopy. RGD-
AAVP was cold-bound to the cells for 30 minutes, warmed, and fixed after 24 hours. The RGD-AAVP was 
immunofluorescence-stained using rabbit anti-fd-phage primary and goat anti-rabbit AlexaFluor-594 secondary 
antibodies (shown in red) and lysosomes were detected using mouse anti-LAMP-1 primary and AlexaFluor-488 
secondary antibodies (green), arrows indicate colocalised fluorescence. Representative single optical slices are 
shown, scale bar=10μm. 
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4.3. Discussion 
Despite the numerous advantages of using the bacteriophage-based RGD-AAVP vector for cancer 
gene therapy, a critical problem is that high titres of RGD-AAVP are required to mediate modest 
transgene expression in mammalian cells. The aim of this work was therefore to elucidate the entry 
and intracellular trafficking steps involved in RGD-AAVP uptake, in order to identify key barriers to 
transduction. The data presented in this chapter comprise the most in-depth analysis of RGD-AAVP 
endocytosis and intracellular trafficking to date.  
Receptor-mediated endocytosis of the vector was first studied using chemical inhibitors, RNAi, and 
dominant negative constructs in combination with flow cytometry and confocal microscopy. The 
requirement for dynamin was initially investigated, in order to discriminate between clathrin/caveolar-
mediated endocytosis and macropinocytotic pathways. The role of dynamin in RGD-AAVP uptake 
was established using two complimentary inhibitors, the chemical agent dynasore, and the dominant 
negative dynamin-II (K44A) construct. Flow cytometric analysis of HEK293 cells treated with non-
toxic concentrations of dynasore revealed significant inhibition of RGD-AAVP uptake (Figure 4.1). 
Dynasore treatment also significantly reduced uptake of both transferrin and cholera toxin B, 
consistent with previous reports (Macia et al. 2006). These findings were complimented by flow 
cytometric analysis of HEK293 cells transfected with the dynamin II-K44A construct (Figure 4.2). 
Confocal analysis of K44A-transfected HEK293 and HeLa cells confirmed the requirement of 
dynamin (II) for endocytosis of the vector, as the numbers of internalised RGD-AAVP particles were 
depleted in the transfected cells (Figure 4.3 and 4.4).  As anticipated, uptake of the control marker for 
clathrin-mediated endocytosis, transferrin, was also inhibited in these experiments. Uptake of cholera 
toxin B was also significantly reduced, as both clathrin-mediated endocytosis and caveolar/lipid raft-
mediated endocytosis require the GTPase action of dynamin. 
The requirement of clathrin was next examined to further characterise the endocytic pathways 
involved in RGD-AAVP uptake. Treatment with hypotonic sucrose significantly reduced uptake of 
RGD-AAVP, transferrin and cholera toxin B, indicating that clathrin may be involved in RGD-AAVP 
uptake (Figure 4.5). These data also suggested that in HEK293 cells, cholera toxin B may also require 
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clathrin for endocytosis. However, given that hypotonic treatment may interfere with alternative 
endocytic process to clathrin, more specific inhibitors were investigated. The dominant-negative 
Eps15 mutant EH29 was therefore used to study clathrin-mediated endocytosis, as this was shown to 
prevent recruitment of AP-2 to the plasma membrane, and therefore arrest clathrin coated pit 
formation (Benmerah et al. 1999).  The dominant negative mutant has been shown to inhibit 
endocytosis of transferrin (Benmerah et al. 1999), and has been used to demonstrate the involvement 
of clathrin in endocytosis of several viruses, including  semliki forest virus (Sieczkarski et al. 2002b), 
sindbis virus (Carbone et al. 1997), dengue virus (Suksanpaisan et al. 2009), and JC virus (Querbes et 
al. 2004). As anticipated, EH29 indeed inhibited transferrin uptake in HEK293 cells and HeLa cells, 
which was demonstrated using flow cytometry and confocal microscopy (Figure 4.6, 4.7 and 4.8). 
However, this mutant did not significantly affect endocytosis of RGD-AAVP (or cholera toxin B). In 
order to qualify whether clathrin was indeed implicated in RGD-AAVP endocytosis, siRNAs against 
clathrin heavy chain were utilised. These gave specific knockdown of clathrin heavy chain (as 
determined by western blot) which significantly inhibited endocytosis of both RGD-AAVP and the 
transferrin control (Figure 4.9). The inhibitory effect of sucrose and siRNAs against clathrin heavy 
chain strongly suggest that RGD-AAVP utilises a clathrin-mediated endocytic pathway. Furthermore, 
electron microscopy of RGD-AAVP uptake revealed close association of the vector with clathrin-
coated pits (Figure 4.22). Also, electron microscopy revealed cholera toxin B association with 
clathrin-coated pits at the plasma membrane of HEK293 cells (Figure 4.19), giving further evidence 
for clathrin-mediated endocytosis of this protein marker in HEK293 cells.  
The lack of inhibitory effect of EH29 expression on endocytosis of RGD-AAVP may be due to 
several factors. Firstly, while the dominant negative mutant did significantly reduce transferrin 
uptake, this was only by approximately 30%. This indicates that expression of the dominant negative 
mutant may not have been high enough to observe a significant change in RGD-AAVP uptake, 
particularly if the vector is capable of using more than one endocytic pathway, which may 
compensate for the loss of Eps15. Secondly, it is possible that RGD-AAVP may not follow the 
consensus model of clathrin endocytosis used by transferrin. Different endocytic receptors require 
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different adaptor proteins for endocytosis (Traub 2009). It has been recently shown that the alternative 
clathrin adaptor Numb can interact with the cytoplasmic domain of the β3 integrin chain, which 
controls αvβ3 integrin endocytosis and cell migration (Nishimura et al. 2007). Numb contains a PTB 
domain which interacts with the NPXY motifs on the cytoplasmic tails of integrins and carboxy-
terminal region which  can interact with the α-adaptin subunit of AP-2 and clathrin accessory proteins 
such as Eps15 and Eps15R through an EH-domain binding NPF motif (Salcini et al. 1997, Santolini et 
al. 2000). Numb knockdown inhibits integrin-β1 and integrin-β3 endocytosis, but has no effect on 
transferrin uptake, demonstrating that disruption of Numb does not impede localisation of the 
adaptor/accessory proteins necessary for transferrin endocytosis. It is possible that Numb may be 
capable of recruiting AP-2 and clathrin to form coated pits independently of Eps15. This hypothesis is 
reinforced by the work of Santolini et al. who, while demonstrating that Numb functions as an 
endocytic adaptor through interaction with AP-2, failed to observe colocalisation with Eps15 in 
coated pits (Santolini et al. 2000). Furthermore, other groups have demonstrated that clathrin-
mediated endocytosis of some viruses is also insensitive to Eps15 inhibition. Pu et al. demonstrated 
that clathrin-mediated uptake of mouse hepatitis virus (type 2) was inhibited through hypotonic 
treatment, treatment with the chemical agent chlorpromazine (which inhibits recruitment of AP-2), 
and knockdown of clathrin heavy chain but was independent of Eps15 (Pu et al. 2008). Similarly, 
Marbug glycoprotein (GP) pseudotyped lentivirus entry was inhibited by chlorpromazine, sucrose, 
and knockdown of clathrin heavy chain but was independent of Eps15 and AP-2 (Bhattacharyya et al. 
2011). It has also been proposed that Influenza virus is also able to follow a clathrin-mediated 
endocytic route which was independent of Eps15 and AP-2 (Lakadamyali et al. 2006). 
The potential role of clathrin in uptake of RGD-AAVP may be surprising, given that clathrin pits have 
been traditionally viewed as restricted to cargoes of up to 200 nm in size (Rejman et al. 2004), 
whereas electron microscopy of RGD-AAVP particles revealed filamentous virions of approximately 
1.4 µm in length (Figure 4.15). However, some publications have suggested that clathrin pits can 
accommodate much larger cargoes such as listeria monocytogenes, which is approximately 2 μm in 
length (Veiga et al. 2005), and ebola virus which measures 80 nm by 970 nm (Sanchez 2007, 
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Bhattacharyya et al. 2010). Recently, a study by Cureton and colleagues demonstrated that Vesicular 
stomatitis virus (VSV), an enveloped virus with bullet-shaped virions that measure 70 by 200 nm, 
enters cells by clathrin-dependent endocytosis. The researchers went on to suggest that the elongated 
shape of a VSV particle prevents full enclosure by the clathrin coat and that stalling of coat assembly 
triggers recruitment of the actin machinery to finish the internalisation process  (Cureton et al. 2010). 
In order to determine whether alternative pathways are also involved in RGD-AAVP uptake, the 
effect of cholesterol depletion and expression of dominant negative caveolin-1 were investigated. 
Dominant negative caveolin-1 expression had no effect on internalisation of RGD-AAVP or 
transferrin in HEK293 or HeLa cells (Figure 4.11, 4.12 and 4.13). Moreover, cholera toxin B was not 
affected by this mutant in HEK293 cells, reinforcing the observation that cholera toxin B is most 
likely internalised by clathrin-mediated endocytosis in this cell line. However, cholesterol depletion 
by treatment with filipin III complex did significantly diminish uptake of both RGD-AAVP and 
cholera toxin B (Figure 4.10). Cholesterol depletion using agents such as nystatin, filipin and methyl-
β-cyclodextrin have been shown to inhibit caveolae and lipid raft-mediated endocytosis and have 
previously been used to distinguish these pathways from both the clathrin-dependent and constitutive 
pinocytotic pathways (Rothberg et al. 1992, Schnitzer et al. 1994, Hailstones et al. 1998). However, 
clathrin- mediated endocytosis and macropinocytosis have also been reported to be sensitive to 
cholesterol depletion under certain conditions (Subtil et al. 1999, Grimmer et al. 2002). Transferrin 
uptake was unaffected by treatment with filipin III complex, suggesting that the prototypical clathrin 
pathway was not affected by this treatment.  
The association of RGD-AAVP with clathrin does not exclude the involvement of other trafficking 
pathways, particularly as integrin heterodimers can follow multiple endocytic routes (Caswell et al. 
2009). Integrins are known to cluster in lipid rafts, and it has been demonstrated that cholesterol 
depletion prevents their clustering and therefore signalling (Le Saux et al. 2011). Alternatively, 
macropinocytosis is also affected by cholesterol depletion. It is tempting to speculate that RGD-
AAVP may induce macropinocytosis following integrin receptor binding, as has been observed for 
the αv integrin binding adenovirus serotypes Ad 2, 3 and 5 (Meier et al. 2002, Amstutz et al. 2008). 
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Future investigations are required to determine if this is the case for RGD-AAVP. During their studies 
of Adenovirus endocytosis, Meier et al. demonstrated that virus binding to αv integrins stimulated 
uptake of dextran (an inert marker of fluid phase uptake) (Meier et al. 2002). It would be interesting 
to see if this is the case for RGD-AAVP, addition of RGD-AAVP or non-targeted control fd-AAVP to 
cells in the presence of fluorescent dextran and subsequent flow cytometric analysis would indicate 
whether RGD binding to αvintegrins is sufficient to stimulate macropinocytosis. Additionally the 
chemical agent 5-(N-ethyl-N-isopropyl) amiloride (EIPA), a potent analogue of amiloride, is known 
to block the formation of macropinosomes in growth factor–stimulated cells without affecting coated 
pit-mediated endocytosis (West et al. 1989). Flow cytometric analysis of RGD-AAVP uptake in 
EIPA-treated cells would indicate whether macropinocytosis is indeed involved in endocytosis of the 
vector. 
Confocal microscopy and electron microscopy were used to study the intracellular trafficking events 
following entry of RGD-AAVP. Electron microscopy of immunogold-labelled RGD-AAVP uptake 
revealed colocalisation with transferrin and cholera toxin B in early endosomes and multivesicular 
bodies in HEK293 cells (Figure 4.16 and 4.19). These data were confirmed using confocal 
microscopy, which demonstrated that the vector colocalised with transferrin and cholera toxin B in 
EEA-1 positive early endosomes in HEK293 and HeLa cells (Figures 4.17, 4.18, 4.20, 4.21). Having 
observed phage trafficking to the multivesicular bodies, it was reasoned that the vector may be 
sequestered further into the endosomal-lysosomal system. Electron microscopy studies using the 
fluid-phase marker HRP (which localises to the degradative pathway) confirmed RGD-AAVP 
trafficking to the early endosomes and multivesicular bodies, and accumulation in lysosomes after 4 
hours (Figure 4.22). Confocal time-course studies in HEK293, HeLa, U87 and DU145 cells showed 
that the vector associated transiently with EEA-1 positive early endosomes (between 10 and 60 
minutes following warm-up, Figure 4.23 and Appendix Bi-iv) and was sequestered by LAMP-1 
positive late endosomes and lysosomes (between 1 and 4 hours following warm-up, Figure 4.24 and 
Appendix Ci-iv), confirming the electron microscopy data and demonstrating that this occurrence is 
not restricted to a single cell-type. Furthermore, extended confocal studies demonstrated that the 
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vector remained associated with the degradative pathway, as RGD-AAVP remained localised to 
LAMP-1 positive compartments 24 hours following addition of the vector (Figure 4.25). 
The experiments presented here do not address whether trafficking to the lysosomes results in 
degradation of RGD-AAVP. As immunofluorescence staining of the vectors was still visible in 
lysosomes after 24 hours, there were clearly phage antigens still present, but it was not clear whether 
the particles remained functional. However, in studies investigating RGD targeted filamentous phage 
trafficking, Ivanenkov et al. demonstrated that the lysosomotropic agent chloroquine, which 
neutralises acidic organelles, increased the numbers of RGD-phage particles that could be recovered 
from lysed cells, indicating that filamentous phage particles are degraded (and therefore lose 
infectivity) in these compartments (Ivanenkov et al. 1999a). These studies would suggest therefore, 
that RGD-AAVP sequestration into the lysosomal compartment results in degradation of the virus 
particles, and that the lysosome also presents a physical barrier to transduction by the phage vector. 
Taken together, these findings indicate that the RGD-AAVP vector is capable of entering mammalian 
cells using the endocytic pathways utilised by eukaryotic viruses. The presented studies demonstrated 
that integrin receptor-mediated endocytosis proceeds through a dynamin- and clathrin-dependent 
mechanism which results in vector trafficking to the early endosomes, and as the vector has no 
intrinsic endosomal escape properties, the vector is further sorted into the late endosomes and 
lysosomes where it is most likely degraded by lysosomal proteases. Sequestration into the degradative 
pathway is therefore a major barrier to transgene delivery by RGD-AAVP, and further modification of 
the vector is therefore required to overcome this limitation and improve gene expression.  
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5. Construction and evaluation of multifunctional AAVP Vectors 
 
5.1. Introduction 
As demonstrated in the preceding chapter, the low transduction efficiencies of the RGD-AAVP in 
mammalian cells are likely due to accumulation of the vector in the cell’s degradative system, thus 
preventing transgene delivery to the nucleus. Bacteriophage have no intrinsic mechanisms for 
endosome escape, as they have not undergone the evolutionary steps utilised by eukaryotic viruses. 
Several viruses have adapted to use the degradative endocytic pathways to their advantage by using 
the low pH to induce conformational changes in the capsid which allow penetration, fusion or capsid 
uncoating, resulting in virus escape to the cytoplasm and, if necessary, translocation to the nucleus 
and replication (Sieczkarski et al. 2002a).  
Understanding the mechanisms of viral and bacterial escape from endosomes is important for 
improving cellular delivery of therapeutic agents. While the most successful gene therapy strategies 
still rely on viral vectors, researchers have attempted to increase the efficiency of non-viral vectors by 
incorporating agents capable of enhancing plasma membrane penetration or endosomal escape. Some 
of these peptides were identified through studies of viruses, and now a range of virus-derived and 
mimetic peptides are being used either as cell-penetrating peptides (CPPs) directly conjugated to 
nucleotides, or incorporated into larger gene carriers such as lipoplexes or polyplexes. A substantial 
amount of research has been directed at engineering endosomal escape strategies, as cell-targeting 
approaches utilise ligand-receptor interactions which lead to endocytosis of the gene carrier. There are 
several mechanistic approaches to potentiating endosomal escape for release of the genetic material 
into the cytosol, including endosomal buffering or inclusion of membrane lytic peptides (reviewed by 
(Ferrer-Miralles et al. 2008)).  
Fusogenic peptides derived from various sources (including viruses) have been used to promote 
endosomal escape and delivery of genetic cargo to the cytosol and/or nucleus (reviewed by (Martin et 
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al. 2007)). In general, fusogenic peptides adopt an α-helical conformation, contain a variety of 
charged residues, exhibit pH specific activity, and are amphipathic (have a hydrophilic and 
hydrophobic face) (Deshayes et al. 2005). Many CPPs are derived from the transduction domains of 
proteins that interact with cell membranes. Examples of these include HIV-derived TAT protein 
(Fawell et al. 1994), homeodomain of antennapedia protein penetratin (Derossi et al. 1994), herpes 
simplex virus type-1 peptide VP22 (Elliott et al. 1997), the galanin-mastoparan (wasp venom peptide 
toxin) fusion peptide transportan (Langel et al. 1996), and influenza-derived peptide INF (Wagner et 
al. 1992).  
Several fusogenic peptides used in gene delivery are derived from the sequence of the N-terminal 
segment of the HA2 subunit of the influenza virus hemagglutinin, which is involved in the fusion of 
the viral envelope with the endosomal membrane. One of the oldest CPPs, INF, designed by Wagner 
and colleagues (Wagner et al. 1992), is a derivative of the HA2 N-terminus which contains acidic 
glutamate residues that are protonated under acidic conditions, resulting in transition to an α-helical 
structure which interacts with endosomal membranes to promote destabilisation. Incorporation of the 
HA2-derived peptides into DNA-polylysine-transferrin gene carrier vehicles resulted in significant 
gene expression in vitro, with up to 1000-fold increase in transgene expression over DNA-polylysine-
transferrin conjugates alone (Wagner et al. 1992). In 1994, Plank et al. reported modified versions of 
the N-terminal domain of HA2, referred to as INF1-INF7, with more potent activity than the parent 
peptide. INF7 (a 23-mer acidic derivative) in particular was shown to have high specificity for low pH 
(5.5), and yielded higher membrane lytic activity (Plank et al. 1994). 
The INF7 peptide has since been used by several investigators to enhance the endosomal escape of 
polyplexes or liposome-encapsulated proteins. Moore et al. incorporated the peptide into PEG-based 
gene delivery vehicles and demonstrated higher transgene delivery efficiency than PEG alone, as well 
as low cytotoxicity and non-specific protein adsorption compared to PEI-based particles in vitro 
(Moore et al. 2008). In a follow-up study, the researchers went on to add nuclear-localisation signal 
(NLS) peptides of SV40 and HIV (TAT) to the INF7-modfified PEG-based vehicles, and reported a 
further improved transgene efficiency and lower cytotoxicity over PEI (Moore et al. 2009). INF7 has 
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also been used to improve transgene delivery in vivo. Recently, El-Sayed et al.  demonstrated 
enhanced in vivo gene transfer to the liver using stearylated INF7 incorporated in octaarginine-
modified PEGylated liposomes following systemic administration (El-Sayed et al. 2012). 
Endosomal buffering is also an attractive approach to attain endosomal release of genetic material. 
Polymers such as PEI have been reported to confer enhanced transgene delivery over cationic 
liposomes as they produce a ‘proton-sponge’ effect (Behr et al. 1989). PEI contains several secondary 
amines which are protonated in the acidic environment of the endosome. As endosomal membrane 
adenosine-5’-triphosphate (ATP)-dependent proton pumps increase the input of protons into the PEI-
containing endosomes, creating an influx of anionic chloride ions that leads to endosome swelling and 
membrane disruption, leading to release of the PEI-encapsulated DNA (Boussif et al. 1995, Thomas 
et al. 2002). Peptide sequences containing histidine have been incorporated into gene delivery 
peptides and carriers, in an effort to translate this proton sponge effect to alternative vehicles. The 
imidazole group of histidine has a pKa of ~6.0 which allows it to become protonated in the acidic 
environment of the endosome. At physiological pH the histidines remain neutrally charged, therefore 
membrane disruption is restricted to the endosome. Several groups have synthesised histidylated 
polylysines and oligolysines to improve delivery of plasmid DNA (Midoux et al. 1999, Benns et al. 
2000) and antisense oligonucleotides (Pichon et al. 2000). Highly branched copolymers of lysine and 
histidine have also been used to deliver siRNA both in vitro and in vivo (Leng et al. 2005, Leng et al. 
2008).  
Histydylation of low molecular weight peptides have also been shown to enhance gene transfer. This 
strategy has been employed to reduce the toxicity encountered when using large polyplexes but retain 
stability at physiological conditions. Read et al. demonstrated that synthetic vectors based on 
reducible polycations consisting of histidine and polylysine flanked by cysteine residues (CH6K3H6C) 
were able to bind DNA (through lysine residues), polymersise through disulphide bonds when 
condensed with DNA, have endosomal buffering capacity and improve reporter gene transfer up to 
five fold over PEI (Read et al. 2005).  An advantage of using this strategy for nucleotide delivery was 
that inter-peptide disulphide bonds could be cleaved by the intracellular reducing environment to 
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release nucleic acids (DNA, mRNA and siRNA) and reduce toxicity (Read et al. 2005, Stevenson et 
al. 2008). 
Another histidine-rich peptide, H5WYG, was developed by Midoux and colleagues. This peptide is a 
derivative of the N-terminal sequence of the HA2 sunbunit, in which 5 amino acids have been 
replaced with histidine residues (Midoux et al. 1998). The peptide was reported to display pH-
dependent cell membrane destabilisation, which was hypothesised to occur through a combination of 
membrane disruption and endosomal buffering. H5WYG increased the expression of genes 
transferred to HepG2 cells as glycosylated polylysine-DNA complexes, and the transfection 
efficiency was not impaired in the presence of serum, making it possible for use in vivo (Midoux et al. 
1998). The H5WYG peptide has been reported to improve gene transfer following incorporation into 
PEG-based gene delivery vehicles (Moore et al. 2008) and more recently, into Bacteriophage MS2 
virus-like particles (VLPs) targeted to hepatic carcinoma cells (HCCs). Ashley et al. reported that the 
potency of the MS2 particles containing a protein or nucleic acid cargo (i.e. ricin toxin A-chain or 
siRNA) is greatly enhanced by the presence of the endosomolytic peptide, presumably through 
promotion of endosomal escape (Ashley et al. 2011).  
In the present study, the efficacy of improving RGD-AAVP-mediated gene transfer through 
endosomal disruption was evaluated. This was performed firstly through chemical means, and 
subsequently through genetic modification of the capsid to incorporate some of the aforementioned 
endosome-escape peptides (EEPs) to produce ‘multifunctional’ AAVP vectors, with a view to 
improving transgene delivery while maintaining tissue-targeting specificity.   
5.2. Results 
5.2.1. AAVP-mediated gene transfer in the presence of lysosomotrophic agents 
Having observed accumulation of RGD-AAVP in the endosomal-lysosomal degradative system in 
four cell lines (HEK293, HeLa, U87 and DU145), it was reasoned that transduction efficiency may be 
increased through chemical disruption of this pathway. The lysosomotropic agents chloroquine and 
bafilomiycin A1 were therefore used to study the effect of endosomal/lysosomal disruption on the 
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transduction efficiency of RGD-AAVP. Bafilomycin A1 is a potent inhibitor of vacuolar H+ ATPase 
proton pump which prevents acidification of endosomes (Yoshimori et al. 1991) while chloroquine is 
a weak base which accumulates in acidic organelles following protonation, resulting in their 
neutralisation (de Duve et al. 1974). Accumulation of protonated chloroquine has also been reported 
to cause swelling and destabilisation of  late endosomes and  lysosomes at high concentrations (Ngaha 
et al. 1982). 
These pharmacological inhibitors are cytotoxic as they interfere with the vital processes of the cell. 
The concentrations of inhibitors to be used were therefore first optimised by evaluation of cell 
viability following treatment using the MTT cell viability assay. HEK293, HeLa, U87 and DU145 
cells were seeded so that they reached approximately the same confluency before treatment with 
increasing concentrations of chloroquine or bafilomycin for 4 hours at 37°C (to imitate transduction 
experimental conditions), after which the inhibitor-containing medium was replaced with complete 
medium (for bafilomycin). Preliminary experiments revealed that overnight treatment with low 
concentrations of bafilomycin was not tolerated by the cells, hence the cells were only treated for 4 
hours. For cells receiving chloroquine, after the initial 4 hour incubation, an equal volume of medium 
was added and the cells incubated overnight at 37°C, the medium was replaced the following 
morning. The MTT cell viability assay was performed 48 hours later (see Materials and Methods) and 
viability data presented as a percentage viability of non-treated control cells. 
As shown in Figure 5.1, a dose-dependent loss of viability was observed in all cell lines treated with 
the pharmacological agents. However, different cell lines tolerated different doses of the inhibitors. In 
line with previous studies using pharmacological agents, the concentrations used for subsequent 
experiments were restricted to those that did not result in a loss of more than 20% cell viability. This 
was in order to control for loss of transduction efficiency by cell death rather than by lysosomotropic 
effect. Based on the MTT results, the maximum concentrations of chloroquine to be used were chosen 
as 200 µM for HEK293, U87 and DU145 cells, and 400 µM for HeLa cells. The maximum 
concentrations of bafilomycin to be used were 20 nM for HEK293, HeLa, and U87 cells, and 5 nM 
for DU145 cells.  
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In order to demonstrate that the chosen non-toxic concentrations of lysosomotropic agents was 
sufficient to confer an effect on the target vesicles, the intracellular pH following treatment with 
bafilomycin and chloroquine was determined by flow cytometry. The effects of bafilomycin and 
chloroquine on acidification of intraceullar oragnelles was measured using the vital dye acridine 
orange (3, 6-bis-dimethylaminoacridine, AO). The dye is a metachromatic fluorophore and 
‘acidotropic’ weak base which permeates into living cells and accumulates in acidic organelles such 
as late endosomes and lysosomes by proton trapping (Allison et al. 1964, de Duve et al. 1974, 
Yoshimori et al. 1991). The accumulation of the dye in acidic organelles produces a change in 
emission of the fluorescent probe from green to orange, due to concentration-dependent stacking of 
the AO. Neutralisation of the acidic compartments is measured by loss of orange fluorescence, which 
can be detected by flow cytometry (in the FL3 channel of the flow cytometer) (Girolomoni et al. 
1991, Thibodeau et al. 2004). HEK293 and HeLa cells were assessed for endosomal pH changes by 
treatment with either 20 nM bafilomycin or 200 µM (HEK293 cells) or 400 µm chloroquine (HeLa 
cells). As shown in figure 5.2, treatment with bafilomycin efficiently reduced the accumulation of 
orange fluorescence in HEK293 and HeLa cells, which correlates with previous studies (Girolomoni 
et al. 1991, Yoshimori et al. 1991). Conversely, the fluorescence of the chloroquine-treated cells 
increased, which meant that the overall pH of the cells had lowered. This may be due to cytoplasmic 
pH lowering as anions are recruited to the late endosomes or lysosomes in the chloroquine treated 
cells. Taken together, these data indicate that the doses of lysosomotropic agents chosen were capable 
of affecting the degradative pathway, though in differing ways.   
Transgene expression in the presence of non-toxic concentrations of the lysosomotropic agents was 
next evaluated in HEK293, HeLa, U87 and DU145 cells. RGD-AAVP and fd-AAVP carrying the 
luciferase and green fluorescence protein reporter genes (RGD-AAVP-LUC, RGD-AAVP-GFP, fd-
AAVP-LUC and fd-AAVP-GFP) were added to HEK293, HeLa, U87 or DU145 cells (at 1x106 
BTU/µl) in the presence of varying concentrations of chloroquine or bafilomycin and transgene 
expression was determined at day 7 post-transduction. The results show that while no significant 
change in luciferase expression was observed in cells treated with bafilomycin (Figures 5.3A, 5.4A, 
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5.5A, and 5.6A), there was a dose-dependent increase in RGD-AAVP-mediated luciferase expression 
with increasing chloroquine concentrations in all cell lines tested. Treatment with 200 μM chloroquine 
resulted in a 2.8-fold increase in RGD-AAVP-mediated luciferase expression over HEK293 cells 
treated with RGD-AAVP-LUC alone, and 9.2-fold increase was observed in U87 cells. Interestingly, 
HeLa and DU145 cells showed no expression of luciferase in cells treated with RGD-AAVP-LUC 
alone but expression rose to detectable levels following chloroquine treatment. Non-targeted fd-
AAVP mediated luciferase expression remained significantly lower than that mediated by RGD-
AAVP in all cell lines tested. These results are mirrored by the increase in AAVP-mediated GFP 
reporter gene expression as shown in Figures 5.3B, 5.4B, 5.5B, and 5.6B. 
Having observed increased transgene expression in the presence of chloroquine but not with 
bafilomycin, it was hypothesised that gene delivery was improved by chloroquine through disruption 
of the endosomal vesicles. In order to understand the morphological implications of bafilomycin and 
chloroquine treatment, alteration of the endo-lysosomal pathway under the same conditions as were 
used for transduction was investigated by electron microscopy of HeLa cells (Figure 5.7). HeLa cells 
were incubated with the fluid-phase marker HRP for one hour to label the degradative pathway prior 
to addition of 20 nM bafilomycin or 400 µM chloroquine for 4 hours. The bafilomycin-treated cells 
were fixed after 4 hours, and chloroquine-treated cells received an equal volume of medium before 
fixation the following day and processing for EM. EM analysis shows that the HRP-positive late 
endosomes and lysosomes of the bafilomycin-treated cells were of similar morphology to non-treated 
cells (Figure 5.7A and 5.7B). However, the HRP-positive late endosomes/lysosomes of chloroquine-
treated cells appeared dilated with associated disturbance of internal membrane structures (Figure 
5.7C).  These data suggest that chloroquine-induced late endosomal/lysosomal perturbation facilitates 
AAVP escape from the degradative pathway, which leads to improved gene delivery. 
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Figure 5.1. Cell viability following treatment with lysosomotropic agents. 
Non-toxic concentrations of chloroquine and bafilomycin were determined by MTT assay in (A) HEK293, (B) 
HeLa, (C) U87 and (D) DU145 cells. Cells were treated with increasing concentrations of the inhibitors for 4 
hours. Medium containing bafilomycin was replaced and cells assayed 48 hours later.  Cells treated with 
chloroquine received an equal volume of medium which was replaced the following day; cells were assayed 48 
hours later. Non-toxic concentrations were determined as those which resulted in less than 20% cell death. Mean 
cell viability was normalised to non-treated controls, with the mean of n=3 independent experiments shown (± 
SEM). 
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Figure 5.2. Effect of lysosomotropic agents on cellular pH.  
(A) HEK293 or (B) HeLa cells were incubated with non-toxic concentrations of bafilomycin for 4 hours, or 
chloroquine overnight before addition of 0.5ug/ml acridine orange and incubation for 15 minutes at 37°C. Live 
cells were washed and trypsinised before analysis by flow cytometry. Acridine orange fluorescence was 
detected in the FL3 channel, non-treated cells served as negative controls and cells receiving acridine orange 
only served as positive control. Data are presented as the percentage fluorescence of treated cells compared to 
positive control cells. The data are the mean of n=3 independent experiments (+ SEM). 
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Figure 5.3. AAVP-mediated transgene expression in HEK293 cells following treatment with 
lysosomotropic agents.  
(A) Cells were transduced with RGD-AAVP-LUC or fd-AAVP-LUC (1x106 TU/cell) in the presence of 
increasing concentrations of chloroquine or bafilomycin. Luciferase assays were performed at day 7 post-
transduction and data normalised to protein content. The results show the mean relative luminescence units/100 
µg protein of triplicate wells + SEM, from one representative of three independent experiments. NT = non-
transduced control cells (background luminescence). (B) Cells were transduced with RGD-AAVP-GFP or fd-
AAVP-GFP (1x106 TU/cell) in the presence of increasing concentrations of chloroquine or bafilomycin. 
Fluorescence images were taken at day 7 post-transduction, images presented are RGD-AAVP-GFP or fd-
AAVP-GFP in the presence of 200 µM chloroquine or 20 nM bafilomycin, compared to controls (cells which 
did not receive inhibitors). Scale bars = 50µm.  
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Figure 5.4. AAVP-mediated transgene expression in HeLa cells following treatment with lysosomotropic 
agents.  
(A) Cells were transduced with RGD-AAVP-LUC or fd-AAVP-LUC (1x106 TU/cell) in the presence of 
increasing concentrations of chloroquine or bafilomycin. Luciferase assays were performed at day 7 post-
transduction and data normalised to protein content. The results show the mean relative luminescence units/100 
µg protein of triplicate wells + SEM, from one representative of three independent experiments. NT = non-
transduced control cells (background luminescence). (B) Cells were transduced with RGD-AAVP-GFP or fd-
AAVP-GFP (1x106 TU/cell) in the presence of increasing concentrations of chloroquine or bafilomycin. 
Fluorescence images were taken at day 7 post-transduction, images presented are RGD-AAVP-GFP or fd-
AAVP-GFP in the presence of 400 µM chloroquine or 20 nM bafilomycin, compared to controls (cells which 
did not receive inhibitors). Scale bars = 50µm.  
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Figure 5.5. AAVP-mediated transgene expression in U87 cells following treatment with lysosomotropic 
agents.  
(A) Cells were transduced with RGD-AAVP-LUC or fd-AAVP-LUC (1x106 TU/cell) in the presence of 
increasing concentrations of chloroquine or bafilomycin. Luciferase assays were performed at day 7 post-
transduction and data normalised to protein content. The results show the mean relative luminescence units/100 
µg protein of triplicate wells + SEM, from one representative of three independent experiments. NT = non-
transduced control cells (background luminescence). (B) Cells were transduced with RGD-AAVP-GFP or fd-
AAVP-GFP (1x106 TU/cell) in the presence of increasing concentrations of chloroquine or bafilomycin. 
Fluorescence images were taken at day 7 post-transduction, images presented are RGD-AAVP-GFP or fd-
AAVP-GFP in the presence of 200 µM chloroquine or 20 nM bafilomycin, compared to controls (cells which 
did not receive inhibitors). Scale bars = 50µm. 
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Figure 5.6. AAVP-mediated transgene expression in DU145 cells following treatment with lysosomotropic 
agents. 
(A) Cells were transduced with RGD-AAVP-LUC or fd-AAVP-LUC (1x106 TU/cell) in the presence of 
increasing concentrations of chloroquine or bafilomycin. Luciferase assays were performed at day 7 post-
transduction and data normalised to protein content. The results show the mean relative luminescence units/100 
µg protein of triplicate wells + SEM, from one representative of three independent experiments. NT = non-
transduced control cells (background luminescence). (B) Cells were transduced with RGD-AAVP-GFP or fd-
AAVP-GFP (1x106 TU/cell) in the presence of increasing concentrations of chloroquine or bafilomycin. 
Fluorescence images were taken at day 7 post-transduction, images presented are RGD-AAVP-GFP or fd-
AAVP-GFP in the presence of 200 µM chloroquine or 5 nM bafilomycin, compared to controls (cells which did 
not receive inhibitors). Scale bars = 50µm. 
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Figure 5.7. Effect of lysosomotropic agents on late endosome/lysosome morphology.  
HeLa cells were incubated with 10mg/ml fluid-phase marker HRP for 1 hour at 37°C to label the degradative 
endocytic compartments. HeLa cells were washed and cells incubated with (A) medium alone or containing (B) 
20 nM bafilomycin or (C) 400 µM chloroquine. Bafilomycin-treated cells were fixed after 4 hours, and 
chloroquine-treated cells received an equal volume of medium before fixation the following day. HRP in the 
samples was reacted with DAB before embedding in resin. 70 nm thick sections were cut and imaged by TEM. 
Scale bar = 1µm. 
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5.2.2. Design and construction of multifunctional AAVP vectors 
Having established endosomal/lysosomal disruption as a viable method for increasing transduction 
efficiency of the targeted AAVP vector, new ‘multifunctional’ AAVP vectors were designed to 
incorporate endosome-escape peptides (EEPs), some of which have previously been used to improve 
transgene delivery of non-viral vectors. Candidate endosome-escape peptides with either fusogenic or 
pH buffering capabilities were chosen for display on the pVIII major capsid protein following 
literature review, and are summarised in table 5.1. The full amino acid sequences can be found in 
table 2.4.  
Name Function and Origin Reference 
H5WYG (23 amino 
acids) 
Synthetic histidylated fusogenic peptide with 
endosomal buffering capacity, derived from 
the N-terminal of influenza HA2 
(Midoux et al. 1998) 
INF7 (23 amino acids) pH-dependent fusogenic peptide derived from the N-terminal of influenza HA2 
(Plank et al. 1994). 
CH6K3H6C (17 amino 
acids) 
Synthetic peptide with endosomal buffering 
capacity (Read et al. 2005) 
CH12C (14 amino acids) 
Derived from CH6K3H6C by removing lysine 
residues (in-house) 
PC1 (12 amino acids) pH-dependent endosomolytic peptide identified by phage display (Hirosue et al. 2006) 
 
Table 5.1. Endosome-escape peptides identified for incorporation into the AAVP vector. 
 
H5WYG, INF7 and CH6K3H6C have been described in detail in the previous section. Briefly, INF7 
and H5WYG are pH-dependent fusogenic peptides derived from the N-terminal sequence of the 
influenza HA2 protein (Plank et al. 1994, Midoux et al. 1998). The H5WYG peptide has five residues 
replaced with histidine, to improve endosomal buffering capacity. The CH6K3H6C peptide is a 
synthetic peptide designed for endosomal buffering through multiple histidine residues, and DNA 
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condensation through lysine residues (Read et al. 2005). As the DNA condenstation capacity is not 
required in the context of the phage vector, a peptide consisting of cysteine-flanked histidine residues, 
CH12C was also included. One final peptide, named PC1, was identified through an in vitro phage 
display-based screen to induce pH-dependent (pH 5) liposome lysis. Due to its tryptophan content, it 
was alleged that the peptide may cause lysis by insertion into lipidic bilayers (Hirosue et al. 2006). 
This peptide was included in the study as this has proven membrane binding ability when displayed in 
the context of the M13-Bacteriophage coat. 
5.2.2.1. Construction of the RGD4C-fUSE5/f88.4 plasmid  
The RGD-AAVP vector was originally constructed by insertion of the RGD targeting ligand into the 
SfiI site of a fUSE5-based filamentous phage display vector. A transgene cassette flanked by AAV 
serotype 2 ITRs was then inserted into a SacI site within the multicloning site (MCS) of the vector 
(Hajitou et al. 2007). In order to produce ‘multifunctional’ AAVP vectors capable of both tumour-
targeting specificity and endosomal escape, new chimeric AAVP vectors were produced which 
contain the RGD targeting ligand on the pIII minor capsid protein, and an EEP on a recombinant 
pVIII major capsid protein. Peptides can be displayed on the wild-type pVIII, however larger peptides 
(over 8 amino acids) interfere with the coat protein function in viral packaging and bacterial 
infectivity (Iannolo et al. 1995, Smith et al. 1997, Carlos F. Barbas et al. 2004). Therefore, new 
vectors were prepared by combining two fd-tet-derived phage display vectors which share a similar 
genomic backbone; fUSE5 (GenBank Accession number: AF218364) containing the targeting ligand 
on the pIII, and f88.4 (GenBank Accession number: AF218363), which contains two copies of the 
pVIII gene (Zacher et al. 1980, Scott et al. 1990, Zhong et al. 1994). One copy of the pVIII is wild-
type, the second is recombinant (rpVIII), expression of which is regulated by the inducible tac 
promoter (Zhong et al. 1994). Insertion of foreign DNA sequences between HindIII and PstI sites on 
the rpVIII results in production of mosaic virions with approximately 150 copies of the rpVIII 
displayed amongst the 3900 copies of the wild-type pVIII. This theoretically allows relatively large 
foreign peptides to be displayed on the virion surface without disruption of the capsid structure 
(Carlos F. Barbas et al. 2004).  
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The cloning strategy used for producing multifunctional AAVP vectors is summarised in Figure 5.8. 
The fUSE5/f88.4 chimera was initially prepared by Ms Justyna Przystal under the supervision of Dr 
Amin Hajitou, following the previously published protocol of Chen et al (Chen et al. 2004). RGD 
ligand-bearing fUSE5 and f88.4 were digested with BamHI and XbaI restriction endonucleases, which 
are two unique restriction sites at similar location in both plasmid vectors. The 3925 bp fragments 
containing RGD from the RGD-fUSE5 plasmid and a 5,360 bp fragment containing the recombinant 
pVIII from the f88.4 plasmid were separated by gel electrophoresis, gel extracted and purified. The 
DNA fragments were ligated overnight and ligation products used for transformation of competent 
E.coli, which were then spread on LB-agar plates containing tetracycline. Multiple colonies were 
picked and grown in LB starter cultures, followed by miniprep purification of plasmid DNA. 
Restriction digests of plasmid DNA from multiple colonies were analyzed and the sequences 
confirmed by PCR using primers flanking the recombinant pVIII and pIII. 
5.2.2.2. Display of endosomal-escape peptides on the recombinant pVIII capsid protein 
The RGD-fUSE5/f88.4 plasmid was then used in the construction of new vectors displaying 
endosomolytic peptides on the recombinant pVIII. The non-targeted f88.4 vector (hereafter named fd-
f88.4) was used for production of non-targeted vectors containing EEPs as controls for non-specific 
uptake. Non-targeted fUSE5/f88.4 plasmids could not be produced because they contain a stop codon 
in thefUSE5 targeting ligand insertion site, which is ablated following insertion of the RGD targeting 
ligand. However, given that the vectors share similar sequences, f88.4 vectors displaying EEPs were 
proposed to be an adequate control for measuring non-specific transgene delivery by non-targeted 
vectors.  The RGD-fUSE5/f88.4 and f88.4 plasmids were digested using HindIII and PstI restriction 
endonucleases to remove a 21bp ‘stuffer sequence’ from the recombinant pVIII of the f88.4 fragment. 
The digested vectors were separated by gel electrophoresis, and 9,285 bp (RGD-fUSE5/f88.4) and 
9,258 bps (fd-f88.4) vector backbones recovered by gel extraction, and digested ends 
dephosphorylated with alkaline phosphatase. Inserts containing endosomolytic peptides were 
generated by annealing complimentary oligonucleotide pairs (the sequences of which are given in 
Table 2.4) which contained HindIII and PstI restriction site overhangs. These were ligated into the 
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complementary sites of the HindIII and PstI digested vectors. The ligation products were used for 
transformation of competent E.Coli by heat-shock, and transformants screened for positive clones by 
PCR of the rpVIII reqion flanking the insert and sequencing (an example positive sequence is shown 
in Appendix section D). 
5.2.2.3. Insertion of recombinant rAAV-GFP into RGD-fUSE5/f88.4 and fd-f88.4 
RGD-fUSE5/f88.4 and fd-f88.4 clones positive for EEPs were prepared for insertion of the 
recombinant rAAV-GFP transgene cassette by digestion with SacI. The digested vectors were 
separated from non-digested plasmid by gel electrophoresis and extracted prior to dephosphorylation 
to prevent self-ligation. An rAAV-GFP-containing plasmid was also digested with SacI and separated 
by gel electrophoresis, the 2,700 bp fragment containing the transgene cassette was purified from the 
gel and ligated into the purified, linearised RGD-fUSE5/f88-EEP and fd-f88-EEP vectors. The 
ligation reactions were transformed by heat-shock into competent E.Coli and positive transformants 
identified by restriction endonuclease reaction using SacI. Phage from positive transformant miniprep 
cultures were amplified by inoculation of E.Coli (see Materials and Methods).  
5.2.2.4. Replacement of GFP with the Luciferase reporter gene 
In order to prepare constructs for future use in vivo, the GFP reporter gene was replaced with 
Luciferase so that AAVP-mediated transduction can be analysed through bioluminescence imaging of 
living animals. The RGD-fUSE5/f88.4-EEP-GFP and fd-f88.4-EEP-GFP constructs and an rAAV-
LUC –containing plasmid were digested with NotI and SphI restriction endonucleases. The digested 
fragments were separated by gel electrophoresis and construct backbone and 3,000 bp luciferase 
transgene purified by gel extraction. The luciferase transgene was ligated into the plasmids and 
transformed into NEB competent bacteria. Transformants were screened for positive clones by 
restriction digestion with NotI and SphI. 
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Figure 5.8. Schematic representation of the cloning strategy used to produce multifunctional AAVP 
vectors.  
The example given illustrates production of targeted vectors with EEPs. Non-targeted viruses were produced 
from the f88.4 parental vector only. Asterisks indicate restriction digest reactions performed at each step. 
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Figure 5.9. Organisation of the targeted multifunctional AAVP particle.  
The targeted vector bears the RGD-targeting ligand on the pIII minor capsid protein. Approximately 150 copies 
of the recombinant pVIII are displayed amongst the wild-type pVIII major capsid proteins, to maintain stability 
and infectivity of the viral particles. 
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5.2.3. In vitro transduction using multifunctional AAVP vectors 
The multifunctional AAVP vector particles were propagated from miniprep cultures containing 
positive clones and purified as previously stated (see materials and methods). A total of 24 new 
AAVP vectors were produced (with the assistance of Mr Marcel Arias), which are detailed in Table 
5.2. A diagram representing a targeted multifunctional AAVP vector is shown in Figure 5.9. 
 GFP Transgene Luciferase Transgene 
pVIII EEP Targeted Non-targeted Targeted Non-targeted 
None RGD-fUSE5/f88.4-GFP fd-f88.4-GFP RGD-fUSE5/f88.4-LUC fd-f88.4-LUC 
H5WYG RGD-fUSE5/f88.4-H5WYG-GFP fd-f88.4-H5WYG-GFP 
RGD-fUSE5/f88.4-
H5WYG-LUC fd-f88.4-H5WYG-LUC 
INF7 RGD-fUSE5/f88.4-INF7-GFP fd-f88.4-INF7-GFP 
RGD-fUSE5/f88.4-
INF7-LUC fd-f88.4-INF7-LUC 
CH6K3H6C 
RGD-fUSE5/f88.4-
CH6K3H6C-GFP 
fd-f88.4- CH6K3H6C -
GFP 
RGD-fUSE5/f88.4- 
CH6K3H6C -LUC 
fd-f88.4- CH6K3H6C -
LUC 
CH12C 
RGD-fUSE5/f88.4-
CH12C-GFP 
fd-f88.4-CH12C-GFP 
RGD-fUSE5/f88.4- 
CH12C -LUC 
fd-f88.4-CH12C-LUC 
PC1 RGD-fUSE5/f88.4-PC1-GFP fd-f88.4-PC1-GFP 
RGD-fUSE5/f88.4-PC1-
LUC fd-f88.4-PC1-LUC 
 
Table 5.2. Multifunctional AAVP vectors produced during the investigation 
 
The yield of multifunctional phage vectors was reduced by approximately 10 fold, compared to the 
parental RGD-AAVP and fd-AAVP vectors without the recombinant pVIII inserts (1x109 BTU/µl for 
multifunctional vectors compared to 1x1010 BTU/µl for the parental vectors). Following preliminary 
experiments, the RGD/fd-AAVP-INF7-GFP and RGD/fd-AAVP-CH12C-GFP vectors were therefore 
excluded from subsequent analysis as it was technically difficult to produce adequate titres of 
multifunctional AAVP particles for transduction experiments. In particular, constructs containing the 
INF7 peptide achieved very low titres, possibly due to toxicity to the E.Coli during propagation. 
The transduction efficiencies of the newly generated multifunctional vectors were compared in vitro. 
RGD-targeted fUSE5/f88.4 vectors carrying EEPs were compared to targeted vectors without the 
endosome-disrupting peptides. Non-targeted (fd) f88.4 vectors with and without EEPs were also 
evaluated, in order to determine whether the presence of the EEPs resulted in an increase in non-
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specific uptake. HEK293 and U87 cells were chosen for analysis of the newly generated vectors, 
HEK293 cells because they are the most ‘permissive’ cell line to transduction by AAVP, and U87 
cells because these cells serve as an in vitro model for glioblastoma, for which the group is interested 
in developing in vivo models. HEK293 and U87 cells were transduced in triplicate wells, with 1x106 
TU/cell RGD-fUSE5/f88.4, RGD-fUSE5/f88.4-EEP (H5WYG, CH6K3H6C, or PC1), fd-f88.4, or fd-
f88.4-EEP (H5WYG, CH6K3H6C, or PC1) carrying the GFP reporter gene for 4 hours. The 
transduced cells were analysed by fluorescence microscopy and numbers of GFP-positive cells were 
counted immediately after transduction (Day 0) and 1, 2, 3, 5 and 7 days post-transduction. No signs 
of toxicity were observed following transduction with the newly generated vectors. The number of 
GFP-positive cells were counted per 10 fields-of-view per well, and the mean number of GFP-positive 
cells in triplicate wells were expressed as fold over RGD-fUSE5/f88.4-GFP. As shown in Figures 
5.10 and 5.11, inclusion of endosome-escape peptides increased the transduction efficiency of the 
targeted vector in both HEK293 and U87 cells. Time-course counts demonstrate that GFP expression 
was observed between 48 and 72 hours after addition of the AAVP vectors, and climbed over the 7 
days following transduction. This follows the same pattern of expression as was observed for the 
parental vectors. However, by 7 days post-transduction, GFP expression was improved by the targeted 
vectors carrying the endosome escape peptides in both HEK293 and U87 cells (Figure 5.10B and 
5.11B).  The pattern of improved expression was observed in three independent experiments, analysed 
by two independent investigators. In HEK293 cells at day 7 post-transduction, RGD-fUSE5/f88.4-
mediated transgene expression was improved by the presence of H5WYG by 2.4 fold (SEM 0.66), 
CH6K3H6C by 3.3 fold (SEM 1.17), and PC1 by 3.7 fold (SEM 1.37) across three independent 
experiments. A similar pattern of improvement was also achieved in U87 cells, with H5WYG 
improving transgene expression by 1.6 fold (SEM 0.12), CH6K3H6C by 2.1 fold (SEM 0.26) and PC1 
by 2.5 fold (SEM 0.33). Transgene delivery by non-targeted vectors bearing the endosomal escape 
peptides remained significantly lower than that of the targeted vectors, which indicates that inclusion 
of the endosomal-escape peptides did not result in an increase in non-specific uptake of the vectors. 
Representative fluorescence images of GFP expression at day 7 are shown in Figure 5.10C and 
5.11C. 
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Figure 5.10. Multifunctional AAVP-mediated transgene expression in HEK293 cells.  
(A) HEK293 cells were transduced for 4 hours with targeted and non-targeted AAVP-GFP vectors bearing 
EEPs (1x106 TU/cell). Transduction efficiency was observed by light microscopy, GFP-positive cells were 
counted immediately after transduction (day 0), and day 1, 2, 3, 5, and 7 post-transduction. GFP-postiive cell 
counts are presented as fold over RGD-AAVP control (bearing no EEP), error bars are + SEM. Time-course 
data are shown in (A), day 7 counts in (B). (C) Fluorescence images were taken at day 7 post-transduction and 
representative images are shown. Scale bar= 50 µm. 
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Figure 5.11. Multifunctional AAVP-mediated transgene expression in U87 cells.  
(A) HEK293 cells were transduced for 4 hours with targeted and non-targeted AAVP-GFP vectors bearing 
EEPs (1x106 TU/cell). Transduction efficiency was observed by light microscopy, GFP-positive cells were 
counted immediately after transduction (day 0), and day 1, 2, 3, 5, and 7 post-transduction. GFP-postiive cell 
counts are presented as fold over RGD-AAVP control (bearing no EEP), error bars are + SEM. Time-course 
data are shown in (A), day 7 counts in (B). (C) Fluorescence images were taken at day 7 post-transduction and 
representative images are shown. Scale bar= 50 µm. 
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5.3. Discussion 
The studies described in the preceding chapters were performed in order to identify the key limitations 
to transgene delivery by RGD-AAVP. It was demonstrated that the vector is efficiently endocytosed 
into several cell lines expressing the αv integrin receptors. However, following endocytosis the 
majority of the phage particles were observed to accumulate in the endo-lysosomal degradative 
pathway. This pathway was therefore identified as a barrier to transduction by the bacteriophage-
based vector. In the present chapter, the efficacy of improving gene delivery through endo-lysosomal 
disruption was evaluated and new multifunctional AAVP vectors were developed, with the hypothesis 
that the vectors could be genetically altered to improve transgene expression through incorporation of 
endosomal-escape peptides into the bacteriophage capsid. 
The efficacy of improving transgene delivery by endosomal disruption was first established using the 
pharmacological agents bafilomycin A1 and chloroquine in HEK293, U87, HeLa and DU145 cells. 
As previously described, Bafilomycin A1 is a specific inhibitor of vascular H+ ATPases which 
inhibits endosomal acidification (Yoshimori et al. 1991). Chloroquine is a weak base which 
accumulates in acidic endosomes and increases endosomal pH (de Duve et al. 1974). These 
lysosomotropic agents have been extensively used to demonstrate the low pH requirements of viral 
uncoating (Perez et al. 1994, Guinea et al. 1995, Martinez et al. 1996). 
Non-toxic concentrations of the inhibitors were first determined by cell viability assays, and 
biological effect of the chosen concentrations was demonstrated by acridine orange analysis of 
intracellular pH (Figure 5.1. and 5.2). Treatment with bafilomycin A1 had no effect on RGD-AAVP-
mediated reporter transgene expression in the cell lines, which suggests that the endosomal pH does 
not influence gene delivery by the vector (Figures 5.3, 5.4, 5.5, 5.6). Chloroquine treatment gave a 
pronounced improvement in all cell lines tested (Figures 5.3, 5.4, 5.5, 5.6). Interestingly, HeLa and 
DU145 cells, which were previously non-permissive to gene transfer by the phage vector, had 
detectable levels of luciferase and GFP expression following treatment with chloroquine (Figure 5.4 
and 5.6). In light of these findings, it was hypothesised that chloroquine-enhanced gene transfer 
occurred through a mechanism unrelated to endosomal pH. Enhanced bacteriophage-mediated 
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transgene expression following chloroquine treatment has also been observed by researchers studying 
bacteriophage λ gene therapy vectors (Volcy et al. 2009). These researchers surmised that chloroquine 
treatment improved gene transfer as the agent can inhibit the action of lysosomal proteases at high 
concentrations (Wibo et al. 1974). The authors demonstrated that gene delivery of bacteriophage λ 
was improved through the use of inhibitors of the lysosomal proteases cathepsins B and L. It would be 
interesting to determine whether inhibition of lysosomal proteases improves gene transfer by AAVP, 
however, given that the endosomal membrane also presents a physical barrier to gene delivery, it is 
unclear how inhibition of these enzymes would allow improved gene expression. 
As chloroquine has been reported to cause swelling and destabilisation of late endosomes and 
lysosomes at high concentrations (de Duve et al. 1974, Ngaha et al. 1982), it was hypothesised that 
improved gene expression in the presence of this agent may be due to physical disruption of the 
endosomal pathway. In order to determine if this was the case, the morphological effects of chemical 
treatment were analysed in HeLa cells by electron microscopy. While late endosomes and lysosomes 
of bafilomycin-treated cells were of similar morphology to non-treated cells, these structures were 
noticeably disturbed in chloroquine-treated cells (Figure 5.7). Chloroquine treatment resulted in 
greatly enlarged late endosomes and lysosomes, with associated disturbance of internal membranes. 
These data indirectly suggest that chloroquine treatment may result in release of the vectors from 
degradative pathway. Unfortunately, it was not possible to demonstrate this effect directly by electron 
microscopy of AAVP release from the lysosomes following chloroquine treatment, as the 
combination of the immunogold labelling protocol and chemical treatment rendered the cells non-
viable. However, these data do suggest that physical disruption of the endo-lysosomal system may be 
an appropriate method for improving gene delivery by the vector.  
Inclusion of endosomal-escape peptides has been demonstrated to improve transgene delivery by MS2 
bacteriophage-derived VLPs (Ashley et al. 2011). Bacteriophage λ vectors displaying the transduction 
domain of the HIV Tat protein have been shown to transduce cells with an efficacy comparable to 
commercially available transfection reagents, however it should be noted that gene transfer by Tat-
displaying phage was receptor-independent, and therefore non-specific (Eguchi et al. 2001). Di 
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Giovine et al. demonstrated that an M13 filamentous phage displaying the full-length adenovirus 
penton base, which has been reported to mediate endosomal disruption activity, was able to transduce 
HeLa cells, similarly, Piersanti et al. showed that addition of the Adenovirus penton base to λ phage 
resulted in promotion of endosomal escape and proteasome resistance by the phage particles (Di 
Giovine et al. 2001, Piersanti et al. 2004b). These previous studies suggest that inclusion of 
endosomal-escape peptides is a viable strategy for improving gene transfer by phage-based vectors. 
Therefore, new AAVP vectors were generated by incorporation of endosomal-escape peptides which 
have previously been shown to improve gene delivery by non-viral or alternative vectors. A variety of 
peptides were chosen, with either fusogenic, membrane lytic, or endosomal buffering capabilities 
(indicated in Table 5.2). Multifunctional AAVP particles were prepared by combining fUSE5 and 
f88.4 fd-tet-derived phage vectors, in order to display the targeting ligand on the minor pIII capsid 
protein, and EEPs on the recombinant pVIII major capsid protein. The presence of the EEPs on the 
rpVIII were confirmed by PCR and sequencing of PCR products from the purified phage vectors 
following amplification in E.coli. Separate experiments performed by Mr Teerapong Yata and Mr. 
Marcel Arias of the Phage Research Group (Imperial College London) attempted to demonstrate that 
functional peptides were incorporated into the AAVP vector using this cloning strategy. RGD-AAVP 
vectors bearing steptavidin-binding peptides (SBP) on the rpVIII were produced and binding to 
streptavidin-coated enzyme-linked immunosorbent assay (ELISA) plates compared to AAVP vectors 
lacking the SBP. The bound phage were titred by infection of E.coli and plaque assay. AAVP bearing 
the SBP showed 100-fold increased binding over AAVP lacking the SBP, suggesting that the cloning 
strategy was capable of producing functional peptides on the rpVIII. 
A total of 24 new AAVP vectors bearing EEP on the rpVIII with GFP or Luciferase reporter genes 
were prepared (plus controls lacking the EEPs). The combination of peptide display on both pIII and 
rpVIII resulted in lowered titres of AAVP which could be produced in E.coli, which limited the 
numbers of experiments that could be performed. Therefore, in order to be able to replicate the 
experiments, the INF7 and CH12C peptides were removed from the studies. Preliminary findings 
suggest that these vectors do not improve transgene delivery, but this needs to be re-evaluated in the 
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future. However, preliminary data from GFP transduction experiments are promising, AAVP vectors 
simultaneously displaying the RGD targeting ligand and H5WYG, CH6K3H6C or PC1 endosomal-
escape peptides demonstrated improved reporter transgene expression over targeted vectors lacking 
EEPs in both HEK293 and U87 cell lines by day 7 post-transduction (Figures 5.10 and 5.11). 
Furthermore, incorporation of the EEPs did not appear to greatly affect the transgene delivery by the 
non-targeted vectors, suggesting that firstly, the function of the RGD-targeting peptide on the pIII was 
not impaired during production of the multifunctional vectors, and secondly, the EEPs did not 
increase non-specific uptake of the vectors. Interestingly, the PC1 peptide gave the greatest 
improvement of RGD-targeted transgene delivery to both HEK293 and U87 cells. The PC1 peptide 
was identified from a phage display screen of peptides with pH-dependent liposomal membrane lytic 
capabilities by Hirosue and Weber, but has not previously been used for intracellular membrane lysis 
(Hirosue et al. 2006). These data are therefore the first to suggest that PC1 may mediate endosomal 
release in the intracellular environment.  
Given the encouraging results from these preliminary experiments, it would be feasible to further 
characterise the multifunctional vectors in vitro. Integrin-targeting specificity by the RGD-AAVP-
EEP vectors could further be demonstrated through flow cytometric analysis of internalised particles 
in M21 and M21L cells, as described in chapter 3. It is assumed that the increased transgene delivery 
by RGD-AAVP vectors displaying EEPs is a result of endosomal disruption by these peptides, 
however, this remains to be proven. This could be demonstrated using several strategies. Confocal 
analysis of RGD-AAVP-EEP intracellular trafficking and association with endosomal and lysosomal 
markers (such as EEA-1 and LAMP-1) may be undertaken to determine whether these vectors remain 
associated with the degradative pathway. Alternatively, ultrastructural analysis by electron 
microscopy may be used to show endosomal/lysosomal disruption following addition of the vectors. 
An interesting approach would be to use pH-sensitive lysosomal markers (such as lysotracker™ or 
pHrodo™ Red dextran) to demonstrate endosomal buffering or lysis. pHrodo™ Red dextran has a 
pH-sensitive fluorescence emission that increases in intensity with increasing acidity. Flow cytometric 
analysis of the loss of pHrodo™ Red dextran fluorescence in the presence of the vectors bearing EEPs 
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would demonstrate endosomal buffering or lysis. Together with ultrastructural analysis by EM, these 
data would indicate whether incorporation of EEPs in the phage coat is sufficient to mediate 
endosomal disruption. 
To conclude, the presented studies demonstrate that disruption of the endosomal/lysosomal pathway is 
a viable strategy for enhancing RGD-AAVP-mediated transgene delivery. Following the observation 
that chloroquine enhanced gene transfer in cells non-permissive to transduction by RGD-AAVP, new 
multifunctional vectors capable of tumour targeting and endosomal release were developed. Display 
of candidate endosomal escape peptides on the targeted vectors resulted in an increase of reporter 
gene expression in the two cell lines tested. These findings are encouraging, and demonstrate the 
feasibility of enhancing AAVP-mediated gene transfer through genetic modification of the 
bacteriophage-based vector.  Furthermore, these studies underline the importance of understanding the 
limitations of gene delivery vectors, so that they may be rationally modified for improved gene 
transfer. 
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6. Final discussion 
 
6.1. Summary of findings 
To date, the fundamental reasons for the low transduction efficiency of the RGD-AAVP vector have 
remained unexplored. The purpose of this thesis was therefore to investigate the entry and 
intracellular trafficking events involved in RGD-AAVP uptake, in order to identify key factors 
limiting gene transfer by the vector. Initial experiments demonstrated that display of the RGD ligand 
on the minor capsid protein pIII promotes efficient uptake of the targeted vector in cell lines 
expressing the integrin receptors. Receptor-mediated endocytosis of the targeted AAVP vector was 
further investigated using various endocytic inhibitors, with analysis by flow cytometry, confocal, and 
electron microscopy. Endocytosis of RGD-AAVP was shown to be both dynamin- and clathrin-
dependent. Following endocytosis, the majority of RGD-AAVP particles were observed to be 
sequestered by the endosomal-lysosomal degradative pathway, which presents a major obstacle to 
transgene delivery by the vector. The efficacy of improving RGD-AAVP-mediated transgene delivery 
by disruption of the endosomal-lysosomal system was demonstrated using the lysosomotropic agent 
chloroquine. Novel multifunctional vectors were therefore designed to improve transgene expression 
through genetic incorporation of peptides on the vector particle which have been previously shown to 
promote endosomal disruption and enhance transgene delivery by other gene therapy vectors. These 
multifunctional vectors were shown to maintain the targeting capacity of the RGD ligand displayed on 
the minor capsid protein pIII, and display of endosomal escape peptides on the recombinant pVIII 
major capsid protein resulted in improved reporter gene expression in mammalian cell lines. 
6.2. Aims of the thesis 
Eukaryotic viral vectors have thus far dominated the field of gene therapy. Given that their parental 
viruses have evolved to gain access to mammalian cells to exploit host cellular machineries for their 
replicative needs, eukaryotic virus-derived gene delivery vectors have an inherent ability to efficiently 
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deliver genes to mammalian cells. However, they have had limited success as systemic gene therapy 
vectors due to undesired uptake in non-target tissues, insertional mutagenesis, and immunogenicity 
(reviewed by (Waehler et al. 2007)). Furthermore, the field of gene therapy was severely impacted 
following some highly publicised adverse reactions to viral vectors, resulting in the deaths of some 
patients (Lehrman 1999, Raper et al. 2003, Hacein-Bey-Abina et al. 2008). Therefore, a significant 
amount of research has been aimed at the generation and improvement of alternative gene delivery 
vehicles such as cationic liposomes and polymers, VLPs, peptide carriers, and bacteriophage, to name 
a few (reviewed by (Seow et al. 2009)). Unfortunately, a common disadvantage of using such gene 
delivery vehicles is low gene transfer efficiency when compared to eukaryotic viruses, and 
bacteriophage vectors are by no means an exception. Bacteriophage-derived vectors have been 
demonstrated to deliver reporter transgenes to mammalian cells following genetic incorporation of 
targeting ligands or antibodies capable of binding internalising receptors (Dunn 1996, Larocca et al. 
1998, Larocca et al. 1999, Poul et al. 1999, Di Giovine et al. 2001, Piersanti et al. 2004a). However, 
transgene expression using these systems is low. For example, Larocca et al. described that 
filamentous phage displaying FGF was able to deliver GFP to COS-1 cells with 0.4% transduction 
efficiency (Larocca et al. 1998). More recently, Di Giovine et al. were able to transduce up to 4% of 
HeLa cells with filamentous phage displaying the full length adenovirus penton base despite 
observations that 100% of cells internalised the virus (Di Giovine et al. 2001). 
In an attempt to improve bacteriophage-mediated transgene expression, Hajitou and colleagues 
developed a novel prokaryotic-eukaryotic hybrid viral vector termed AAV/Phage or AAVP (Hajitou 
et al. 2006). The introduction of AAV ITRs into an RGD-targeted M13 filamentous bacteriophage 
resulted in increased transduction efficiency over conventional phage-based vectors through improved 
fate of the delivered transgenes (Hajitou et al. 2006). However, despite the apparent success of this 
novel vector in several in vivo cancer models, high titres of AAVP are required for transduction of 
large numbers of mammalian cells in vitro. The discrepancy between low reporter transgene 
expression in vitro and therapeutic efficacy in vivo can be ascribed to the choice of therapeutic 
transgenes and targeting of the angiogenic vasculature. Therapeutic efficacy of the RGD-AAVP 
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vector was reported using the combination of the suicide gene HSVtk with the prodrug ganciclovir. 
RGD-AAVP therapy using this GDEPT system was recently demonstrated to mediate tumour cell 
death both in vitro and in vivo via a heterotypic bystander effect between HSVtk-transduced 
endothelial cells and non-transduced tumour cells (Trepel et al. 2009).  The bystander effect resulted 
in significant tumour regression and reduced the need for high numbers of cells to be transduced in 
order to mediate a therapeutic effect. Furthermore, given the estimates that up of 100 tumour cells are 
sustained by a single endothelial cell (Folkman 1997), gene targeting of angiogenic vasculature often 
leads to enhanced therapeutic efficacy in vivo. Therefore, while the transduction efficiency of RGD-
AAVP is low, the therapeutic effect in vivo is likely to be substantially increased by the combination 
of tumour endothelium destruction and heterotypic bystander effect from the GDEPT therapy. 
However, despite observations of reduced tumour growth and improved survival rates in several 
animal models, few instances of total disease eradication have thus far been achieved following 
administration of multiple doses of the vector (Hajitou et al. 2006, Hajitou et al. 2007, Paoloni et al. 
2009). Therefore, it is imperative that the transduction efficiency of RGD-AAVP be improved in 
order for this vector to be considered a viable alternative to conventional gene therapy vectors. 
It is well established that overall efficiency of transduction by receptor-mediated gene transfer is 
dependent on success of three steps; 1) endocytosis by receptor-ligand targeting, 2) endosomal escape 
and 3) nuclear localisation (Martin et al. 2007).  Given that the AAVP vector is derived from 
bacteriophage, which has not evolved the adaptations  necessary for endosomal escape and nuclear 
localisation, it was hypothesised that low transduction efficiency may be due to sequestration by the 
cell’s degradative pathways which eukaryotic viruses have evolved to utilise or avoid. The aim of this 
work was therefore to elucidate the entry and intracellular trafficking steps involved in RGD-AAVP 
uptake, in order to identify key barriers to transduction. A secondary aim of the project was to 
engineer novel and more efficient vectors based on evidence from these observations.  
6.3. Endocytosis and intracellular trafficking of AAVP 
In vitro experiments have previously shown that while 100% of cells internalise targeted RGD-
AAVP, only up to 10% express the transgene (Hajitou et al. 2006, Hajitou et al. 2007). Integrin-
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AAVP interaction has been previously shown by either blocking RGD-AAVP binding to the αv 
integrin-positive KS1767 (Karposi’s sarcoma) cell line using synthetic RGD ligand, before cell lysis 
and titration of internalised particles, or by comparison of internalisation of RGD-AAVP and AAVP 
bearing mutated/scrambled ligands by immunofluorescence staining and microscopy (Hajitou et al. 
2006). Past these initial experiments, little is known about the mechanisms of RGD-AAVP 
endocytosis and intracellular trafficking. As endocytosis following receptor-ligand binding presents 
the first major obstacle to gene delivery by the RGD-AAVP vector, initial experiments were first 
performed to confirm that the angiogenic αv integrin heterodimers mediate efficient uptake of the 
RGD-AAVP vector. Using integrin positive (M21) and negative (M21-L) melanoma cell lines, it was 
shown that efficient uptake of the vector requires the presence of the αvβ3 and αvβ5 heterodimers. 
However, αv integrin receptor-mediated endocytosis of the targeted vector is not sufficient to confer 
efficient transgene delivery by the targeted AAVP vector, as some cell lines remained non-permissive 
to transduction by AAVP. In the most permissive cell line (HEK293), reporter transgene expression 
was dose-dependent, but remained low following transduction with high titres of the vector, 
confirming previously published observations (Hajitou et al. 2006). These initial findings confirmed 
the hypothesis that post-entry events were therefore likely to be limiting to transgene delivery by the 
targeted vector.  
In order to elucidate the key barriers to transduction by the AAVP vector, the mechanisms of 
endocytosis and intracellular trafficking were further investigated using various endocytic inhibitors 
and analysis by flow cytometry, confocal microscopy, and electron microscopy. Based on these 
findings, a model of receptor-mediated endocytosis of RGD-AAVP was constructed and is presented 
in Figure 6.1. 
Quantitative flow cytometric analysis of reduced RGD-AAVP uptake in the presence of inhibitors of 
both dynamin (dynasore and the dominant negative mutant dynamin K44A) and clathrin (sucrose and 
siRNAs against the clathrin heavy chain) strongly suggest that the targeted vector is endocytosed by 
the clathrin-mediated pathway. These data are reinforced two lines of evidence; firstly, αvβ3 and αvβ5 
heterodimers are known to associate with clathrin-coated pits (De Deyne et al. 1998). Secondly, 
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similar studies of eukaryotic viruses which utilise RGD ligand-αv integrin interactions are able to gain 
entry into mammalian cells via clathrin-mediated endocytosis. Adenovirus serotype 2 is one such 
example; binding to the cell surface is mediated by high affinity interactions between the adenovirus 
fiber knob and the Coxsackie and Adenovirus Receptor (CAR). A second low-affinity interaction 
between RGD domains on the adenovirus penton base and αvβ3 and αvβ5 integrins triggers receptor-
mediated endocytosis into clathrin-coated pits (Wickham et al. 1993, Meier et al. 2002). Similarly, 
foot and mouth disease virus (FMDV) interacts with αv integrins through a conserved RGD sequence 
on the βG-βH loop of the capsid protein VP1, which initiates clathrin-mediated endocytosis of the 
virus (O'Donnell et al. 2005). 
While these experiments strongly suggest that RGD-AAVP uptake is clathrin-dependent, it is possible 
that RGD-AAVP does not follow the prototypical clathrin pathway, given that expression of the 
dominant-negative Eps15 mutant EH29 failed to inhibit uptake of the vector. As discussed in Chapter 
4.3, it is possible that the levels of EH29 expression obtained in these experiments were not sufficient 
to show a significant effect, as uptake of transferrin (a protein which is predominantly endocytosed by 
the clathrin pathway) was only reduced by approximately 30% in EH29-expressing cells. 
Alternatively, it has been recently shown that the alternative clathrin adaptor Numb can interact with 
the cytoplasmic domain of the β3 integrin chain, which controls αvβ3 integrin endocytosis and cell 
migration (Nishimura et al. 2007). It is possible that Numb may be capable of recruiting AP-2 and 
clathrin to form coated pits independently of Eps15. This hypothesis is reinforced by the work of 
Santolini et al. who, while demonstrating that Numb functions as an endocytic adaptor through 
interaction with AP-2, failed to observe colocalisation with Eps15 in coated pits (Santolini et al. 
2000). Furthermore, other groups have demonstrated that clathrin-mediated endocytosis of some 
viruses is also insensitive to Eps15 inhibition (Lakadamyali et al. 2006, Pu et al. 2008, Bhattacharyya 
et al. 2011). 
The association of RGD-AAVP with the clathrin pathway does not exclude the involvement of other 
trafficking pathways in endocytosis of the vector, particularly as integrin heterodimers can follow 
multiple endocytic routes (reviewed by (Caswell et al. 2009)). Uptake of RGD-AAVP was shown to 
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be diminished by the cholesterol sequestering agent filipin III. Several pathways are sensitive to 
cholesterol depletion, including clathrin- and caveolae-mediated endocytosis and macropinocytosis 
(Schnitzer et al. 1994, Hailstones et al. 1998, Subtil et al. 1999, Grimmer et al. 2002). Given that no 
caveolae were observed in the model cell line, and that transferrin was insensitive to filipin treatment, 
it can be hypothesised that RGD-AAVP may induce macropinocytosis following integrin receptor 
binding, as has been observed for the αv integrin binding adenovirus serotypes 2, 3 and 5 (Meier et al. 
2002, Amstutz et al. 2008). However, further studies are required to determine if this is the case for 
RGD-AAVP (detailed in Chapter 4.3). 
Following endocytosis, the RGD-AAVP vector was observed to associate with the early endosomes, 
late endosomes and lysosomes, as determined by confocal and electron microscopy studies. Extended 
confocal studies demonstrated that RGD-AAVP remained localised to the late endosomal/lysosomal 
compartments 24 hours following addition of the vector, suggesting that the vector remains associated 
with the endosomal-lysosomal degradative pathway. These findings are reinforced by early studies of 
internalisation of RGD-targeted filamentous bacteriophage. Hart et al. were the first to demonstrate 
that incorporation of the RGD ligand on the phage pVIII major capsid protein resulted in receptor-
mediated endocytosis of the phage (Hart et al. 1994). The researchers observed accumulation of 
internalised phage in perinuclear compartments after 6 hours incubation, which did not colocalise 
with the transferrin receptor. Given the findings presented in this thesis, it can be suggested that the 
researchers were observing sequestration of the phage particles by the lysosomal compartments. 
Furthermore, studies by Ivanenkov et al. demonstrated that integrin-targeted phage display vectors 
were subject to degradation in intracellular compartments. The researchers demonstrated that 
treatment with the lysosomotropic weak base chloroquine increased the number of viable phage that 
could be rescued from mammalian cells, suggesting that the phage were inactivated in lysosomes 
(Ivanenkov et al. 1999a). While the studies presented in this thesis have not addressed whether RGD-
AAVP is degraded in the lysosomal compartments, the previous findings of Ivanenkov et al. 
indirectly suggest that this is indeed the case.  
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Taken together, these studies validate the primary hypothesis of this thesis, i.e. that the low 
transduction efficiency of RGD-AAVP is due to sequestration by the cells degradative endosomal-
lysosomal compartments, from which the vector is unable to escape. 
 
 
Figure 6.1. Model of the intracellular trafficking of RGD-AAVP.  
RGD-AAVP is internalised primarily through the dynamin and clathrin-dependent endocytic pathway and is 
subsequently sorted into the EEA-1 positive early endosomal compartments. From the early endosome, the 
vectors are delivered to the multivesicular bodies (MVB)/late endosomes and further to the lysosomes where 
they are degraded. Treatment with the lysosomotropic agent chloroquine, or incorporation of endosomal-escape 
peptides (EEPs) promotes improved transgene expression, presumably through release of the vectors from the 
endosomal-lysosomal system. It remains to be determined how these released vectors are capable of transferring 
their transgenes to the nucleus.  
 
6.4. Construction and evaluation of multifunctional AAVP vectors 
The presented studies of entry and intracellular trafficking of RGD-AAVP identified sequestration by 
the endosomal-lysosomal system as a major obstacle to transduction by the gene delivery vector. 
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Several viruses have adapted to use this degradative endocytic pathway to their advantage by using 
the low pH to induce conformational changes in the capsid which allow penetration, fusion or capsid 
uncoating, resulting in virus escape to the cytoplasm and, if necessary, translocation to the nucleus 
and replication (detailed in Chapter 5.1). However, bacteriophage have no intrinsic mechanisms for 
endosome escape, as they have not undergone the evolutionary steps utilised by such eukaryotic 
viruses. Therefore, the efficacy of improving gene transfer through disruption of the endosomal-
lysosomal pathway was first evaluated using lysosomotropic agents. 
Treatment with the specific inhibitor of vascular H+ ATPases, bafilomycin A1, had no effect on RGD-
AAVP-mediated reporter transgene expression in the cell lines, which suggests that the endosomal pH 
does not influence gene delivery by the vector. However, the weak base chloroquine was 
demonstrated to improve transgene delivery by AAVP in several cell lines, and importantly, resulted 
in transduction of cells previously non-permissive to RGD-AAVP-mediated gene transfer. Electron 
microscopic analysis of chloroquine-treated cells demonstrated late endosomal and lysosomal 
swelling and disruption, consistent with previously published observations (de Duve et al. 1974, 
Ngaha et al. 1982). These data indirectly suggest that lysosomal disruption may result in release of the 
AAVP into the cell cytoplasm which results in improved gene transfer. The finding that chloroquine 
improves phage-mediated gene transfer is supported by studies by Volcy et al., who demonstrated 
improved reporter gene expression by lambda phage vectors in the presence of this drug  (Volcy et al. 
2009). However, these researchers concluded that the improved gene transfer in the presence of 
chloroquine was due to inhibition of lysosomal proteases (namely, cathepsins B and L), rather than 
physical perturbation of the endosomal membranes. The actions of lysosomal proteases have not been 
addressed in this thesis, and it would be interesting to determine whether specific inhibition of such 
lysosomal cathepsins improves gene transfer by the RGD-AAVP vector, however, given that the 
endosomal membrane also presents a physical barrier to gene delivery, it is unclear how inhibition of 
these enzymes would allow improved gene expression. 
Having established endosomal/lysosomal disruption as a potential method for increasing transduction 
efficiency of the targeted AAVP vector, new ‘multifunctional’ AAVP vectors were designed to 
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incorporate endosome-escape peptides (EEPs), some of which have previously been used to improve 
transgene delivery of non-viral vectors (Midoux et al. 1998, Read et al. 2005, Moore et al. 2008). 
Candidate endosome-escape peptides with either fusogenic (H5WYG), membrane-lytic (PC1), or pH 
buffering capabilities (CH6K3H6C ) were chosen for display on the recombinant pVIII major capsid 
protein of newly generated RGD-AAVP-fUSE5-f88.4 vectors (Midoux et al. 1998, Read et al. 2005, 
Hirosue et al. 2006). Comparison of the transduction efficiencies of AAVP vectors bearing EEPs in 
vitro revealed improved transgene expression over RGD-AAVP vectors lacking EEPs. Furthermore, 
incorporation of the EEPs did not appear to greatly affect the transgene delivery by the non-targeted 
vectors, suggesting that firstly, the function of the RGD-targeting peptide on the pIII was not impaired 
during production of the multifunctional vectors, and secondly, the EEPs did not increase non-specific 
uptake of the vectors. These preliminary findings therefore validate the secondary objective of this 
thesis; that improved gene delivery vectors may be engineered based on evidence from entry and 
intracellular trafficking studies of RGD-AAVP. 
6.5. Other limiting factors involved in RGD-AAVP-mediated gene transfer 
While the data presented in this thesis have identified the endosomal-lysosomal degradative pathway 
as a key barrier to transduction by RGD-AAVP, these findings do not exclude the involvement of 
other post-entry events in the regulation of gene expression by the phage-derived vector. Given that 
AAVP is able to mediate modest transgene expression in HEK293 cells when administered at high 
titres, it stands to reason that a small percentage of the phage particles are able to access the cell 
cytoplasm in order to deliver reporter transgenes to the nucleus. It is possible therefore, that RGD-
AAVP may also be subject to degradation by the cytosolic ubiquitin-proteasome pathway, which 
constitutes a major proteolytic system in eukaryotic cells.  
Proteasomes are multi-subunit enzyme complexes which recognise and degrade ubiquitinated 
proteins. The proteasomal degradation pathway is involved in the regulation of cell cycle progression 
(e.g. through degradation of cyclins), receptor signalling (e.g. by degradation of activated protein 
kinases) degradation of misfolded proteins, and antigen processing (Kisselev et al. 2001). The 
proteasome also has functions at various levels in eukaryotic virus infection. Proteasome activity is 
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required for infection of some eukaryotic viruses, including reovirus (Chen et al. 2008), herpes 
simplex virus (HSV) (Delboy et al. 2008), and mouse hepatitis virus (MHV) (Yu et al. 2005). Other 
eukaryotic viruses (notably AAV) are subject to degradation by the proteasome (Yan et al. 2002), and 
viral infectivity can be enhanced through the use of proteasomal inhibitors (Jennings et al. 2005, Tang 
et al. 2005). 
Evidence for the involvement of the proteasome in degradation of RGD-AAVP was recently 
described (Przystal et al. 2012). Treatment with the 26S proteasome complex inhibitors MG132 (Z-
leu-leu-leu-al) and LLnL was shown to improve RGD-AAVP-mediated transgene delivery both in 
vitro and in mice bearing subcutaneous human melanoma tumour xenografts. These recent findings 
are consistent with those of Volcy et al. who demonstrated improved transgene delivery by 
bacteriophage lambda in the presence of MG132 (Volcy et al. 2009). However, it should be noted that 
this inhibitor may have functions outside of proteasomal degradation. For example, MG132 has been 
shown to inhibit lysosomal proteases in addition to the proteasome (Tsubuki et al. 1996). It was 
reported that treatment with MG132 increased the presence of intracellular RGD-AAVP colocalised 
with polyubiquitin (shown by confocal microscopy), indirectly suggesting that the drug prevented 
degradation of ubiquitinated phage particles. However, it has not yet been directly demonstrated that 
the AAVP particles are polyubiquitinated and degraded by the proteasomal complex. Thus, while it is 
suggested that the proteasome functions to limit transduction efficiency of AAVP, further research 
may be required to conclusively demonstrate this. 
Nuclear import efficiency is another important kinetic block that influences transgene expression in 
eukaryotic cells. It remains unclear how unmodified RGD-AAVP vectors which escape the cell’s 
degradative pathways are able to traverse the cell cytoplasm and gain access to the nucleus for 
delivery of virally-encoded transgenes.  
The active transport of macromolecular cargo between the cytoplasmic and nuclear compartments is 
facilitated by specific soluble carrier proteins. These carrier proteins are referred to as ‘karyopherins’, 
with ‘importins’ involved in import and ‘exportins’ involved in export of nuclear cargo (reviewed by 
(Lange et al. 2007). Proteins destined for transport to the nucleus contain amino acid sequences 
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termed nuclear localisation signals (NLS). These sequences are recognised by importins which 
facilitate transport through the nuclear complexes present on the nuclear envelope. Some eukaryotic 
viruses NLS (such as sequence PKKKRKV, present in the SV40 large T antigen) which are exposed 
following capsid uncoating during endocytosis/fusion at the plasma membrane and serve to transport 
viral genomes through the nuclear pore complexes for replication of viral genomes in the nucleus 
(Kalderon et al. 1984, Greber et al. 2005). As prokaryotic viruses, bacteriophage do not carry any 
recognised NLS on the phage capsid. However, it has been reported that incorporation of the SV40 
NLS on the capsid of phage lambda resulted in improved transgene delivery over wild-type phage 
(Akuta et al. 2002). Recent unpublished work performed by Mr Teerapong Yata (of the Phage 
Research Group at Imperial College) has also demonstrated improved gene transfer efficiency in vitro 
by multifunctional RGD-AAVP vectors displaying this peptide on the recombinant pVIII major 
capsid protein. These studies therefore suggest that nuclear import is another important barrier to 
efficient transgene delivery by the RGD-AAVP vector. Furthermore, treatment of cells with 
chloroquine resulted in improved transduction efficiency of RGD-AAVP bearing the SV40 NLS over 
the targeted vector, or RGD-AAVP-NLS without chloroquine treatment. These findings suggest that 
RGD-AAVP vectors bearing both NLS and endosomal escape peptides may prove more efficient over 
RGD-AAVP bearing EEPs or NLS alone. Given that peptides and proteins may be displayed on the 
amino terminus of the M13 phage minor  pVII and pIX coat proteins (Gao et al. 1999), simultaneous 
display of both peptides may be possible through display of NLS on one of these coat proteins, and 
EEPs on the recombinant pVIII of multifunctional RGD-AAVP vectors. 
6.6. Future studies 
Multifunctional AAVP-mediated reporter gene expression remains low compared to that mediated by 
eukaryotic viruses. However, given the comparatively good safety profile of bacteriophage-based 
gene therapy vectors, combined with high transgene cargo potential, and low cost of production and 
purification to high titres, the comparative advantages of using bacteriophage as a gene carrier means 
that further research into development of the RGD-AAVP vector remains justified.  
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Therefore, future efforts will be focussed on evaluating the efficacy of the newly generated 
multifunctional AAVP vectors. Given the encouraging results from the preliminary experiments 
presented in this thesis, it would be feasible to further characterise the multifunctional vectors in vitro. 
The data presented in Chapter 5.2 suggest that the EEPs do not interfere with the targeting potential 
of the AAVP vectors, as gene delivery by non-targeted AAVP-EEP remained significantly lower than 
that of the RGD-targeted vectors. Integrin-targeting specificity by the RGD-AAVP-EEP vectors could 
further be demonstrated through flow cytometric analysis of internalised particles in integrin-positive 
(M21) and negative (M21-L) cell lines. It is assumed that the increased transgene delivery by RGD-
AAVP vectors displaying EEPs is a result of endosomal disruption by these peptides, however, this 
remains to be proven. This could be demonstrated through confocal analysis of RGD-AAVP-EEP 
intracellular trafficking and association with endosomal and lysosomal markers (such as EEA-1 and 
LAMP-1), by flow cytometric analysis of EEP-mediated liberation of pH-dependent dyes from the 
endosomes/lysosomes (such as lysotracker™ or pHrodo™ Red dextran) or by ultrastructural analysis 
of endosomal compartments following addition of AAVP-EEPs by electron microscopy.  
Following further characterisation of the newly generated vectors in vitro, in vivo studies should be 
performed to determine whether these vectors remain capable of efficiently targeting the tumour 
endothelium. As the vectors have been demonstrated to transduce the human glioblastoma cell line 
U87, this could serve as a useful in vivo cancer model. In vivo studies will be performed in a similar 
manner to the initial studies of the prototype AAVP vector (Hajitou et al. 2006).  In order to establish 
tumour-specific targeting, the previously prepared AAVP-EEP vectors bearing the luciferase 
transgene will be systemically administered to nude mice bearing U87 intracranial xenografts. 
Targeted and non-targeted AAVP vectors with and without the EEPs will be compared to determine 
whether the inclusion of EEPs improves transgene expression. Bioluminescence imaging of luciferase 
expression will serve to establish the peak of transgene expression in vivo and will also determine 
whether transgene expression is restricted to the tumour site. If this is the case, vectors bearing the 
HSVtk suicide gene will be prepared for use in anti-tumour therapy. The therapeutic efficacy of RGD-
AAVP-EEP-HSVtk may be evaluated in live animals by establishing luciferase-expressing glioma 
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tumours. Targeted and non-targeted (control) AAVP vectors carrying HSVtk will be administered via 
intravenous injections through the tail vein and the prodrug ganciclovir administered at the established 
point of peak transgene expression. Therapeutic efficacy will be determined through the loss of 
tumoural luciferase expression. Tumours will be excised and compared for angiogenesis and vascular 
damage. Blood-vessel immunohistochemistry will be performed using antibodies against CD31 and 
apoptosis assessed using terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-
labelling (TUNEL) staining. Histopathological analysis of tumour size will also be performed on 
tumours recovered after therapy. 
Given that the EEP PC1 demonstrated the greatest improvement to RGD-AAVP-mediated reporter 
gene expression in vitro, this will be the likely candidate to be taken to in vivo studies. Furthermore, it 
can be hypothesised that given the appropriate choice of suicide gene (HSVtk), together with targeting 
the tumour vasculature, improvement of therapeutic efficacy may be significantly greater than 
reporter gene expression observed in vitro. 
6.7. Concluding remarks 
The studies presented in this thesis comprise the most in-depth analysis of RGD-AAVP endocytosis 
and intracellular trafficking to date. The targeted AAVP vector was demonstrated to follow similar 
endocytic routes to RGD ligand-bearing eukaryotic viruses, however, unlike such viruses, the vector 
was shown to be sequestered by the endosomal-lysosomal degradative pathway which ultimately 
limits gene transfer efficiency. Novel multifunctional AAVP vectors bearing endosomal escape 
peptides demonstrated improved transductional capabilities over RGD-AAVP. These data are 
encouraging, and demonstrate the feasibility of enhancing gene transfer through rational modification 
of the capsid of the RGD-AAVP vector. Finally, the findings presented in this thesis underline the 
necessity for such studies for the design and improvement of gene therapy vectors. 
   
  
200
7. References 
Abonour, R., Williams, D. A., Einhorn, L., Hall, K. M., Chen, J., Coffman, J., Traycoff, C. M., Bank, A., 
Kato, I., Ward, M., Williams, S. D., Hromas, R., Robertson, M. J., Smith, F. O., Woo, D., Mills, B., Srour, E. F. 
and Cornetta, K. (2000). Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into 
autologous human long-term repopulating hematopoietic stem cells. Nat Med. 6(6): 652-658. 
Adjei, A. A. (2001). Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 93(14): 
1062-1074. 
Adjei, A. A. (2008). K-ras as a target for lung cancer therapy. J Thorac Oncol. 3(6 Suppl 2): S160-
163. 
Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., 
Koi, M., Fishel, R. and Howell, S. B. (1996). Loss of DNA mismatch repair in acquired resistance to 
cisplatin. Cancer Res. 56(13): 3087-3090. 
Agosto, M. A., Ivanovic, T. and Nibert, M. L. (2006). Mammalian reovirus, a nonfusogenic 
nonenveloped virus, forms size-selective pores in a model membrane. Proc Natl Acad Sci U S A. 103(44): 
16496-16501. 
Akinc, A., Thomas, M., Klibanov, A. M. and Langer, R. (2005). Exploring polyethylenimine-mediated 
DNA transfection and the proton sponge hypothesis. J Gene Med. 7(5): 657-663. 
Akuta, T., Eguchi, A., Okuyama, H., Senda, T., Inokuchi, H., Suzuki, Y., Nagoshi, E., Mizuguchi, H., 
Hayakawa, T., Takeda, K., Hasegawa, M. and Nakanishi, M. (2002). Enhancement of phage-mediated gene 
transfer by nuclear localization signal. Biochem Biophys Res Commun. 297(4): 779-786. 
Al-Dosari, M. S. and Gao, X. (2009). Nonviral gene delivery: principle, limitations, and recent 
progress. AAPS J. 11(4): 671-681. 
Allison, A. C. and Young, M. R. (1964). Uptake of Dyes and Drugs by Living Cells in Culture. Life 
Sci. 3: 1407-1414. 
Alton, E. W., Stern, M., Farley, R., Jaffe, A., Chadwick, S. L., Phillips, J., Davies, J., Smith, S. N., 
Browning, J., Davies, M. G., Hodson, M. E., Durham, S. R., Li, D., Jeffery, P. K., Scallan, M., Balfour, R., 
Eastman, S. J., Cheng, S. H., Smith, A. E., Meeker, D. and Geddes, D. M. (1999). Cationic lipid-mediated 
CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-
controlled trial. Lancet. 353(9157): 947-954. 
Alvarez, R. D., Gomez-Navarro, J., Wang, M., Barnes, M. N., Strong, T. V., Arani, R. B., Arafat, W., 
Hughes, J. V., Siegal, G. P. and Curiel, D. T. (2000). Adenoviral-mediated suicide gene therapy for ovarian 
cancer. Mol Ther. 2(5): 524-530. 
Amalfitano, A., Hauser, M. A., Hu, H., Serra, D., Begy, C. R. and Chamberlain, J. S. (1998). Production 
and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol. 
72(2): 926-933. 
Ambudkar, S. V., Kimchi-Sarfaty, C., Sauna, Z. E. and Gottesman, M. M. (2003). P-glycoprotein: from 
genomics to mechanism. Oncogene. 22(47): 7468-7485. 
Amstutz, B., Gastaldelli, M., Kalin, S., Imelli, N., Boucke, K., Wandeler, E., Mercer, J., Hemmi, S. and 
Greber, U. F. (2008). Subversion of CtBP1-controlled macropinocytosis by human adenovirus serotype 3. 
EMBO J. 27(7): 956-969. 
Arap, W., Haedicke, W., Bernasconi, M., Kain, R., Rajotte, D., Krajewski, S., Ellerby, H. M., Bredesen, 
D. E., Pasqualini, R. and Ruoslahti, E. (2002a). Targeting the prostate for destruction through a vascular 
address. Proc Natl Acad Sci U S A. 99(3): 1527-1531. 
Arap, W., Kolonin, M. G., Trepel, M., Lahdenranta, J., Cardo-Vila, M., Giordano, R. J., Mintz, P. J., 
Ardelt, P. U., Yao, V. J., Vidal, C. I., Chen, L., Flamm, A., Valtanen, H., Weavind, L. M., Hicks, M. E., 
Pollock, R. E., Botz, G. H., Bucana, C. D., Koivunen, E., Cahill, D., Troncoso, P., Baggerly, K. A., Pentz, R. D., 
Do, K. A., Logothetis, C. J. and Pasqualini, R. (2002b). Steps toward mapping the human vasculature by 
phage display. Nat Med. 8(2): 121-127. 
Arap, W., Pasqualini, R. and Ruoslahti, E. (1998). Cancer treatment by targeted drug delivery to 
tumor vasculature in a mouse model. Science. 279(5349): 377-380. 
Arias-Salgado, E. G., Lizano, S., Sarkar, S., Brugge, J. S., Ginsberg, M. H. and Shattil, S. J. (2003). Src 
kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc Natl Acad Sci U S 
A. 100(23): 13298-13302. 
Armentano, D., Sookdeo, C. C., Hehir, K. M., Gregory, R. J., St George, J. A., Prince, G. A., Wadsworth, 
S. C. and Smith, A. E. (1995). Characterization of an adenovirus gene transfer vector containing an E4 
deletion. Hum Gene Ther. 6(10): 1343-1353. 
201
Armentano, D., Zabner, J., Sacks, C., Sookdeo, C. C., Smith, M. P., St George, J. A., Wadsworth, S. C., 
Smith, A. E. and Gregory, R. J. (1997). Effect of the E4 region on the persistence of transgene expression 
from adenovirus vectors. J Virol. 71(3): 2408-2416. 
Ashley, C. E., Carnes, E. C., Phillips, G. K., Durfee, P. N., Buley, M. D., Lino, C. A., Padilla, D. P., 
Phillips, B., Carter, M. B., Willman, C. L., Brinker, C. J., Caldeira Jdo, C., Chackerian, B., Wharton, W. and 
Peabody, D. S. (2011). Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. 
ACS Nano. 5(7): 5729-5745. 
Bache, K. G., Brech, A., Mehlum, A. and Stenmark, H. (2003). Hrs regulates multivesicular body 
formation via ESCRT recruitment to endosomes. J Cell Biol. 162(3): 435-442. 
Bar, H., Yacoby, I. and Benhar, I. (2008). Killing cancer cells by targeted drug-carrying phage 
nanomedicines. BMC Biotechnol. 8: 37. 
Barry, M. A., Dower, W. J. and Johnston, S. A. (1996). Toward cell-targeting gene therapy vectors: 
selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med. 2(3): 299-305. 
Bartlett, J. S., Wilcher, R. and Samulski, R. J. (2000). Infectious entry pathway of adeno-associated 
virus and adeno-associated virus vectors. J Virol. 74(6): 2777-2785. 
Barton, E. S., Forrest, J. C., Connolly, J. L., Chappell, J. D., Liu, Y., Schnell, F. J., Nusrat, A., Parkos, C. 
A. and Dermody, T. S. (2001). Junction adhesion molecule is a receptor for reovirus. Cell. 104(3): 441-451. 
Bast, R. C., Kufe, D. W., Pollock, R. E., Weichselbaum, R. R., Holland, J. F., Frei, E. (2000). Cancer 
Medicine 5th Edition, B. C. Becker. 
Behr, J. P., Demeneix, B., Loeffler, J. P. and Perez-Mutul, J. (1989). Efficient gene transfer into 
mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc Natl Acad Sci U S A. 86(18): 
6982-6986. 
Benmerah, A., Bayrou, M., Cerf-Bensussan, N. and Dautry-Varsat, A. (1999). Inhibition of clathrin-
coated pit assembly by an Eps15 mutant. J Cell Sci. 112 ( Pt 9): 1303-1311. 
Benmerah, A., Lamaze, C., Begue, B., Schmid, S. L., Dautry-Varsat, A. and Cerf-Bensussan, N. (1998). 
AP-2/Eps15 interaction is required for receptor-mediated endocytosis. J Cell Biol. 140(5): 1055-1062. 
Benns, J. M., Choi, J. S., Mahato, R. I., Park, J. S. and Kim, S. W. (2000). pH-sensitive cationic 
polymer gene delivery vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) comb shaped polymer. 
Bioconjug Chem. 11(5): 637-645. 
Bergelson, J. M., Krithivas, A., Celi, L., Droguett, G., Horwitz, M. S., Wickham, T., Crowell, R. L. and 
Finberg, R. W. (1998). The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J 
Virol. 72(1): 415-419. 
Bhattacharyya, S., Hope, T. J. and Young, J. A. (2011). Differential requirements for clathrin 
endocytic pathway components in cellular entry by Ebola and Marburg glycoprotein pseudovirions. 
Virology. 419(1): 1-9. 
Bhattacharyya, S., Warfield, K. L., Ruthel, G., Bavari, S., Aman, M. J. and Hope, T. J. (2010). Ebola 
virus uses clathrin-mediated endocytosis as an entry pathway. Virology. 401(1): 18-28. 
Bi, W., Kim, Y. G., Feliciano, E. S., Pavelic, L., Wilson, K. M., Pavelic, Z. P. and Stambrook, P. J. 
(1997). An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck 
origin in athymic mice. Cancer Gene Ther. 4(4): 246-252. 
Biasco, L., Baricordi, C. and Aiuti, A. (2012). Retroviral integrations in gene therapy trials. Mol Ther. 
20(4): 709-716. 
Binetruy-Tournaire, R., Demangel, C., Malavaud, B., Vassy, R., Rouyre, S., Kraemer, M., Plouet, J., 
Derbin, C., Perret, G. and Mazie, J. C. (2000). Identification of a peptide blocking vascular endothelial 
growth factor (VEGF)-mediated angiogenesis. EMBO J. 19(7): 1525-1533. 
Blackburn, R. V., Galoforo, S. S., Corry, P. M. and Lee, Y. J. (1998). Adenoviral-mediated transfer of 
a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res. 58(7): 1358-1362. 
Blumenthal, R., Seth, P., Willingham, M. C. and Pastan, I. (1986). pH-dependent lysis of liposomes by 
adenovirus. Biochemistry. 25(8): 2231-2237. 
Bolard, J. (1986). How do the polyene macrolide antibiotics affect the cellular membrane 
properties? Biochim Biophys Acta. 864(3-4): 257-304. 
Bos, J. L. (1989). ras oncogenes in human cancer: a review. Cancer Res. 49(17): 4682-4689. 
Boucrot, E., Saffarian, S., Zhang, R. and Kirchhausen, T. (2010). Roles of AP-2 in clathrin-mediated 
endocytosis. PLoS One. 5(5): e10597. 
Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B. and Behr, J. P. 
(1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: 
polyethylenimine. Proc Natl Acad Sci U S A. 92(16): 7297-7301. 
Brandhorst, D., Zwilling, D., Rizzoli, S. O., Lippert, U., Lang, T. and Jahn, R. (2006). Homotypic fusion 
of early endosomes: SNAREs do not determine fusion specificity. Proc Natl Acad Sci U S A. 103(8): 2701-
2706. 
202
Brannon-Peppas, L. and Blanchette, J. O. (2004). Nanoparticle and targeted systems for cancer 
therapy. Adv Drug Deliv Rev. 56(11): 1649-1659. 
Breckpot, K., Aerts, J. L. and Thielemans, K. (2007). Lentiviral vectors for cancer immunotherapy: 
transforming infectious particles into therapeutics. Gene Ther. 14(11): 847-862. 
Breckpot, K., Heirman, C., De Greef, C., van der Bruggen, P. and Thielemans, K. (2004). Identification 
of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic 
cells transduced with lentiviruses. J Immunol. 172(4): 2232-2237. 
Bright, N. A., Reaves, B. J., Mullock, B. M. and Luzio, J. P. (1997). Dense core lysosomes can fuse 
with late endosomes and are re-formed from the resultant hybrid organelles. J Cell Sci. 110 ( Pt 17): 2027-
2040. 
Brock, C. S. and Lee, S. M. (2002). Anti-angiogenic strategies and vascular targeting in the 
treatment of lung cancer. Eur Respir J. 19(3): 557-570. 
Brodsky, F. M., Chen, C. Y., Knuehl, C., Towler, M. C. and Wakeham, D. E. (2001). Biological basket 
weaving: formation and function of clathrin-coated vesicles. Annu Rev Cell Dev Biol. 17: 517-568. 
Brooks, P. C., Clark, R. A. and Cheresh, D. A. (1994a). Requirement of vascular integrin alpha v beta 
3 for angiogenesis. Science. 264(5158): 569-571. 
Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G. and Cheresh, D. A. 
(1994b). Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of 
angiogenic blood vessels. Cell. 79(7): 1157-1164. 
Brooks, P. C., Stromblad, S., Klemke, R., Visscher, D., Sarkar, F. H. and Cheresh, D. A. (1995). 
Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin 
Invest. 96(4): 1815-1822. 
Brown, B. D., Venneri, M. A., Zingale, A., Sergi Sergi, L. and Naldini, L. (2006). Endogenous 
microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene 
transfer. Nat Med. 12(5): 585-591. 
Buckley, C. D., Pilling, D., Henriquez, N. V., Parsonage, G., Threlfall, K., Scheel-Toellner, D., 
Simmons, D. L., Akbar, A. N., Lord, J. M. and Salmon, M. (1999). RGD peptides induce apoptosis by direct 
caspase-3 activation. Nature. 397(6719): 534-539. 
Bullough, P. A., Hughson, F. M., Skehel, J. J. and Wiley, D. C. (1994). Structure of influenza 
haemagglutinin at the pH of membrane fusion. Nature. 371(6492): 37-43. 
Buning, H., Perabo, L., Coutelle, O., Quadt-Humme, S. and Hallek, M. (2008). Recent developments in 
adeno-associated virus vector technology. J Gene Med. 10(7): 717-733. 
Burns, J. C., Friedmann, T., Driever, W., Burrascano, M. and Yee, J. K. (1993). Vesicular stomatitis 
virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene 
transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A. 90(17): 8033-8037. 
Burtrum, D., Zhu, Z., Lu, D., Anderson, D. M., Prewett, M., Pereira, D. S., Bassi, R., Abdullah, R., 
Hooper, A. T., Koo, H., Jimenez, X., Johnson, D., Apblett, R., Kussie, P., Bohlen, P., Witte, L., Hicklin, D. J. 
and Ludwig, D. L. (2003). A fully human monoclonal antibody to the insulin-like growth factor I receptor 
blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 63(24): 8912-
8921. 
Butterfield, L. H., Comin-Anduix, B., Vujanovic, L., Lee, Y., Dissette, V. B., Yang, J. Q., Vu, H. T., 
Seja, E., Oseguera, D. K., Potter, D. M., Glaspy, J. A., Economou, J. S. and Ribas, A. (2008). Adenovirus 
MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 31(3): 294-
309. 
Caplen, N. J., Alton, E. W., Middleton, P. G., Dorin, J. R., Stevenson, B. J., Gao, X., Durham, S. R., 
Jeffery, P. K., Hodson, M. E., Coutelle, C. and et al. (1995). Liposome-mediated CFTR gene transfer to the 
nasal epithelium of patients with cystic fibrosis. Nat Med. 1(1): 39-46. 
Carbone, R., Fre, S., Iannolo, G., Belleudi, F., Mancini, P., Pelicci, P. G., Torrisi, M. R. and Di Fiore, P. 
P. (1997). eps15 and eps15R are essential components of the endocytic pathway. Cancer Res. 57(24): 5498-
5504. 
Carlos F. Barbas, I., Barbas, C. F., Burton, D. R., Scott, J. K. and Silverman, G. J. (2004). Phage 
Display, Cold Spring Harbor Laboratory Press. 
Carr, C. M. and Kim, P. S. (1993). A spring-loaded mechanism for the conformational change of 
influenza hemagglutinin. Cell. 73(4): 823-832. 
Carron, C. P., Meyer, D. M., Pegg, J. A., Engleman, V. W., Nickols, M. A., Settle, S. L., Westlin, W. F., 
Ruminski, P. G. and Nickols, G. A. (1998). A peptidomimetic antagonist of the integrin alpha(v)beta3 
inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res. 
58(9): 1930-1935. 
203
Caruso, M., Panis, Y., Gagandeep, S., Houssin, D., Salzmann, J. L. and Klatzmann, D. (1993). 
Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc 
Natl Acad Sci U S A. 90(15): 7024-7028. 
Casado, E., Nettelbeck, D. M., Gomez-Navarro, J., Hemminki, A., Gonzalez Baron, M., Siegal, G. P., 
Barnes, M. N., Alvarez, R. D. and Curiel, D. T. (2001). Transcriptional targeting for ovarian cancer gene 
therapy. Gynecol Oncol. 82(2): 229-237. 
Caswell, P. T., Vadrevu, S. and Norman, J. C. (2009). Integrins: masters and slaves of endocytic 
transport. Nat Rev Mol Cell Biol. 10(12): 843-853. 
Cawood, R., Chen, H. H., Carroll, F., Bazan-Peregrino, M., van Rooijen, N. and Seymour, L. W. (2009). 
Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its 
ability to kill cancer cells. PLoS Pathog. 5(5): e1000440. 
Chardonnet, Y. and Dales, S. (1970). Early events in the interaction of adenoviruses with HeLa cells. 
I. Penetration of type 5 and intracellular release of the DNA genome. Virology. 40(3): 462-477. 
Chauthaiwale, V. M., Therwath, A. and Deshpande, V. V. (1992). Bacteriophage lambda as a cloning 
vector. Microbiol Rev. 56(4): 577-591. 
Chen, H. H., Mack, L. M., Kelly, R., Ontell, M., Kochanek, S. and Clemens, P. R. (1997). Persistence in 
muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A. 94(5): 1645-1650. 
Chen, L., Zurita, A. J., Ardelt, P. U., Giordano, R. J., Arap, W. and Pasqualini, R. (2004). Design and 
validation of a bifunctional ligand display system for receptor targeting. Chem Biol. 11(8): 1081-1091. 
Chen, Y. T., Lin, C. H., Ji, W. T., Li, S. K. and Liu, H. J. (2008). Proteasome inhibition reduces avian 
reovirus replication and apoptosis induction in cultured cells. J Virol Methods. 151(1): 95-100. 
Cheng, S. Y., Huang, H. J., Nagane, M., Ji, X. D., Wang, D., Shih, C. C., Arap, W., Huang, C. M. and 
Cavenee, W. K. (1996). Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of 
endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 93(16): 8502-8507. 
Cheresh, D. A. and Spiro, R. C. (1987). Biosynthetic and functional properties of an Arg-Gly-Asp-
directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von 
Willebrand factor. J Biol Chem. 262(36): 17703-17711. 
Choi, V. W., McCarty, D. M. and Samulski, R. J. (2005). AAV hybrid serotypes: improved vectors for 
gene delivery. Curr Gene Ther. 5(3): 299-310. 
Christoforidis, S., McBride, H. M., Burgoyne, R. D. and Zerial, M. (1999). The Rab5 effector EEA1 is 
a core component of endosome docking. Nature. 397(6720): 621-625. 
Clay, T. M., Custer, M. C., Sachs, J., Hwu, P., Rosenberg, S. A. and Nishimura, M. I. (1999). Efficient 
transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor 
reactivity. J Immunol. 163(1): 507-513. 
Clayman, G. L., Frank, D. K., Bruso, P. A. and Goepfert, H. (1999). Adenovirus-mediated wild-type 
p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res. 5(7): 1715-
1722. 
Clemens, P. R., Kochanek, S., Sunada, Y., Chan, S., Chen, H. H., Campbell, K. P. and Caskey, C. T. 
(1996). In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral 
genes. Gene Ther. 3(11): 965-972. 
Coffin, J. M., Hughes, S. H. and Varmus, H. E. (1997). Retroviruses, Cold Spring Harbor Laboratory 
Press. 
Conner, S. D. and Schmid, S. L. (2002). Identification of an adaptor-associated kinase, AAK1, as a 
regulator of clathrin-mediated endocytosis. J Cell Biol. 156(5): 921-929. 
Conway, J. E., Zolotukhin, S., Muzyczka, N., Hayward, G. S. and Byrne, B. J. (1997). Recombinant 
adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus 
type 1 amplicon expressing Rep and Cap. J Virol. 71(11): 8780-8789. 
Cosset, F. L., Morling, F. J., Takeuchi, Y., Weiss, R. A., Collins, M. K. and Russell, S. J. (1995). 
Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol. 69(10): 6314-6322. 
Coyne, C. B., Shen, L., Turner, J. R. and Bergelson, J. M. (2007). Coxsackievirus entry across 
epithelial tight junctions requires occludin and the small GTPases Rab34 and Rab5. Cell Host Microbe. 
2(3): 181-192. 
Cureton, D. K., Massol, R. H., Whelan, S. P. and Kirchhausen, T. (2010). The length of vesicular 
stomatitis virus particles dictates a need for actin assembly during clathrin-dependent endocytosis. PLoS 
Pathog. 6(9): e1001127. 
Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A. and Corti, A. (2000). Enhancement of tumor 
necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N 
(CD13). Nat Biotechnol. 18(11): 1185-1190. 
Daecke, J., Fackler, O. T., Dittmar, M. T. and Krausslich, H. G. (2005). Involvement of clathrin-
mediated endocytosis in human immunodeficiency virus type 1 entry. J Virol. 79(3): 1581-1594. 
204
Damke, H., Baba, T., van der Bliek, A. M. and Schmid, S. L. (1995). Clathrin-independent pinocytosis 
is induced in cells overexpressing a temperature-sensitive mutant of dynamin. J Cell Biol. 131(1): 69-80. 
Damke, H., Baba, T., Warnock, D. E. and Schmid, S. L. (1994). Induction of mutant dynamin 
specifically blocks endocytic coated vesicle formation. J Cell Biol. 127(4): 915-934. 
Damm, E. M., Pelkmans, L., Kartenbeck, J., Mezzacasa, A., Kurzchalia, T. and Helenius, A. (2005). 
Clathrin- and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae. J 
Cell Biol. 168(3): 477-488. 
Davidoff, A. M., Nathwani, A. C., Spurbeck, W. W., Ng, C. Y., Zhou, J. and Vanin, E. F. (2002). rAAV-
mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor 
growth in mice. Cancer Res. 62(11): 3077-3083. 
De Deyne, P. G., O'Neill, A., Resneck, W. G., Dmytrenko, G. M., Pumplin, D. W. and Bloch, R. J. 
(1998). The vitronectin receptor associates with clathrin-coated membrane domains via the cytoplasmic 
domain of its beta5 subunit. J Cell Sci. 111 ( Pt 18): 2729-2740. 
de Duve, C., de Barsy, T., Poole, B., Trouet, A., Tulkens, P. and Van Hoof, F. (1974). Commentary. 
Lysosomotropic agents. Biochem Pharmacol. 23(18): 2495-2531. 
Dehari, H., Ito, Y., Nakamura, T., Kobune, M., Sasaki, K., Yonekura, N., Kohama, G. and Hamada, H. 
(2003). Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. 
Cancer Gene Ther. 10(1): 75-85. 
Delboy, M. G., Roller, D. G. and Nicola, A. V. (2008). Cellular proteasome activity facilitates herpes 
simplex virus entry at a postpenetration step. J Virol. 82(7): 3381-3390. 
Denny, W. A. (2003). Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene 
Therapy). J Biomed Biotechnol. 2003(1): 48-70. 
Derossi, D., Joliot, A. H., Chassaing, G. and Prochiantz, A. (1994). The third helix of the 
Antennapedia homeodomain translocates through biological membranes. J Biol Chem. 269(14): 10444-
10450. 
Desgrosellier, J. S. and Cheresh, D. A. (2010). Integrins in cancer: biological implications and 
therapeutic opportunities. Nat Rev Cancer. 10(1): 9-22. 
Deshayes, S., Morris, M. C., Divita, G. and Heitz, F. (2005). Cell-penetrating peptides: tools for 
intracellular delivery of therapeutics. Cell Mol Life Sci. 62(16): 1839-1849. 
Di Giovine, M., Salone, B., Martina, Y., Amati, V., Zambruno, G., Cundari, E., Failla, C. M. and Saggio, 
I. (2001). Binding properties, cell delivery, and gene transfer of adenoviral penton base displaying 
bacteriophage. Virology. 282(1): 102-112. 
Dmitriev, I., Kashentseva, E., Rogers, B. E., Krasnykh, V. and Curiel, D. T. (2000). Ectodomain of 
coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus 
targeting to epidermal growth factor receptor-positive cells. J Virol. 74(15): 6875-6884. 
Dmitriev, I., Krasnykh, V., Miller, C. R., Wang, M., Kashentseva, E., Mikheeva, G., Belousova, N. and 
Curiel, D. T. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded 
tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J 
Virol. 72(12): 9706-9713. 
Doherty, G. J. and McMahon, H. T. (2009). Mechanisms of endocytosis. Annu Rev Biochem. 78: 857-
902. 
Dong, J. Y., Fan, P. D. and Frizzell, R. A. (1996). Quantitative analysis of the packaging capacity of 
recombinant adeno-associated virus. Hum Gene Ther. 7(17): 2101-2112. 
Drummond, J. T., Anthoney, A., Brown, R. and Modrich, P. (1996). Cisplatin and adriamycin 
resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J 
Biol Chem. 271(33): 19645-19648. 
Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J. and Engelhardt, J. F. (1998). 
Circular intermediates of recombinant adeno-associated virus have defined structural characteristics 
responsible for long-term episomal persistence in muscle tissue. J Virol. 72(11): 8568-8577. 
Duckworth, D. H. (1976). "Who discovered bacteriophage?". Bacteriol Rev. 40(4): 793-802. 
Dullaers, M., Van Meirvenne, S., Heirman, C., Straetman, L., Bonehill, A., Aerts, J. L., Thielemans, K. 
and Breckpot, K. (2006). Induction of effective therapeutic antitumor immunity by direct in vivo 
administration of lentiviral vectors. Gene Ther. 13(7): 630-640. 
Dunn, I. S. (1996). Mammalian cell binding and transfection mediated by surface-modified 
bacteriophage lambda. Biochimie. 78(10): 856-861. 
Ebert, D. H., Deussing, J., Peters, C. and Dermody, T. S. (2002). Cathepsin L and cathepsin B mediate 
reovirus disassembly in murine fibroblast cells. J Biol Chem. 277(27): 24609-24617. 
Eguchi, A., Akuta, T., Okuyama, H., Senda, T., Yokoi, H., Inokuchi, H., Fujita, S., Hayakawa, T., 
Takeda, K., Hasegawa, M. and Nakanishi, M. (2001). Protein transduction domain of HIV-1 Tat protein 
promotes efficient delivery of DNA into mammalian cells. J Biol Chem. 276(28): 26204-26210. 
205
El-Mousawi, M., Tchistiakova, L., Yurchenko, L., Pietrzynski, G., Moreno, M., Stanimirovic, D., 
Ahmad, D. and Alakhov, V. (2003). A vascular endothelial growth factor high affinity receptor 1-specific 
peptide with antiangiogenic activity identified using a phage display peptide library. J Biol Chem. 278(47): 
46681-46691. 
El-Sayed, A., Masuda, T., Akita, H. and Harashima, H. (2012). Stearylated INF7 peptide enhances 
endosomal escape and gene expression of PEGylated nanoparticles both in vitro and in vivo. J Pharm Sci. 
101(2): 879-882. 
Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Rio, G. D., Krajewski, S., Lombardo, 
C. R., Rao, R., Ruoslahti, E., Bredesen, D. E. and Pasqualini, R. (1999). Anti-cancer activity of targeted pro-
apoptotic peptides. Nat Med. 5(9): 1032-1038. 
Elliott, G. and O'Hare, P. (1997). Intercellular trafficking and protein delivery by a herpesvirus 
structural protein. Cell. 88(2): 223-233. 
Engelhardt, J. F., Ye, X., Doranz, B. and Wilson, J. M. (1994). Ablation of E2A in recombinant 
adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc 
Natl Acad Sci U S A. 91(13): 6196-6200. 
Eriksson, F., Culp, W. D., Massey, R., Egevad, L., Garland, D., Persson, M. A. and Pisa, P. (2007). 
Tumor specific phage particles promote tumor regression in a mouse melanoma model. Cancer Immunol 
Immunother. 56(5): 677-687. 
Erles, K., Sebokova, P. and Schlehofer, J. R. (1999). Update on the prevalence of serum antibodies 
(IgG and IgM) to adeno-associated virus (AAV). J Med Virol. 59(3): 406-411. 
Esslinger, C., Chapatte, L., Finke, D., Miconnet, I., Guillaume, P., Levy, F. and MacDonald, H. R. 
(2003). In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell 
responses. J Clin Invest. 111(11): 1673-1681. 
Evans, D. J. and Almond, J. W. (1998). Cell receptors for picornaviruses as determinants of cell 
tropism and pathogenesis. Trends Microbiol. 6(5): 198-202. 
Ewers, H., Romer, W., Smith, A. E., Bacia, K., Dmitrieff, S., Chai, W., Mancini, R., Kartenbeck, J., 
Chambon, V., Berland, L., Oppenheim, A., Schwarzmann, G., Feizi, T., Schwille, P., Sens, P., Helenius, A. and 
Johannes, L. (2010). GM1 structure determines SV40-induced membrane invagination and infection. Nat 
Cell Biol. 12(1): 11-18; sup pp 11-12. 
Ezratty, E. J., Bertaux, C., Marcantonio, E. E. and Gundersen, G. G. (2009). Clathrin mediates integrin 
endocytosis for focal adhesion disassembly in migrating cells. J Cell Biol. 187(5): 733-747. 
Ezzeddine, Z. D., Martuza, R. L., Platika, D., Short, M. P., Malick, A., Choi, B. and Breakefield, X. O. 
(1991). Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex 
virus thymidine kinase gene. New Biol. 3(6): 608-614. 
Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L. L., Pepinsky, B. and Barsoum, J. (1994). Tat-
mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A. 91(2): 664-668. 
Felding-Habermann, B., Mueller, B. M., Romerdahl, C. A. and Cheresh, D. A. (1992). Involvement of 
integrin alpha V gene expression in human melanoma tumorigenicity. J Clin Invest. 89(6): 2018-2022. 
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. 
M. and Danielsen, M. (1987). Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. 
Proc Natl Acad Sci U S A. 84(21): 7413-7417. 
Ferguson, S. M. and De Camilli, P. (2012). Dynamin, a membrane-remodelling GTPase. Nat Rev Mol 
Cell Biol. 13(2): 75-88. 
Ferguson, S. M., Raimondi, A., Paradise, S., Shen, H., Mesaki, K., Ferguson, A., Destaing, O., Ko, G., 
Takasaki, J., Cremona, O., E, O. T. and De Camilli, P. (2009). Coordinated actions of actin and BAR 
proteins upstream of dynamin at endocytic clathrin-coated pits. Dev Cell. 17(6): 811-822. 
Ferrer-Miralles, N., Vazquez, E. and Villaverde, A. (2008). Membrane-active peptides for non-viral 
gene therapy: making the safest easier. Trends Biotechnol. 26(5): 267-275. 
Firat, H., Zennou, V., Garcia-Pons, F., Ginhoux, F., Cochet, M., Danos, O., Lemonnier, F. A., Langlade-
Demoyen, P. and Charneau, P. (2002). Use of a lentiviral flap vector for induction of CTL immunity against 
melanoma. Perspectives for immunotherapy. J Gene Med. 4(1): 38-45. 
Fischer, D., Li, Y., Ahlemeyer, B., Krieglstein, J. and Kissel, T. (2003). In vitro cytotoxicity testing of 
polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials. 24(7): 1121-1131. 
Fogelman, I., Davey, V., Ochs, H. D., Elashoff, M., Feinberg, M. B., Mican, J., Siegel, J. P., Sneller, M. 
and Lane, H. C. (2000). Evaluation of CD4+ T cell function In vivo in HIV-infected patients as measured 
by bacteriophage phiX174 immunization. J Infect Dis. 182(2): 435-441. 
Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med. 285(21): 1182-
1186. 
Folkman, J. (1997). Principles and practice of oncology. Philadelphia, Lippincott. 
206
Fox, G., Parry, N. R., Barnett, P. V., McGinn, B., Rowlands, D. J. and Brown, F. (1989). The cell 
attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-
aspartic acid). J Gen Virol. 70 ( Pt 3): 625-637. 
Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L. and 
Abraham, G. N. (1993). The "bystander effect": tumor regression when a fraction of the tumor mass is 
genetically modified. Cancer Res. 53(21): 5274-5283. 
Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A. and Cheresh, D. A. (1995). 
Definition of two angiogenic pathways by distinct alpha v integrins. Science. 270(5241): 1500-1502. 
Fukuda, M. (1990). [Lysosomal membrane glycoproteins; structure, biosynthesis, and trafficking to 
lysosome]. Seikagaku. 62(10): 1225-1240. 
Fukui, T., Hayashi, Y., Kagami, H., Yamamoto, N., Fukuhara, H., Tohnai, I., Ueda, M., Mizuno, M. and 
Yoshida, J. (2001). Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-
associated virus vector. Oral Oncol. 37(3): 211-215. 
Galvez, B. G., Matias-Roman, S., Yanez-Mo, M., Vicente-Manzanares, M., Sanchez-Madrid, F. and 
Arroyo, A. G. (2004). Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic 
in human endothelial cells. Mol Biol Cell. 15(2): 678-687. 
Gao, C., Mao, S., Lo, C. H., Wirsching, P., Lerner, R. A. and Janda, K. D. (1999). Making artificial 
antibodies: a format for phage display of combinatorial heterodimeric arrays. Proc Natl Acad Sci U S A. 
96(11): 6025-6030. 
Gao, X., Kim, K. S. and Liu, D. (2007). Nonviral gene delivery: what we know and what is next. 
AAPS J. 9(1): E92-104. 
Gavrilovskaya, I. N., Shepley, M., Shaw, R., Ginsberg, M. H. and Mackow, E. R. (1998). beta3 
Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci U S 
A. 95(12): 7074-7079. 
Gazit, G., Kane, S. E., Nichols, P. and Lee, A. S. (1995). Use of the stress-inducible grp78/BiP 
promoter in targeting high level gene expression in fibrosarcoma in vivo. Cancer Res. 55(8): 1660-1663. 
Georges, R. N., Mukhopadhyay, T., Zhang, Y., Yen, N. and Roth, J. A. (1993). Prevention of 
orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras 
construct. Cancer Res. 53(8): 1743-1746. 
Gianni, T., Gatta, V. and Campadelli-Fiume, G. (2010). {alpha}V{beta}3-integrin routes herpes 
simplex virus to an entry pathway dependent on cholesterol-rich lipid rafts and dynamin2. Proc Natl Acad 
Sci U S A. 107(51): 22260-22265. 
Gilgenkrantz, H., Duboc, D., Juillard, V., Couton, D., Pavirani, A., Guillet, J. G., Briand, P. and Kahn, A. 
(1995). Transient expression of genes transferred in vivo into heart using first-generation adenoviral 
vectors: role of the immune response. Hum Gene Ther. 6(10): 1265-1274. 
Gill, D. R., Southern, K. W., Mofford, K. A., Seddon, T., Huang, L., Sorgi, F., Thomson, A., MacVinish, 
L. J., Ratcliff, R., Bilton, D., Lane, D. J., Littlewood, J. M., Webb, A. K., Middleton, P. G., Colledge, W. H., 
Cuthbert, A. W., Evans, M. J., Higgins, C. F. and Hyde, S. C. (1997). A placebo-controlled study of liposome-
mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 4(3): 199-209. 
Girolomoni, G., Stone, D. K., Bergstresser, P. R. and Cruz, P. D., Jr. (1991). Vacuolar acidification and 
bafilomycin-sensitive proton translocating ATPase in human epidermal Langerhans cells. J Invest 
Dermatol. 96(5): 735-741. 
Gold, S., Monaghan, P., Mertens, P. and Jackson, T. (2010). A clathrin independent macropinocytosis-
like entry mechanism used by bluetongue virus-1 during infection of BHK cells. PLoS One. 5(6): e11360. 
Goldman, C. K., Kendall, R. L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G. Y., Siegal, G. P., 
Mao, X., Bett, A. J., Huckle, W. R., Thomas, K. A. and Curiel, D. T. (1998). Paracrine expression of a native 
soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. 
Proc Natl Acad Sci U S A. 95(15): 8795-8800. 
Goncalves, M. A. (2005). Adeno-associated virus: from defective virus to effective vector. Virol J. 2: 
43. 
Goodrum, F. D. and Ornelles, D. A. (1998). p53 status does not determine outcome of E1B 55-
kilodalton mutant adenovirus lytic infection. J Virol. 72(12): 9479-9490. 
Gottesman, M. M. (2003). Cancer gene therapy: an awkward adolescence. Cancer Gene Ther. 10(7): 
501-508. 
Greber, U. F. and Fornerod, M. (2005). Nuclear import in viral infections. Curr Top Microbiol 
Immunol. 285: 109-138. 
Greber, U. F., Willetts, M., Webster, P. and Helenius, A. (1993). Stepwise dismantling of adenovirus 2 
during entry into cells. Cell. 75(3): 477-486. 
Greco, O. and Dachs, G. U. (2001). Gene directed enzyme/prodrug therapy of cancer: historical 
appraisal and future prospectives. J Cell Physiol. 187(1): 22-36. 
207
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., 
Butler, A., Stevens, C., Edkins, S., O'Meara, S., Vastrik, I., Schmidt, E. E., Avis, T., Barthorpe, S., Bhamra, G., 
Buck, G., Choudhury, B., Clements, J., Cole, J., Dicks, E., Forbes, S., Gray, K., Halliday, K., Harrison, R., 
Hills, K., Hinton, J., Jenkinson, A., Jones, D., Menzies, A., Mironenko, T., Perry, J., Raine, K., Richardson, D., 
Shepherd, R., Small, A., Tofts, C., Varian, J., Webb, T., West, S., Widaa, S., Yates, A., Cahill, D. P., Louis, D. 
N., Goldstraw, P., Nicholson, A. G., Brasseur, F., Looijenga, L., Weber, B. L., Chiew, Y. E., DeFazio, A., 
Greaves, M. F., Green, A. R., Campbell, P., Birney, E., Easton, D. F., Chenevix-Trench, G., Tan, M. H., Khoo, 
S. K., Teh, B. T., Yuen, S. T., Leung, S. Y., Wooster, R., Futreal, P. A. and Stratton, M. R. (2007). Patterns of 
somatic mutation in human cancer genomes. Nature. 446(7132): 153-158. 
Gridley, D. S. and Slater, J. M. (2004a). Combining gene therapy and radiation against cancer. Curr 
Gene Ther. 4(3): 231-248. 
Gridley, D. S. and Slater, J. M. (2004b). Gene therapy: A possible aid to cancer radiotherapy. Discov 
Med. 4(24): 408-414. 
Griffiths, G., Hoflack, B., Simons, K., Mellman, I. and Kornfeld, S. (1988). The mannose 6-phosphate 
receptor and the biogenesis of lysosomes. Cell. 52(3): 329-341. 
Grifman, M., Trepel, M., Speece, P., Gilbert, L. B., Arap, W., Pasqualini, R. and Weitzman, M. D. 
(2001). Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol 
Ther. 3(6): 964-975. 
Grimmer, S., van Deurs, B. and Sandvig, K. (2002). Membrane ruffling and macropinocytosis in 
A431 cells require cholesterol. J Cell Sci. 115(Pt 14): 2953-2962. 
Gruenberg, J. (2001). The endocytic pathway: a mosaic of domains. Nat Rev Mol Cell Biol. 2(10): 
721-730. 
Gruenberg, J. and Stenmark, H. (2004). The biogenesis of multivesicular endosomes. Nat Rev Mol Cell 
Biol. 5(4): 317-323. 
Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B. and Marme, D. (1995). Both v-Ha-Ras and v-Raf 
stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem. 270(43): 
25915-25919. 
Gu, Z., Noss, E. H., Hsu, V. W. and Brenner, M. B. (2011). Integrins traffic rapidly via circular dorsal 
ruffles and macropinocytosis during stimulated cell migration. J Cell Biol. 193(1): 61-70. 
Guinea, R. and Carrasco, L. (1995). Requirement for vacuolar proton-ATPase activity during entry 
of influenza virus into cells. J Virol. 69(4): 2306-2312. 
Guo, W. and Giancotti, F. G. (2004). Integrin signalling during tumour progression. Nat Rev Mol Cell 
Biol. 5(10): 816-826. 
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., 
Caccavelli, L., Delabesse, E., Beldjord, K., Asnafi, V., MacIntyre, E., Dal Cortivo, L., Radford, I., Brousse, N., 
Sigaux, F., Moshous, D., Hauer, J., Borkhardt, A., Belohradsky, B. H., Wintergerst, U., Velez, M. C., Leiva, L., 
Sorensen, R., Wulffraat, N., Blanche, S., Bushman, F. D., Fischer, A. and Cavazzana-Calvo, M. (2008). 
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 
118(9): 3132-3142. 
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., 
Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J. I., de Saint 
Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-
Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L. E., Wissler, M., 
Prinz, C., Rabbitts, T. H., Le Deist, F., Fischer, A. and Cavazzana-Calvo, M. (2003). LMO2-associated clonal 
T cell proliferation in two patients after gene therapy for SCID-X1. Science. 302(5644): 415-419. 
Haigler, H. T., McKanna, J. A. and Cohen, S. (1979). Rapid stimulation of pinocytosis in human 
carcinoma cells A-431 by epidermal growth factor. J Cell Biol. 83(1): 82-90. 
Hailstones, D., Sleer, L. S., Parton, R. G. and Stanley, K. K. (1998). Regulation of caveolin and 
caveolae by cholesterol in MDCK cells. J Lipid Res. 39(2): 369-379. 
Hajitou, A., Lev, D. C., Hannay, J. A., Korchin, B., Staquicini, F. I., Soghomonyan, S., Alauddin, M. M., 
Benjamin, R. S., Pollock, R. E., Gelovani, J. G., Pasqualini, R. and Arap, W. (2008). A preclinical model for 
predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proc Natl Acad 
Sci U S A. 105(11): 4471-4476. 
Hajitou, A., Rangel, R., Trepel, M., Soghomonyan, S., Gelovani, J. G., Alauddin, M. M., Pasqualini, R. 
and Arap, W. (2007). Design and construction of targeted AAVP vectors for mammalian cell transduction. 
Nat Protoc. 2(3): 523-531. 
Hajitou, A., Trepel, M., Lilley, C. E., Soghomonyan, S., Alauddin, M. M., Marini, F. C., 3rd, Restel, B. 
H., Ozawa, M. G., Moya, C. A., Rangel, R., Sun, Y., Zaoui, K., Schmidt, M., von Kalle, C., Weitzman, M. D., 
Gelovani, J. G., Pasqualini, R. and Arap, W. (2006). A hybrid vector for ligand-directed tumor targeting 
and molecular imaging. Cell. 125(2): 385-398. 
208
Hamasaki, M., Araki, N. and Hatae, T. (2004). Association of early endosomal autoantigen 1 with 
macropinocytosis in EGF-stimulated A431 cells. Anat Rec A Discov Mol Cell Evol Biol. 277(2): 298-306. 
Hanahan, D. and Weinberg, R. A. (2000). The hallmarks of cancer. Cell. 100(1): 57-70. 
Hanahan, D. and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell. 144(5): 646-
674. 
Hannigan, G. E., Leung-Hagesteijn, C., Fitz-Gibbon, L., Coppolino, M. G., Radeva, G., Filmus, J., Bell, 
J. C. and Dedhar, S. (1996). Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-
integrin-linked protein kinase. Nature. 379(6560): 91-96. 
Harrison, R. E., Bucci, C., Vieira, O. V., Schroer, T. A. and Grinstein, S. (2003). Phagosomes fuse with 
late endosomes and/or lysosomes by extension of membrane protrusions along microtubules: role of Rab7 
and RILP. Mol Cell Biol. 23(18): 6494-6506. 
Hart, S. L., Knight, A. M., Harbottle, R. P., Mistry, A., Hunger, H. D., Cutler, D. F., Williamson, R. and 
Coutelle, C. (1994). Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-
Asp-containing peptide. J Biol Chem. 269(17): 12468-12474. 
Harui, A., Suzuki, S., Kochanek, S. and Mitani, K. (1999). Frequency and stability of chromosomal 
integration of adenovirus vectors. J Virol. 73(7): 6141-6146. 
Harvie, P., Wong, F. M. and Bally, M. B. (2000). Use of poly(ethylene glycol)-lipid conjugates to 
regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci. 89(5): 652-
663. 
Haviv, Y. S. and Blackwell, J. (2001). Transcriptional regulation in cancer gene therapy. Isr Med 
Assoc J. 3(7): 517-522. 
He, Y., Zhang, J., Mi, Z., Robbins, P. and Falo, L. D., Jr. (2005). Immunization with lentiviral vector-
transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J 
Immunol. 174(6): 3808-3817. 
Heikkila, O., Susi, P., Tevaluoto, T., Harma, H., Marjomaki, V., Hyypia, T. and Kiljunen, S. (2010). 
Internalization of coxsackievirus A9 is mediated by {beta}2-microglobulin, dynamin, and Arf6 but not by 
caveolin-1 or clathrin. J Virol. 84(7): 3666-3681. 
Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D. and Kirn, D. H. (1997). 
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy 
that can be augmented by standard chemotherapeutic agents. Nat Med. 3(6): 639-645. 
Helenius, A., Kartenbeck, J., Simons, K. and Fries, E. (1980). On the entry of Semliki forest virus into 
BHK-21 cells. J Cell Biol. 84(2): 404-420. 
Henley, J. R., Krueger, E. W., Oswald, B. J. and McNiven, M. A. (1998). Dynamin-mediated 
internalization of caveolae. J Cell Biol. 141(1): 85-99. 
Heuser, J. E. and Anderson, R. G. (1989). Hypertonic media inhibit receptor-mediated endocytosis by 
blocking clathrin-coated pit formation. J Cell Biol. 108(2): 389-400. 
Hewlett, L. J., Prescott, A. R. and Watts, C. (1994). The coated pit and macropinocytic pathways 
serve distinct endosome populations. J Cell Biol. 124(5): 689-703. 
Hicke, L. and Dunn, R. (2003). Regulation of membrane protein transport by ubiquitin and 
ubiquitin-binding proteins. Annu Rev Cell Dev Biol. 19: 141-172. 
Hilderbrand, S. A., Kelly, K. A., Niedre, M. and Weissleder, R. (2008). Near infrared fluorescence-
based bacteriophage particles for ratiometric pH imaging. Bioconjug Chem. 19(8): 1635-1639. 
Hinshaw, J. E. and Schmid, S. L. (1995). Dynamin self-assembles into rings suggesting a mechanism 
for coated vesicle budding. Nature. 374(6518): 190-192. 
Hirosue, S. and Weber, T. (2006). pH-Dependent lytic peptides discovered by phage display. 
Biochemistry. 45(20): 6476-6487. 
Hoeijmakers, J. H. (2001). Genome maintenance mechanisms for preventing cancer. Nature. 
411(6835): 366-374. 
Hoggan, M. D., Blacklow, N. R. and Rowe, W. P. (1966). Studies of small DNA viruses found in 
various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad 
Sci U S A. 55(6): 1467-1474. 
Hollinshead, M., Vanderplasschen, A., Smith, G. L. and Vaux, D. J. (1999). Vaccinia virus 
intracellular mature virions contain only one lipid membrane. J Virol. 73(2): 1503-1517. 
Hollstein, M., Moeckel, G., Hergenhahn, M., Spiegelhalder, B., Keil, M., Werle-Schneider, G., Bartsch, 
H. and Brickmann, J. (1998). On the origins of tumor mutations in cancer genes: insights from the p53 
gene. Mutat Res. 405(2): 145-154. 
Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. (1991). p53 mutations in human cancers. 
Science. 253(5015): 49-53. 
209
Honing, S., Ricotta, D., Krauss, M., Spate, K., Spolaore, B., Motley, A., Robinson, M., Robinson, C., 
Haucke, V. and Owen, D. J. (2005). Phosphatidylinositol-(4,5)-bisphosphate regulates sorting signal 
recognition by the clathrin-associated adaptor complex AP2. Mol Cell. 18(5): 519-531. 
Hood, J. D. and Cheresh, D. A. (2002). Role of integrins in cell invasion and migration. Nat Rev 
Cancer. 2(2): 91-100. 
Hood, J. D., Frausto, R., Kiosses, W. B., Schwartz, M. A. and Cheresh, D. A. (2003). Differential 
alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol. 162(5): 
933-943. 
Hopkins, C. R., Miller, K. and Beardmore, J. M. (1985). Receptor-mediated endocytosis of transferrin 
and epidermal growth factor receptors: a comparison of constitutive and ligand-induced uptake. J Cell 
Sci Suppl. 3: 173-186. 
Hruska, K. A., Rolnick, F., Huskey, M., Alvarez, U. and Cheresh, D. (1995). Engagement of the 
osteoclast integrin alpha v beta 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase 
activity. Endocrinology. 136(7): 2984-2992. 
Hu, J. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., Harrington, K. J., James, N. 
D., Love, C. A., McNeish, I., Medley, L. C., Michael, A., Nutting, C. M., Pandha, H. S., Shorrock, C. A., 
Simpson, J., Steiner, J., Steven, N. M., Wright, D. and Coombes, R. C. (2006). A phase I study of 
OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte 
macrophage colony-stimulating factor. Clin Cancer Res. 12(22): 6737-6747. 
Hu, W. S. and Pathak, V. K. (2000). Design of retroviral vectors and helper cells for gene therapy. 
Pharmacol Rev. 52(4): 493-511. 
Huang, F., Khvorova, A., Marshall, W. and Sorkin, A. (2004). Analysis of clathrin-mediated 
endocytosis of epidermal growth factor receptor by RNA interference. J Biol Chem. 279(16): 16657-16661. 
Hyde, S. C., Pringle, I. A., Abdullah, S., Lawton, A. E., Davies, L. A., Varathalingam, A., Nunez-
Alonso, G., Green, A. M., Bazzani, R. P., Sumner-Jones, S. G., Chan, M., Li, H., Yew, N. S., Cheng, S. H., 
Boyd, A. C., Davies, J. C., Griesenbach, U., Porteous, D. J., Sheppard, D. N., Munkonge, F. M., Alton, E. W. 
and Gill, D. R. (2008). CpG-free plasmids confer reduced inflammation and sustained pulmonary gene 
expression. Nat Biotechnol. 26(5): 549-551. 
Iannolo, G., Minenkova, O., Petruzzelli, R. and Cesareni, G. (1995). Modifying filamentous phage 
capsid: limits in the size of the major capsid protein. J Mol Biol. 248(4): 835-844. 
Iannolo, G., Salcini, A. E., Gaidarov, I., Goodman, O. B., Jr., Baulida, J., Carpenter, G., Pelicci, P. G., Di 
Fiore, P. P. and Keen, J. H. (1997). Mapping of the molecular determinants involved in the interaction 
between eps15 and AP-2. Cancer Res. 57(2): 240-245. 
Immonen, A., Vapalahti, M., Tyynela, K., Hurskainen, H., Sandmair, A., Vanninen, R., Langford, G., 
Murray, N. and Yla-Herttuala, S. (2004). AdvHSV-tk gene therapy with intravenous ganciclovir improves 
survival in human malignant glioma: a randomised, controlled study. Mol Ther. 10(5): 967-972. 
Ivanenkov, V., Felici, F. and Menon, A. G. (1999a). Uptake and intracellular fate of phage display 
vectors in mammalian cells. Biochim Biophys Acta. 1448(3): 450-462. 
Ivanenkov, V. V., Felici, F. and Menon, A. G. (1999b). Targeted delivery of multivalent phage display 
vectors into mammalian cells. Biochim Biophys Acta. 1448(3): 463-472. 
Jayanna, P. K., Bedi, D., Gillespie, J. W., DeInnocentes, P., Wang, T., Torchilin, V. P., Bird, R. C. and 
Petrenko, V. A. (2010). Landscape phage fusion protein-mediated targeting of nanomedicines enhances 
their prostate tumor cell association and cytotoxic efficiency. Nanomedicine. 6(4): 538-546. 
Jaye, D. L., Geigerman, C. M., Fuller, R. E., Akyildiz, A. and Parkos, C. A. (2004). Direct 
fluorochrome labeling of phage display library clones for studying binding specificities: applications in 
flow cytometry and fluorescence microscopy. J Immunol Methods. 295(1-2): 119-127. 
Jennings, K., Miyamae, T., Traister, R., Marinov, A., Katakura, S., Sowders, D., Trapnell, B., Wilson, J. 
M., Gao, G. and Hirsch, R. (2005). Proteasome inhibition enhances AAV-mediated transgene expression in 
human synoviocytes in vitro and in vivo. Mol Ther. 11(4): 600-607. 
Jin, H. and Varner, J. (2004). Integrins: roles in cancer development and as treatment targets. Br J 
Cancer. 90(3): 561-565. 
Kalderon, D., Roberts, B. L., Richardson, W. D. and Smith, A. E. (1984). A short amino acid sequence 
able to specify nuclear location. Cell. 39(3 Pt 2): 499-509. 
Kanai, F., Lan, K. H., Shiratori, Y., Tanaka, T., Ohashi, M., Okudaira, T., Yoshida, Y., Wakimoto, H., 
Hamada, H., Nakabayashi, H., Tamaoki, T. and Omata, M. (1997). In vivo gene therapy for alpha-
fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase 
gene. Cancer Res. 57(3): 461-465. 
Kanerva, A., Mikheeva, G. V., Krasnykh, V., Coolidge, C. J., Lam, J. T., Mahasreshti, P. J., Barker, S. 
D., Straughn, M., Barnes, M. N., Alvarez, R. D., Hemminki, A. and Curiel, D. T. (2002). Targeting adenovirus 
210
to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res. 8(1): 
275-280. 
Kawabata, K., Takakura, Y. and Hashida, M. (1995). The fate of plasmid DNA after intravenous 
injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm Res. 12(6): 825-830. 
Kelly, B. T., McCoy, A. J., Spate, K., Miller, S. E., Evans, P. R., Honing, S. and Owen, D. J. (2008). A 
structural explanation for the binding of endocytic dileucine motifs by the AP2 complex. Nature. 
456(7224): 976-979. 
Kelly, E. and Russell, S. J. (2007). History of oncolytic viruses: genesis to genetic engineering. Mol 
Ther. 15(4): 651-659. 
Kelly, E. J. and Russell, S. J. (2009). MicroRNAs and the regulation of vector tropism. Mol Ther. 
17(3): 409-416. 
Kern, A., Schmidt, K., Leder, C., Muller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, 
J. A. and Kleinschmidt, J. A. (2003). Identification of a heparin-binding motif on adeno-associated virus 
type 2 capsids. J Virol. 77(20): 11072-11081. 
Kerr, M. C., Lindsay, M. R., Luetterforst, R., Hamilton, N., Simpson, F., Parton, R. G., Gleeson, P. A. 
and Teasdale, R. D. (2006). Visualisation of macropinosome maturation by the recruitment of sorting 
nexins. J Cell Sci. 119(Pt 19): 3967-3980. 
Kerr, M. C. and Teasdale, R. D. (2009). Defining macropinocytosis. Traffic. 10(4): 364-371. 
Kieser, A., Weich, H. A., Brandner, G., Marme, D. and Kolch, W. (1994). Mutant p53 potentiates 
protein kinase C induction of vascular endothelial growth factor expression. Oncogene. 9(3): 963-969. 
Kim, J. H., Majumder, N., Lin, H., Watkins, S., Falo, L. D., Jr. and You, Z. (2005). Induction of 
therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther. 16(11): 
1255-1266. 
Kircheis, R., Ostermann, E., Wolschek, M. F., Lichtenberger, C., Magin-Lachmann, C., Wightman, L., 
Kursa, M. and Wagner, E. (2002). Tumor-targeted gene delivery of tumor necrosis factor-alpha induces 
tumor necrosis and tumor regression without systemic toxicity. Cancer Gene Ther. 9(8): 673-680. 
Kirn, D. (2001). Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of 
phase I and II trials. Expert Opin Biol Ther. 1(3): 525-538. 
Kisselev, A. F. and Goldberg, A. L. (2001). Proteasome inhibitors: from research tools to drug 
candidates. Chem Biol. 8(8): 739-758. 
Knudson, A. G., Jr. (1971). Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad 
Sci U S A. 68(4): 820-823. 
Knurr, J., Benedek, O., Heslop, J., Vinson, R. B., Boydston, J. A., McAndrew, J., Kearney, J. F. and 
Turnbough, C. L., Jr. (2003). Peptide ligands that bind selectively to spores of Bacillus subtilis and closely 
related species. Appl Environ Microbiol. 69(11): 6841-6847. 
Kobayashi, T., Stang, E., Fang, K. S., de Moerloose, P., Parton, R. G. and Gruenberg, J. (1998). A lipid 
associated with the antiphospholipid syndrome regulates endosome structure and function. Nature. 
392(6672): 193-197. 
Kock, H., Harris, M. P., Anderson, S. C., Machemer, T., Hancock, W., Sutjipto, S., Wills, K. N., 
Gregory, R. J., Shepard, H. M., Westphal, M. and Maneval, D. C. (1996). Adenovirus-mediated p53 gene 
transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer. 67(6): 808-815. 
Kohn, D. B., Sadelain, M. and Glorioso, J. C. (2003). Occurrence of leukaemia following gene therapy 
of X-linked SCID. Nat Rev Cancer. 3(7): 477-488. 
Koivunen, E., Wang, B. and Ruoslahti, E. (1995). Phage libraries displaying cyclic peptides with 
different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y). 13(3): 265-270. 
Koizumi, N., Mizuguchi, H., Hosono, T., Ishii-Watabe, A., Uchida, E., Utoguchi, N., Watanabe, Y. and 
Hayakawa, T. (2001). Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide. 
Biochim Biophys Acta. 1568(1): 13-20. 
Kotin, R. M., Linden, R. M. and Berns, K. I. (1992). Characterization of a preferred site on human 
chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. 
EMBO J. 11(13): 5071-5078. 
Kotin, R. M., Siniscalco, M., Samulski, R. J., Zhu, X. D., Hunter, L., Laughlin, C. A., McLaughlin, S., 
Muzyczka, N., Rocchi, M. and Berns, K. I. (1990). Site-specific integration by adeno-associated virus. Proc 
Natl Acad Sci U S A. 87(6): 2211-2215. 
Krag, D. N., Fuller, S. P., Oligino, L., Pero, S. C., Weaver, D. L., Soden, A. L., Hebert, C., Mills, S., Liu, 
C. and Peterson, D. (2002). Phage-displayed random peptide libraries in mice: toxicity after serial panning. 
Cancer Chemother Pharmacol. 50(4): 325-332. 
Kurzchalia, T. V. and Parton, R. G. (1999). Membrane microdomains and caveolae. Curr Opin Cell 
Biol. 11(4): 424-431. 
211
Lakadamyali, M., Rust, M. J. and Zhuang, X. (2006). Ligands for clathrin-mediated endocytosis are 
differentially sorted into distinct populations of early endosomes. Cell. 124(5): 997-1009. 
Lalani, A. S., Chang, B., Lin, J., Case, S. S., Luan, B., Wu-Prior, W. W., VanRoey, M. and Jooss, K. 
(2004). Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene 
therapy. Mol Ther. 9(1): 56-66. 
Lane, D. P., Cheok, C. F. and Lain, S. (2010). p53-based cancer therapy. Cold Spring Harb Perspect 
Biol. 2(9): a001222. 
Lange, A., Mills, R. E., Lange, C. J., Stewart, M., Devine, S. E. and Corbett, A. H. (2007). Classical 
nuclear localization signals: definition, function, and interaction with importin alpha. J Biol Chem. 282(8): 
5101-5105. 
Langel, U., Pooga, M., Kairane, C., Zilmer, M. and Bartfai, T. (1996). A galanin-mastoparan chimeric 
peptide activates the Na+,K(+)-ATPase and reverses its inhibition by ouabain. Regul Pept. 62(1): 47-52. 
Larocca, D., Kassner, P. D., Witte, A., Ladner, R. C., Pierce, G. F. and Baird, A. (1999). Gene transfer 
to mammalian cells using genetically targeted filamentous bacteriophage. FASEB J. 13(6): 727-734. 
Larocca, D., Witte, A., Johnson, W., Pierce, G. F. and Baird, A. (1998). Targeting bacteriophage to 
mammalian cell surface receptors for gene delivery. Hum Gene Ther. 9(16): 2393-2399. 
Le, P. U., Guay, G., Altschuler, Y. and Nabi, I. R. (2002). Caveolin-1 is a negative regulator of 
caveolae-mediated endocytosis to the endoplasmic reticulum. J Biol Chem. 277(5): 3371-3379. 
Le Saux, G., Magenau, A., Gunaratnam, K., Kilian, K. A., Bocking, T., Gooding, J. J. and Gaus, K. 
(2011). Spacing of integrin ligands influences signal transduction in endothelial cells. Biophys J. 101(4): 
764-773. 
Lee, K. Y., Kwon, I. C., Kim, Y. H., Jo, W. H. and Jeong, S. Y. (1998). Preparation of chitosan self-
aggregates as a gene delivery system. J Control Release. 51(2-3): 213-220. 
Lehrman, S. (1999). Virus treatment questioned after gene therapy death. Nature. 401(6753): 517-
518. 
Leng, Q., Scaria, P., Lu, P., Woodle, M. C. and Mixson, A. J. (2008). Systemic delivery of HK Raf-1 
siRNA polyplexes inhibits MDA-MB-435 xenografts. Cancer Gene Ther. 15(8): 485-495. 
Leng, Q., Scaria, P., Zhu, J., Ambulos, N., Campbell, P. and Mixson, A. J. (2005). Highly branched HK 
peptides are effective carriers of siRNA. J Gene Med. 7(7): 977-986. 
Levitt, N. C. and Hickson, I. D. (2002). Caretaker tumour suppressor genes that defend genome 
integrity. Trends Mol Med. 8(4): 179-186. 
Lewis, P., Hensel, M. and Emerman, M. (1992). Human immunodeficiency virus infection of cells 
arrested in the cell cycle. EMBO J. 11(8): 3053-3058. 
Li, C., Bowles, D. E., van Dyke, T. and Samulski, R. J. (2005a). Adeno-associated virus vectors: 
potential applications for cancer gene therapy. Cancer Gene Ther. 12(12): 913-925. 
Li, E., Stupack, D., Bokoch, G. M. and Nemerow, G. R. (1998a). Adenovirus endocytosis requires 
actin cytoskeleton reorganization mediated by Rho family GTPases. J Virol. 72(11): 8806-8812. 
Li, H., Alonso-Vanegas, M., Colicos, M. A., Jung, S. S., Lochmuller, H., Sadikot, A. F., Snipes, G. J., 
Seth, P., Karpati, G. and Nalbantoglu, J. (1999). Intracerebral adenovirus-mediated p53 tumor suppressor 
gene therapy for experimental human glioma. Clin Cancer Res. 5(3): 637-642. 
Li, Q., Kawamura, K., Yamanaka, M., Okamoto, S., Yang, S., Yamauchi, S., Fukamachi, T., Kobayashi, 
H., Tada, Y., Takiguchi, Y., Tatsumi, K., Shimada, H., Hiroshima, K. and Tagawa, M. Upregulated p53 
expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity 
of cisplatin and pemetrexed. Cancer Gene Ther. 19(3): 218-228. 
Li, S., Rizzo, M. A., Bhattacharya, S. and Huang, L. (1998b). Characterization of cationic lipid-
protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther. 5(7): 930-937. 
Li, S. D. and Huang, L. (2006). Gene therapy progress and prospects: non-viral gene therapy by 
systemic delivery. Gene Ther. 13(18): 1313-1319. 
Li, X. H., Peng, Y., Li, X. P., Liu, X. and Li, G. (2005b). [Adeno-associated virus-mediated gene 
transfer of endostatin for inhibiting growth and metastasis of human nasopharyngeal carcinoma in nude 
mice]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 40(12): 881-886. 
Liberali, P., Kakkonen, E., Turacchio, G., Valente, C., Spaar, A., Perinetti, G., Bockmann, R. A., Corda, 
D., Colanzi, A., Marjomaki, V. and Luini, A. (2008). The closure of Pak1-dependent macropinosomes 
requires the phosphorylation of CtBP1/BARS. EMBO J. 27(7): 970-981. 
Lipardi, C., Mora, R., Colomer, V., Paladino, S., Nitsch, L., Rodriguez-Boulan, E. and Zurzolo, C. 
(1998). Caveolin transfection results in caveolae formation but not apical sorting of 
glycosylphosphatidylinositol (GPI)-anchored proteins in epithelial cells. J Cell Biol. 140(3): 617-626. 
Liu, F., Qi, H., Huang, L. and Liu, D. (1997). Factors controlling the efficiency of cationic lipid-
mediated transfection in vivo via intravenous administration. Gene Ther. 4(6): 517-523. 
212
Liu, F., Song, Y. and Liu, D. (1999). Hydrodynamics-based transfection in animals by systemic 
administration of plasmid DNA. Gene Ther. 6(7): 1258-1266. 
Liu, Q. and Muruve, D. A. (2003). Molecular basis of the inflammatory response to adenovirus 
vectors. Gene Ther. 10(11): 935-940. 
Liu, T. C. and Kirn, D. (2007). Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-
concept and future directions. Cancer Res. 67(2): 429-432. 
Liu, T. C. and Kirn, D. (2008). Gene therapy progress and prospects cancer: oncolytic viruses. Gene 
Ther. 15(12): 877-884. 
Lizee, G., Gonzales, M. I. and Topalian, S. L. (2004). Lentivirus vector-mediated expression of 
tumor-associated epitopes by human antigen presenting cells. Hum Gene Ther. 15(4): 393-404. 
Macia, E., Ehrlich, M., Massol, R., Boucrot, E., Brunner, C. and Kirchhausen, T. (2006). Dynasore, a 
cell-permeable inhibitor of dynamin. Dev Cell. 10(6): 839-850. 
Madsen, D., Cantwell, E. R., O'Brien, T., Johnson, P. A. and Mahon, B. P. (2009). Adeno-associated 
virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid 
protein VP1. J Gen Virol. 90(Pt 11): 2622-2633. 
Maeda, T., Kawasaki, K. and Ohnishi, S. (1981). Interaction of influenza virus hemagglutinin with 
target membrane lipids is a key step in virus-induced hemolysis and fusion at pH 5.2. Proc Natl Acad Sci U 
S A. 78(7): 4133-4137. 
Maginnis, M. S., Forrest, J. C., Kopecky-Bromberg, S. A., Dickeson, S. K., Santoro, S. A., Zutter, M. M., 
Nemerow, G. R., Bergelson, J. M. and Dermody, T. S. (2006). Beta1 integrin mediates internalization of 
mammalian reovirus. J Virol. 80(6): 2760-2770. 
Maginnis, M. S., Mainou, B. A., Derdowski, A., Johnson, E. M., Zent, R. and Dermody, T. S. (2008). 
NPXY motifs in the beta1 integrin cytoplasmic tail are required for functional reovirus entry. J Virol. 
82(7): 3181-3191. 
Maier, O., Galan, D. L., Wodrich, H. and Wiethoff, C. M. (2010). An N-terminal domain of 
adenovirus protein VI fragments membranes by inducing positive membrane curvature. Virology. 402(1): 
11-19. 
Malik, P. and Perham, R. N. (1996). New vectors for peptide display on the surface of filamentous 
bacteriophage. Gene. 171(1): 49-51. 
Malys, N., Chang, D. Y., Baumann, R. G., Xie, D. and Black, L. W. (2002). A bipartite bacteriophage 
T4 SOC and HOC randomized peptide display library: detection and analysis of phage T4 terminase 
(gp17) and late sigma factor (gp55) interaction. J Mol Biol. 319(2): 289-304. 
Mann, R., Mulligan, R. C. and Baltimore, D. (1983). Construction of a retrovirus packaging mutant 
and its use to produce helper-free defective retrovirus. Cell. 33(1): 153-159. 
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J., Ozelo, M. C., Hoots, K., 
Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Rustagi, P. K., Nakai, H., Chew, 
A., Leonard, D., Wright, J. F., Lessard, R. R., Sommer, J. M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., 
Mingozzi, F., Couto, L., Ertl, H. C., High, K. A. and Kay, M. A. (2006). Successful transduction of liver in 
hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 12(3): 
342-347. 
Margadant, C., Monsuur, H. N., Norman, J. C. and Sonnenberg, A. (2011). Mechanisms of integrin 
activation and trafficking. Curr Opin Cell Biol. 23(5): 607-614. 
Marjomaki, V., Pietiainen, V., Matilainen, H., Upla, P., Ivaska, J., Nissinen, L., Reunanen, H., Huttunen, 
P., Hyypia, T. and Heino, J. (2002). Internalization of echovirus 1 in caveolae. J Virol. 76(4): 1856-1865. 
Marsh, M. and Helenius, A. (2006). Virus entry: open sesame. Cell. 124(4): 729-740. 
Marsh, M. and Pelchen-Matthews, A. (2000). Endocytosis in viral replication. Traffic. 1(7): 525-532. 
Martin, K. and Helenius, A. (1991). Transport of incoming influenza virus nucleocapsids into the 
nucleus. J Virol. 65(1): 232-244. 
Martin, M. E. and Rice, K. G. (2007). Peptide-guided gene delivery. AAPS J. 9(1): E18-29. 
Martinez-Torrecuadrada, J., Cifuentes, G., Lopez-Serra, P., Saenz, P., Martinez, A. and Casal, J. I. 
(2005). Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain 
Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res. 11(17): 6280-6290. 
Martinez, C. G., Guinea, R., Benavente, J. and Carrasco, L. (1996). The entry of reovirus into L cells is 
dependent on vacuolar proton-ATPase activity. J Virol. 70(1): 576-579. 
Matsui, W. and Kirchhausen, T. (1990). Stabilization of clathrin coats by the core of the clathrin-
associated protein complex AP-2. Biochemistry. 29(48): 10791-10798. 
Matthews, T. and Boehme, R. (1988). Antiviral activity and mechanism of action of ganciclovir. Rev 
Infect Dis. 10 Suppl 3: S490-494. 
McConnell, M. J. and Imperiale, M. J. (2004). Biology of adenovirus and its use as a vector for gene 
therapy. Hum Gene Ther. 15(11): 1022-1033. 
213
McMahon, H. T. and Boucrot, E. (2011). Molecular mechanism and physiological functions of 
clathrin-mediated endocytosis. Nat Rev Mol Cell Biol. 12(8): 517-533. 
Medina-Kauwe, L. K. (2003). Endocytosis of adenovirus and adenovirus capsid proteins. Adv Drug 
Deliv Rev. 55(11): 1485-1496. 
Meier, O., Boucke, K., Hammer, S. V., Keller, S., Stidwill, R. P., Hemmi, S. and Greber, U. F. (2002). 
Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. 
J Cell Biol. 158(6): 1119-1131. 
Mellstroom, K., Hoglund, A. S., Nister, M., Heldin, C. H., Westermark, B. and Lindberg, U. (1983). The 
effect of platelet-derived growth factor on morphology and motility of human glial cells. J Muscle Res Cell 
Motil. 4(5): 589-609. 
Mercer, J. and Helenius, A. (2008). Vaccinia virus uses macropinocytosis and apoptotic mimicry to 
enter host cells. Science. 320(5875): 531-535. 
Mercer, J. and Helenius, A. (2009). Virus entry by macropinocytosis. Nat Cell Biol. 11(5): 510-520. 
Merrifield, C. J., Qualmann, B., Kessels, M. M. and Almers, W. (2004). Neural Wiskott Aldrich 
Syndrome Protein (N-WASP) and the Arp2/3 complex are recruited to sites of clathrin-mediated 
endocytosis in cultured fibroblasts. Eur J Cell Biol. 83(1): 13-18. 
Midoux, P., Kichler, A., Boutin, V., Maurizot, J. C. and Monsigny, M. (1998). Membrane 
permeabilization and efficient gene transfer by a peptide containing several histidines. Bioconjug Chem. 
9(2): 260-267. 
Midoux, P. and Monsigny, M. (1999). Efficient gene transfer by histidylated polylysine/pDNA 
complexes. Bioconjug Chem. 10(3): 406-411. 
Miller, D. G., Adam, M. A. and Miller, A. D. (1990). Gene transfer by retrovirus vectors occurs only 
in cells that are actively replicating at the time of infection. Mol Cell Biol. 10(8): 4239-4242. 
Miller, D. G., Rutledge, E. A. and Russell, D. W. (2002). Chromosomal effects of adeno-associated 
virus vector integration. Nat Genet. 30(2): 147-148. 
Misinzo, G., Delputte, P. L., Lefebvre, D. J. and Nauwynck, H. J. (2009). Porcine circovirus 2 infection 
of epithelial cells is clathrin-, caveolae- and dynamin-independent, actin and Rho-GTPase-mediated, and 
enhanced by cholesterol depletion. Virus Res. 139(1): 1-9. 
Mitjans, F., Sander, D., Adan, J., Sutter, A., Martinez, J. M., Jaggle, C. S., Moyano, J. M., Kreysch, H. 
G., Piulats, J. and Goodman, S. L. (1995). An anti-alpha v-integrin antibody that blocks integrin function 
inhibits the development of a human melanoma in nude mice. J Cell Sci. 108 ( Pt 8): 2825-2838. 
Miyamoto, S., Teramoto, H., Gutkind, J. S. and Yamada, K. M. (1996). Integrins can collaborate with 
growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of 
integrin aggregation and occupancy of receptors. J Cell Biol. 135(6 Pt 1): 1633-1642. 
Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H. and Verma, I. M. (1998). Development of a self-
inactivating lentivirus vector. J Virol. 72(10): 8150-8157. 
Mizuno, M., Yoshida, J., Colosi, P. and Kurtzman, G. (1998). Adeno-associated virus vector 
containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally 
implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn J Cancer Res. 
89(1): 76-80. 
Molek, P., Strukelj, B. and Bratkovic, T. (2011). Peptide phage display as a tool for drug discovery: 
targeting membrane receptors. Molecules. 16(1): 857-887. 
Molenaar, T. J., Michon, I., de Haas, S. A., van Berkel, T. J., Kuiper, J. and Biessen, E. A. (2002). 
Uptake and processing of modified bacteriophage M13 in mice: implications for phage display. Virology. 
293(1): 182-191. 
Montesano, R., Roth, J., Robert, A. and Orci, L. (1982). Non-coated membrane invaginations are 
involved in binding and internalization of cholera and tetanus toxins. Nature. 296(5858): 651-653. 
Moolten, F. L. (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase 
genes: paradigm for a prospective cancer control strategy. Cancer Res. 46(10): 5276-5281. 
Moolten, F. L. and Wells, J. M. (1990). Curability of tumors bearing herpes thymidine kinase genes 
transferred by retroviral vectors. J Natl Cancer Inst. 82(4): 297-300. 
Moore, N. M., Sheppard, C. L., Barbour, T. R. and Sakiyama-Elbert, S. E. (2008). The effect of 
endosomal escape peptides on in vitro gene delivery of polyethylene glycol-based vehicles. J Gene Med. 
10(10): 1134-1149. 
Moore, N. M., Sheppard, C. L. and Sakiyama-Elbert, S. E. (2009). Characterization of a 
multifunctional PEG-based gene delivery system containing nuclear localization signals and endosomal 
escape peptides. Acta Biomater. 5(3): 854-864. 
Mori, K., Kubo, T., Kibayashi, Y., Ohkuma, T. and Kaji, A. (1996). Anti-vaccinia virus effect of M13 
bacteriophage DNA. Antiviral Res. 31(1-2): 79-86. 
214
Morille, M., Passirani, C., Vonarbourg, A., Clavreul, A. and Benoit, J. P. (2008). Progress in developing 
cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials. 29(24-25): 3477-3496. 
Moriyama, T., Marquez, J. P., Wakatsuki, T. and Sorokin, A. (2007). Caveolar endocytosis is critical 
for BK virus infection of human renal proximal tubular epithelial cells. J Virol. 81(16): 8552-8562. 
Morris, J. C., Ramsey, W. J., Wildner, O., Muslow, H. A., Aguilar-Cordova, E. and Blaese, R. M. (2000). 
A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine 
kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous 
metastatic malignant melanoma. Hum Gene Ther. 11(3): 487-503. 
Moskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G. and Patel, S. 
D. (2000). Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: 
implications for gene therapy and virus structure. J Virol. 74(4): 1761-1766. 
Moyer, C. L. and Nemerow, G. R. (2011). Viral weapons of membrane destruction: variable modes 
of membrane penetration by non-enveloped viruses. Curr Opin Virol. 1(1): 44-49. 
Mu, F. T., Callaghan, J. M., Steele-Mortimer, O., Stenmark, H., Parton, R. G., Campbell, P. L., 
McCluskey, J., Yeo, J. P., Tock, E. P. and Toh, B. H. (1995). EEA1, an early endosome-associated protein. 
EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine "fingers" and 
contains a calmodulin-binding IQ motif. J Biol Chem. 270(22): 13503-13511. 
Mullock, B. M., Bright, N. A., Fearon, C. W., Gray, S. R. and Luzio, J. P. (1998). Fusion of lysosomes 
with late endosomes produces a hybrid organelle of intermediate density and is NSF dependent. J Cell 
Biol. 140(3): 591-601. 
Murray, J. W., Bananis, E. and Wolkoff, A. W. (2000). Reconstitution of ATP-dependent movement 
of endocytic vesicles along microtubules in vitro: an oscillatory bidirectional process. Mol Biol Cell. 11(2): 
419-433. 
Muruve, D. A. (2004). The innate immune response to adenovirus vectors. Hum Gene Ther. 15(12): 
1157-1166. 
Muruve, D. A., Barnes, M. J., Stillman, I. E. and Libermann, T. A. (1999). Adenoviral gene therapy 
leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. 
Hum Gene Ther. 10(6): 965-976. 
Muzyczka, N. and Berns, K. I. (2001). Parvoviridae: the viruses and their replication. Fields 
Virology. D. M. Knipe, P. M. Howley, D. E. Griffin et al. 530 Walnut Street Philadelphia, PA 19106 USA, 
Lippincott Williams and Wilkins: 2327-2359. 
Nabel, G. J., Nabel, E. G., Yang, Z. Y., Fox, B. A., Plautz, G. E., Gao, X., Huang, L., Shu, S., Gordon, D. 
and Chang, A. E. (1993). Direct gene transfer with DNA-liposome complexes in melanoma: expression, 
biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A. 90(23): 11307-11311. 
Nabi, I. R. and Le, P. U. (2003). Caveolae/raft-dependent endocytosis. J Cell Biol. 161(4): 673-677. 
Nakai, H., Montini, E., Fuess, S., Storm, T. A., Grompe, M. and Kay, M. A. (2003). AAV serotype 2 
vectors preferentially integrate into active genes in mice. Nat Genet. 34(3): 297-302. 
Nakamura, T., Sato, K. and Hamada, H. (2002). Effective gene transfer to human melanomas via 
integrin-targeted adenoviral vectors. Hum Gene Ther. 13(5): 613-626. 
Nakano, M. Y., Boucke, K., Suomalainen, M., Stidwill, R. P. and Greber, U. F. (2000). The first step of 
adenovirus type 2 disassembly occurs at the cell surface, independently of endocytosis and escape to the 
cytosol. J Virol. 74(15): 7085-7095. 
Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M. and Trono, D. 
(1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 
272(5259): 263-267. 
Nemerow, G. R. (2000). Cell receptors involved in adenovirus entry. Virology. 274(1): 1-4. 
Neves, S., Faneca, H., Bertin, S., Konopka, K., Duzgunes, N., Pierrefite-Carle, V., Simoes, S. and 
Pedroso de Lima, M. C. (2009). Transferrin lipoplex-mediated suicide gene therapy of oral squamous cell 
carcinoma in an immunocompetent murine model and mechanisms involved in the antitumoral response. 
Cancer Gene Ther. 16(1): 91-101. 
Ngaha, E. O. and Akanji, M. A. (1982). Effect of chloroquine on the stability of rat kidney lysosomes 
in vivo and in vitro. Comp Biochem Physiol C. 73(1): 109-113. 
Ngo, M. C., Rooney, C. M., Howard, J. M. and Heslop, H. E. (2011). Ex vivo gene transfer for 
improved adoptive immunotherapy of cancer. Hum Mol Genet. 20(R1): R93-99. 
Nibert, M. L., Odegard, A. L., Agosto, M. A., Chandran, K. and Schiff, L. A. (2005). Putative 
autocleavage of reovirus mu1 protein in concert with outer-capsid disassembly and activation for 
membrane permeabilization. J Mol Biol. 345(3): 461-474. 
Nichols, B. J. (2002). A distinct class of endosome mediates clathrin-independent endocytosis to the 
Golgi complex. Nat Cell Biol. 4(5): 374-378. 
215
Nicklin, S. A., White, S. J., Watkins, S. J., Hawkins, R. E. and Baker, A. H. (2000). Selective targeting 
of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation. 
102(2): 231-237. 
Nielsen, E., Christoforidis, S., Uttenweiler-Joseph, S., Miaczynska, M., Dewitte, F., Wilm, M., Hoflack, 
B. and Zerial, M. (2000). Rabenosyn-5, a novel Rab5 effector, is complexed with hVPS45 and recruited to 
endosomes through a FYVE finger domain. J Cell Biol. 151(3): 601-612. 
Nishimura, T. and Kaibuchi, K. (2007). Numb controls integrin endocytosis for directional cell 
migration with aPKC and PAR-3. Dev Cell. 13(1): 15-28. 
Nowell, P. C. (1976). The clonal evolution of tumour cell populations. Science. 194(4260): 23-28. 
O'Donnell, V., LaRocco, M., Duque, H. and Baxt, B. (2005). Analysis of foot-and-mouth disease virus 
internalization events in cultured cells. J Virol. 79(13): 8506-8518. 
O'Shea, C. C., Johnson, L., Bagus, B., Choi, S., Nicholas, C., Shen, A., Boyle, L., Pandey, K., Soria, C., 
Kunich, J., Shen, Y., Habets, G., Ginzinger, D. and McCormick, F. (2004). Late viral RNA export, rather 
than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 6(6): 611-623. 
Ogris, M., Brunner, S., Schuller, S., Kircheis, R. and Wagner, E. (1999). PEGylated DNA/transferrin-
PEI complexes: reduced interaction with blood components, extended circulation in blood and potential 
for systemic gene delivery. Gene Ther. 6(4): 595-605. 
Ogris, M., Walker, G., Blessing, T., Kircheis, R., Wolschek, M. and Wagner, E. (2003). Tumor-targeted 
gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA 
complexes. J Control Release. 91(1-2): 173-181. 
Ohno, H., Stewart, J., Fournier, M. C., Bosshart, H., Rhee, I., Miyatake, S., Saito, T., Gallusser, A., 
Kirchhausen, T. and Bonifacino, J. S. (1995). Interaction of tyrosine-based sorting signals with clathrin-
associated proteins. Science. 269(5232): 1872-1875. 
Okegawa, T., Pong, R. C., Li, Y., Bergelson, J. M., Sagalowsky, A. I. and Hsieh, J. T. (2001). The 
mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human 
bladder cancer: a functional analysis of car protein structure. Cancer Res. 61(17): 6592-6600. 
Oren, M. (2003). Decision making by p53: life, death and cancer. Cell Death Differ. 10(4): 431-442. 
Orlandi, P. A. and Fishman, P. H. (1998). Filipin-dependent inhibition of cholera toxin: evidence for 
toxin internalization and activation through caveolae-like domains. J Cell Biol. 141(4): 905-915. 
Owen, D. J., Collins, B. M. and Evans, P. R. (2004). Adaptors for clathrin coats: structure and 
function. Annu Rev Cell Dev Biol. 20: 153-191. 
Pan, J. G., Zhou, X., Luo, R. and Han, R. F. (2012). The adeno-associated virus-mediated HSV-
TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma. Med Oncol. 29(3): 
1938-1947. 
Paoloni, M. C., Tandle, A., Mazcko, C., Hanna, E., Kachala, S., Leblanc, A., Newman, S., Vail, D., 
Henry, C., Thamm, D., Sorenmo, K., Hajitou, A., Pasqualini, R., Arap, W., Khanna, C. and Libutti, S. K. 
(2009). Launching a novel preclinical infrastructure: comparative oncology trials consortium directed 
therapeutic targeting of TNFalpha to cancer vasculature. PLoS One. 4(3): e4972. 
Parton, R. G. and Simons, K. (2007). The multiple faces of caveolae. Nat Rev Mol Cell Biol. 8(3): 185-
194. 
Pasqualini, R., Koivunen, E. and Ruoslahti, E. (1997). Alpha v integrins as receptors for tumor 
targeting by circulating ligands. Nat Biotechnol. 15(6): 542-546. 
Pasqualini, R. and Ruoslahti, E. (1996). Organ targeting in vivo using phage display peptide 
libraries. Nature. 380(6572): 364-366. 
Pearson, S., Jia, H. and Kandachi, K. (2004). China approves first gene therapy. Nat Biotechnol. 22(1): 
3-4. 
Pelkmans, L., Burli, T., Zerial, M. and Helenius, A. (2004). Caveolin-stabilized membrane domains as 
multifunctional transport and sorting devices in endocytic membrane traffic. Cell. 118(6): 767-780. 
Pelkmans, L., Kartenbeck, J. and Helenius, A. (2001). Caveolar endocytosis of simian virus 40 reveals 
a new two-step vesicular-transport pathway to the ER. Nat Cell Biol. 3(5): 473-483. 
Pelkmans, L., Puntener, D. and Helenius, A. (2002). Local actin polymerization and dynamin 
recruitment in SV40-induced internalization of caveolae. Science. 296(5567): 535-539. 
Peng, Z. (2005). Current status of gendicine in China: recombinant human Ad-p53 agent for 
treatment of cancers. Hum Gene Ther. 16(9): 1016-1027. 
Perez, L. and Carrasco, L. (1994). Involvement of the vacuolar H(+)-ATPase in animal virus entry. J 
Gen Virol. 75 ( Pt 10): 2595-2606. 
Persano, L., Crescenzi, M. and Indraccolo, S. (2007). Anti-angiogenic gene therapy of cancer: current 
status and future prospects. Mol Aspects Med. 28(1): 87-114. 
216
Pichon, C., Roufai, M. B., Monsigny, M. and Midoux, P. (2000). Histidylated oligolysines increase the 
transmembrane passage and the biological activity of antisense oligonucleotides. Nucleic Acids Res. 28(2): 
504-512. 
Piersanti, S., Cherubini, G., Martina, Y., Salone, B., Avitabile, D., Grosso, F., Cundari, E., Di Zenzo, G. 
and Saggio, I. (2004a). Mammalian cell transduction and internalization properties of lambda phages 
displaying the full-length adenoviral penton base or its central domain. J Mol Med (Berl). 82(7): 467-476. 
Piersanti, S., Cherubini, G., Martina, Y., Salone, B., Avitabile, D., Grosso, F., Cundari, E., Di Zenzo, G. 
and Saggio, I. (2004b). Mammalian cell transduction and internalization properties of lambda phages 
displaying the full-length adenoviral penton base or its central domain. J Mol Med. 82(7): 467-476. 
Pierschbacher, M. D. and Ruoslahti, E. (1984). Cell attachment activity of fibronectin can be 
duplicated by small synthetic fragments of the molecule. Nature. 309(5963): 30-33. 
Plank, C., Oberhauser, B., Mechtler, K., Koch, C. and Wagner, E. (1994). The influence of endosome-
disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J Biol Chem. 269(17): 
12918-12924. 
Poul, M. A., Becerril, B., Nielsen, U. B., Morisson, P. and Marks, J. D. (2000). Selection of tumor-
specific internalizing human antibodies from phage libraries. J Mol Biol. 301(5): 1149-1161. 
Poul, M. A. and Marks, J. D. (1999). Targeted gene delivery to mammalian cells by filamentous 
bacteriophage. J Mol Biol. 288(2): 203-211. 
Przystal, J. M., Umukoro, E., Stoneham, C. A., Yata, T., O'Neill, K., Syed, N. and Hajitou, A. (2012). 
Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated 
virus/phage. Mol Oncol. 
Pu, Y. and Zhang, X. (2008). Mouse hepatitis virus type 2 enters cells through a clathrin-mediated 
endocytic pathway independent of Eps15. J Virol. 82(16): 8112-8123. 
Pytela, R., Pierschbacher, M. D. and Ruoslahti, E. (1985). A 125/115-kDa cell surface receptor specific 
for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from 
fibronectin. Proc Natl Acad Sci U S A. 82(17): 5766-5770. 
Qazilbash, M. H., Xiao, X., Seth, P., Cowan, K. H. and Walsh, C. E. (1997). Cancer gene therapy using 
a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther. 4(7): 675-682. 
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V. and Srivastava, A. (1999). Human fibroblast 
growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med. 5(1): 71-77. 
Querbes, W., Benmerah, A., Tosoni, D., Di Fiore, P. P. and Atwood, W. J. (2004). A JC virus-induced 
signal is required for infection of glial cells by a clathrin- and eps15-dependent pathway. J Virol. 78(1): 
250-256. 
Raiborg, C., Bache, K. G., Gillooly, D. J., Madshus, I. H., Stang, E. and Stenmark, H. (2002). Hrs sorts 
ubiquitinated proteins into clathrin-coated microdomains of early endosomes. Nat Cell Biol. 4(5): 394-398. 
Ram, Z., Culver, K. W., Walbridge, S., Blaese, R. M. and Oldfield, E. H. (1993). In situ retroviral-
mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53(1): 83-88. 
Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G. P., Wilson, J. M. and Batshaw, M. 
L. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient 
patient following adenoviral gene transfer. Mol Genet Metab. 80(1-2): 148-158. 
Read, M. L., Singh, S., Ahmed, Z., Stevenson, M., Briggs, S. S., Oupicky, D., Barrett, L. B., Spice, R., 
Kendall, M., Berry, M., Preece, J. A., Logan, A. and Seymour, L. W. (2005). A versatile reducible polycation-
based system for efficient delivery of a broad range of nucleic acids. Nucleic Acids Res. 33(9): e86. 
Rejman, J., Oberle, V., Zuhorn, I. S. and Hoekstra, D. (2004). Size-dependent internalization of 
particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 377(Pt 1): 159-169. 
Richards, C. A., Austin, E. A. and Huber, B. E. (1995). Transcriptional regulatory sequences of 
carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene 
therapy. Hum Gene Ther. 6(7): 881-893. 
Ricotta, D., Conner, S. D., Schmid, S. L., von Figura, K. and Honing, S. (2002). Phosphorylation of the 
AP2 mu subunit by AAK1 mediates high affinity binding to membrane protein sorting signals. J Cell Biol. 
156(5): 791-795. 
Rink, J., Ghigo, E., Kalaidzidis, Y. and Zerial, M. (2005). Rab conversion as a mechanism of 
progression from early to late endosomes. Cell. 122(5): 735-749. 
Rohde, G., Wenzel, D. and Haucke, V. (2002). A phosphatidylinositol (4,5)-bisphosphate binding site 
within mu2-adaptin regulates clathrin-mediated endocytosis. J Cell Biol. 158(2): 209-214. 
Rohwer, F. (2003). Global phage diversity. Cell. 113(2): 141. 
Roivainen, M., Hyypia, T., Piirainen, L., Kalkkinen, N., Stanway, G. and Hovi, T. (1991). RGD-
dependent entry of coxsackievirus A9 into host cells and its bypass after cleavage of VP1 protein by 
intestinal proteases. J Virol. 65(9): 4735-4740. 
217
Rols, M. P., Delteil, C., Golzio, M., Dumond, P., Cros, S. and Teissie, J. (1998). In vivo electrically 
mediated protein and gene transfer in murine melanoma. Nat Biotechnol. 16(2): 168-171. 
Rosenberg, A. H., Griffin, K., Washington, M. T., Patel, S. S. and Studier, F. W. (1996). Selection, 
identification, and genetic analysis of random mutants in the cloned primase/helicase gene of 
bacteriophage T7. J Biol Chem. 271(43): 26819-26824. 
Rosenberg, S. A., Yang, J. C. and Restifo, N. P. (2004). Cancer immunotherapy: moving beyond 
current vaccines. Nat Med. 10(9): 909-915. 
Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Ferson, D. Z., Hong, W. K., 
Komaki, R., Lee, J. J., Nesbitt, J. C., Pisters, K. M., Putnam, J. B., Schea, R., Shin, D. M., Walsh, G. L., 
Dolormente, M. M., Han, C. I., Martin, F. D., Yen, N., Xu, K., Stephens, L. C., McDonnell, T. J., 
Mukhopadhyay, T. and Cai, D. (1996). Retrovirus-mediated wild-type p53 gene transfer to tumors of 
patients with lung cancer. Nat Med. 2(9): 985-991. 
Roth, T. F. and Porter, K. R. (1964). Yolk Protein Uptake in the Oocyte of the Mosquito Aedes 
Aegypti. L. J Cell Biol. 20: 313-332. 
Rothberg, K. G., Heuser, J. E., Donzell, W. C., Ying, Y. S., Glenney, J. R. and Anderson, R. G. (1992). 
Caveolin, a protein component of caveolae membrane coats. Cell. 68(4): 673-682. 
Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M. and zur Hausen, H. (1998). Replication 
of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol. 
72(12): 9470-9478. 
Ruoslahti, E. (1996). RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 12: 
697-715. 
Russell, W. C. (2009). Adenoviruses: update on structure and function. J Gen Virol. 90(Pt 1): 1-20. 
Sachs, M. D., Rauen, K. A., Ramamurthy, M., Dodson, J. L., De Marzo, A. M., Putzi, M. J., Schoenberg, 
M. P. and Rodriguez, R. (2002). Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical 
bladder cancer. Urology. 60(3): 531-536. 
Sachse, M., Urbe, S., Oorschot, V., Strous, G. J. and Klumperman, J. (2002). Bilayered clathrin coats 
on endosomal vacuoles are involved in protein sorting toward lysosomes. Mol Biol Cell. 13(4): 1313-1328. 
Salcini, A. E., Confalonieri, S., Doria, M., Santolini, E., Tassi, E., Minenkova, O., Cesareni, G., Pelicci, 
P. G. and Di Fiore, P. P. (1997). Binding specificity and in vivo targets of the EH domain, a novel protein-
protein interaction module. Genes Dev. 11(17): 2239-2249. 
Sallinen, H., Anttila, M., Narvainen, J., Koponen, J., Hamalainen, K., Kholova, I., Heikura, T., Toivanen, 
P., Kosma, V. M., Heinonen, S., Alitalo, K. and Yla-Herttuala, S. (2009). Antiangiogenic gene therapy with 
soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther. 
17(2): 278-284. 
Samulski, R. J., Chang, L. S. and Shenk, T. (1987). A recombinant plasmid from which an infectious 
adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol. 61(10): 
3096-3101. 
Samulski, R. J., Zhu, X., Xiao, X., Brook, J. D., Housman, D. E., Epstein, N. and Hunter, L. A. (1991). 
Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 10(12): 3941-
3950. 
Sanchez, A. (2007). Analysis of filovirus entry into vero e6 cells, using inhibitors of endocytosis, 
endosomal acidification, structural integrity, and cathepsin (B and L) activity. J Infect Dis. 196 Suppl 2: 
S251-258. 
Sandmair, A. M., Loimas, S., Puranen, P., Immonen, A., Kossila, M., Puranen, M., Hurskainen, H., 
Tyynela, K., Turunen, M., Vanninen, R., Lehtolainen, P., Paljarvi, L., Johansson, R., Vapalahti, M. and Yla-
Herttuala, S. (2000). Thymidine kinase gene therapy for human malignant glioma, using replication-
deficient retroviruses or adenoviruses. Hum Gene Ther. 11(16): 2197-2205. 
Santolini, E., Puri, C., Salcini, A. E., Gagliani, M. C., Pelicci, P. G., Tacchetti, C. and Di Fiore, P. P. 
(2000). Numb is an endocytic protein. J Cell Biol. 151(6): 1345-1352. 
Scallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B. and Pierce, 
G. F. (2006). Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 
neutralizing titers in SCID mice. Blood. 107(5): 1810-1817. 
Schiffelers, R. M., Ansari, A., Xu, J., Zhou, Q., Tang, Q., Storm, G., Molema, G., Lu, P. Y., Scaria, P. V. 
and Woodle, M. C. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted 
sterically stabilized nanoparticle. Nucleic Acids Res. 32(19): e149. 
Schlaepfer, D. D., Hanks, S. K., Hunter, T. and van der Geer, P. (1994). Integrin-mediated signal 
transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature. 372(6508): 786-
791. 
Schlossman, D. M., Schmid, S. L., Braell, W. A. and Rothman, J. E. (1984). An enzyme that removes 
clathrin coats: purification of an uncoating ATPase. J Cell Biol. 99(2): 723-733. 
218
Schmid, E. M. and McMahon, H. T. (2007). Integrating molecular and network biology to decode 
endocytosis. Nature. 448(7156): 883-888. 
Schmidt, F. I., Bleck, C. K., Helenius, A. and Mercer, J. (2011). Vaccinia extracellular virions enter 
cells by macropinocytosis and acid-activated membrane rupture. EMBO J. 30(17): 3647-3661. 
Schnitzer, J. E., Oh, P., Pinney, E. and Allard, J. (1994). Filipin-sensitive caveolae-mediated transport 
in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select 
macromolecules. J Cell Biol. 127(5): 1217-1232. 
Scott, J. K. and Smith, G. P. (1990). Searching for peptide ligands with an epitope library. Science. 
249(4967): 386-390. 
Semerdjieva, S., Shortt, B., Maxwell, E., Singh, S., Fonarev, P., Hansen, J., Schiavo, G., Grant, B. D. and 
Smythe, E. (2008). Coordinated regulation of AP2 uncoating from clathrin-coated vesicles by rab5 and 
hRME-6. J Cell Biol. 183(3): 499-511. 
Seow, Y. and Wood, M. J. (2009). Biological gene delivery vehicles: beyond viral vectors. Mol Ther. 
17(5): 767-777. 
Shalev, M., Kadmon, D., Teh, B. S., Butler, E. B., Aguilar-Cordova, E., Thompson, T. C., Herman, J. R., 
Adler, H. L., Scardino, P. T. and Miles, B. J. (2000). Suicide gene therapy toxicity after multiple and repeat 
injections in patients with localized prostate cancer. J Urol. 163(6): 1747-1750. 
Shi, F. and Sottile, J. (2008). Caveolin-1-dependent beta1 integrin endocytosis is a critical regulator 
of fibronectin turnover. J Cell Sci. 121(Pt 14): 2360-2371. 
Shi, W. and Bartlett, J. S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 
(AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol Ther. 7(4): 515-525. 
Siders, W. M., Shields, J., Kaplan, J., Lukason, M., Woodworth, L., Wadsworth, S. and Scaria, A. 
(2009). Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, 
limit transgene expression in mice. Hum Gene Ther. 20(1): 11-20. 
Sieczkarski, S. B. and Whittaker, G. R. (2002a). Dissecting virus entry via endocytosis. J Gen Virol. 
83(Pt 7): 1535-1545. 
Sieczkarski, S. B. and Whittaker, G. R. (2002b). Influenza virus can enter and infect cells in the 
absence of clathrin-mediated endocytosis. J Virol. 76(20): 10455-10464. 
Skehel, J. J. and Wiley, D. C. (2000). Receptor binding and membrane fusion in virus entry: the 
influenza hemagglutinin. Annu Rev Biochem. 69: 531-569. 
Smith, G. P. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens 
on the virion surface. Science. 228(4705): 1315-1317. 
Smith, G. P. and Petrenko, V. A. (1997). Phage Display. Chem Rev. 97(2): 391-410. 
Smith, G. P. and Scott, J. K. (1993). Libraries of peptides and proteins displayed on filamentous 
phage. Methods Enzymol. 217: 228-257. 
Smith, R. H. (2008). Adeno-associated virus integration: virus versus vector. Gene Ther. 15(11): 817-
822. 
St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, 
G. J., Lengauer, C., Vogelstein, B. and Kinzler, K. W. (2000). Genes expressed in human tumor 
endothelium. Science. 289(5482): 1197-1202. 
Staba, M. J., Wickham, T. J., Kovesdi, I. and Hallahan, D. E. (2000). Modifications of the fiber in 
adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther. 7(1): 13-19. 
Stanislawski, T., Voss, R. H., Lotz, C., Sadovnikova, E., Willemsen, R. A., Kuball, J., Ruppert, T., 
Bolhuis, R. L., Melief, C. J., Huber, C., Stauss, H. J. and Theobald, M. (2001). Circumventing tolerance to a 
human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol. 2(10): 962-970. 
Stenmark, H. (2009). Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 10(8): 
513-525. 
Stenmark, H., Parton, R. G., Steele-Mortimer, O., Lutcke, A., Gruenberg, J. and Zerial, M. (1994). 
Inhibition of rab5 GTPase activity stimulates membrane fusion in endocytosis. EMBO J. 13(6): 1287-1296. 
Sternberg, N. and Hoess, R. H. (1995). Display of peptides and proteins on the surface of 
bacteriophage lambda. Proc Natl Acad Sci U S A. 92(5): 1609-1613. 
Stevenson, M., Ramos-Perez, V., Singh, S., Soliman, M., Preece, J. A., Briggs, S. S., Read, M. L. and 
Seymour, L. W. (2008). Delivery of siRNA mediated by histidine-containing reducible polycations. J 
Control Release. 130(1): 46-56. 
Stewart, P. L., Chiu, C. Y., Huang, S., Muir, T., Zhao, Y., Chait, B., Mathias, P. and Nemerow, G. R. 
(1997). Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody 
neutralization. EMBO J. 16(6): 1189-1198. 
Stewart, P. L. and Nemerow, G. R. (2007). Cell integrins: commonly used receptors for diverse viral 
pathogens. Trends Microbiol. 15(11): 500-507. 
219
Subtil, A., Gaidarov, I., Kobylarz, K., Lampson, M. A., Keen, J. H. and McGraw, T. E. (1999). Acute 
cholesterol depletion inhibits clathrin-coated pit budding. Proc Natl Acad Sci U S A. 96(12): 6775-6780. 
Suksanpaisan, L., Susantad, T. and Smith, D. R. (2009). Characterization of dengue virus entry into 
HepG2 cells. J Biomed Sci. 16: 17. 
Sulakvelidze, A., Alavidze, Z. and Morris, J. G., Jr. (2001). Bacteriophage therapy. Antimicrob Agents 
Chemother. 45(3): 649-659. 
Sumida, S. M., Truitt, D. M., Lemckert, A. A., Vogels, R., Custers, J. H., Addo, M. M., Lockman, S., 
Peter, T., Peyerl, F. W., Kishko, M. G., Jackson, S. S., Gorgone, D. A., Lifton, M. A., Essex, M., Walker, B. D., 
Goudsmit, J., Havenga, M. J. and Barouch, D. H. (2005). Neutralizing antibodies to adenovirus serotype 5 
vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. 174(11): 7179-
7185. 
Summerford, C., Bartlett, J. S. and Samulski, R. J. (1999). AlphaVbeta5 integrin: a co-receptor for 
adeno-associated virus type 2 infection. Nat Med. 5(1): 78-82. 
Summerford, C. and Samulski, R. J. (1998). Membrane-associated heparan sulfate proteoglycan is a 
receptor for adeno-associated virus type 2 virions. J Virol. 72(2): 1438-1445. 
Summers, W. C. (2001). Bacteriophage therapy. Annu Rev Microbiol. 55: 437-451. 
Suomalainen, M., Nakano, M. Y., Keller, S., Boucke, K., Stidwill, R. P. and Greber, U. F. (1999). 
Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear 
targeting of adenovirus. J Cell Biol. 144(4): 657-672. 
Suzuki, S., Argraves, W. S., Pytela, R., Arai, H., Krusius, T., Pierschbacher, M. D. and Ruoslahti, E. 
(1986). cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin 
reveal a transmembrane domain and homologies with other adhesion protein receptors. Proc Natl Acad 
Sci U S A. 83(22): 8614-8618. 
Swanson, J. A. and Watts, C. (1995). Macropinocytosis. Trends Cell Biol. 5(11): 424-428. 
Swisher, S. G., Roth, J. A., Komaki, R., Gu, J., Lee, J. J., Hicks, M., Ro, J. Y., Hong, W. K., Merritt, J. 
A., Ahrar, K., Atkinson, N. E., Correa, A. M., Dolormente, M., Dreiling, L., El-Naggar, A. K., Fossella, F., 
Francisco, R., Glisson, B., Grammer, S., Herbst, R., Huaringa, A., Kemp, B., Khuri, F. R., Kurie, J. M., Liao, Z., 
McDonnell, T. J., Morice, R., Morello, F., Munden, R., Papadimitrakopoulou, V., Pisters, K. M., Putnam, J. B., 
Jr., Sarabia, A. J., Shelton, T., Stevens, C., Shin, D. M., Smythe, W. R., Vaporciyan, A. A., Walsh, G. L. and 
Yin, M. (2003). Induction of p53-regulated genes and tumor regression in lung cancer patients after 
intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 9(1): 93-101. 
Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Connors, D. 
G., El-Naggar, A. K., Fossella, F., Glisson, B. S., Hong, W. K., Khuri, F. R., Kurie, J. M., Lee, J. J., Lee, J. S., 
Mack, M., Merritt, J. A., Nguyen, D. M., Nesbitt, J. C., Perez-Soler, R., Pisters, K. M., Putnam, J. B., Jr., Richli, 
W. R., Savin, M., Schrump, D. S., Shin, D. M., Shulkin, A., Walsh, G. L., Wait, J., Weill, D. and Waugh, M. K. 
(1999). Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 
91(9): 763-771. 
Tanaka, T., Kuroki, M., Hamada, H., Kato, K., Kinugasa, T., Shibaguchi, H., Zhao, J. and Kuroki, M. 
(2007). Cancer-targeting gene therapy using tropism-modified adenovirus. Anticancer Res. 27(6A): 3679-
3684. 
Tandle, A., Blazer, D. G., 3rd and Libutti, S. K. (2004). Antiangiogenic gene therapy of cancer: recent 
developments. J Transl Med. 2(1): 22. 
Tandle, A., Hanna, E., Lorang, D., Hajitou, A., Moya, C. A., Pasqualini, R., Arap, W., Adem, A., 
Starker, E., Hewitt, S. and Libutti, S. K. (2009). Tumor vasculature-targeted delivery of tumor necrosis 
factor-alpha. Cancer. 115(1): 128-139. 
Tang, S. C., Sambanis, A. and Sibley, E. (2005). Proteasome modulating agents induce rAAV2-
mediated transgene expression in human intestinal epithelial cells. Biochem Biophys Res Commun. 331(4): 
1392-1400. 
Temming, K., Schiffelers, R. M., Molema, G. and Kok, R. J. (2005). RGD-based strategies for selective 
delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat. 8(6): 381-402. 
Thibodeau, M. S., Giardina, C., Knecht, D. A., Helble, J. and Hubbard, A. K. (2004). Silica-induced 
apoptosis in mouse alveolar macrophages is initiated by lysosomal enzyme activity. Toxicol Sci. 80(1): 34-
48. 
Thomas, C. E., Ehrhardt, A. and Kay, M. A. (2003). Progress and problems with the use of viral 
vectors for gene therapy. Nat Rev Genet. 4(5): 346-358. 
Thomas, M. and Klibanov, A. M. (2002). Enhancing polyethylenimine's delivery of plasmid DNA 
into mammalian cells. Proc Natl Acad Sci U S A. 99(23): 14640-14645. 
Thompson, H. M. and McNiven, M. A. (2006). Discovery of a new 'dynasore'. Nat Chem Biol. 2(7): 
355-356. 
220
Thomsen, P., Roepstorff, K., Stahlhut, M. and van Deurs, B. (2002). Caveolae are highly immobile 
plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol Biol 
Cell. 13(1): 238-250. 
Tordsson, J. M., Ohlsson, L. G., Abrahmsen, L. B., Karlstrom, P. J., Lando, P. A. and Brodin, T. N. 
(2000). Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant 
melanoma. Cancer Immunol Immunother. 48(12): 691-702. 
Torgersen, M. L., Skretting, G., van Deurs, B. and Sandvig, K. (2001). Internalization of cholera toxin 
by different endocytic mechanisms. J Cell Sci. 114(Pt 20): 3737-3747. 
Touraine, R. L., Vahanian, N., Ramsey, W. J. and Blaese, R. M. (1998). Enhancement of the herpes 
simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by 
pharmacologic manipulation of gap junctions. Hum Gene Ther. 9(16): 2385-2391. 
Traub, L. M. (2009). Tickets to ride: selecting cargo for clathrin-regulated internalization. Nat Rev 
Mol Cell Biol. 10(9): 583-596. 
Trepel, M., Grifman, M., Weitzman, M. D. and Pasqualini, R. (2000). Molecular adaptors for vascular-
targeted adenoviral gene delivery. Hum Gene Ther. 11(14): 1971-1981. 
Trepel, M., Stoneham, C. A., Eleftherohorinou, H., Mazarakis, N. D., Pasqualini, R., Arap, W. and 
Hajitou, A. (2009). A heterotypic bystander effect for tumor cell killing after adeno-associated 
virus/phage-mediated, vascular-targeted suicide gene transfer. Mol Cancer Ther. 8(8): 2383-2391. 
Tsai, B. (2007). Penetration of nonenveloped viruses into the cytoplasm. Annu Rev Cell Dev Biol. 23: 
23-43. 
Tsubuki, S., Saito, Y., Tomioka, M., Ito, H. and Kawashima, S. (1996). Differential inhibition of 
calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem. 119(3): 
572-576. 
Ungewickell, E., Ungewickell, H., Holstein, S. E., Lindner, R., Prasad, K., Barouch, W., Martin, B., 
Greene, L. E. and Eisenberg, E. (1995). Role of auxilin in uncoating clathrin-coated vesicles. Nature. 
378(6557): 632-635. 
Valsesia-Wittmann, S., Morling, F. J., Nilson, B. H., Takeuchi, Y., Russell, S. J. and Cosset, F. L. 
(1996). Improvement of retroviral retargeting by using amino acid spacers between an additional binding 
domain and the N terminus of Moloney murine leukemia virus SU. J Virol. 70(3): 2059-2064. 
van Bergen En Henegouwen, P. M. (2009). Eps15: a multifunctional adaptor protein regulating 
intracellular trafficking. Cell Commun Signal. 7: 24. 
van der Bliek, A. M., Redelmeier, T. E., Damke, H., Tisdale, E. J., Meyerowitz, E. M. and Schmid, S. L. 
(1993). Mutations in human dynamin block an intermediate stage in coated vesicle formation. J Cell Biol. 
122(3): 553-563. 
Van Hamme, E., Dewerchin, H. L., Cornelissen, E., Verhasselt, B. and Nauwynck, H. J. (2008). 
Clathrin- and caveolae-independent entry of feline infectious peritonitis virus in monocytes depends on 
dynamin. J Gen Virol. 89(Pt 9): 2147-2156. 
VandenDriessche, T., Thorrez, L., Naldini, L., Follenzi, A., Moons, L., Berneman, Z., Collen, D. and 
Chuah, M. K. (2002). Lentiviral vectors containing the human immunodeficiency virus type-1 central 
polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. 
Blood. 100(3): 813-822. 
Veiga, E. and Cossart, P. (2005). Listeria hijacks the clathrin-dependent endocytic machinery to 
invade mammalian cells. Nat Cell Biol. 7(9): 894-900. 
Veldwijk, M. R., Berlinghoff, S., Laufs, S., Hengge, U. R., Zeller, W. J., Wenz, F. and Fruehauf, S. 
(2004). Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors. 
Cancer Gene Ther. 11(8): 577-584. 
Verma, I. M. and Weitzman, M. D. (2005). Gene therapy: twenty-first century medicine. Annu Rev 
Biochem. 74: 711-738. 
Vile, R. G., Castleden, S., Marshall, J., Camplejohn, R., Upton, C. and Chong, H. (1997). Generation of 
an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a 
mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer. 
71(2): 267-274. 
Vile, R. G. and Hart, I. R. (1993). In vitro and in vivo targeting of gene expression to melanoma cells. 
Cancer Res. 53(5): 962-967. 
Vogelstein, B. and Kinzler, K. W. (2004). Cancer genes and the pathways they control. Nat Med. 
10(8): 789-799. 
Vogelstein, B., Lane, D. and Levine, A. J. (2000). Surfing the p53 network. Nature. 408(6810): 307-
310. 
Volcy, K. and Dewhurst, S. (2009). Proteasome inhibitors enhance bacteriophage lambda (lambda) 
mediated gene transfer in mammalian cells. Virology. 384(1): 77-87. 
221
Volpers, C. and Kochanek, S. (2004). Adenoviral vectors for gene transfer and therapy. J Gene Med. 
6 Suppl 1: S164-171. 
Waehler, R., Russell, S. J. and Curiel, D. T. (2007). Engineering targeted viral vectors for gene 
therapy. Nat Rev Genet. 8(8): 573-587. 
Wagner, E., Plank, C., Zatloukal, K., Cotten, M. and Birnstiel, M. L. (1992). Influenza virus 
hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA 
complexes: toward a synthetic virus-like gene-transfer vehicle. Proc Natl Acad Sci U S A. 89(17): 7934-
7938. 
Walther, W., Stein, U., Fichtner, I., Alexander, M., Shoemaker, R. H. and Schlag, P. M. (2000). Mdr1 
promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in 
vivo gene therapy and chemotherapy of tumors. Cancer Gene Ther. 7(6): 893-900. 
Wang, B., He, J., Liu, C. and Chang, L. J. (2006). An effective cancer vaccine modality: lentiviral 
modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine. 24(17): 3477-3489. 
Wang, H., Yang, P., Liu, K., Guo, F., Zhang, Y., Zhang, G. and Jiang, C. (2008). SARS coronavirus 
entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 
18(2): 290-301. 
Wang, T., Petrenko, V. A. and Torchilin, V. P. (2010). Paclitaxel-loaded polymeric micelles modified 
with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased 
cytotoxicity. Mol Pharm. 7(4): 1007-1014. 
Watanabe, M., Nasu, Y., Kashiwakura, Y., Kusumi, N., Tamayose, K., Nagai, A., Sasano, T., Shimada, 
T., Daida, H. and Kumon, H. (2005). Adeno-associated virus 2-mediated intratumoral prostate cancer gene 
therapy: long-term maspin expression efficiently suppresses tumor growth. Hum Gene Ther. 16(6): 699-
710. 
Wayner, E. A., Orlando, R. A. and Cheresh, D. A. (1991). Integrins alpha v beta 3 and alpha v beta 5 
contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J Cell Biol. 
113(4): 919-929. 
Wei, M. X., Tamiya, T., Rhee, R. J., Breakefield, X. O. and Chiocca, E. A. (1995). Diffusible cytotoxic 
metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome 
P450 2B1 cancer gene therapy paradigm. Clin Cancer Res. 1(10): 1171-1177. 
Weis, S. M. and Cheresh, D. A. (2011). alphav Integrins in Angiogenesis and Cancer. Cold Spring 
Harb Perspect Med. 1(1): a006478. 
West, M. A., Bretscher, M. S. and Watts, C. (1989). Distinct endocytotic pathways in epidermal 
growth factor-stimulated human carcinoma A431 cells. J Cell Biol. 109(6 Pt 1): 2731-2739. 
Wibo, M. and Poole, B. (1974). Protein degradation in cultured cells. II. The uptake of chloroquine 
by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1. J Cell Biol. 63(2 Pt 
1): 430-440. 
Wickham, T. J., Filardo, E. J., Cheresh, D. A. and Nemerow, G. R. (1994). Integrin alpha v beta 5 
selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol. 127(1): 257-264. 
Wickham, T. J., Mathias, P., Cheresh, D. A. and Nemerow, G. R. (1993). Integrins alpha v beta 3 and 
alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 73(2): 309-319. 
Wickham, T. J., Roelvink, P. W., Brough, D. E. and Kovesdi, I. (1996). Adenovirus targeted to 
heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol. 
14(11): 1570-1573. 
Wieffer, M., Maritzen, T. and Haucke, V. (2009). SnapShot: endocytic trafficking. Cell. 137(2): 382 
e381-383. 
Wiethoff, C. M., Wodrich, H., Gerace, L. and Nemerow, G. R. (2005). Adenovirus protein VI mediates 
membrane disruption following capsid disassembly. J Virol. 79(4): 1992-2000. 
Wiley, D. C. and Skehel, J. J. (1987). The structure and function of the hemagglutinin membrane 
glycoprotein of influenza virus. Annu Rev Biochem. 56: 365-394. 
Willingham, M. C., Hanover, J. A., Dickson, R. B. and Pastan, I. (1984). Morphologic characterization 
of the pathway of transferrin endocytosis and recycling in human KB cells. Proc Natl Acad Sci U S A. 
81(1): 175-179. 
Winter, G., Griffiths, A. D., Hawkins, R. E. and Hoogenboom, H. R. (1994). Making antibodies by 
phage display technology. Annu Rev Immunol. 12: 433-455. 
Wu, G. Y. and Wu, C. H. (1988). Receptor-mediated gene delivery and expression in vivo. J Biol 
Chem. 263(29): 14621-14624. 
Wu, X. and Pandolfi, P. P. (2001). Mouse models for multistep tumorigenesis. Trends Cell Biol. 
11(11): S2-9. 
Xia, Z. J., Chang, J. H., Zhang, L., Jiang, W. Q., Guan, Z. Z., Liu, J. W., Zhang, Y., Hu, X. H., Wu, G. 
H., Wang, H. Q., Chen, Z. C., Chen, J. C., Zhou, Q. H., Lu, J. W., Fan, Q. X., Huang, J. J. and Zheng, X. 
222
(2004). [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus 
(H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck 
or esophagus]. Ai Zheng. 23(12): 1666-1670. 
Xu, L., Huang, C. C., Huang, W., Tang, W. H., Rait, A., Yin, Y. Z., Cruz, I., Xiang, L. M., Pirollo, K. F. 
and Chang, E. H. (2002). Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-
immunoliposomes. Mol Cancer Ther. 1(5): 337-346. 
Yamamoto, M., Alemany, R., Adachi, Y., Grizzle, W. E. and Curiel, D. T. (2001). Characterization of 
the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in 
suicide gene therapy of gastrointestinal cancers. Mol Ther. 3(3): 385-394. 
Yamashiro, D. J., Tycko, B., Fluss, S. R. and Maxfield, F. R. (1984). Segregation of transferrin to a 
mildly acidic (pH 6.5) para-Golgi compartment in the recycling pathway. Cell. 37(3): 789-800. 
Yan, Z., Ritchie, T. C., Duan, D. and Engelhardt, J. F. (2002). Recombinant AAV-mediated gene 
delivery using dual vector heterodimerization. Methods Enzymol. 346: 334-357. 
Yang, N. S., Burkholder, J., Roberts, B., Martinell, B. and McCabe, D. (1990). In vivo and in vitro gene 
transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci U S A. 87(24): 9568-
9572. 
Yang, Y., Li, Q., Ertl, H. C. and Wilson, J. M. (1995). Cellular and humoral immune responses to 
viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 69(4): 
2004-2015. 
Yee, J. K., Friedmann, T. and Burns, J. C. (1994). Generation of high-titer pseudotyped retroviral 
vectors with very broad host range. Methods Cell Biol. 43 Pt A: 99-112. 
Yoshida, K., Kawami, H., Yamaguchi, Y., Kuniyasu, H., Nishiyama, M., Hirai, T., Yanagihara, K., 
Tahara, E. and Toge, T. (1995). Retrovirally transmitted gene therapy for gastric carcinoma using herpes 
simplex virus thymidine kinase gene. Cancer. 75(6 Suppl): 1467-1471. 
Yoshimori, T., Yamamoto, A., Moriyama, Y., Futai, M. and Tashiro, Y. (1991). Bafilomycin A1, a 
specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in 
lysosomes of cultured cells. J Biol Chem. 266(26): 17707-17712. 
Yu, G. Y. and Lai, M. M. (2005). The ubiquitin-proteasome system facilitates the transfer of murine 
coronavirus from endosome to cytoplasm during virus entry. J Virol. 79(1): 644-648. 
Yu, S. F., von Ruden, T., Kantoff, P. W., Garber, C., Seiberg, M., Ruther, U., Anderson, W. F., Wagner, 
E. F. and Gilboa, E. (1986). Self-inactivating retroviral vectors designed for transfer of whole genes into 
mammalian cells. Proc Natl Acad Sci U S A. 83(10): 3194-3198. 
Zaboikin, M., Srinivasakumar, N. and Schuening, F. (2006). Gene therapy with drug resistance genes. 
Cancer Gene Ther. 13(4): 335-345. 
Zacher, A. N., 3rd, Stock, C. A., Golden, J. W., 2nd and Smith, G. P. (1980). A new filamentous phage 
cloning vector: fd-tet. Gene. 9(1-2): 127-140. 
Zerial, M. and McBride, H. (2001). Rab proteins as membrane organizers. Nat Rev Mol Cell Biol. 
2(2): 107-117. 
Zhang, J. S., Liu, F. and Huang, L. (2005). Implications of pharmacokinetic behavior of lipoplex for 
its inflammatory toxicity. Adv Drug Deliv Rev. 57(5): 689-698. 
Zhang, L., Agosto, M. A., Ivanovic, T., King, D. S., Nibert, M. L. and Harrison, S. C. (2009). 
Requirements for the formation of membrane pores by the reovirus myristoylated micro1N peptide. J 
Virol. 83(14): 7004-7014. 
Zhang, L., Yang, N., Mohamed-Hadley, A., Rubin, S. C. and Coukos, G. (2003). Vector-based RNAi, a 
novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. 
Biochem Biophys Res Commun. 303(4): 1169-1178. 
Zhang, Y., Mukhopadhyay, T., Donehower, L. A., Georges, R. N. and Roth, J. A. (1993). Retroviral 
vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of 
the malignant phenotype. Hum Gene Ther. 4(4): 451-460. 
Zhang, Z., Jiang, G., Yang, F. and Wang, J. (2006). Knockdown of mutant K-ras expression by 
adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells. Cancer Biol Ther. 
5(11): 1481-1486. 
Zhao, Y., Zhu, L., Lee, S., Li, L., Chang, E., Soong, N. W., Douer, D. and Anderson, W. F. (1999). 
Identification of the block in targeted retroviral-mediated gene transfer. Proc Natl Acad Sci U S A. 96(7): 
4005-4010. 
Zhong, G., Smith, G. P., Berry, J. and Brunham, R. C. (1994). Conformational mimicry of a 
chlamydial neutralization epitope on filamentous phage. J Biol Chem. 269(39): 24183-24188. 
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L. and Trono, D. (1998). Self-
inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 72(12): 9873-9880. 
223
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. and Trono, D. (1997). Multiply attenuated lentiviral 
vector achieves efficient gene delivery in vivo. Nat Biotechnol. 15(9): 871-875. 
 
 
  
224
Appendix A 
Components of Complex Reagents 
Name  Components and Storage 
Luria-Bertani (LB) broth  18 g of LB powder (Sigma) was dissolved in 1 L H2O, 
autoclaved, and stored at RT.  
LB-agar  9 g of LB powder and 9 g of agar were dissolved in 450 ml of 
H2O. The LB-agar was steriled by autoclaving and allowed to 
cool to ~55°C, before addition of antibiotics (40 µg/ml 
Tetracycline, 100 μg/ml Kanamycin) and pouring plates.  
Terrific Broth (TB)  9.6 g of tryptone (Sigma), 19.2 g of yeast extract (Sigma) and 
3.2 ml of glycerol dissolved in 1 L of H2O. Autoclaved before 
addition of 100 ml of TB supplements and 50 mg of 
kanamycin (Sigma).  
TB supplement  23.1 g of KH2PO4 (Sigma) and 125.4 g of K2HPO4 (Sigma) in 
1 liter of ddH2O. Filtered through 0.22 μm filter units and 
stored at 4°C. 
PEG/NaCl 500 g of PEG (Sigma) and 584.5 g of NaCl (Sigma) were 
dissolved in 2.38 L ddH2O (autoclaved). Stored at 4°C. 
50x TAE buffer 242 g of Tris (Sigma), 100mL of 0.5M EDTA (pH 8.0) and 
57.1mL of Glacial Acetic Acid (Fisher) were added to ddH2O 
to a final volume of 1 L. Autoclaved and store at RT. 
Mowiol 6g glycerol (99.5%, Sigma) and 2.4 g Polyvinyl alcohol 
(Sigma) were dissolved in 50 ml H2O for 2 hours at 50°C 
before addition of 12 ml 0.2 M Tris buffer (0.97g/40 ml  H2O, 
pH 8.5). Left to dissolve overnight before centrifugation at 
2500 rpm (to remove solids). Aliquotted and stored at -20°C. 
Acidic glycine wash buffer 
 
0.1M glycine (0.75 g/100 ml H2O, Sigma), 0.1M sodium 
chloride (0.58 g/100 ml  H2O, Sigma) was prepared and 
adjusted to pH 3 by addition of  HCl. 
Epon 812 resin 21.2 g Epon 812, 9.2 g  Methyl Nadic Anhydride (MNA), 14.8 
g  Dodecenyl Succinic Anhydride (DDSA) and 0.8 g  2,4,6- 
Tri(Dimethylaminomethyl) Phenol (DMP-30) (all from TAAB 
Laboratories) were mixed by vortexing and aliquots stored at -
20°C. 
Lysis (protein extraction) Buffer 250 mM sodium chloride, 50 mM Tris-HCl (pH 7.4), 1 mM 
EDTA, 0.25% Triton-X100 were prepared in ddH2O and 
supplemented with protease inhibitor mixture (Roche Applied 
Science). Aliquots were stored at -20°C. 
SDS sample buffer (3X) 150 mM Tris-HCl (pH 6.8), 6% SDS (w/v), 30% glycerol, 
0.3% (w/v) bromophenol blue were prepared in ddH2O. β-
mercaptoethanol was added to a final concentration of 2.5% 
(w/v) immediately before use. 
Stacking gel (5% acrylamide) 0.85 ml 30% acrylamide, 0.625 ml 1M Tris-HCl (pH 6.8), 50 
µl 10%  Ammonium persulphate (APS), 50 µl 10% SDS, and 
3.4 ml H2O were combined before addition of 5 µl TEMED 
(5ml total volume). 
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Resolving gel (8% acrylamide) 2.7 ml 30% acrylamide, 2.5 ml 1.5 M Tris-HCl (pH8.8), 100 µl 
10% APS, 100 µl 10% SDS,  and 4.6 ml H2O were combined 
before addition of 6 µl TEMED (10ml final volume). 
Running buffer (5X) 125 mM Tris Base (15.1 g, Sigma), 1.25M glycine (93.8 g) and 
0.5% SDS (5 g) were prepared in 1L ddH2O. 
Transfer buffer (10X) 480 mM Tris Base (60.5 g), 390 mM glycine (29.3 g) and 
0.375% SDS (3.75 g) were dissolved in 1L ddH2O. Methanol 
was added to a final concentration of 20% before use. 
Tris Buffered Saline (TBS) (10X) 150mM sodium chloride (88 g), 27mM potassium chloride 
(2g) and 20mM Tris Base (24g) were dissolved in 1L ddH2O 
and pH adjusted to 7.6 with concentrated HCl. TBS-Tween 
was prepared by addition of Tween-20 to 1X TBS to a final 
concentration of 0.1%. 
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Appendix B 
 
Confocal microscopic analysis of RGD-AAVP colocalisation with EEA-1 in HEK293, HeLa, U87 
and DU145 cells. 
RGD-AAVP was cold-bound to (i) HEK293, (ii) HeLa, (iii) U87 or (iv) DU145  cells for 30 minutes 
before either fixation while on ice (0-timepoint control) or warming to 37°C for 10, 30, 60, 120 or  
240 minutes (times indicated on left-hand side). The RGD-AAVP was immunofluorescently-stained 
using rabbit anti-fd primary and goat anti-rabbit AlexaFluor-594 secondary antibodies (shown in red), 
early-endosomes were detected using mouse anti-EEA-1 primary and AlexaFluor-488 secondary 
antibodies (green). Representative single optical sections are shown, scale bars=10 μm. 
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Appendix C 
 
Confocal microscopic analysis of RGD-AAVP colocalisation with LAMP-1 in HEK293, HeLa, 
U87 and DU145 cells. 
RGD-AAVP was cold-bound to (i) HEK293, (ii) HeLa, (iii) U87 or (iv) DU145  cells for 30 minutes 
before either fixation while on ice (0-timepoint control) or warming to 37°C for 10, 30, 60, 120 or  
240 minutes (times indicated on left-hand side). The RGD-AAVP was immunofluorescently-stained 
using rabbit anti-fd primary and goat anti-rabbit AlexaFluor-594 secondary antibodies (shown in red), 
early-endosomes were detected using mouse anti-LAMP-1 primary and AlexaFluor-488 secondary 
antibodies (green). Representative single optical sections are shown, scale bars=10 μm. 
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Appendix D 
 
Sequencing analysis of rpVIII inserts 
In the example below, the presence of the EEP PC1 was confirmed following ligation of the 
oligonucleotide insert into HindIII/PstI-digested RGD-fUSE5-f88.4 or f88.4. Constructs were 
sequenced following PCR amplification of regions flanking the insert using primers specific to the 
f88.4 recombinant pVIII sequence. 
PC1 oligonucleotide insert:   
5’AGCTTTGCCAACGTCCATTGGTATGATAGCTTCGTGCCGTGGGGCCATCAGCCTGCA3’ 
                  H  W  Y  D  S  F  V  P  W  G  H  Q 
Highlighted in green: HindIII site, in yellow: PstI site, in grey: stuffer sequence 
 
RGD-PC1-GFP: 
GCGCTCTTGTTCCTATGCTAAGCTTTGCCAACGTCCATTGGTATGATAGCTTCGTGCCGTGGGGCCAT
CAGCCTGCAGAAGGTGATGACCCGGCTAAAGCTGCTTTTGACTCTCTTCAGGCTTCTGCTACTGAATA
CATCGGCTACGCTTGGGCTATGGTGGTTGTTATCGTTGGTGCTACTATTGGCATCAAACTTTTCAAAA
AATTCACTTCTAAAGCGTCTTAATGAACTCAGATACCCAGCCCGCCTAATGAGCGGGCTTTTTTTTAA
GCTAGCTTATGATGATGATGTGCTTAAAAACTTACTCAATGGCTGGTTTATGCATATCGCAATACATG
CGAAAAACCTAAAAGAGCTTGCCGATAAAAAAGGCCAATTTATTGCTATTTACCGCGGCTTTTTATTG
AGCTTGAAAGATAAATAAAATAGATAGGTTTTATTTGAAGCTAAATCTTCTTTATCGTAAAAAATGCC
CTCTTGGGTTATCAAGAGGGTCATTATATTCGCGGAATAACATCATTTGGTGACGAATAGCTAG 
 
Fd-PC1-GFP: 
GCGACTCTTGTTCCTATGCTAAGCTTTGCCAACGTCCATTGGTATGATAGCTTCGTGCCGTGGGGCCA
TCAGCCTGCAGAAGGTGATGACCCGGCTAAAGCTGCTTTTGACTCTCTTCAGGCTTCTGCTACTGAAT
ACATCGGCTACGCTTGGGCTATGGTGGTTGTTATCGTTGGTGCTACTATTGGCATCAAACTTTTCAAA
AAATTCACTTCTAAAGCGTCTTAATGAACTCAGATACCCAGCCCGCCTAATGAGCGGGCTTTTTTTTA
AGCTAGCTTATGATGATGATGTGCTTAAAAACTTACTCAATGGCTGGTTTATGCATATCGCAATACAT
GCGAAAAACCTAAAAGAGCTTGCCGATAAAAAAGGCCAATTTATTGCTATTTACCGCGGCTTTTTATT
GAGCTTGAAAGATAAATAAAATAGATAGGTTTTATTTGAAGCTAAATCTTCTTTATCGTAAAAAATGC
CCTCTTGGGTTATCAAGAGGGTCATTATATTCGCGGAATAACATCATTGGTGACGAAAAAGTAAC 
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